
<html lang="en"     class="pb-page"  data-request-id="704c299d-1414-4925-8463-2808098ded40"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c00950;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives" /></meta><meta name="dc.Creator" content="Chunqiu  Yu" /></meta><meta name="dc.Creator" content="Zhibin  Wang" /></meta><meta name="dc.Creator" content="Zeren  Sun" /></meta><meta name="dc.Creator" content="Lei  Zhang" /></meta><meta name="dc.Creator" content="Wanwan  Zhang" /></meta><meta name="dc.Creator" content="Yungen  Xu" /></meta><meta name="dc.Creator" content="Jing-Jing  Zhang" /></meta><meta name="dc.Description" content="Platinum drugs are common in chemotherapy, but their clinical applications have been limited due to drug resistance and severe toxic effects. The combination of platinum drugs with other drugs with..." /></meta><meta name="Description" content="Platinum drugs are common in chemotherapy, but their clinical applications have been limited due to drug resistance and severe toxic effects. The combination of platinum drugs with other drugs with..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 19, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00950" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00950" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00950" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00950" /></link>
        
    
    

<title>Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00950" /></meta><meta property="og:title" content="Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0008.jpeg" /></meta><meta property="og:description" content="Platinum drugs are common in chemotherapy, but their clinical applications have been limited due to drug resistance and severe toxic effects. The combination of platinum drugs with other drugs with different mechanisms of anticancer action, especially checkpoint inhibitors, is increasingly popular. This combination is the leading strategy to improve the therapeutic efficiency and minimize the side effects of platinum drugs. In this review, we focus on the mechanistic basis of the combinations of platinum-based drugs with other drugs to inspire the development of more promising platinum-based combination regimens in clinical trials as well as novel multitargeting platinum drugs overcoming drug resistance and toxicities resulting from current platinum drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00950"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00950">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00950&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00950&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00950&amp;href=/doi/10.1021/acs.jmedchem.0c00950" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13397-13412</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00915" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00976" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chunqiu Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunqiu Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunqiu++Yu">Chunqiu Yu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhibin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhibin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhibin++Wang">Zhibin Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zeren Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zeren Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zeren++Sun">Zeren Sun</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhang">Lei Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wanwan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wanwan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wanwan++Zhang">Wanwan Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yungen Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yungen Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>Y.X.: phone, (86)-25-83271244; email, <a href="/cdn-cgi/l/email-protection#3d45445a7d5e4d4813585948135e53"><span class="__cf_email__" data-cfemail="651d1c02250615104b0001104b060b">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yungen++Xu">Yungen Xu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6586-8482" title="Orcid link">http://orcid.org/0000-0001-6586-8482</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jing-Jing Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing-Jing Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</div><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>J.-J. Z.: phone, (86)-25-83271244; email, <a href="/cdn-cgi/l/email-protection#6c060616040d020b02062c5d5a5f420f0301"><span class="__cf_email__" data-cfemail="0c666676646d626b62664c3d3a3f226f6361">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing-Jing++Zhang">Jing-Jing Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6251-2066" title="Orcid link">http://orcid.org/0000-0002-6251-2066</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00950&amp;href=/doi/10.1021%2Facs.jmedchem.0c00950" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13397–13412</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 19, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 June 2020</li><li><span class="item_label"><b>Published</b> online</span>19 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00950" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00950</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13397%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChunqiu%2BYu%252C%2BZhibin%2BWang%252C%2BZeren%2BSun%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c00950%26title%3DPlatinum-Based%2BCombination%2BTherapy%253A%2BMolecular%2BRationale%252C%2BCurrent%2BClinical%2BUses%252C%2Band%2BFuture%2BPerspectives%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13412%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00950"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1044</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00950" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chunqiu&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Zhibin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zeren&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wanwan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yungen&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jing-Jing&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13397-13412&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00950&quot;},&quot;abstract&quot;:&quot;Platinum drugs are common in chemotherapy, but their clinical applications have been limited due to drug resistance and severe toxic effects. The combination of platinum drugs with other drugs with different mechanisms of anticancer action, especially checkpoint inhibitors, is increasingly popular. This combination is the leading strategy to improve the therapeutic efficiency and minimize the side effects of platinum drugs. In this review, we focus on the mechanistic basis of the combinations of platinum-based drugs with other drugs to inspire the development of more promising platinum-based combination regimens in clinical trials as well as novel multitargeting platinum drugs overcoming drug resistance and toxicities resulting from current platinum drugs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00950&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00950" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00950&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00950" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00950&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00950" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00950&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00950&amp;href=/doi/10.1021/acs.jmedchem.0c00950" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00950" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00950" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00950%26sid%3Dliteratum%253Aachs%26pmid%3D32813515%26genre%3Darticle%26aulast%3DYu%26date%3D2020%26atitle%3DPlatinum-Based%2BCombination%2BTherapy%253A%2BMolecular%2BRationale%252C%2BCurrent%2BClinical%2BUses%252C%2Band%2BFuture%2BPerspectives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13397%26epage%3D13412%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292098" title="Platinum">Platinum</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Platinum drugs are common in chemotherapy, but their clinical applications have been limited due to drug resistance and severe toxic effects. The combination of platinum drugs with other drugs with different mechanisms of anticancer action, especially checkpoint inhibitors, is increasingly popular. This combination is the leading strategy to improve the therapeutic efficiency and minimize the side effects of platinum drugs. In this review, we focus on the mechanistic basis of the combinations of platinum-based drugs with other drugs to inspire the development of more promising platinum-based combination regimens in clinical trials as well as novel multitargeting platinum drugs overcoming drug resistance and toxicities resulting from current platinum drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Platinum-based drugs remain among the most common chemotherapeutics because of their broad-spectrum anticancer activities, economic price, and unique anticancer mechanism. The anticancer property of the first-generation platinum drug, cisplatin, was identified in 1965,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and the first clinical study was launched in 1971.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Cisplatin has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of testicular and bladder cancers since 1978 as well as head and neck, lung, colorectal, and ovarian cancers. The second-generation platinum-based carboplatin was approved by the FDA for the treatment of ovarian cancer, and nedaplatin has been approved for the treatment of head and neck cancer, esophageal cancer, small cell lung cancer (SCLC), and non-small-cell lung cancer (NSCLC) in Japan. Third-generation drugs like heptaplatin and lobaplatin have been approved for the treatment of gastric cancers in Korea and chronic myelogenous leukemia in China. Oxaliplatin is the most recently approved platinum drug and has been primarily used to treat colon cancer.</div><div class="NLM_p">Clinically used platinum drugs are square-planar platinum(II) complexes with two leaving ligands and two nonleaving ligands coordinated to the platinum(II) center (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). These drugs possess unique anticancer properties by forming platinum–DNA adducts via ligand exchange reactions. However, drug resistance and side effects hamper their clinical applications. Novel platinum complexes with enhanced binding specificity to the molecular targets (e.g., DNA) of the cancer cells or novel mechanisms of anticancer action have remained a popular strategy to overcome these problems. Many other types of novel platinum complexes have been investigated. Nevertheless, most of these new platinum complexes were developed by substitution of the amine ligands and/or chloride leaving groups of cisplatin, which makes them straightforward analogues of cisplatin. Further, these complexes have a similar anticancer mechanism by interacting with DNA.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Such modifications are not likely to make major breakthroughs conceptually or practically. As a result, there are only a handful of successful cases so far.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> In addition to structural modifications, another strategy is to use delivery systems in biological matrices, such as conjugation of nanoparticles that enhance the binding specificity of the platinum drugs. A notable example is the preparation of a liposome-conjugated platinum complex lipoplatin (Regulin, Inc.). This complex leads to liposome nanoparticles with an average diameter of 110 nm in aqueous solution and is one of the most promising liposomal platinum drugs under current clinical investigation. A phase III trial revealed that this complex has potent anticancer efficacy with lower toxicity and fewer side effects than cisplatin.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> Combination therapies of lipoplatin with other anticancer drugs have also been investigated in clinical trials.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Such platinum-based combination therapy can improve the sensitivity of platinum-based treatment with reduced drug dosage. As a result, it can also decrease the toxicity. Platinum-based combination therapy has been applied in clinical settings to overcome the resistant and toxic problems of platinum drugs. Encouraged by the promising clinical success of such combination therapy, the number of clinical trials investigating a direct combination of platinum drugs with other drugs in cancer treatment initiated each year has increased over the past 5 years (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of clinically used platinum drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Number of clinical trials investigating direct platinum-based combination therapy started each year over past 5 years (the data were collected from <a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a> on April 21, 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Novel platinum complexes have been comprehensively reviewed.<a onclick="showRef(event, 'ref2 ref3 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref8">(2,3,8)</a> Platinum-based nanodrug delivery systems have also been reviewed thoroughly.<a onclick="showRef(event, 'ref7 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref9">(7,9)</a> Surprisingly, platinum-based combination therapy has only been mentioned in reports reviewing platinum drugs considering their successful application in the clinic. To the best of our knowledge, the underlying molecular rationale of platinum-based combinations has never been systematically reviewed. This review offers a separate introduction of platinum-based combination therapy focusing on the underlying molecular rationale, which should provide rationale evidence for future clinical trials of novel platinum-based combinations and the development of new multitargeting platinum drugs. The review begins with the mechanisms of anticancer action, drug resistance, and toxicity of platinum drugs in <a class="ref internalNav" href="#sec2" aria-label="sections 2">sections 2</a>–<a class="ref internalNav" href="#sec4" aria-label="4">4</a>. The influence of structural properties on anticancer effects is introduced in <a class="ref internalNav" href="#sec5" aria-label="section 5">section 5</a>. Studies of platinum-based combinations are reviewed based on the underlying mechanism in <a class="ref internalNav" href="#sec6" aria-label="section 6">section 6</a>. Furthermore, the current clinical applications of platinum-based combination therapy, limitations, and suggestions for future research are discussed in <a class="ref internalNav" href="#sec7" aria-label="sections 7">sections 7</a> and <a class="ref internalNav" href="#sec8" aria-label="8">8</a>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Mechanism of Anticancer Action of Platinum Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Covalent binding of the platinum center to DNA is currently accepted and is mainly responsible for the anticancer efficacy of platinum drugs.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This process involves four steps including cellular uptake, aquation, formation of DNA–platinum adducts, and induction of cell death. The mechanism will be briefly introduced below using cisplatin as a representative agent (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Main mechanisms of anticancer action and drug resistance of cisplatin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cisplatin can be taken up by cells via passive diffusion or active transport. Active transport is normally mediated by copper transporter 1 (CTR1), Na<sup>+</sup>, K<sup>+</sup>-ATPase, and heteromeric volume-regulated anion channels (VRACs)<sup>2</sup>. There is a sequence of ligand substitution facilitated by the trans effect in square-planar cisplatin upon crossing the cell membranes.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> First, one or two chlorides of cisplatin are displaced by water molecule(s), resulting in the formation of monoaqua [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> or diaqua [Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>]<sup>2+</sup> complexes. The positive charge on these complexes attract them to the negatively charged nuclear DNA. After entering the nucleus, they further interact with nucleophilic centers on purine bases of DNA, especially the N7 positions of guanine and/or adenine bases to form platinum–DNA adducts via ligand exchange. This reaction leads to an intrastrand or interstrand cross-linkage. These platinum–DNA adducts can activate cellular processing leading to apoptosis, which has been discussed in detail elsewhere.<a onclick="showRef(event, 'ref3 ref12'); return false;" href="javascript:void(0);" class="ref ref3 ref12">(3,12)</a> Here, we briefly discuss how DNA damage leads to apoptosis. The platinum–DNA adducts can be recognized by proteins like non-histone chromosomal high-mobility group proteins 1 and 2 (HMG1 and HMG2) and mismatch repair proteins (MMR). HMG1 and HMG2 can activate tumor suppressor p53 and facilitate the binding of p53 to DNA.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This then activates several target genes like p21 (related to cell cycle progression) and B cell lymphoma-2 (Bcl-2)-associated X protein (Bax; proapoptotic gene). Activation of p21 can result in cell cycle arrest for DNA repair,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> while increased expression of Bax can lead to the release of cytochrome <i>c</i> from mitochondria, subsequent cleavage of procaspase 9, activation of caspases 3, 6, and 7, and finally apoptotic cell death.<a onclick="showRef(event, 'ref2 ref12'); return false;" href="javascript:void(0);" class="ref ref2 ref12">(2,12)</a> Apoptosis can also be initiated by activation of p53 and c-ABL (v-abl Abelson murine leukemia viral oncogene homolog 1) when MMR fails to repair DNA damage.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Activated c-ABL can induce p73, a homolog of p53 with proapoptotic function. This activation can further potentiate the activation of caspases, thus resulting in apoptosis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Moreover, DNA damage caused by cisplatin can activate the ERK (extracellular regulated protein kinases), JNK (c-Jun N-terminal kinase), and p38 MAPK (mitogen-activated protein kinase) pathways (ERK/JNK/MAPK pathways).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> These activated cascades display dual roles. Some studies have shown that these activations can lead to apoptosis, whereas others indicate that they may promote cell survival.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">In addition to the interaction with DNA, emerging evidence has indicated that part of the anticancer efficacy of platinum drugs may be due to their modulation of the immune system.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> However, the underlying mechanisms have not yet been clearly elucidated. Sensitizing tumor cells to cytotoxic T cells is one of the most common mechanisms and has been reviewed in detail.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Here, we briefly introduce the mechanism using cisplatin as an example (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Cisplatin promotes the release or exposure of damage-associated molecular pattern (DAMP) molecules like ATP and high-mobility group box 1 (HMGB1). DAMP molecules further activate respective receptors on the dendritic cell (DC) plasma membrane, resulting in maturation of DCs. The maturation of DCs downregulates programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) on the DCs. This in turn enhances T-cell activation. The mature DCs migrate to the lymph node and prime naïve, tumor-specific T cells into effector cytotoxic T cells. Cytotoxic T cells then migrate from lymph nodes to the tumor microenvironment where they recognize their respective antigen target on cancer cells and undertake cytolytic function by secretion of perforin and granzyme-B.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modulation of the immune system by cisplatin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  Resistance Mechanism of Platinum Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The most common resistance mechanism of platinum drugs includes decreased accumulation of active platinum species, DNA repair, and defects in the apoptotic pathway induced by DNA damage. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> illustrates these mechanisms using cisplatin as a representative agent.</div><div class="NLM_p">The decrease in active platinum species involves decreased influx and increased efflux of cisplatin as well as deactivation of cisplatin by cytoplasmic nucleophiles. Downregulation of CTR1 or increased expression of two copper-extruding P-type ATPases (ATP7A and ATP7B) was observed in cisplatin-resistant cells.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Additionally, inhibition of Na<sup>+</sup>, K<sup>+</sup>-ATPase and the loss of LRRC8A and LRRC8D subunits of VRACs can lead to cisplatin-resistance.<a onclick="showRef(event, 'ref2 ref22'); return false;" href="javascript:void(0);" class="ref ref2 ref22">(2,22)</a> Moreover, high drug efflux capacity of the ATP-binding cassette (ABC) transporters can result in strong resistance.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Cytoplasmic thiol-containing nucleophiles like glutathione (GSH) and methionine can detoxify the active monoaqua- or diaquaplatinum complexes by forming platinum–nucleophiles conjugates.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Some of these conjugates like glutathione-S-transferase (GSTs) mediating platinum–GSH conjugates can be further excreted out of the cells via multidrug resistance proteins (MRP), which are subfamilies of the ABC transporters.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The platinum–DNA adducts can be recognized by several cellular proteins, which results in resistance. Nucleotide excision repair proteins (NER) can repair DNA damage and remove platinum–DNA adducts.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Excision-repair cross-complementation group 1 (ERCC1), a rate-limiting DNA-repair protein in the nucleotide excision repair pathway, is related to platinum-induced resistance.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Overexpression and constitutive activation of poly(ADP-ribose) polymerases (PARPs) that are critically involved in base excision repair were also observed in cisplatin-resistant cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The DNA double-strand-break repair protein RAD51 can be activated via the monoubiquitination in Fanconi anemia (FA) complementation group D2 (FANCD2) in response to DNA damage and accounts for cisplatin resistance. Mutation of MMR proteins is also reported to be related to cisplatin resistance.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Defects in the apoptosis pathway induced by DNA damage can also result in resistance. Aberration of the ERK/JNK/MAPK pathways, inactivation of p53, deficiency of c-ABL, and downregulation of HMG1/2 proteins have been related to resistance.<a onclick="showRef(event, 'ref3 ref15 ref24'); return false;" href="javascript:void(0);" class="ref ref3 ref15 ref24">(3,15,24)</a> Moreover, the AKT (v-akt murine thymoma viral oncogene homolog) pathway activated by DNA damage can protect cells from apoptotic cell death induced by cisplatin.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p last">Moreover, survival pathways that do not result from DNA-damage can be activated by platinum drugs and lead to resistance. For example, overexpression of the HER2/neu oncogene (HER-2), a member of the epidermal growth factor receptor (EGFR) family, has been reported to lead to resistance in cisplatin-treated NSCLC patients.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Both survivin and prostaglandin–endoperoxide synthase 2 (COX-2) are also related to resistance in cancer cells. The overexpression of COX-2 can stabilize the survivin proteins in human lung cancer cells, which can ultimately lead to a reduction in apoptosis.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">4.  Mechanism Underlying Platinum-Induced Toxicity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">How platinum drugs result in toxicity has not been fully understood; it is hypothesized to be multifactorial in nature.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35">(31−35)</a> For instance, reactive oxygen species (ROS) can lead to cell dysfunction and tissue damage by interfering with the antioxidant defense system.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Amplified renal injury and dysfunction was observed <i>in vivo</i> when epithelial cells in the kidneys were damaged by ROS.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Mitochondrial ROS production, intrinsic apoptosis, and inflammation can cause cisplatin-induced nephrotoxicity,<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> while the generation of ROS in the cochlea by cisplatin led to ototoxic damage.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The oxidative stress also plays an important role in the pathological process of platinum-induced cardiotoxicity.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In some cases, cisplatin-induced hearing loss can be ascribed to the nitrative stress.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">5.  Influence of Structural Properties on the Anticancer Effects of Platinum Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66285" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66285" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The structural property of platinum drugs plays an important role in their anticancer effect. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> shows that clinically used platinum drugs have a neutral and square-planar structure with two cis am(m)ine and two cis anionic ligands. The two am(m)ine ligands are referred as “non-leaving group ligands” because they remain bound to the platinum cation after the intracellular transformation. The two anionic ligands are referred as the “leaving group ligands”; they can be either monodentate anionic or chelating dianionic fragments.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">The trans effect in square-planar platinum drugs facilitates the ligands substitution, which renders the anticancer activities of platinum drugs.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> The coordinated ligands significantly influence the aquation, ligand exchange reaction with DNA, and deactivation by thiol-containing biomolecules during platinum transformation. These features are highly related to the cytotoxicity, drug resistance, and side effects of platinum drugs.</div><div class="NLM_p">Compared to cisplatin, the second-generation platinum drug carboplatin can reduce neurotoxicity and ototoxicity resulting from a lower aquation rate due to the bidentate cyclobutane dicarboxylate ligand. The bidentate oxalate ligand of the third-generation drug oxaliplatin also displays a reduced toxic profile due to reduced reactivity. Moreover, the lipophilic (1<i>R</i>,2<i>R</i>)-1,2-diaminocyclohexane (DACH) ligand of oxaliplatin increases the passive uptake of oxaliplatin versus cisplatin and carboplatin. The bulkier DACH ligand can also lead to a different conformational distortion of oxaliplatin–DNA adducts. Such conformation cannot be recognized by MMR proteins. As a result, oxaliplatin has a different activity spectrum than cisplatin or carboplatin.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p last">We note, however, that no new platinum drugs have been approved in the clinic since the third generation due to the limitation in structural diversity. Combination therapy is a strategy currently used in the clinic to address problems related to platinum drugs.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">6.  Platinum-based Combinations Based on the Underlying Molecular Rationale</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this section, combinations that directly combine platinum drugs with other molecules are described based on the underlying mechanism followed by the introduction of platinum(IV) prodrugs containing bioactive axial ligands as indirect combinations.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">6.1.  Combination of Platinum Drugs with Agents Targeting Decreased Accumulation of Reactive Platinum</h3><div class="NLM_p">Emodin (1,3,8-trihydroxy-6-methylanthraquinone), caffeic acid, Yu Ping Feng San (YPFS), verapamil, <span class="smallcaps smallerCapital">d</span>-penicillamine, and shMT/rPOA oligo-peptoplex showed synergistic anticancer effects with platinum drugs by interfering with the efflux of available platinum.</div><div class="NLM_p">Emodin is a ROS generator and significantly enhances the cytotoxicity of cisplatin, carboplatin, and oxaliplatin toward the gallbladder carcinoma cell line SGC996 versus single platinum drugs. This might be related to a reduction in GSH levels and the downregulation of multidrug resistance protein 1 (MRP1), a subfamily of the ABC transporters.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Emodin also sensitized T24 and J82 human bladder cancer cells to cisplatin by suppressing the expression of MRP1 and decreasing GSH–cisplatin conjugates.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Caffeic acid inhibits GSTs and glutathione reductase (GSR) and enhances the cytotoxicity of cisplatin toward ovarian carcinoma cell lines. Caffeic acid also increases the amount of platinum bound to nuclear DNA when co-treated with cisplatin.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> YPFS is an ancient Chinese herbal decoction composed of Astragali radix, Atractylodis Macrocephalae rhizoma, and Saposhnikoviae radix. It exhibits a synergistic enhancement of cytotoxicity with cisplatin in cisplatin-resistant NSCLC cells (A549/cisplatin). This enhancement is related to the notably reduced expression of multidrug resistance protein 2 (MRP2), which is also a subfamily of the ABC transporters.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Verapamil sensitized gallbladder cancer cell lines SGC996 and GBC-SD to cisplatin, carboplatin, or oxaliplatin via inhibition of the transport function of ABC transporter P-glycoprotein (MDR1) or stimulation of GSH transport by MRP1.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The copper chelator <span class="smallcaps smallerCapital">d</span>-penicillamine displayed synergistic cytotoxicity in the oxaliplatin-resistant cell line S3 generated from human cervical carcinoma SiHa cells when combined with oxaliplatin or cisplatin. Enhanced effects were also observed in the oxaliplatin-resistant S3 xenograft tumors co-treated with cisplatin and <span class="smallcaps smallerCapital">d</span>-penicillamine. <span class="smallcaps smallerCapital">d</span>-Penicillamine could promote the expression of CTR1 and suppress the expression of ATP7A via upregulation of stimulatory protein 1 (Sp1).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A synergistic cytotoxic effect of cisplatin and shMT/rPOA oligo-peptoplex was also observed in cisplatin-resistant cell lines derived from mouse melanoma cancer cell line B16F10 and the corresponding mouse cancer model. The oligo-peptoplex is formed by the short hairpin RNA targeting metallothionein and a reducible polymer poly(oligo-<span class="smallcaps smallerCapital">d</span>-arginine).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The combination regimen, underlying mechanism, and the most promising results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Platinum-Based Combinations to Attenuate Resistance Due to Decreased Accumulation of Reactive Platinum<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">regimen</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">cell type</th><th class="colsep0 rowsep0" align="center">cell-based results</th><th class="colsep0 rowsep0" align="center">model</th><th class="colsep0 rowsep0" align="center">animal-based results</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Emodin + cisplatin</td><td class="colsep0 rowsep0" align="left">Reduction in glutathione levels and downregulation of MRP1</td><td class="colsep0 rowsep0" align="left">SGC996</td><td class="colsep0 rowsep0" align="left">Percentage of inhibition: 70%* (cisplatin 2 μg/mL, 48 h); 75%* (cisplatin 2 μg/mL + emodin 50 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">SGC996</td><td class="colsep0 rowsep0" align="left">Weight of tumors: 0.3 mg* (cisplatin 1 mg/kg, 18 d); 0.1 mg* (cisplatin 1 mg/kg + emodin 50 mg/kg, 18 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caffeic acid + cisplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of GSTs and GSR</td><td class="colsep0 rowsep0" align="left">A2780cisR</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> values: 10 μM (cisplatin, 48 h); 3.5 μM (cisplatin + caffeic acid 100 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YPFS + cisplatin</td><td class="colsep0 rowsep0" align="left">Downregulation of MRP2</td><td class="colsep0 rowsep0" align="left">A549/DDP</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> values: 61.8 μM (cisplatin, 48 h); 12.8 μM (cisplatin + YPFS 1 mg/mL, 48 h)</td><td class="colsep0 rowsep0" align="left">A549/DDP</td><td class="colsep0 rowsep0" align="left">Inhibitory rate: 47.7% (cisplatin 3 mg/kg, 40 d); 77.9% (cisplatin 3 mg/kg + YPFS 4 g/kg, 40 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Verapamil + cisplatin/carboplatin/oxaliplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of the transport function of MDR1 or stimulation of GSH transport by MRP1</td><td class="colsep0 rowsep0" align="left">SGC996</td><td class="colsep0 rowsep0" align="left">Inhibition 60%* (cisplatin 2 μg/mL, 48 h); 80%* (cisplatin 2 μg/mL + verapamil 40 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">SGC996</td><td class="colsep0 rowsep0" align="left">Volume of tumors: 150 mm<sup>3</sup>* (cisplatin 2 mg/kg, 18 d); 80 mm<sup>3</sup>* (cisplatin 2 mg/kg + verapamil 20 mg/kg, 18 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Penicillamine + cisplatin/oxaliplatin</td><td class="colsep0 rowsep0" align="left">Upregulation of CTR1 and Sp1</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">S3</td><td class="colsep0 rowsep0" align="left">Volume of tumors: 350 mm<sup>3</sup>* (oxaliplatin 5 mg/kg, 3 wk); 100 mm<sup>3</sup>* (oxaliplatin 5 mg/kg + <span class="smallcaps smallerCapital">d</span>-penicillamine 50 mg/kg, 3 wk)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">shMT/rPOA oligopeptoplex + cisplatin</td><td class="colsep0 rowsep0" align="left">Downregulation of metallothionein</td><td class="colsep0 rowsep0" align="left">B16F10 (cisplatin-resistant)</td><td class="colsep0 rowsep0" align="left">45% decrease of cell viability compared to cisplatin alone (cisplatin 25 μg/mL, 24 h + shMT/rPOA oligo-peptoplexes 1 μg (weight ratio 1:2), 30 h)</td><td class="colsep0 rowsep0" align="left">B16F10 (cisplatin-resistant)</td><td class="colsep0 rowsep0" align="left">Volume of tumors: around 1365 mm<sup>3</sup> (cisplatin 3 mg/kg, 12 d); around 836 mm<sup>3</sup> (cisplatin 3 mg/kg + shMT/rPOA oligo-peptoplexes (shMT 3 μg/rPOA 6 μg), 12 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">*: Data were estimated based on the figures in the corresponding references. na: not available. ref: references.</p></div></div></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">6.2.  Combination of Platinum Drugs with Agents Targeting DNA Repair</h3><div class="NLM_p">Compounds that can enhance the platinum–DNA interaction or interfere with DNA repair are often used in combination with platinum drugs to alleviate resistance. Transplatin can induce small kinked loops in cellular DNA when co-treated with cisplatin. There were increased interstrand cross-links of DNA and enhanced cytotoxicity.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The 5-fluorouracil (5-FU) and AG337 are classical and nonclassical thymidylate synthase inhibitors, respectively. They enhance the anticancer activity of oxaliplatin in human colon, breast, and ovarian cancers by inhibiting DNA synthesis resulting from alternation of the pyrimidine pathway.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Caffeine exerted a synergistic anticancer effect with cisplatin in hepatocellular carcinoma cells by inhibiting DNA repair resulting from the decreased monoubiquitination of the FANCD2 protein.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Estrogen sensitizes prostate cancer cells LNCaP to cisplatin possibly by increasing the expression of HMG1 by methylation of estrogen receptor-α.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> PARP inhibitors have also been reported to enhance the anticancer activity of platinum drugs by influencing the repair of DNA damage. There was a strong synergy between the PARP inhibitor AZD2281 and cisplatin in BRCA2-deficient mammary tumor cells.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Moreover, in a genetically engineered mouse model of BRCA1-associated breast cancer, AZD2281 increased recurrence-free and overall survival when co-treated with cisplatin or carboplatin.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The PARP-1 inhibitor CEP-6800 increased the anticancer effects against Calu-6 non-small-cell lung carcinoma xenografts and cell lines when used in combination with cisplatin.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> JNK also plays an important role in the activation of the DNA repair mechanism after cisplatin treatment. The JNK inhibitor SP600125 enhanced the cytotoxicity of cisplatin in ovarian cancer cells versus cisplatin alone.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Downregulation of endoglin was reported to improve DNA damage repair due to the downregulation of silent information regulator type 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent class III histone deacetylase. This model improved platinum sensitivity both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The combination regimen, underlying mechanism, and most promising results are displayed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Platinum-Based Combinations Attenuate Resistance Due to DNA Repair<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">regimen</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">cell type</th><th class="colsep0 rowsep0" align="center">cell-based results</th><th class="colsep0 rowsep0" align="center">model</th><th class="colsep0 rowsep0" align="center">animal-based results</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Transplatin + cisplatin</td><td class="colsep0 rowsep0" align="left">Induce small kinked loops in cellular DNA</td><td class="colsep0 rowsep0" align="left">SW620</td><td class="colsep0 rowsep0" align="left">Percentage of survival cells vs control: 95%* (cisplatin 30 μM, 2 h); 45%* (cisplatin 30 μM, 2 h + transplatin 200 μM, 2 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-FU + oxaliplatin</td><td class="colsep0 rowsep0" align="left">Alteration of the pyrimidine pathway</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="left">Volume of tumors: 280 mm<sup>3</sup>* (oxaliplatin 10 mg/kg, 33 d); 180 mm<sup>3</sup>* (oxaliplatin 10 mg/kg + 5-FU 50 mg/kg, 33 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caffeine + cisplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of DNA repair by decreasing monoubiquitination of the FANCD2 protein</td><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> values: 3.8 μg/mL (cisplatin, 48 h); 2.8 μg/mL (cisplatin + caffeine 200 μg/mL, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Estrogen + cisplatin</td><td class="colsep0 rowsep0" align="left">Upregulation of HMG1</td><td class="colsep0 rowsep0" align="left">MCF-7</td><td class="colsep0 rowsep0" align="left">Percentage of survival cells vs control: 70%* (cisplatin 100 μM, 2 h); 50%* (cisplatin 100 μM + 17β-oestradiol (E2) 0.1 μM, 2 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD2281 + cisplatin/carboplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of PARP</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">K14cre; Brca1<sup>F/F</sup>; p53<sup>F/F</sup></td><td class="colsep0 rowsep0" align="left">Relapse time: 40 d* (cisplatin 6 mg/kg); 150 d* (cisplatin 6 mg/kg, 1 d + AZD2281 50 mg/kg, 100 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a>, <a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CEP-6800 + cisplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of PARP-1</td><td class="colsep0 rowsep0" align="left">normal human renal cells</td><td class="colsep0 rowsep0" align="left">No increased toxicity compared with cisplatin alone (cisplatin + CEP-6800 1 μM, 72 h)</td><td class="colsep0 rowsep0" align="left">Calu-6</td><td class="colsep0 rowsep0" align="left">Reduction of tumor volume: 76% (cisplatin 5 mg/kg, 28 d); 84.4% (cisplatin 5 mg/kg + CEP-6800 30 mg/kg, 28 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SP600125 + cisplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of JNK which can promote DNA repair</td><td class="colsep0 rowsep0" align="left">A2780CP</td><td class="colsep0 rowsep0" align="left">Numbers of cells (×10<sup>4</sup>): 180* (cisplatin 50 μM, 3 d); 5* (cisplatin 50 μM + SP600125 20 μM, 3 d)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">*: Data were estimated based on the figures in the corresponding references. na: not available. ref: references.</p></div></div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">6.3.  Combination of Platinum Drugs with Agents Targeting Defects in Apoptotic Pathway Induced by DNA Damage</h3><div class="NLM_p">Apoptosis-enhancing agents can reduce platinum-induced resistance resulting from defects in the apoptotic pathway induced by DNA damage. Checkpoint kinase 1 (Chk1) inhibitor SCH900776 (MK-8776) effectively potentiated the cytotoxic effects of cisplatin in human colon HCT116 cancer cells. Significant increases in apoptosis were observed in the combined treatment, which is affected by the p21, p53, and phosphatase and tensin homolog (PTEN) status.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Paris saponin I (PSI) is a cytotoxic agent that causes cancer cell apoptosis via increased expression of Bax and cytochrome <i>c</i>. PSI also activates caspase and decreases expression of Bcl-2 and activity of specific kinase-1/2. PSI sensitized gastric cancer cell lines to cisplatin with increased apoptosis.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> 1,25-Dihydroxyvitamin D3 enhanced cisplatin-induced apoptosis in BGC-823 human gastric cancer cells involving the upregulation of Bax and the decrease of ERK and AKT phosphorylation levels; there was an increase in the expression of p21 and p27.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Emetine is a natural alkaloid and sensitized ovarian carcinoma cells to cisplatin. Enhanced apoptosis related with the activation of caspases 3, 7, and 8 and downregulation of B-cell lymphoma-extra large (Bcl-xL) accounted for the synergistic effect.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Birinapant also promoted apoptosis in CA125-negative high-grade serious ovarian cancer cells when treated in combination with cisplatin. Improved disease-free survival <i>in vivo</i> was also observed in the corresponding tumor-bearing mice during the co-treatment.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Baicalein is a bioactive flavonoid component in <i>Scutellaria baicalensis</i> and is a traditional Chinese medicine. Baicalein enhanced the cytotoxicity of cisplatin on human A549 lung cancer cells with increased apoptosis due to upregulated expression of Bax and caspase-3 and decreased expression of Bcl-2.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Mucin 1 (MUC1) is a transmembrane glycoprotein overexpressed in most breast cancers; it plays an important role in antiapoptosis. A monoclonal antibody against MUC1 displayed synergistic cytotoxicity on breast cancer MCF-7 cells with a novel berenil complex of platinum(II) (Pt12); this is related to enhanced apoptosis.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The resveratrol dimer ε-viniferin is well-known for the apoptotic effects toward cancer cells. ε-Viniferin increased the sensitivity of cisplatin on C6 cells resulting from enhanced apoptosis related to activation of caspase-3, -8, and -9.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Curcumin is a natural compound isolated from <i>Curcuma longa</i>. It sensitized NSCLC cells to carboplatin with increased apoptosis, which is mediated by the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB). There was inhibition of the Akt/IKKα pathway and activation of ERK1/2 with subsequent activation of caspases and p53.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> ABT-737 is a BH3 mimetic reported to displace Bcl-xL from mitochondria and induce oligomerization of BAK (Bcl-2 homologous antagonist/killer). It also displayed strong synergistic cytotoxicity with cisplatin toward NSCLC cells. Significant tumor regression was also observed in a murine lung cancer model co-treated with ABT-737 and cisplatin. This synergistic effect might be related to the signal transducer and activation of transcription 3 (STAT3).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The combination regimen, underlying mechanism, and the most promising results are given in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Platinum-Based Combination Therapy Attenuates Resistance Due to Cell Death Pathways Following DNA Damage<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">regimen</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">cell type</th><th class="colsep0 rowsep0" align="center">cell-based results</th><th class="colsep0 rowsep0" align="center">model</th><th class="colsep0 rowsep0" align="center">animal-based results</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SCH900776 + cisplatin</td><td class="colsep0 rowsep0" align="left">Related to status of p21, p53, and PTEN</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSI + cisplatin</td><td class="colsep0 rowsep0" align="left">Upregulation of Bax and cytochrome <i>c</i></td><td class="colsep0 rowsep0" align="left">SGC-7901</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> values: 30.4 μM (cisplatin, 48 h); 20.3 μM (cisplatin + PSI 0.3 μg/mL, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1,25-dihydroxyvitamin D3 + cisplatin</td><td class="colsep0 rowsep0" align="left">Upregulation of Bax and downregulation of ERK and AKT phosphorylation levels</td><td class="colsep0 rowsep0" align="left">BGC-823</td><td class="colsep0 rowsep0" align="left">Fluorescence intensity of the DNA fragments: 14.17 (cisplatin 0.2 μg/mL, 2 h + medium, 70 h); 23.07 (cisplatin 0.2 μg/mL, 2 h + 1,25(OH)<sub>2</sub>D<sub>3</sub> 10 nM, 70 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Emetine + cisplatin</td><td class="colsep0 rowsep0" align="left">Activation of caspases-3, -7, and -8 and downregulation of Bcl-xL</td><td class="colsep0 rowsep0" align="left">SKOV3</td><td class="colsep0 rowsep0" align="left">Colony number: 58% (cisplatin 20 μM, 48 h); 17% (cisplatin 20 μM + emetine 2.5 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Baicalein + cisplatin</td><td class="colsep0 rowsep0" align="left">Upregulation of Bax and caspase-3 and downregulation of Bcl-2</td><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">Viability: no significant difference between the cisplatin and baicalein–cisplatin combination groups</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ε-Viniferin + cisplatin</td><td class="colsep0 rowsep0" align="left">Activation of caspase-3, -8, and -9</td><td class="colsep0 rowsep0" align="left">C6</td><td class="colsep0 rowsep0" align="left">Cell proliferation percentage: 71% (cisplatin 35 μM, 48 h); 22%* (cisplatin 16.25 μM + ε-viniferin 127.5 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Curcumin + carboplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of the Akt/IKKα pathway, and activation of ERK1/2</td><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">Percentage of cell viability: 87%* (carboplatin 100 μM, 24 h); 73%* (carboplatin 100 μM + curcumin (10 μM, 24 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABT-737 + cisplatin</td><td class="colsep0 rowsep0" align="left">Related to STAT3 activation</td><td class="colsep0 rowsep0" align="left">H460</td><td class="colsep0 rowsep0" align="left">Percentage of cell death: 7.6% (cisplatin 1 μM, 48 h); 21.4% (cisplatin 1 μM + ABT-737 1 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">AdCre</td><td class="colsep0 rowsep0" align="left">Percentage of tumor volume decreased: 14.9% (cisplatin 5 mg/kg, 2 wks); 79.9% (cisplatin 5 mg/kg + ABT-737 50 mg/kg, 2 wks)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">*: Data were estimated based on the figures in the corresponding references. na: not available. ref: references.</p></div></div></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">6.4.  Combination of Platinum Drugs with Agents Targeting Cell Survival Pathway Not Activated by DNA Damage</h3><div class="NLM_p">Upregulation of HSPs (heat shock proteins) is associated with cisplatin resistance. The HSP70 (heat shock protein 70) inhibitor pifithrin-μ displayed strong synergistic effects with oxaliplatin in HT29 colorectal cancer cells.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> AUY922 is a HSP90 (heat shock protein 90) inhibitor that sensitizes the p53 mutant head and neck cell lines to concurrent cisplatin radiotherapy via modulation of the DNA damage response. This results in chromosomal fragmentation.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> A combination treatment with oxaliplatin and the COX-2 inhibitor etodolac increased the growth inhibition and death of human colon cancer cells. This observation might be ascribed to the inhibition of survivin protein.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The proteasomal inhibitor MG132 prevented ubiquitylation-mediated polymerase II degradation triggered by cisplatin in HeLa cells.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The histone deacetalyse (HDAC) inhibitor, panobinostat, reduces hypoxia-induced cisplatin resistance in NSCLC with increased apoptosis. Destabilization and degradation of hypoxia-inducible factor-1α (HIF-1α) and HDAC4 (responsible for acetylation and de/stabilization of HIF-1α) were also observed in the co-treatment.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Another HDAC inhibitor, vorinostat, enhanced the cytotoxicity of cisplatin toward Calu6 and H23 parental non-small-cell lung carcinoma cell lines and their resistant sublines dependent on an increase in transcription factor 3 (ATF3) expression.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Methylseleninic acid sensitized neurogenic locus notch homolog 3 (Notch3)-activated OVCA429 ovarian cancer cells to carboplatin, which is associated with a cell cycle arrest at the G2/M phase and the induction of Notch3 intracellular domain 3 (NICD3) target gene hairy and enhancer of split homolog-1 (HES1).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Lysosomes targeting chloroquine have also been reported as cisplatin sensitizers in refractory NSCLC cells via lysosome membrane permeabilization or autophagy suppression.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> RNAi-mediated silencing of MK2 sensitized high-grade serous ovarian tumors to concurrent platinum/taxane chemotherapy in vivo with an improved overall survival of 37%.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The relative combination regimen, mechanism, and the most promising results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Platinum-Based Combination Therapy Attenuates Resistance Independent of Cell Death Pathways Attributed to DNA Damage<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">regimen</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">cell type</th><th class="colsep0 rowsep0" align="center">cell-based results</th><th class="colsep0 rowsep0" align="center">model</th><th class="colsep0 rowsep0" align="center">animal-based results</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pifithrin-μ + oxaliplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of HSP70</td><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="left">Strong synergism: oxaliplatin 10 μM + pifithrin-μ 10 μM</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUY922 + cisplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of HSP90</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">FaDu</td><td class="colsep0 rowsep0" align="left">Percentage increase over basal volume: 720%* (cisplatin 5 mg/kg, 19 d); 600%* (cisplatin 5 mg/kg + AUY922 40 mg/kg, 19 d)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Etodolac + oxaliplatin</td><td class="colsep0 rowsep0" align="left">Inhibition of survivin protein</td><td class="colsep0 rowsep0" align="left">RKO</td><td class="colsep0 rowsep0" align="left">Percentage of cells survived: 80%* (oxaliplatin 1 μM, 24 h); 20%* (oxaliplatin 1 μM + etodolac 0.5 mM, 24 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Panobinostat + cisplatin</td><td class="colsep0 rowsep0" align="left">Degradation of hypoxia-inducible factor HIF-1α and HDAC4</td><td class="colsep0 rowsep0" align="left">A549 (hypoxia)</td><td class="colsep0 rowsep0" align="left">Percentage of cells survived: 60%* (cisplatin 16 μM, 48 h); 20%* (cisplatin 16 μM + panobinostat 16 nM, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vorinostat + cisplatin</td><td class="colsep0 rowsep0" align="left">Increase in ATF3 expression</td><td class="colsep0 rowsep0" align="left">Calu6cisR1</td><td class="colsep0 rowsep0" align="left">Percentage of cells survived: 70%* (cisplatin 1 μg/mL, 48 h); 22%* (cisplatin 1 μg/mL, 48 h + vorinostat 5 μM, 72 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Methylseleninic acid + carboplatin</td><td class="colsep0 rowsep0" align="left">Induction of NICD3 target gene HES1</td><td class="colsep0 rowsep0" align="left">OVCA429/NICD3</td><td class="colsep0 rowsep0" align="left">Percentage of cells survived: 91.7% (carboplatin 25 μM, 48 h); 36.2% (carboplatin 25 μM + methylseleninic acid 2 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Chloroquine + cisplatin</td><td class="colsep0 rowsep0" align="left">Lysosome membrane permeabilization or autophagy suppression</td><td class="colsep0 rowsep0" align="left">A549cisR</td><td class="colsep0 rowsep0" align="left">Percentage of cells survived: 65%* (cisplatin 100 μM, 48 h); 25%* (cisplatin 100 μM + chloroquine 100 μM, 48 h)</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">*: Data were estimated based on the figures in the corresponding references. na: not available. ref: references.</p></div></div></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">6.5.  Combination of Platinum Drugs with Checkpoint Inhibitors</h3><div class="NLM_p last">Platinum drugs can modulate the immune system, and the combination of platinum-based therapy with immunotherapy is emerging as a novel and promising anticancer strategy.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Combinations involving checkpoint inhibition have displayed remarkable success.<a onclick="showRef(event, 'ref17 ref77'); return false;" href="javascript:void(0);" class="ref ref17 ref77">(17,77)</a> Immune checkpoint molecules like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-L1 are cell-surface receptors on T cells that induce a cascade of signaling events that restrain T-cell proliferation and killing capacity. As a result, checkpoint blockade can enhance the killing capacity of T cells, which makes the combination of immune checkpoint inhibitors with platinum drugs rational.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Strong synergistic activity of platinum drugs with checkpoint inhibition has been observed in mouse models.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> For instance, in two versatile mouse epithelial ovarian cancer (EOC) models, cisplatin modulated the immune environment partly via the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway. STING is a DNA sensing pathway, and the combination of cisplatin and PD-1/PD-L1 blockade increased survival in mice with aggressive tumors that were moderately cisplatin-resistant.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The combination of cisplatin with a CTLA-4-blocking antibody displayed promising antitumor effects in a murine AB-12 mesothelioma model by improving infiltration of cytotoxic T cells.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> The combination of oxaliplatin with MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody, also showed strong anticancer effects in a mouse syngeneic model of CT26 colorectal cancer.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> A delivery strategy has also been recently applied in this combination therapy. Delivery of PD-L1 inhibitors locally using a PD-L1 trap in the form of the respective plasmid DNA via lipid-protamine-DNA nanoparticles exhibited strong synergism with oxaliplatin in orthotopic murine colon, breast cancer, and melanoma models.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">6.6.  Platinum-Based Combination Therapy To Reduce Toxicity</h3><div class="NLM_p last">Preventative agents like antioxidants, modulators of nitric oxide, diuretics, cytoprotective, and antiapoptotic agents have been used together with cisplatin to ameliorate or prevent cisplatin nephrotoxicity.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Antioxidants, including aminoguanidine and vitamins C–E, have been reported to be protective against cisplatin-induced nephrotoxicity.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> An exogenous atrial natriuretic peptide was also reported to prevent cisplatin-induced nephrotoxicity.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Antioxidants like <span class="smallcaps smallerCapital">d</span>-methionine can decrease cisplatin-induced ototoxicity.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The dietary carotenoid lutein was reported to protect against DNA damage and alter the redox status induced by cisplatin in a human derived liver cell line HepG2, which indicates its potential for chemoprevention.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Melatonin is a pineal secretory product with antioxidant properties; it can protect against cisplatin-induced nephrotoxicity in rats.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Moreover, genetic disruption of the Abl nuclear import reduced renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Antioxidant erdosteine [<i>N</i>-(carboxymethythioacetyl)homocysteine thiolactone] was also reported to partially protect the cochlea against cisplatin toxicity <i>in vivo</i>.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Melanocortins, like the adrenocorticotropic hormone (ACTH)-analogue ORG 2766 and α-melanocyte stimulating hormone (α-MSH), can delay cisplatin-induced ototoxicity.<a onclick="showRef(event, 'ref91 ref92 ref93 ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref91 ref92 ref93 ref94 ref95">(91−95)</a> The hearing loss caused by local cisplatin administration in guinea pigs was delayed by co-treatment with α-MSH.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Peroxynitrite decomposition catalysts (PNDCs) can potentially mitigate nitrative stress-induced otopathology.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Cisplatin-induced nitrative stress was attenuated by co-treatment with the SRI110 PNDC. Co-treatment with SRI110 also mitigated cisplatin-induced hearing loss in a CBA/J mouse model.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Apelin-13 is a bioactive peptide that can scavenge free radicals. Apelin-13 attenuates cisplatin-induced cardiotoxicity by inhibiting ROS-mediated DNA damage and regulation of the MAPKs and AKT pathways. Inhibited myocardial cells undergo apoptosis and have improved angiogenesis in mice hearts when co-treated with apelin-13 and cisplatin.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">6.7.  Platinum(IV) Prodrugs Containing Bioactive Axial Ligands as Indirect Platinum-Based Combinations</h3><div class="NLM_p">Platinum(IV) complexes act as prodrugs of platinum drugs which are platinum(II) complexes. They have been intensively studied to overcome the shortcomings of platinum drugs. Platinum(IV) complexes are octahedral complexes retaining the square-planar platinum(II) coordination sphere in the equatorial position and containing two axial ligands.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> They are converted into platinum drugs by losing two axial ligands under certain intracellular conditions like reducing environments.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Those platinum(IV) prodrugs containing bioactive axial ligands indirectly provide combination compositions comprising platinum drugs and bioactive molecules by releasing the active species inside cells. These platinum(IV) prodrugs have been reviewed comprehensively recently.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> Here, we briefly describe these prodrugs by dividing them into three categories based on the underlying synergistic anticancer mechanism: complexes overcoming resistance; complexes targeting the tumor microenvironment; and complexes reducing toxicities. The structures of representative complexes are shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of platinum(IV) complexes overcoming resistance of platinum drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of platinum(IV) complexes targeting tumor microenvironment or reducing toxicities of platinum drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">According to the previously introduced resistance mechanism, the following types of platinum(IV) prodrugs are preferably applied to overcome resistance of platinum drugs: platinum(IV) complexes containing ligands such as GSTs inhibitors ethacryinic acids (<b>1</b>)<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> and 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (<b>2</b>)<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> to target decreased accumulation of reactive platinum; platinum(IV) complexes containing ligands like DNA cross-linking agent chlorambucil (<b>3</b>)<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> and NER inhibitor (<i>E</i>)-2-([{8a,9a-dihydro-9<i>H</i>-fluoren-9-ylidene}hydrazono]methyl)benzoic acid (<b>4</b>)<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> to target DNA repair; platinum(IV) complexes containing ligands targeting defects in apoptotic pathway induced by DNA damage such as α-tocopherol succinate (<b>5</b>)<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> that inhibits antiapoptotic proteins Bcl-xL and Bcl-2; and platinum(IV) complexes targeting the cell survival pathways not activated by DNA damage such as HDAC inhibitor valproic acid <b>(6</b>)<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> and COX<b>s</b> inhibitor aspirin (<b>7</b>)<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106,107)</a> and indomethacin (<b>8</b>).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> A recently reported platinum(IV) complex containing 3-chlorobenzo[<i>b</i>]thiophene-2-carboxylic acid (<b>9</b>) displayed multifunctional anticancer activity. It promoted apoptosis and inhibited DNA damage repair simultaneouly by targeting myeloid cell leukemia (Mcl-1) and displayed promising anticancer effect <i>in vivo</i>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><div class="NLM_p">To target the tumor microenvironment, immune checkpoint inhibitors like IDO (indoleamine-2,3-dioxygenase) inhibitor (<span class="smallcaps smallerCapital">d</span>)-1-methyltryptophan (<b>10</b>)<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> are introduced to the platinum(IV) center to achieve a combination of platinum drugs with checkpoint inhibitors.</div><div class="NLM_p last">Moreover, tumor-targeted moieties like biotin (<b>11</b>)<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> and human serum albumin (<b>12</b>)<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> are applied to the platinum(IV) system to reduce the sides effects of platinum drugs.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">7.  Platinum-Based Combination Therapy in the Clinic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this section, drugs that are currently applied in the clinic together with platinum drugs will be described, and the clinical application of the combination regimens will also be introduced.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">7.1.  Drugs Used Clinically in Combination with Platinum Drugs</h3><div class="NLM_p">Platinum-based combination therapy is the most applied strategy to overcome the resistant and toxic problems of platinum drugs in clinical settings. According to the U.S. Food & Drug administration, clinical information on platinum-based combinations can only be collected back to 2006 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, the data were collected from <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a>). The drugs administrated clinically with platinum drugs can be divided into the following types based on the underlying mechanism: checkpoint inhibitors including anti-PD-L1 immune checkpoint antibody, atezolizumab, and anti-PD-1 immune checkpoint antibody, pembrolizumab; apoptosis enhancers like paclitaxel, which induces mitotic arrest, and microtubule associate inhibitor, docetaxel; agents enhancing DNA damage such as topoisomerase inhibitors, etoposide and topotecan, hydrochloride, nucleotide analogue gemcitabine, and DNA/RNA synthesis inhibitor fluoropyrimidine; drugs including anti-HER2 antibody, trastuzumab, and anti-EGFR antibody, necitumumab, which inhibit the survival pathways independent of DNA-damage; and other agents including the antivascular endothelial growth factor (VEGF) antibody, bevacizumab with antiangiogenic properties, and growth factor receptor-tyrosine kinase inhibitor pemetrexed.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Platinum-Based Combination Therapy Approved for Clinical Applications Since 2006</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">regimen</th><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">approved year</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Atezolizumab + paclitaxel protein-bound + carboplatin</td><td class="colsep0 rowsep0" align="left">Metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations</td><td class="colsep0 rowsep0" align="left">2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Atezolizumab + carboplatin + etoposide</td><td class="colsep0 rowsep0" align="left">Extensive-stage small cell lung cancer</td><td class="colsep0 rowsep0" align="left">2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Atezolizumab + bevacizumab + paclitaxel + carboplatin</td><td class="colsep0 rowsep0" align="left">Metastatic nonsquamous, NSCLC with no EGFR or ALK genomic tumor aberrations</td><td class="colsep0 rowsep0" align="left">2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel</td><td class="colsep0 rowsep0" align="left">Metastatic squamous NSCLC</td><td class="colsep0 rowsep0" align="left">2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pembrolizumab + pemetrexed + cisplatin/carboplatin</td><td class="colsep0 rowsep0" align="left">Metastatic, nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations</td><td class="colsep0 rowsep0" align="left">2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pembrolizumab + pemetrexed + carboplatin</td><td class="colsep0 rowsep0" align="left">Untreated metastatic nonsquamous NSCLC</td><td class="colsep0 rowsep0" align="left">2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Necitumumab + gemcitabine + cisplatin</td><td class="colsep0 rowsep0" align="left">Metastatic squamous NSCLC</td><td class="colsep0 rowsep0" align="left">2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bevacizumab + fluoropyrimidine + irinotecan/oxaliplatin</td><td class="colsep0 rowsep0" align="left">Metastatic colorectal cancer</td><td class="colsep0 rowsep0" align="left">2013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Paclitaxel protein-bound particles + carboplatin</td><td class="colsep0 rowsep0" align="left">Locally advanced or metastatic NSCLC</td><td class="colsep0 rowsep0" align="left">2012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Trastuzumab + cisplatin + fluoropyrimidine/capecitabine/5-fluorouracil</td><td class="colsep0 rowsep0" align="left">HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma</td><td class="colsep0 rowsep0" align="left">2010</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Docetaxel + cisplatin + fluorouracil</td><td class="colsep0 rowsep0" align="left">Inoperable, locally advanced squamous cell carcinoma of the head and neck</td><td class="colsep0 rowsep0" align="left">2006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bevacizumab + carboplatin + paclitaxel</td><td class="colsep0 rowsep0" align="left">Unresectable, locally advanced, recurrent, or metastatic, nonsquamous, NSCLC</td><td class="colsep0 rowsep0" align="left">2006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gemcitabine + carboplatin</td><td class="colsep0 rowsep0" align="left">Advanced ovarian cancer</td><td class="colsep0 rowsep0" align="left">2006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Topotecan hydrochloride + cisplatin</td><td class="colsep0 rowsep0" align="left">Stage IVB recurrent or persistent carcinoma of the cervix</td><td class="colsep0 rowsep0" align="left">2006</td></tr></tbody></table></div></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">7.2.  Platinum-Based Combinations in the Clinic</h3><div class="NLM_p">Of the 14 regimens approved by FDA for cancers treatment since 2006 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), six were approved in the past 3 years. This suggests promising progress of platinum-based combination therapy. In 2019, FDA approved the carboplatin, atezolizumab, and paclitaxel protein-bound regimen and the carboplatin, atezolizumab, and etoposide regimen to treat metastatic nonsquamous NSCLC and extensive-stage small cell lung cancer (ES-SCLC), respectively. The carboplatin, atezolizumab, bevacizumab, and paclitaxel regimen as well as the pembrolizumab, pemetrexed and either cisplatin or carboplatin regimen were approved by FDA to treat metastatic nonsquamous NSCLC in 2018. The carboplatin, pembrolizumab, and either paclitaxel or nab-paclitaxel regimen were also approved to treat metastatic squamous NSCLC in 2018. The carboplatin, pembrolizumab, and pemetrexed regimen was approved to treat metastatic NSCLC in 2017. Moreover, the cisplatin, necitumumab, and gemcitabine regimen; the carboplatin and paclitaxel protein-bound particles regimen; and the carboplatin, bevacizumab, and paclitaxel regimen are currently used in the clinic to treat NSCLC. The oxaliplatin, bevacizumab, and fluoropyrimidine regimen is used to treat metastatic colorectal cancer. The cisplatin, trastuzumab, and fluoropyrimidine (capecitabine or 5-fluorouracil) regimen is used to treat metastatic gastric or gastroesophageal junction adenocarcinoma. The cisplatin, docetaxel, and fuorouracil regimen is used to treat squamous cell carcinoma of the head and neck. Carboplatin, in combination with gemcitabine, is approved to treat advanced ovarian cancer, while cisplatin, in combination with topotecan hydrochloride, is applied to treat carcinoma of the cervix.</div><div class="NLM_p">Encouraged by clinical success, thousands of platinum-based combination regimens are being tested in clinical trials. One popular combination is platinum drugs with checkpoint inhibitors, which is also known as chemoimmunotherapy, and is gaining intense attention, as demonstrated by the increased number of relevant clinical trials initiated over past 10 years (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>)</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Number of clinical trials investigating platinum-based combinations containing checkpoint inhibitors started over the past 10 years (the data were collected from <a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a> on May 3, 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">8.  Conclusion and Future Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61322" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61322" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Platinum-based combination therapy has been one of the most promising strategies to overcome drug resistance and side toxicities ascribed to platinum drugs. The addition of modern immunotherapy to platinum-based chemotherapy is of particular interest. The combination of platinum drugs with drugs targeting cancer stem cells might be a promising future direction because the presence of cancer stem cells is generally considered to be a contributing factor of resistance following chemotherapeutic treatment.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Targeting the cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1) can significantly resensitize cisplatin resistant lung cancer cells to cisplatin.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Platinum-based drugs comprise almost 50% of clinical anticancer regimens as a single agent or combined with other anticancer drugs.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115,116)</a> Regardless of the achievements of platinum-based combination therapy in clinical settings, overall therapeutic outcomes are compromised by pharmacokinetics, metabolism, and side effects.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Transferring the combination regimens to a proper drug delivery system may deliver benefits. Encapsulation of the combined drugs into nanocarriers is useful because the nanoparticles can selectively accumulate at tumor sites versus normal tissues via the enhanced permeation and retention effect.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Carriers can also protect the drug payload against premature degradation and blood clearance to reduce side effects. Very recently, nanoformulations called OLICARB have been prepared by encapsulation of carboplatin and PARP inhibitor olaparib into liposomal constructs. OLICARB can impart the combination hypersensitivity and selectivity for breast tumor cells.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> A 2015 review summarized advances in drug delivery systems for platinum-based combination therapies.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> However, searching for proper methods to translate these combinations to an appropriate drug delivery system remains challenging. The development of novel multitargeting platinum complexes might be a promising alternative strategy for future research on platinum-based anticancer drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00950" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yungen Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span>; 
    <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Drug Design and Optimization, Department of Medicinal
Chemistry, China Pharmaceutical University, Nanjing 210009, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6586-8482" title="Orcid link">http://orcid.org/0000-0001-6586-8482</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#265e5f416645565308434253084548"><span class="__cf_email__" data-cfemail="a8d0d1cfe8cbd8dd86cdccdd86cbc6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing-Jing Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span>; 
    <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Drug Design and Optimization, Department of Medicinal
Chemistry, China Pharmaceutical University, Nanjing 210009, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6251-2066" title="Orcid link">http://orcid.org/0000-0002-6251-2066</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cca6a6b6a4ada2aba2a68cfdfaffe2afa3a1"><span class="__cf_email__" data-cfemail="3d575747555c535a53577d0c0b0e135e5250">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunqiu Yu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhibin Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zeren Sun</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wanwan Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.Y. and Z.W. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chunqiu Yu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2485-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Chunqiu Yu</b> received her Bachelor’s degree in Medicinal Chemistry from China Pharmaceutical University in 2018 and is currently pursuing a Master’s degree under the supervision of associate researcher Jing-Jing Zhang at the same university. She is working on the design, synthesis, and mechanism study of small molecules with multiple anticancer activities.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Zhibin Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2490-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhibin Wang</b> obtained his Bachelor’s degree in Pharmaceutical Engineering in 2016 and Master’s degree in Medicinal Chemistry (with Prof. Yungen Xu) in 2019 from China Pharmaceutical University. His research interests include design and synthesis of antitumor drugs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Zeren Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2495-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zeren Sun</b> received his Bachelor’s degree in Pharmacy from Fujian Medical University in 2019 and is currently pursuing a Master’s degree under the supervision of associate researcher Jing-Jing Zhang at China Pharmaceutical University. He is working on the design, synthesis, and biological evaluation of small molecular inhibitors with potential anticancer activities.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Lei Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2500-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lei Zhang</b> received his Bachelor’s degree in Pharmacy from Guilin Medical University in 2019 and is currently pursuing a Master’s degree under the supervision of associate researcher Jing-Jing Zhang at China Pharmaceutical University. He is working on the design, synthesis, and biological evaluation of small molecules with multiple biological activities.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Wanwan Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2505-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wanwan Zhang</b> obtained her Bachelor’s degree in Pharmaceutical Engineering from Shenyang Pharmaceutical University in 2017. She is currently studying at China Pharmaceutical University for a Master’s degree in Medicinal chemistry under the supervision of associate researcher Jing-Jing Zhang. Her study focuses on the design, synthesis, and biological evaluation of novel small molecules with multiple targets.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Yungen Xu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2510-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yungen Xu</b> received his Ph.D. degree in 2000 from China Pharmaceutical University and worked at Chempacific Corporation (USA) as a Visiting Scholar from 2004 to 2006. He is currently a full professor and serves as the Director of the Department of Medicinal Chemistry at China Pharmaceutical University. His research interests mainly include anticancer drugs, anti-inflammatory drugs, analgesics, and immunotherapy drugs. He is also devoted to the development of new and more efficient synthetic processes of marketed drugs. He owns over 60 invention patents, and his research programs have successfully led to the discovery of three candidate drugs.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Jing-Jing Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=BIO-d7e2515-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jing-Jing Zhang</b>, Ph.D., is currently an associate researcher in China Pharmaceutical University. She received her Bachelor’s degree in Chemistry and Master’s degree in Organic Chemistry from Nanjing University in 2006 and 2009, respectively. Thereafter, she got her Ph.D. degree in Chemical Biology from the University of Hong Kong in 2014. From 2014 to 2016, she worked at Technische Universität Braunschweig and Universität Heidelberg and was sponsored by Alexander von Humboldt Research Fellowship. Her research interests include design and synthesis of novel compounds with multiple anticancer activities and study of the underlying mechanism.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65737" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65737" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work is financially supported by the Natural Science Foundation of Jiangsu Province (Grant BK20170728). We acknowledge Dr. Raymond Wai-Yin Sun and Dr. Mohamed A. Abu el Maaty for proofreading the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">SCLC</td><td class="NLM_def"><p class="first last">small cell lung cancer</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">CTR1</td><td class="NLM_def"><p class="first last">copper transporter 1</p></td></tr><tr><td class="NLM_term">ATPase</td><td class="NLM_def"><p class="first last">adenosine triphosphatase</p></td></tr><tr><td class="NLM_term">VRAC</td><td class="NLM_def"><p class="first last">volume-regulated anion channel</p></td></tr><tr><td class="NLM_term">HMG1</td><td class="NLM_def"><p class="first last">high-mobility group proteins 1</p></td></tr><tr><td class="NLM_term">HMG2</td><td class="NLM_def"><p class="first last">high-mobility group proteins 2</p></td></tr><tr><td class="NLM_term">MMR</td><td class="NLM_def"><p class="first last">mismatch repair protein</p></td></tr><tr><td class="NLM_term">Bcl-2</td><td class="NLM_def"><p class="first last">B cell lymphoma-2</p></td></tr><tr><td class="NLM_term">Bax</td><td class="NLM_def"><p class="first last">Bcl-2-associated X protein</p></td></tr><tr><td class="NLM_term">c-ABL</td><td class="NLM_def"><p class="first last">v-abl Abelson murine leukemia viral oncogene homolog 1</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular regulated protein kinases</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">DAMP</td><td class="NLM_def"><p class="first last">damage-associated molecular pattern</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">HMGB1</td><td class="NLM_def"><p class="first last">high-mobility group box 1</p></td></tr><tr><td class="NLM_term">DC</td><td class="NLM_def"><p class="first last">dendritic cell</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed death-ligand 1</p></td></tr><tr><td class="NLM_term">PD-L2</td><td class="NLM_def"><p class="first last">programmed death-ligand 2</p></td></tr><tr><td class="NLM_term">ATP7A/ATP7B</td><td class="NLM_def"><p class="first last">copper-extruding P-type ATPase</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">GSTs</td><td class="NLM_def"><p class="first last">glutathione-<i>S</i>-transferase</p></td></tr><tr><td class="NLM_term">MRP</td><td class="NLM_def"><p class="first last">multidrug resistance protein</p></td></tr><tr><td class="NLM_term">NER</td><td class="NLM_def"><p class="first last">nucleotide excision repair protein</p></td></tr><tr><td class="NLM_term">ERCC1</td><td class="NLM_def"><p class="first last">excision-repair cross-complementation group 1</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">Poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">RAD51</td><td class="NLM_def"><p class="first last">DNA double-strand-break repair protein</p></td></tr><tr><td class="NLM_term">FA</td><td class="NLM_def"><p class="first last">Fanconi anemia</p></td></tr><tr><td class="NLM_term">FANCD2</td><td class="NLM_def"><p class="first last">Fanconi anemia complementation group D2</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">v-akt murine thymoma viral oncogene homolog</p></td></tr><tr><td class="NLM_term">HER-2</td><td class="NLM_def"><p class="first last">HER2/neu oncogene</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">COX-2</td><td class="NLM_def"><p class="first last">prostaglandin-endoperoxide synthase 2</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">DACH</td><td class="NLM_def"><p class="first last">diaminocyclohexane</p></td></tr><tr><td class="NLM_term">YPFS</td><td class="NLM_def"><p class="first last">Yu Ping Feng San</p></td></tr><tr><td class="NLM_term">MRP1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1</p></td></tr><tr><td class="NLM_term">GSR</td><td class="NLM_def"><p class="first last">glutathione reductase</p></td></tr><tr><td class="NLM_term">MRP2</td><td class="NLM_def"><p class="first last">multidrug resistance protein 2</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">ABC transporter P-glycoprotein</p></td></tr><tr><td class="NLM_term">Sp1</td><td class="NLM_def"><p class="first last">stimulatory protein 1</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">5-FU</td><td class="NLM_def"><p class="first last">5-fluorouracil</p></td></tr><tr><td class="NLM_term">SIRT1</td><td class="NLM_def"><p class="first last">silent information regulator type 1</p></td></tr><tr><td class="NLM_term">Chk1</td><td class="NLM_def"><p class="first last">checkpoint kinase 1</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homolog</p></td></tr><tr><td class="NLM_term">PSI</td><td class="NLM_def"><p class="first last">Paris saponin I</p></td></tr><tr><td class="NLM_term">Bcl-xL</td><td class="NLM_def"><p class="first last">B-cell lymphoma-extra large</p></td></tr><tr><td class="NLM_term">MUC1</td><td class="NLM_def"><p class="first last">mucin 1</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κ-light-chain-enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">BAK</td><td class="NLM_def"><p class="first last">Bcl-2 homologous antagonist/killer</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activation of transcription 3</p></td></tr><tr><td class="NLM_term">HSP</td><td class="NLM_def"><p class="first last">heat shock protein</p></td></tr><tr><td class="NLM_term">HSP70</td><td class="NLM_def"><p class="first last">heat shock protein 70</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetalyse</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor-1α</p></td></tr><tr><td class="NLM_term">ATF3</td><td class="NLM_def"><p class="first last">transcription factor 3</p></td></tr><tr><td class="NLM_term">Notch3</td><td class="NLM_def"><p class="first last">Notch homolog 3</p></td></tr><tr><td class="NLM_term">NICD3</td><td class="NLM_def"><p class="first last">Notch3 intracellular domain 3</p></td></tr><tr><td class="NLM_term">HES1</td><td class="NLM_def"><p class="first last">hairy and enhancer of split homolog-1</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1</p></td></tr><tr><td class="NLM_term">EOC</td><td class="NLM_def"><p class="first last">epithelial ovarian cancer</p></td></tr><tr><td class="NLM_term">cGAS</td><td class="NLM_def"><p class="first last">cyclic GMP-AMP synthase</p></td></tr><tr><td class="NLM_term">STING</td><td class="NLM_def"><p class="first last">stimulator of interferon gene</p></td></tr><tr><td class="NLM_term">ACTH</td><td class="NLM_def"><p class="first last">adrenocorticotropic hormone</p></td></tr><tr><td class="NLM_term">α-MSH</td><td class="NLM_def"><p class="first last">α-melanocyte stimulating hormone</p></td></tr><tr><td class="NLM_term">PNDC</td><td class="NLM_def"><p class="first last">peroxynitrite decomposition catalyst</p></td></tr><tr><td class="NLM_term">Mcl-1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia</p></td></tr><tr><td class="NLM_term">IDO</td><td class="NLM_def"><p class="first last">indoleamine-2,3-dioxygenase</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">ES-SCLC</td><td class="NLM_def"><p class="first last">extensive-stage small cell lung cancer</p></td></tr><tr><td class="NLM_term">ALDH1</td><td class="NLM_def"><p class="first last">aldehyde dehydrogenase 1</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 119 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Camp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krigas, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1038/205698a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2F205698a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14287410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaF2MXns1aruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=1965&pages=698-699&author=B.+Rosenbergauthor=L.+Van+Campauthor=T.+Krigas&title=Inhibition+of+cell+division+in+Escherichia+coli+by+electrolysis+products+from+a+platinum+electrode&doi=10.1038%2F205698a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode</span></div><div class="casAuthors">Rosenberg, Barnett; Van Camp, Loretta; Krigas, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">4972</span>),
    <span class="NLM_cas:pages">698-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">E. coli cells grown in a continuous culture app. with an esp. designed chamber contg. 2 Pt electrodes were subjected to an elec. field in an O atm.  With an applied voltage of 500 to 6000 cycles/sec., cell division ceased and filamentous growth occurred.  A similar effect was shown with a soln. of 10 ppm. (NH4)2PtCl6.  Pt(IV) was found in the electrolyzed medium in concns. of 8 ppm.  Other transition metal ions, including Rh, in concns. of 1-10 ppm. inhibited cell division in E. coli while not interfering with growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDyKBEDeGaCrVg90H21EOLACvtfcHk0lgXQaL3gGwRWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXns1aruw%253D%253D&md5=2d2e79bfe93d202de21a43b131ea95b2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F205698a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F205698a0%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DB.%26aulast%3DVan%2BCamp%26aufirst%3DL.%26aulast%3DKrigas%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520cell%2520division%2520in%2520Escherichia%2520coli%2520by%2520electrolysis%2520products%2520from%2520a%2520platinum%2520electrode%26jtitle%3DNature%26date%3D1965%26volume%3D205%26spage%3D698%26epage%3D699%26doi%3D10.1038%2F205698a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilruba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalayda, G. V.</span></span> <span> </span><span class="NLM_article-title">Platinum-based drugs: past, present and future</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-2976-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs00280-016-2976-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26886018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2016&pages=1103-1124&author=S.+Dilrubaauthor=G.+V.+Kalayda&title=Platinum-based+drugs%3A+past%2C+present+and+future&doi=10.1007%2Fs00280-016-2976-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum-based drugs: past, present and future</span></div><div class="casAuthors">Dilruba, Shahana; Kalayda, Ganna V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1103-1124</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms.  Their clin. success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment.  Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clin. application so far.  Nedaplatin, lobaplatin and heptaplatin received only regional approval.  Some new platinum complexes and platinum drug formulations are undergoing clin. trials.  Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biol. active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems.  For each class of compds., a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clin. used platinum drugs, and the clin. perspectives are discussed.  A crit. anal. of lessons to be learned is presented.  Finally, a general outlook regarding future directions in the field of new platinum drugs is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfV4v-5JjduLVg90H21EOLACvtfcHk0lijDHHLRv1wZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D&md5=1e1882f631ad56ef1a07b2075b1faa5e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-2976-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-2976-z%26sid%3Dliteratum%253Aachs%26aulast%3DDilruba%26aufirst%3DS.%26aulast%3DKalayda%26aufirst%3DG.%2BV.%26atitle%3DPlatinum-based%2520drugs%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D77%26spage%3D1103%26epage%3D1124%26doi%3D10.1007%2Fs00280-016-2976-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular processing of platinum anticancer drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=15789122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+processing+of+platinum+anticancer+drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular processing of platinum anticancer drugs</span></div><div class="casAuthors">Wang, Dong; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy.  Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs.  This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signaling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death.  Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJfZNaqwy67Vg90H21EOLACvtfcHk0lijDHHLRv1wZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D&md5=e44a8e87683ba5cfe3e165f9f4229fee</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520processing%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-prodrug-constructed liposomes as a versatile theranostic nanoplatform for bimodal imaging guided combination cancer therapy</span>. <i>Adv. Funct. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2207</span>– <span class="NLM_lpage">2217</span>, <span class="refDoi"> DOI: 10.1002/adfm.201504899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fadfm.201504899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2207-2217&author=L.+Fengauthor=M.+Gaoauthor=D.+Taoauthor=Q.+Chenauthor=H.+Wangauthor=Z.+Dongauthor=M.+Chenauthor=Z.+Liu&title=Cisplatin-prodrug-constructed+liposomes+as+a+versatile+theranostic+nanoplatform+for+bimodal+imaging+guided+combination+cancer+therapy&doi=10.1002%2Fadfm.201504899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-Prodrug-Constructed Liposomes as a Versatile Theranostic Nanoplatform for Bimodal Imaging Guided Combination Cancer Therapy</span></div><div class="casAuthors">Feng, Liangzhu; Gao, Min; Tao, Danlei; Chen, Qian; Wang, Hairong; Dong, Ziliang; Chen, Meiwan; Liu, Zhuang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Functional Materials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2207-2217</span>CODEN:
                <span class="NLM_cas:coden">AFMDC6</span>;
        ISSN:<span class="NLM_cas:issn">1616-301X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Up to date, a large variety of liposomal nanodrugs have been explored for cancer nanomedicine, showing encouraging results in both preclin. animal expts. and clin. treatment of cancer patients.  Herein, a phospholipid conjugated with a cisplatin prodrug is used as the major structure component of liposomes together with other com. lipids via self-assembling.  By doping with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR), a lipophilic dye with strong near IR (NIR) absorbance and fluorescence, the obtained DiR-Pt(IV)-liposome is found to be an effective probe for in vivo NIR fluorescence and photoacoustic bimodal imaging.  Attributing to its intrinsically doped cis-Pt(IV) prodrug, efficient photothermal conversion ability, and excellent tumor homing ability, DiR-Pt(IV)-liposome confers greatly enhanced therapeutic outcomes in the combined photothermal-chemotherapy.  Moreover, Pt(IV)-liposome is also demonstrated to be an efficient carrier for both small hydrophilic mols. and proteins, which are encapsulated inside the water-cavity of liposomes, further demonstrating the versatile functions of this nanoplatform.  This study develops a unique type of liposomal nanomedicine with a prodrug conjugated phospholipid as the major structure component.  Such Pt(IV)-liposome is featured with advantages including precisely defined/easily tunable drug compns., stealth-like pharmacokinetics, efficient tumor passive uptake, and the capabilities to simultaneously load with various types of imaging or therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Zlhkd_J0E7Vg90H21EOLACvtfcHk0lijDHHLRv1wZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCls7o%253D&md5=897cc57ee8a6149233004a1c58a3a237</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fadfm.201504899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadfm.201504899%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DCisplatin-prodrug-constructed%2520liposomes%2520as%2520a%2520versatile%2520theranostic%2520nanoplatform%2520for%2520bimodal%2520imaging%2520guided%2520combination%2520cancer%2520therapy%26jtitle%3DAdv.%2520Funct.%2520Mater.%26date%3D2016%26volume%3D26%26spage%3D2207%26epage%3D2217%26doi%3D10.1002%2Fadfm.201504899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stathopoulos, G. P.</span></span> <span> </span><span class="NLM_article-title">Liposomal cisplatin: a new cisplatin formulation</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1097/CAD.0b013e32833d9adf</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2FCAD.0b013e32833d9adf" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20671511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=732-736&author=G.+P.+Stathopoulos&title=Liposomal+cisplatin%3A+a+new+cisplatin+formulation&doi=10.1097%2FCAD.0b013e32833d9adf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Liposomal cisplatin: a new cisplatin formulation</span></div><div class="casAuthors">Stathopoulos, George P.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Over the last three decades, cisplatin has been one of the most effective cytotoxic agents, but its administration has been hindered by its nephrotoxicity, neurotoxicity and myelo toxicity.  Recently, liposomal cisplatin, lipoplatin, has been formulated and tested thoroughly in preclin. (in vitro) and phase I, II and III trials, as documented in the literature.  Expts. in animals showed that lipoplatin is less toxic than cisplatin and that it produces tumor redn.  The histol. examn. of treated tumors from mouse xenografts was consistent with apoptosis in the tumor cells in a mechanism similar to that of cisplatin.  Lipoplatin infusion in patients and measurements of platinum levels in tumor specimens showed 10-50 times higher levels in tumors and metastases than in the adjacent normal specimens.  A phase I-II study using a combination of lipoplatin and gemcitabine in pretreated patients (with disease progression or stable disease) with advanced pancreatic cancer was conducted.  No nephrotoxicity was obsd.  With lipoplatin monotherapy the dose-limiting toxicity was detd. to be 350 mg/m and the max. tolerated dose 300 mg/m; when used in combination with paclitaxel the dose-limiting toxicity for lipoplatin was 250 mg/m and for paclitaxel 175 mg/m, and the max. tolerated dose was 200 and 175 mg/m, resp.  In two phase II randomized studies comparing the lipoplatin combination vs. the cisplatin combination, it was found that the former was statistically significantly less toxic than the latter, whereas the response rate and survival were similar.  Up to now, the data on lipoplatin treatment in malignant tumors are quite impressive, because of the negligible toxicity and because it is equal if not superior to cisplatin with regard to response rate.  This review aims to chronol. document publications relevant to liposomal cisplatin to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprIdRClLKAibVg90H21EOLACvtfcHk0lje9Ee3SDqCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCmsr8%253D&md5=e47a8de4563457e9b9bd7b513743422a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e32833d9adf&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e32833d9adf%26sid%3Dliteratum%253Aachs%26aulast%3DStathopoulos%26aufirst%3DG.%2BP.%26atitle%3DLiposomal%2520cisplatin%253A%2520a%2520new%2520cisplatin%2520formulation%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2010%26volume%3D21%26spage%3D732%26epage%3D736%26doi%3D10.1097%2FCAD.0b013e32833d9adf" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulikas, T.</span></span> <span> </span><span class="NLM_article-title">Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1517/13543780903114168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1517%2F13543780903114168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=19604121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1197-1218&author=T.+Boulikas&title=Clinical+overview+on+Lipoplatin%3A+a+successful+liposomal+formulation+of+cisplatin&doi=10.1517%2F13543780903114168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin</span></div><div class="casAuthors">Boulikas, Teni</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1197-1218</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Nanoparticle formulations for packaging existing drugs have been used to treat cancer.  Lipoplatin is a liposomal cisplatin encapsulated into liposome nanoparticles of an av. diam. of 110 nm.  Lipoplatin has substantially reduced the renal toxicity, peripheral neuropathy, ototoxicity, myelotoxicity as well as nausea/vomiting and asthenia of cisplatin in Phase I, II and III clin. studies with enhanced or similar efficacy to cisplatin.  During clin. development, 10- to 200-fold higher accumulation of Lipoplatin in solid tumors compared to adjacent normal tissue was found in patients.  Targeting of tumor vasculature by Lipoplatin in animals suggested its antiangiogenesis potential and Lipoplatin was proposed to act like a double-sword: as chemotherapy and an antiangiogenesis drug.  Lipoplatin has finished successfully one Phase III non-inferiority clin. study as first-line against NSCLC in its combination with paclitaxel showing statistically significant redn. in nephrotoxicity; two more Phase III studies are in progress, one in NSCLC with gemcitabine also showing noninferiority with reduced toxicity and another in squamous cell carcinoma of the head and neck with 5-fluorouracil.  A registrational Phase II/III study against pancreatic cancer is in progress under the orphan drug status granted to Lipoplatin by the European Medicines Agency.  Phase II studies are continuing in advanced breast cancer with vinorelbine and gastrointestinal cancers with radiotherapy and 5-fluorouracil.  The highlights of the clin. development of Lipoplatin are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_giP1ppFTrVg90H21EOLACvtfcHk0lje9Ee3SDqCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCmtb4%253D&md5=3e7d4f4710792af5700e2b24a9627837</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543780903114168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903114168%26sid%3Dliteratum%253Aachs%26aulast%3DBoulikas%26aufirst%3DT.%26atitle%3DClinical%2520overview%2520on%2520Lipoplatin%253A%2520a%2520successful%2520liposomal%2520formulation%2520of%2520cisplatin%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1197%26epage%3D1218%26doi%3D10.1517%2F13543780903114168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oberoi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nukolova, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabanov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronich, T. K.</span></span> <span> </span><span class="NLM_article-title">Nanocarriers for delivery of platinum anticancer drugs</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1667</span>– <span class="NLM_lpage">1685</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2013.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.addr.2013.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24113520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1667-1685&author=H.+S.+Oberoiauthor=N.+V.+Nukolovaauthor=A.+V.+Kabanovauthor=T.+K.+Bronich&title=Nanocarriers+for+delivery+of+platinum+anticancer+drugs&doi=10.1016%2Fj.addr.2013.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers for delivery of platinum anticancer drugs</span></div><div class="casAuthors">Oberoi, Hardeep S.; Nukolova, Natalia V.; Kabanov, Alexander V.; Bronich, Tatiana K.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">1667-1685</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clin. use esp. for management of tumors of the ovary, testes, and the head and neck.  However, several dose limiting toxicities assocd. with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life.  These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy.  Nanocarrier-based delivery of platinum compds. is one such area of intense research effort beginning to provide encouraging preclin. and clin. results and may allow the development of the next generation of platinum chemotherapy.  This review highlights current understanding on the pharmacol. and limitations of platinum compds. in clin. use, and provides a comprehensive anal. of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9t-JIgD2CMrVg90H21EOLACvtfcHk0lje9Ee3SDqCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO&md5=25ea0f4f9f5f2712c294c8f37bb541ce</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DOberoi%26aufirst%3DH.%2BS.%26aulast%3DNukolova%26aufirst%3DN.%2BV.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26aulast%3DBronich%26aufirst%3DT.%2BK.%26atitle%3DNanocarriers%2520for%2520delivery%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1667%26epage%3D1685%26doi%3D10.1016%2Fj.addr.2013.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazarević, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rilak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugarčić, Ž. D.</span></span> <span> </span><span class="NLM_article-title">Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.ejmech.2017.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28442170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFelur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=8-31&author=T.+Lazarevi%C4%87author=A.+Rilakauthor=%C5%BD.+D.+Bugar%C4%8Di%C4%87&title=Platinum%2C+palladium%2C+gold+and+ruthenium+complexes+as+anticancer+agents%3A+Current+clinical+uses%2C+cytotoxicity+studies+and+future+perspectives&doi=10.1016%2Fj.ejmech.2017.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives</span></div><div class="casAuthors">Lazarevic, Tatjana; Rilak, Ana; Bugarcic, Zivadin D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-31</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidn. state, the types and no. of coordinated ligands and the coordination geometry.  This review illustrates notable recent progress in the field of medicinal bioinorg. chem. as many new approaches to the design of innovative metal-based anticancer drugs are emerging.  Current research addressing the problems assocd. with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy.  Examples of metal compds. and chelating agents currently in clin. use, clin. trials or preclin. development are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzaU1RDFb8E7Vg90H21EOLACvtfcHk0lje9Ee3SDqCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFelur8%253D&md5=4fd6838043aff980baa053436e87219a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DLazarevi%25C4%2587%26aufirst%3DT.%26aulast%3DRilak%26aufirst%3DA.%26aulast%3DBugar%25C4%258Di%25C4%2587%26aufirst%3D%25C5%25BD.%2BD.%26atitle%3DPlatinum%252C%2520palladium%252C%2520gold%2520and%2520ruthenium%2520complexes%2520as%2520anticancer%2520agents%253A%2520Current%2520clinical%2520uses%252C%2520cytotoxicity%2520studies%2520and%2520future%2520perspectives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D8%26epage%3D31%26doi%3D10.1016%2Fj.ejmech.2017.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The Platin-X series: activation, targeting, and delivery</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">12992</span>– <span class="NLM_lpage">13004</span>, <span class="refDoi"> DOI: 10.1039/C6DT01738J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC6DT01738J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27493131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=12992-13004&author=U.+Basuauthor=B.+Banikauthor=R.+Wenauthor=R.+K.+Pathakauthor=S.+Dhar&title=The+Platin-X+series%3A+activation%2C+targeting%2C+and+delivery&doi=10.1039%2FC6DT01738J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Platin-X series: activation, targeting, and delivery</span></div><div class="casAuthors">Basu, Uttara; Banik, Bhabatosh; Wen, Ru; Pathak, Rakesh K.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">12992-13004</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorg. chem.  Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation.  Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append addnl. functional groups/ligands for prodrug activation, tumor targeting, or drug delivery.  The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs.  Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery.  In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnol.-based delivery platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYcK59HMDWBbVg90H21EOLACvtfcHk0lgSknVtaCdRSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J&md5=3d4894b6935545dceab775c94b75d38c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1039%2FC6DT01738J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01738J%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DU.%26aulast%3DBanik%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DR.%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520Platin-X%2520series%253A%2520activation%252C%2520targeting%252C%2520and%2520delivery%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D12992%26epage%3D13004%26doi%3D10.1039%2FC6DT01738J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3486</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+next+generation+of+platinum+drugs%3A+targeted+Pt%28II%29+agents%2C+nanoparticle+delivery%2C+and+Pt%28IV%29+prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0lgSknVtaCdRSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520next%2520generation%2520of%2520platinum%2520drugs%253A%2520targeted%2520Pt%2528II%2529%2520agents%252C%2520nanoparticle%2520delivery%252C%2520and%2520Pt%2528IV%2529%2520prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babkov, A. V.</span></span> <span> </span><span class="NLM_article-title">The mechanical nature of the trans-effect in ligand substitution reactions of square-planar complexes</span>. <i>Polyhedron</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1016/S0277-5387(00)81209-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0277-5387%2800%2981209-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaL1cXltlGrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1988&pages=1203-1206&author=A.+V.+Babkov&title=The+mechanical+nature+of+the+trans-effect+in+ligand+substitution+reactions+of+square-planar+complexes&doi=10.1016%2FS0277-5387%2800%2981209-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanical nature of the trans-effect in ligand substitution reactions of square-planar complexes</span></div><div class="casAuthors">Babkov, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Polyhedron</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1203-6</span>CODEN:
                <span class="NLM_cas:coden">PLYHDE</span>;
        ISSN:<span class="NLM_cas:issn">0277-5387</span>.
    </div><div class="casAbstract">The kinetic trans-effect in associative ligand substitution reactions of square-planar complexes is explained theor. on the basis of the angular deformability of the bond in the trans-activating ligands.  The ability of these ligands, under the condition of low energy input, to leave the plane of the complex dets. the ease with which the transition of the complex into the pentacoordinate state takes place in the substitution process.  The most general property of ligands exhibiting a strong trans-effect is the large angular unfolding of the donor orbital in the direction of the central atom.  This facilitates coordination between the bond-cleaving process and the formation of chem. bonds in the intermediate compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_lArySZoXA7Vg90H21EOLACvtfcHk0lgSknVtaCdRSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltlGrtrc%253D&md5=93a3494d80aa67a0ca023225f222a28e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0277-5387%2800%2981209-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0277-5387%252800%252981209-7%26sid%3Dliteratum%253Aachs%26aulast%3DBabkov%26aufirst%3DA.%2BV.%26atitle%3DThe%2520mechanical%2520nature%2520of%2520the%2520trans-effect%2520in%2520ligand%2520substitution%2520reactions%2520of%2520square-planar%2520complexes%26jtitle%3DPolyhedron%26date%3D1988%26volume%3D7%26spage%3D1203%26epage%3D1206%26doi%3D10.1016%2FS0277-5387%2800%2981209-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Third row transition metals for the treatment of cancer</span>. <i>Philos. Trans. R. Soc., A</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">2037</span>),  <span class="NLM_fpage">20140185</span>, <span class="refDoi"> DOI: 10.1098/rsta.2014.0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1098%2Frsta.2014.0185" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=20140185&issue=2037&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=Third+row+transition+metals+for+the+treatment+of+cancer&doi=10.1098%2Frsta.2014.0185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1098%2Frsta.2014.0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsta.2014.0185%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThird%2520row%2520transition%2520metals%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520A%26date%3D2015%26volume%3D373%26issue%3D2037%26spage%3D20140185%26doi%3D10.1098%2Frsta.2014.0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, K. G.K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prives, C.</span></span> <span> </span><span class="NLM_article-title">High mobility group protein-1 (HMG-1) is a unique activator of p53</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1101/gad.12.4.462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1101%2Fgad.12.4.462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=9472015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=462-472&author=L.+Jayaramanauthor=N.+C.+Moorthyauthor=K.+G.K.+Murthyauthor=J.+L.+Manleyauthor=M.+Bustinauthor=C.+Prives&title=High+mobility+group+protein-1+%28HMG-1%29+is+a+unique+activator+of+p53&doi=10.1101%2Fgad.12.4.462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">High mobility group protein-1 (HMG-1) is a unique activator of p53</span></div><div class="casAuthors">Jayaraman, Lata; Moorthy, Narayani Chandra; Murthy, Kanneganti G. K.; Manley, James L.; Bustin, Michael; Prives, Carol</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-472</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The binding of p53 protein to DNA is stimulated by its interaction with covalent as well as noncovalent modifiers.  The authors report the identification of a factor from HeLa nuclear exts. that activates p53 DNA binding.  This factor was purified to homogeneity and identified as the high mobility group protein, HMG-1.  HMG-1 belongs to a family of highly conserved chromatin-assocd. nucleoproteins that bend DNA and facilitate the binding of various transcription factors to their cognate DNA sequences.  The authors demonstrate that recombinant His-tagged HMG-1 enhances p53 DNA binding in vitro and also that HMG-1 and p53 can interact directly in vitro.  Unexpectedly, HMG-1 also stimulates DNA binding by p53Δ30, a carboxy-terminally deleted form of the protein that is considered to be constitutively active, suggesting that HMG-1 stimulates p53 by a mechanism that is distinct from other known activators of p53.  Finally, using transient transfection assays the authors show that HMG-1 can increase p53 and p53Δ30-mediated transactivation in vivo.  HMG-1 promotes the assembly of higher order p53 nucleoprotein structures, and these data, along with the fact that HMG-1 is capable of bending DNA, suggest that HMG-1 may activate p53 DNA binding by a novel mechanism involving a structural change in the target DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJiVQXNeAsNbVg90H21EOLACvtfcHk0ljqJZ0CRxF-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlShsbY%253D&md5=a2b2b9628bca1b06ff2958ed621c2c86</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.4.462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.4.462%26sid%3Dliteratum%253Aachs%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DMoorthy%26aufirst%3DN.%2BC.%26aulast%3DMurthy%26aufirst%3DK.%2BG.K.%26aulast%3DManley%26aufirst%3DJ.%2BL.%26aulast%3DBustin%26aufirst%3DM.%26aulast%3DPrives%26aufirst%3DC.%26atitle%3DHigh%2520mobility%2520group%2520protein-1%2520%2528HMG-1%2529%2520is%2520a%2520unique%2520activator%2520of%2520p53%26jtitle%3DGenes%2520Dev.%26date%3D1998%26volume%3D12%26spage%3D462%26epage%3D472%26doi%3D10.1101%2Fgad.12.4.462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span> <span> </span><span class="NLM_article-title">Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2005.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.drup.2005.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=15894512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVSlsr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=131-146&author=V.+Brabecauthor=J.+Kasparkova&title=Modifications+of+DNA+by+platinum+complexes.+Relation+to+resistance+of+tumors+to+platinum+antitumor+drugs&doi=10.1016%2Fj.drup.2005.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Modifications of DNA by platinum complexes</span></div><div class="casAuthors">Brabec, Viktor; Kasparkova, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-146</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The importance of platinum drugs in cancer chemotherapy is underscored by the clin. success of cisplatin [cis-diamminedichloroplatinum(II)] and its analogs and by clin. trials of other, less toxic platinum complexes that are active against resistant tumors.  The antitumor effect of platinum complexes is believed to result from their ability to form various types of adducts with DNA.  Nevertheless, drug resistance can occur by several ways: increased drug efflux, drug inactivation, alterations in drug target, processing of drug-induced damage, and evasion of apoptosis.  This review focuses on mechanisms of resistance and sensitivity of tumors to conventional cisplatin assocd. with DNA modifications.  We also discuss mol. mechanisms underlying resistance and sensitivity of tumors to the new platinum compds. synthesized with the goal to overcome resistance of tumors to established platinum drugs.  Importantly, a no. of new platinum compds. were designed to test the hypothesis that there is a correlation between the extent of resistance of tumors to these agents and their ability to induce a certain kind of damage or conformational change in DNA.  Hence, information on DNA-binding modes, as well as recognition and repair of DNA damage is discussed, since this information may be exploited for improved structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoliOk5cSz47LVg90H21EOLACvtfcHk0ljqJZ0CRxF-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVSlsr7K&md5=0b2aedfc594780c9727404fce1b1669d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2005.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2005.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrabec%26aufirst%3DV.%26aulast%3DKasparkova%26aufirst%3DJ.%26atitle%3DModifications%2520of%2520DNA%2520by%2520platinum%2520complexes.%2520Relation%2520to%2520resistance%2520of%2520tumors%2520to%2520platinum%2520antitumor%2520drugs%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2005%26volume%3D8%26spage%3D131%26epage%3D146%26doi%3D10.1016%2Fj.drup.2005.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Regulation of cell death by the Abl tyrosine kinase</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5643</span>– <span class="NLM_lpage">5650</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fsj.onc.1203878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=11114745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2nurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5643-5650&author=J.+Y.+Wang&title=Regulation+of+cell+death+by+the+Abl+tyrosine+kinase&doi=10.1038%2Fsj.onc.1203878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell death by the Abl tyrosine kinase</span></div><div class="casAuthors">Wang, Jean Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5643-5650</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with ∼72 refs.  The c-abl proto-oncogene encodes a protein tyrosine kinase that is distributed in the nucleus and the cytoplasm of proliferating cells.  In the nucleus, c-Abl activity is neg. regulated by the retinoblastoma protein (RB) and pos. regulated by DNA damage signals.  Activation of the c-Abl kinase by DNA damage requires the function of ATM, which regulates cell cycle checkpoint, DNA repair and apoptosis in response to DNA damage.  Cells lacking c-Abl can activate cell cycle checkpoints and DNA repair, but show defects in apoptosis.  The apoptosis defect of c-Abl deficient cells is correlated with a defect in the induction and activation of p73, which is a functional homolog of the p53 tumor suppressor protein and has pro-apoptotic activity.  The inhibition of c-Abl by RB is consistent with RB's ability to block apoptosis; while the activation of c-Abl by ATM is consistent with ATM's ability to activate cell death.  The oncogenic Bcr-Abl tyrosine kinase is a potent inhibitor of apoptosis, and it is retained exclusively in the cytoplasm of transformed cells.  Interestingly, when Bcr-Abl is trapped inside of the nucleus through a combined disruption of its cytoplasmic retention and its nuclear export, this oncogenic Abl kinase induces apoptosis.  Taken together, the current results support a role for the nuclear c-Abl tyrosine kinase in the regulation of apoptosis.  Whether the cytoplasmic c-Abl kinase can actively inhibit apoptosis remains to be detd.; however, a deliberate retention of c-Abl in the cytoplasm could potentially contribute to the attenuation of apoptosis response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkGJbCJsFvBLVg90H21EOLACvtfcHk0ljqJZ0CRxF-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2nurg%253D&md5=46b8a4dd07791d0209b219af768a6aa9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203878%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BY.%26atitle%3DRegulation%2520of%2520cell%2520death%2520by%2520the%2520Abl%2520tyrosine%2520kinase%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5643%26epage%3D5650%26doi%3D10.1038%2Fsj.onc.1203878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Englinger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffeter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terenzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span> <span> </span><span class="NLM_article-title">Metal drugs and the anticancer immune response</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1519-1624&author=B.+Englingerauthor=C.+Pirkerauthor=P.+Heffeterauthor=A.+Terenziauthor=C.+R.+Kowolauthor=B.+K.+Kepplerauthor=W.+Berger&title=Metal+drugs+and+the+anticancer+immune+response&doi=10.1021%2Facs.chemrev.8b00396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Metal drugs and the anticancer immune response</span></div><div class="casAuthors">Englinger, Bernhard; Pirker, Christine; Heffeter, Petra; Terenzi, Alessio; Kowol, Christian R.; Keppler, Bernhard K.; Berger, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1519-1624</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance").  Hence, a clin. apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion").  Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion.  This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clin. settings.  This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects.  It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses.  Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment.  On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpduZa3EdGgurVg90H21EOLACvtfcHk0livChZC7yZV2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO&md5=9cf67c2ef463cd26be88b178b5b6534a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00396%26sid%3Dliteratum%253Aachs%26aulast%3DEnglinger%26aufirst%3DB.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DTerenzi%26aufirst%3DA.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DBerger%26aufirst%3DW.%26atitle%3DMetal%2520drugs%2520and%2520the%2520anticancer%2520immune%2520response%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1519%26epage%3D1624%26doi%3D10.1021%2Facs.chemrev.8b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hato, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesterhuis, W. J.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2831</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-13-3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24879823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Kks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2831-2837&author=S.+V.+Hatoauthor=A.+Khongauthor=I.+J.+de+Vriesauthor=W.+J.+Lesterhuis&title=Molecular+pathways%3A+the+immunogenic+effects+of+platinum-based+chemotherapeutics&doi=10.1158%2F1078-0432.CCR-13-3141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics</span></div><div class="casAuthors">Hato, Stanleyson V.; Khong, Andrea; de Vries, I. Jolanda M.; Lesterhuis, W. Joost</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2831-2837</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The platinum-based drugs cisplatin, carboplatin, and oxaliplatin belong to the most widely used chemotherapeutics in oncol., showing clin. efficacy against many solid tumors.  Their main mechanism of action is believed to be the induction of cancer cell apoptosis as a response to their covalent binding to DNA.  In recent years, this picture has increased in complexity, based on studies indicating that cellular mols. other than DNA may potentially act as targets, and that part of the antitumor effects of platinum drugs occurs through modulation of the immune system.  These immunogenic effects include modulation of STAT signaling; induction of an immunogenic type of cancer cell death through exposure of calreticulin and release of ATP and high-mobility group protein box-1 (HMGB-1); and enhancement of the effector immune response through modulation of programmed death receptor 1-ligand and mannose-6-phosphate receptor expression.  Both basic and clin. studies indicate that at least part of the antitumor efficacy of platinum chemotherapeutics may be due to immune potentiating mechanisms.  Clin. studies exploiting this novel mechanism of action of these old cancer drugs were initiated.  Here, we review the literature on the immunogenic effects of platinum, summarize the clin. advances using platinum as a cytotoxic compd. with immune adjuvant properties, and discuss the limitations to these studies and the gaps in our understanding of the immunol. effects of these drugs.  Clin Cancer Res; 20(11); 2831-7. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW0TjczqF-MbVg90H21EOLACvtfcHk0livChZC7yZV2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Kks7g%253D&md5=87b6f62ab4e87dfb208c8b827370b608</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3141%26sid%3Dliteratum%253Aachs%26aulast%3DHato%26aufirst%3DS.%2BV.%26aulast%3DKhong%26aufirst%3DA.%26aulast%3Dde%2BVries%26aufirst%3DI.%2BJ.%26aulast%3DLesterhuis%26aufirst%3DW.%2BJ.%26atitle%3DMolecular%2520pathways%253A%2520the%2520immunogenic%2520effects%2520of%2520platinum-based%2520chemotherapeutics%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2831%26epage%3D2837%26doi%3D10.1158%2F1078-0432.CCR-13-3141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Biasi, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villena-Vargas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adusumilli, P. S.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5384</span>– <span class="NLM_lpage">5391</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-14-1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25204552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5384-5391&author=A.+R.+de%0ABiasiauthor=J.+Villena-Vargasauthor=P.+S.+Adusumilli&title=Cisplatin-induced+antitumor+immunomodulation%3A+a+review+of+preclinical+and+clinical+evidence&doi=10.1158%2F1078-0432.CCR-14-1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence</span></div><div class="casAuthors">de Biasi, Andreas R.; Villena-Vargas, Jonathan; Adusumilli, Prasad S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5384-5391</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Contrary to the long held belief that chemotherapy is immunosuppressive, emerging evidence indicates that the anticancer activity of cisplatin is not limited to its ability to inhibit mitosis, but that cisplatin also has important immunomodulatory effects.  We therefore methodically examd. the relevant preclin. literature and identified four main mechanisms of cisplatin-induced antitumor immunomodulation: (i) MHC class I expression upregulation; (ii) recruitment and proliferation of effector cells; (iii) upregulation of the lytic activity of cytotoxic effectors; and (iv) downregulation of the immunosuppressive microenvironment.  Cisplatin-based combination chemotherapy's antitumor immunomodulatory effects are also beginning to be harnessed in the clinic; we therefore addnl. reviewed the applicable clin. literature and discussed how monitoring various components of the immune system (and their responses to cisplatin) can add new levels of sophistication to disease monitoring and prognostication.  In summation, this growing body of literature on cisplatin-induced antitumor immunomodulation ultimately highlights the therapeutic potential of synergistic strategies that combine traditional chemotherapy with immunotherapy.  Clin Cancer Res; 20(21); 5384-91. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiV10JQeEbqrVg90H21EOLACvtfcHk0livChZC7yZV2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7rI&md5=f62672b07b6156ff3b13844d34d83089</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1298%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBiasi%26aufirst%3DA.%2BR.%26aulast%3DVillena-Vargas%26aufirst%3DJ.%26aulast%3DAdusumilli%26aufirst%3DP.%2BS.%26atitle%3DCisplatin-induced%2520antitumor%2520immunomodulation%253A%2520a%2520review%2520of%2520preclinical%2520and%2520clinical%2520evidence%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5384%26epage%3D5391%26doi%3D10.1158%2F1078-0432.CCR-14-1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manorek, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, S. B.</span></span> <span> </span><span class="NLM_article-title">Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1390</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1124/mol.106.022624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1124%2Fmol.106.022624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16847145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOjtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=1390-1394&author=A.+K.+Holzerauthor=G.+H.+Manorekauthor=S.+B.+Howell&title=Contribution+of+the+major+copper+influx+transporter+CTR1+to+the+cellular+accumulation+of+cisplatin%2C+carboplatin%2C+and+oxaliplatin&doi=10.1124%2Fmol.106.022624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin</span></div><div class="casAuthors">Holzer, Alison K.; Manorek, Gerald H.; Howell, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1390-1394</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The goal of this study was to det. the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP).  Wild-type murine embryonic fibroblasts (CTR1+/+) and a subline in which both alleles of CTR1 were deleted (CTR1-/-) were tested for their ability to accumulate platinum when exposed to increasing concns. of DDP, CBDCA, or L-OHP for 1 h.  They were also tested for their sensitivity to the growth-inhibitory effect of each drug.  Platinum content was measured by ion-coupled plasmon mass spectroscopy.  The exptl. model was validated by measuring copper accumulation and cytotoxicity.  CTR1-/- cells accumulated only 5.7% as much copper as CTR1+/+ cells during a 1-h exposure to 2 μM copper.  When exposed to DDP, CBDCA, or L-OHP at 2 μM, accumulation in the CTR1-/- cells was only 35 to 36% of that in the CTR1+/+ cells.  When tested at a 5-fold higher concn., this deficit remained for DDP and CBDCA, but accumulation of L-OHP was no longer CTR1-dependent.  There was an assocn. between the effect of loss of CTR1 function on uptake of the platinum drugs and their cytotoxicity.  The CTR1-/- cells were 3.2-fold resistant to DDP, 2.0-fold resistant to CBDCA, but only 1.7-fold resistant to L-OHP.  Thus, whereas CTR1 controls the cellular accumulation of all three drugs at low concns., accumulation of L-OHP is not dependent on CTR1 at higher concns.  The authors conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clin. spectrum of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXnxzqXfOgNbVg90H21EOLACvtfcHk0lgoOcOejjkDhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOjtL7O&md5=5c59b1c5c2b70ed0a2a300fd2c510b6d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.022624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.022624%26sid%3Dliteratum%253Aachs%26aulast%3DHolzer%26aufirst%3DA.%2BK.%26aulast%3DManorek%26aufirst%3DG.%2BH.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26atitle%3DContribution%2520of%2520the%2520major%2520copper%2520influx%2520transporter%2520CTR1%2520to%2520the%2520cellular%2520accumulation%2520of%2520cisplatin%252C%2520carboplatin%252C%2520and%2520oxaliplatin%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D1390%26epage%3D1394%26doi%3D10.1124%2Fmol.106.022624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safaei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samimi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochdi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, S. B.</span></span> <span> </span><span class="NLM_article-title">Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6559</span>– <span class="NLM_lpage">6565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12438251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFOks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6559-6565&author=K.+Katanoauthor=A.+Kondoauthor=R.+Safaeiauthor=A.+Holzerauthor=G.+Samimiauthor=M.+Mishimaauthor=Y.-M.+Kuoauthor=M.+Rochdiauthor=S.+B.+Howell&title=Acquisition+of+resistance+to+cisplatin+is+accompanied+by+changes+in+the+cellular+pharmacology+of+copper"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper</span></div><div class="casAuthors">Katano, Kuniyuki; Kondo, Akira; Safaei, Roohangiz; Holzer, Alison; Samimi, Goli; Mishima, Misako; Kuo, Yien-Ming; Rochdi, Myriam; Howell, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6559-6565</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Impaired uptake of cisplatin (DDP) consistently accompanies the acquisition of resistance to the platinum drugs.  The pathways by which DDP enters or exits from cells remain poorly defined.  Using three pairs of human ovarian carcinoma cell lines, each consisting of a sensitive parental line and a stably DDP-resistant subline derived by in vitro selection, resistance to DDP was found to be accompanied by cross-resistance to Cu.  Accumulation of DDP in the resistant sublines ranged from 38 to 67% of that in the parental line at 1 h, and DNA adduct formation varied from 10 to 38% of that in the sensitive cells.  The DDP-resistant cells had 22-56% lower basal levels of copper, and the copper levels were only 27-46% of those obsd. in the sensitive parental lines after a 24-h exposure to medium supplemented with copper.  The initial influx rate for DDP in the three resistant cell lines ranged from 23 to 55% of that in the sensitive cells of each pair; the initial influx rate for copper in the resistant cells varied from 56 to 75% of control.  Studies performed using one pair of cell lines demonstrated that for both copper and DDP the initial efflux rate was lower, whereas the terminal efflux rate was higher in the resistant cells.  On Western blot anal. all three resistant lines exhibited increased expression of one or the other of the two copper export pumps (ATP7A or ATP7B) with no change in the HAH1 chaperone.  We conclude that the acquisition of DDP resistance in ovarian carcinoma is accompanied by alterations in the cellular pharmacol. of DDP that are paralleled by similar changes in the uptake and efflux of copper.  These results are consistent with the concept that DDP enters and exits from the cell via transporters that normally mediate copper homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnqIiTYYPGbVg90H21EOLACvtfcHk0lgoOcOejjkDhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFOks74%253D&md5=5697c2f333988b90acdfe44a5144e279</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatano%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DA.%26aulast%3DSafaei%26aufirst%3DR.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DSamimi%26aufirst%3DG.%26aulast%3DMishima%26aufirst%3DM.%26aulast%3DKuo%26aufirst%3DY.-M.%26aulast%3DRochdi%26aufirst%3DM.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26atitle%3DAcquisition%2520of%2520resistance%2520to%2520cisplatin%2520is%2520accompanied%2520by%2520changes%2520in%2520the%2520cellular%2520pharmacology%2520of%2520copper%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6559%26epage%3D6565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safaei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samimi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, S. B.</span></span> <span> </span><span class="NLM_article-title">The role of copper transporters in the development of resistance to Pt drugs</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2004.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jinorgbio.2004.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=15458823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2mtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2004&pages=1607-1613&author=R.+Safaeiauthor=A.+K.+Holzerauthor=K.+Katanoauthor=G.+Samimiauthor=S.+B.+Howell&title=The+role+of+copper+transporters+in+the+development+of+resistance+to+Pt+drugs&doi=10.1016%2Fj.jinorgbio.2004.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of copper transporters in the development of resistance to Pt drugs</span></div><div class="casAuthors">Safaei, Roohangiz; Holzer, Alison K.; Katano, Kuniyuki; Samimi, Goli; Howell, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1607-1613</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent studies in yeast, mouse and human cells suggest that the conserved metal binding transporters of the Cu homeostasis pathway can mediate resistance to Pt drugs in cancer cells.  This review summarizes the data available from these studies.  The observation that cells selected for resistance to Cu or the Pt drugs display bidirectional cross-resistance, parallel defects in the transport of Cu and the Pt drugs and altered expression of Cu transporters is consistent with the concept that the Cu homeostasis proteins regulate sensitivity to the Pt drugs by influencing their uptake, efflux and intracellular distribution.  This model is supported by the finding that when mammalian and yeast cells are genetically engineered to express altered levels of the Cu transporters they exhibit altered sensitivity to Pt drugs and are defective in intracellular Pt accumulation due to altered uptake and/or efflux rates.  Neg. assocns. between the expression of ATP7A and ATP7B and the outcome of Pt therapy further support the significance of the Cu homeostasis proteins as both markers of and contributors to Pt resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS2olePtMTlLVg90H21EOLACvtfcHk0lgoOcOejjkDhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2mtbo%253D&md5=d6ce56766a657676bea1ddd6ea367925</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2004.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2004.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DSafaei%26aufirst%3DR.%26aulast%3DHolzer%26aufirst%3DA.%2BK.%26aulast%3DKatano%26aufirst%3DK.%26aulast%3DSamimi%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26atitle%3DThe%2520role%2520of%2520copper%2520transporters%2520in%2520the%2520development%2520of%2520resistance%2520to%2520Pt%2520drugs%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2004%26volume%3D98%26spage%3D1607%26epage%3D1613%26doi%3D10.1016%2Fj.jinorgbio.2004.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planells-Cases, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhards, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucukosmanoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reincke, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummelkamp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jentsch, T. J.</span></span> <span> </span><span class="NLM_article-title">Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2993</span>– <span class="NLM_lpage">3008</span>, <span class="refDoi"> DOI: 10.15252/embj.201592409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.15252%2Fembj.201592409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26530471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGitbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=2993-3008&author=R.+Planells-Casesauthor=D.+Lutterauthor=C.+Guyaderauthor=N.+M.+Gerhardsauthor=F.+Ullrichauthor=D.+A.+Elgerauthor=A.+Kucukosmanogluauthor=G.+Xuauthor=F.+K.+Vossauthor=S.+M.+Reinckeauthor=T.+Stauberauthor=V.+A.+Blomenauthor=D.+J.+Visauthor=L.+F.+Wesselsauthor=T.+R.+Brummelkampauthor=P.+Borstauthor=S.+Rottenbergauthor=T.+J.+Jentsch&title=Subunit+composition+of+VRAC+channels+determines+substrate+specificity+and+cellular+resistance+to+Pt-based+anti-cancer+drugs&doi=10.15252%2Fembj.201592409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs</span></div><div class="casAuthors">Planells-Cases, Rosa; Lutter, Darius; Guyader, Charlotte; Gerhards, Nora M.; Ullrich, Florian; Elger, Deborah A.; Kucukosmanoglu, Asli; Xu, Guotai; Voss, Felizia K.; Reincke, S. Momsen; Stauber, Tobias; Blomen, Vincent A.; Vis, Daniel J.; Wessels, Lodewyk F.; Brummelkamp, Thijn R.; Borst, Piet; Rottenberg, Sven; Jentsch, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2993-3008</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although platinum-based drugs are widely used chemotherapeutics for cancer treatment, the determinants of tumor cell responsiveness remain poorly understood.  The authors show that the loss of subunits LRRC8A and LRRC8D of the heteromeric LRRC8 vol.-regulated anion channels (VRACs) increased resistance to clin. relevant cisplatin/carboplatin concns.  Under isotonic conditions, about 50% of cisplatin uptake depended on LRRC8A and LRRC8D, but neither on LRRC8C nor on LRRC8E.  Cell swelling strongly enhanced LRRC8-dependent cisplatin uptake, bolstering the notion that cisplatin enters cells through VRAC.  LRRC8A disruption also suppressed drug-induced apoptosis independently from drug uptake, possibly by impairing VRAC-dependent apoptotic cell vol. decrease.  Hence, by mediating cisplatin uptake and facilitating apoptosis, VRAC plays a dual role in the cellular drug response.  Incorporation of the LRRC8D subunit into VRAC substantially increased its permeability for cisplatin and the cellular osmolyte taurine, indicating that LRRC8 proteins form the channel pore.  The authors' work suggests that LRRC8D-contg. VRACs are crucial for cell vol. regulation by an important org. osmolyte and may influence cisplatin/carboplatin responsiveness of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMK0m-YSkAN7Vg90H21EOLACvtfcHk0liNek-BEsD6QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGitbrM&md5=0560c891ce3b7b49b84d80c105152375</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.15252%2Fembj.201592409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201592409%26sid%3Dliteratum%253Aachs%26aulast%3DPlanells-Cases%26aufirst%3DR.%26aulast%3DLutter%26aufirst%3DD.%26aulast%3DGuyader%26aufirst%3DC.%26aulast%3DGerhards%26aufirst%3DN.%2BM.%26aulast%3DUllrich%26aufirst%3DF.%26aulast%3DElger%26aufirst%3DD.%2BA.%26aulast%3DKucukosmanoglu%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DVoss%26aufirst%3DF.%2BK.%26aulast%3DReincke%26aufirst%3DS.%2BM.%26aulast%3DStauber%26aufirst%3DT.%26aulast%3DBlomen%26aufirst%3DV.%2BA.%26aulast%3DVis%26aufirst%3DD.%2BJ.%26aulast%3DWessels%26aufirst%3DL.%2BF.%26aulast%3DBrummelkamp%26aufirst%3DT.%2BR.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJentsch%26aufirst%3DT.%2BJ.%26atitle%3DSubunit%2520composition%2520of%2520VRAC%2520channels%2520determines%2520substrate%2520specificity%2520and%2520cellular%2520resistance%2520to%2520Pt-based%2520anti-cancer%2520drugs%26jtitle%3DEMBO%2520J.%26date%3D2015%26volume%3D34%26spage%3D2993%26epage%3D3008%26doi%3D10.15252%2Fembj.201592409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashikata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobiume, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetsuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takechi, M.</span></span> <span> </span><span class="NLM_article-title">Snail-induced CD44<sup>high</sup> cells in HNSCC with high ABC transporter capacity exhibit potent resistance to cisplatin and docetaxel</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7908</span>– <span class="NLM_lpage">7918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotl2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=7908-7918&author=M.+Hashikataauthor=H.+Shigeishiauthor=G.+Okuiauthor=K.+Yamamotoauthor=K.+Tobiumeauthor=S.+Seinoauthor=R.+Uetsukiauthor=H.+Katoauthor=Y.+Ishiokaauthor=S.+Onoauthor=K.+Ohtaauthor=K.+Higashikawaauthor=M.+Sugiyamaauthor=M.+Takechi&title=Snail-induced+CD44high+cells+in+HNSCC+with+high+ABC+transporter+capacity+exhibit+potent+resistance+to+cisplatin+and+docetaxel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Snail-induced CD44high cells in HNSCC with high ABC transporter capacity exhibit potent resistance to cisplatin and docetaxel</span></div><div class="casAuthors">Hashikata, Miho; Shigeishi, Hideo; Okui, Gaku; Yamamoto, Kazuhiro; Tobiume, Kei; Seino, Sayaka; Uetsuki, Ryo; Kato, Hiroki; Ishioka, Yasuki; Ono, Shigehiro; Ohta, Kouji; Higashikawa, Koichiro; Sugiyama, Masaru; Takechi, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">7908-7918</span>CODEN:
                <span class="NLM_cas:coden">IJCEC7</span>;
        ISSN:<span class="NLM_cas:issn">1936-2625</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">CD44high head and neck squamous cell carcinoma (HNSCC) cells with cancer stem cell (CSC)-like properties have been speculated to be involved in resistance to apoptosis induced by anti-cancer drugs and thereby assocd. with tumor recurrence.  To clarify the chemotherapeutic resistance of CD44high HNSCC cells, we examd. the apoptotic effects of cisplatin and docetaxel in sorted populations (i.e., CD44high/ESAlow, CD44high/ESAhigh and CD44low cells) from the HNSCC cell line HTB-41.  Furthermore, we examd. whether Snail, which leads to the epithelial to mesenchymal transition (EMT) program, can induce formation of CD44high/ESAlow cells in an HNSCC cell population.  CD44high/ESAlow cells showed mesenchymal features and potent resistance to both cisplatin- and docetaxel-induced apoptosis. siRNA knockdown of ABCC2 significantly induced apoptosis of CD44high/ESAlow cells in the presence of cisplatin, while ABCG2 knockdown induced apoptosis of those cells in the presence of docetaxel.  These findings suggest that strong resistance to cisplatin by CD44high/ESAlow cells may be attributable to a high level of ABC transporter activity.  Furthermore, development of CD44high/ESAlow cells was induced in the HNSCC cell line OM-1 by Snail transfection and those sorted from OM-1 cells harboring a Snail-transgene showed strong resistance to cisplatin- and docetaxel-induced apoptosis.  Our results indicate that CD44high/ESAlow HNSCC cells play important roles in cisplatin and docetaxel resistance caused by high drug efflux activity.  Furthermore, Snail may be involved in induction of both mesenchymal characteristics and CSC-like properties of HNSCC cells.  A better understanding of the phenotypic plasticity of HNSCC cells is necessary to improve the results of chemotherapy with cisplatin and docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjJux65nkjbVg90H21EOLACvtfcHk0liNek-BEsD6QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotl2qsrY%253D&md5=ded73771328b77b4f06528623b59bc9c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHashikata%26aufirst%3DM.%26aulast%3DShigeishi%26aufirst%3DH.%26aulast%3DOkui%26aufirst%3DG.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTobiume%26aufirst%3DK.%26aulast%3DSeino%26aufirst%3DS.%26aulast%3DUetsuki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DIshioka%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DHigashikawa%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTakechi%26aufirst%3DM.%26atitle%3DSnail-induced%2520CD44high%2520cells%2520in%2520HNSCC%2520with%2520high%2520ABC%2520transporter%2520capacity%2520exhibit%2520potent%2520resistance%2520to%2520cisplatin%2520and%2520docetaxel%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2016%26volume%3D9%26spage%3D7908%26epage%3D7918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of cisplatin resistance</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1883</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+mechanisms+of+cisplatin+resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0liNek-BEsD6QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520of%2520cisplatin%2520resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M. T.</span></span> <span> </span><span class="NLM_article-title">Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy</span>. <i>Met.-Based Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">430939</span>, <span class="refDoi"> DOI: 10.1155/2010/430939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1155%2F2010%2F430939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20885916" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=430939&author=H.+H.+W.+Chenauthor=M.+T.+Kuo&title=Role+of+glutathione+in+the+regulation+of+cisplatin+resistance+in+cancer+chemotherapy&doi=10.1155%2F2010%2F430939"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2010%2F430939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2010%252F430939%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BH.%2BW.%26aulast%3DKuo%26aufirst%3DM.%2BT.%26atitle%3DRole%2520of%2520glutathione%2520in%2520the%2520regulation%2520of%2520cisplatin%2520resistance%2520in%2520cancer%2520chemotherapy%26jtitle%3DMet.-Based%2520Drugs%26date%3D2010%26volume%3D2010%26spage%3D430939%26doi%3D10.1155%2F2010%2F430939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olaussen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountzios, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer</span>. <i>Curr. Opin. Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1097/MCP.0b013e32816b5c63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2FMCP.0b013e32816b5c63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=17534174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVajur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=284-289&author=K.+A.+Olaussenauthor=G.+Mountziosauthor=J.-C.+Soria&title=ERCC1+as+a+risk+stratifier+in+platinum-based+chemotherapy+for+nonsmall-cell+lung+cancer&doi=10.1097%2FMCP.0b013e32816b5c63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer</span></div><div class="casAuthors">Olaussen, Ken Andre; Mountzios, Giannis; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">284-289</span>CODEN:
                <span class="NLM_cas:coden">COPMFY</span>;
        ISSN:<span class="NLM_cas:issn">1070-5287</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  High ERCC1 expression is predictive of resistance to platinum-based therapy.  Thus, there is solid evidence to support ERCC1 as a useful marker of clin. resistance to platinum-based chemotherapy in the adjuvant setting of nonsmall-cell lung cancer.  Meanwhile, optimization of methodol. and standardization of tech. procedures seem necessary before larger prospective studies can address the same question.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruNAbPz6aB6rVg90H21EOLACvtfcHk0lg-VDwKoddAWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVajur0%253D&md5=743b4f9b02e1b1eb88190ab6a372755e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e32816b5c63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e32816b5c63%26sid%3Dliteratum%253Aachs%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DMountzios%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DERCC1%2520as%2520a%2520risk%2520stratifier%2520in%2520platinum-based%2520chemotherapy%2520for%2520nonsmall-cell%2520lung%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D284%26epage%3D289%26doi%3D10.1097%2FMCP.0b013e32816b5c63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enot, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaussen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.4161/cc.24034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.4161%2Fcc.24034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23428903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFegs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=877-883&author=J.+Michelsauthor=I.+Vitaleauthor=L.+Senovillaauthor=D.+P.+Enotauthor=P.+Garciaauthor=D.+Lissaauthor=K.+A.+Olaussenauthor=C.+Brennerauthor=J.+C.+Soriaauthor=M.+Castedoauthor=G.+Kroemer&title=Synergistic+interaction+between+cisplatin+and+PARP+inhibitors+in+non-small+cell+lung+cancer&doi=10.4161%2Fcc.24034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Michels, Judith; Vitale, Ilio; Senovilla, Laura; Enot, David P.; Garcia, Pauline; Lissa, Delphine; Olaussen, Ken A.; Brenner, Catherine; Soria, Jean-Charles; Castedo, Maria; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">877-883</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective std. treatment of non-small cell lung carcinoma (NSCLC).  Here, we report a novel strategy to improve the efficacy of CDDP.  In conditions in which CDDP alone or either of two PARP inhibitors, PJ34 hydrochloride hydrate or CEP 8983, used as standalone treatments were inefficient in killing NSCLC cells, the combination of CDDP plus PJ34 or that of CDDP plus CEP 8983 were found to kill a substantial fraction of the cells.  This cytotoxic synergy could be recapitulated by combining CDDP and the siRNA-mediated depletion of the principal PARP isoform, PARP1, indicating that it is mediated by on-target effects of PJ34 or CEP 8983.  CDDP and PARP inhibitors synergized in inducing DNA damage foci, mitochondrial membrane permeabilization leading to cytochrome c release, and dissipation of the inner transmembrane potential, caspase activation, plasma membrane rupture and loss of clonogenic potential in NSCLC cells.  Collectively, our results indicate that CDDP can be advantageously combined with PARP inhibitors to kill several NSCLC cell lines, independently from their p53 status.  Combined treatment with CDDP and PARP inhibitors elicits the intrinsic pathway of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvs-_LhEGU-LVg90H21EOLACvtfcHk0lg-VDwKoddAWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFegs7c%253D&md5=1b4e720bd82ae15ac0d8363aaf4ee994</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4161%2Fcc.24034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.24034%26sid%3Dliteratum%253Aachs%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DEnot%26aufirst%3DD.%2BP.%26aulast%3DGarcia%26aufirst%3DP.%26aulast%3DLissa%26aufirst%3DD.%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DBrenner%26aufirst%3DC.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DSynergistic%2520interaction%2520between%2520cisplatin%2520and%2520PARP%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCell%2520Cycle%26date%3D2013%26volume%3D12%26spage%3D877%26epage%3D883%26doi%3D10.4161%2Fcc.24034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span> <span> </span><span class="NLM_article-title">DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3799</span>– <span class="NLM_lpage">3808</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.05.4171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1200%2FJCO.2005.05.4171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16896009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVaqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=3799-3808&author=R.+D.+Kennedyauthor=A.+D.+D%E2%80%99Andrea&title=DNA+repair+pathways+in+clinical+practice%3A+lessons+from+pediatric+cancer+susceptibility+syndromes&doi=10.1200%2FJCO.2005.05.4171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes</span></div><div class="casAuthors">Kennedy, Richard D.; D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3799-3808</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair.  Cancer cells are often defective in one of six major DNA repair pathways, namely: mismatch repair, base excision repair, nucleotide excision repair, homologous recombination, nonhomologous endjoining and translesion synthesis.  The specific DNA repair pathway affected is predictive of the kinds of mutations, the tumor drug sensitivity, and the treatment outcome.  The study of rare inherited DNA repair disorders, such as Fanconi anemia, has yielded new insights to drug sensitivity and treatment of sporadic cancers, such as breast or ovarian epithelial tumors, in the general population.  The Fanconi anemia pathway is an example of how DNA repair pathways can be deregulated in cancer cells and how biomarkers of the integrity of these pathways could be useful as a guide to cancer management and may be used in the development of novel therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUIOsyxbFHCrVg90H21EOLACvtfcHk0lg-VDwKoddAWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVaqsLw%253D&md5=c4e88a82fe518518dea05a7791d6558d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.05.4171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.05.4171%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DR.%2BD.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DDNA%2520repair%2520pathways%2520in%2520clinical%2520practice%253A%2520lessons%2520from%2520pediatric%2520cancer%2520susceptibility%2520syndromes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D3799%26epage%3D3808%26doi%3D10.1200%2FJCO.2005.05.4171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fijołek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiatr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowińska-Zakrzewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giedronowicz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langfort, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orłowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszkowski, K.</span></span> <span> </span><span class="NLM_article-title">p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer</span>. <i>Int. J. Biol. Markers</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1177/172460080602100203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1177%2F172460080602100203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16847810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFWktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=81-87&author=J.+Fijo%C5%82ekauthor=E.+Wiatrauthor=E.+Rowi%C5%84ska-Zakrzewskaauthor=D.+Giedronowiczauthor=R.+Langfortauthor=M.+Chabowskiauthor=T.+Or%C5%82owskiauthor=K.+Roszkowski&title=p53+and+HER2%2Fneu+expression+in+relation+to+chemotherapy+response+in+patients+with+non-small+cell+lung+cancer&doi=10.1177%2F172460080602100203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer</span></div><div class="casAuthors">Fijolek, J.; Wiatr, E.; Rowinska-Zakrzewska, E.; Giedronowicz, D.; Langfort, R.; Chabowski, M.; Orlowski, T.; Roszkowski, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Markers</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-87</span>CODEN:
                <span class="NLM_cas:coden">IBMAEP</span>;
        ISSN:<span class="NLM_cas:issn">0393-6155</span>.
    
            (<span class="NLM_cas:orgname">Wichtig Editore</span>)
        </div><div class="casAbstract">The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy.  The study population included 67 consecutive patients with non-small cell lung cancer (NSCLC) in stage II or III who were operated on at the Institute of Tuberculosis, Warsaw, Poland, between 20 Apr. 2001 and 10 Mar. 2003.  All patients received two cycles of chemotherapy consisting of cisplatin and vinorelbine prior to the operation.  The response to therapy was assessed as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), on the basis of CT scans performed before and after neoadjuvant chemotherapy.  P53 and HER2/neu protein expression were evaluated by immunohistochem. (IHC) using antibodies against p53 (clone PAb 1801, Novocastra) and against HER2/neu (Dako) in paraffin-embedded specimens of tumors.  A response to therapy (CR+PR) was obsd. in 27 patients, while 40 patients (SD+PD) were regarded as resistant to therapy.  Resistance was obsd. significantly more often in tumors above 3 cm in diam.  P53 expression was found in 16 tumors (23.9%) and HER2/neu in 26 tumors (38.8%).  We obsd. a nonsignificant tendency to chemoresistance in tumors with HER-2/neu overexpression and also in tumors with p53 overexpression.  If we consider HER-2/neu and p53 together, chemoresistance was obsd. statistically significantly more often when one or both markers were pos. (p<0.05).  This significance was independent of tumor size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5IyIFPHMLhLVg90H21EOLACvtfcHk0li5dy0q6Pgscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFWktLs%253D&md5=22f6fdbad1bc9c2a5e7c59a12a5293b6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F172460080602100203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F172460080602100203%26sid%3Dliteratum%253Aachs%26aulast%3DFijo%25C5%2582ek%26aufirst%3DJ.%26aulast%3DWiatr%26aufirst%3DE.%26aulast%3DRowi%25C5%2584ska-Zakrzewska%26aufirst%3DE.%26aulast%3DGiedronowicz%26aufirst%3DD.%26aulast%3DLangfort%26aufirst%3DR.%26aulast%3DChabowski%26aufirst%3DM.%26aulast%3DOr%25C5%2582owski%26aufirst%3DT.%26aulast%3DRoszkowski%26aufirst%3DK.%26atitle%3Dp53%2520and%2520HER2%252Fneu%2520expression%2520in%2520relation%2520to%2520chemotherapy%2520response%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Biol.%2520Markers%26date%3D2006%26volume%3D21%26spage%3D81%26epage%3D87%26doi%3D10.1177%2F172460080602100203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, P.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.-I.</span></span> <span> </span><span class="NLM_article-title">Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2005.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.bcp.2005.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16004971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=658-667&author=J.+Linauthor=P.-W.+Hsiaoauthor=T.+H.+Chiuauthor=J.-I.+Chao&title=Combination+of+cyclooxygenase-2+inhibitors+and+oxaliplatin+increases+the+growth+inhibition+and+death+in+human+colon+cancer+cells&doi=10.1016%2Fj.bcp.2005.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells</span></div><div class="casAuthors">Lin, Johnson; Hsiao, Po-Wen; Chiu, Ted H.; Chao, Jui-I.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">658-667</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cyclooxygenase-2 (COX-2) protein is highly expressed in a variety of human cancers and has been reported to promote tumor growth.  Non-steroidal anti-inflammatory drugs such as etodolac and celecoxib have been shown to inhibit COX-2 activity and may play a role in the chemoprevention of cancer.  Oxaliplatin is a third-generation platinum compd. that exhibits a different spectrum of activity compared with cisplatin.  Other cisplatin-resistant tumors can still respond to oxaliplatin.  However, the anticancer ability of the combination of COX-2 inhibitors and oxaliplatin is still unknown.  In this study, we investigated the effects of combination of COX-2 inhibitors and oxaliplatin on the cell growth and survival in human colon cancer cells.  Treatments with etodolac (0.3-0.5 mM) or celecoxib (20-80 μM) for 24 h concn.-dependently induced the cytotoxicity in the RKO colon carcinoma cells.  Etodolac and celecoxib did not alter the COX-2 protein levels but inhibited its enzyme activity to reduce prostaglandin E2 prodn.  Furthermore, the cell survival was concn.-dependently decreased following oxaliplatin (1-100 μM, 24 h) treatment.  Combination of oxaliplatin and etodolac additively increased the death and growth inhibition of RKO cells.  Survivin, an inhibitor protein of apoptosis, mediates anti-apoptosis and promotes cell division in cancer cells.  Oxaliplatin or COX-2 inhibitors significantly decreased the levels of survivin proteins.  Moreover, survivin proteins were markedly diminished following co-treatment with oxaliplatin and etodolac.  Together, this is the first report that combination of COX-2 inhibitors and oxaliplatin can increase the redn. of survivin protein expression, growth inhibition, and death in human colon cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAfA_FTW3tP7Vg90H21EOLACvtfcHk0li5dy0q6Pgscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrs%253D&md5=a4e3c4b0af0d01a1d3fb8624103c1410</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2005.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2005.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DP.-W.%26aulast%3DChiu%26aufirst%3DT.%2BH.%26aulast%3DChao%26aufirst%3DJ.-I.%26atitle%3DCombination%2520of%2520cyclooxygenase-2%2520inhibitors%2520and%2520oxaliplatin%2520increases%2520the%2520growth%2520inhibition%2520and%2520death%2520in%2520human%2520colon%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2005%26volume%3D70%26spage%3D658%26epage%3D667%26doi%3D10.1016%2Fj.bcp.2005.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panichpisal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtzman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, K.</span></span> <span> </span><span class="NLM_article-title">Cisplatin nephrotoxicity: a review</span>. <i>Am. J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1097/MAJ.0b013e31812dfe1e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2FMAJ.0b013e31812dfe1e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=17700201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BD2svot1Gqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2007&pages=115-124&author=X.+Yaoauthor=K.+Panichpisalauthor=N.+Kurtzmanauthor=K.+Nugent&title=Cisplatin+nephrotoxicity%3A+a+review&doi=10.1097%2FMAJ.0b013e31812dfe1e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin nephrotoxicity: a review</span></div><div class="casAuthors">Yao Xin; Panichpisal Kessarin; Kurtzman Neil; Nugent Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of the medical sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-24</span>
        ISSN:<span class="NLM_cas:issn">0002-9629</span>.
    </div><div class="casAbstract">BACKGROUND:  Cisplatin is a major antineoplastic drug for the treatment of solid tumors, but it has dose-dependent renal toxicity.  METHODS:  We reviewed clinical and experimental literature on cisplatin nephrotoxicity to identify new information on the mechanism of injury and potential approaches to prevention and/or treatment.  RESULTS:  Unbound cisplatin is freely filtered at the glomerulus and taken up into renal tubular cells mainly by a transport-mediated process.  The drug is at least partially metabolized into toxic species.  Cisplatin has multiple intracellular effects, including regulating genes, causing direct cytotoxicity with reactive oxygen species, activating mitogen-activated protein kinases, inducing apoptosis, and stimulating inflammation and fibrogenesis.  These events cause tubular damage and tubular dysfunction with sodium, potassium, and magnesium wasting.  Most patients have a reversible decrease in glomerular filtration, but some have an irreversible decrease in glomerular filtration.  Volume expansion and saline diuresis remain the most effective preventive strategies.  CONCLUSIONS:  Understanding the mechanisms of injury has led to multiple approaches to prevention.  Furthermore, the experimental approaches in these studies with cisplatin are potentially applicable to other drugs causing renal dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTPybNzmIWpnthwrmtH4OBfW6udTcc2eZRdBMbt4CzVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svot1Gqsw%253D%253D&md5=200e6829fafd9fe4b941ee5f387412e6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FMAJ.0b013e31812dfe1e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMAJ.0b013e31812dfe1e%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DX.%26aulast%3DPanichpisal%26aufirst%3DK.%26aulast%3DKurtzman%26aufirst%3DN.%26aulast%3DNugent%26aufirst%3DK.%26atitle%3DCisplatin%2520nephrotoxicity%253A%2520a%2520review%26jtitle%3DAm.%2520J.%2520Med.%2520Sci.%26date%3D2007%26volume%3D334%26spage%3D115%26epage%3D124%26doi%3D10.1097%2FMAJ.0b013e31812dfe1e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vougiouka, M.</span></span> <span> </span><span class="NLM_article-title">Cisplatin and platinum drugs at the molecular level (Review)</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1663</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.3892/or.10.6.1663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2For.10.6.1663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14534679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlCktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=1663-1682&author=T.+Boulikasauthor=M.+Vougiouka&title=Cisplatin+and+platinum+drugs+at+the+molecular+level+%28Review%29&doi=10.3892%2For.10.6.1663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin and platinum drugs at the molecular level (review)</span></div><div class="casAuthors">Boulikas, Teni; Vougiouka, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1663-1682</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review.  Over twenty years of intensive work toward improvement of cisplatin, and with hundreds of platinum drugs tested, has resulted in the introduction of the widely used carboplatin and of oxaliplatin used only for a very narrow spectrum of cancers.  A no. of interesting platinum compds. including the orally administered platinum drug JM216, nedaplatin, the sterically hindered platinum(II) complex ZD0473, the trinuclear platinum complex BBR3464, and the liposomal forms Lipoplatin and SPI-77 are under clin. evaluation.  This review summarizes the mol. mechanisms of platinum compds. for DNA damage, DNA repair and induction of apoptosis via activation or modulation of signaling pathways and explores the basis of platinum resistance.  Cisplatin, carboplatin, oxaliplatin and most other platinum compds. induce damage to tumors via induction of apoptosis; this is mediated by activation of signal transduction leading to the death receptor mechanisms as well as mitochondrial pathways.  Apoptosis is responsible for the characteristic nephrotoxicity, ototoxicity and most other toxicities of the drugs.  The major limitation in the clin. applications of cisplatin has been the development of cisplatin resistance by tumors.  Mechanisms explaining cisplatin resistance include the redn. in cisplatin accumulation inside cancer cells because of barriers across the cell membrane, the faster repair of cisplatin adducts, the modulation of apoptotic pathways in various cells, the upregulation in transcription factors, the loss of p53 and other protein functions and a higher concn. of glutathione and metallothioneins in some type of tumors.  A no. of exptl. strategies to overcome cisplatin resistance are at the preclin. or clin. level such as introduction of the bax gene, inhibition of the JNK pathway, introduction of a functional p53 gene, treatment of tumors with aldose reductase inhibitors and others.  Particularly important are combinations of platinum drug treatments with other drugs, radiation and the emerging gene therapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOSyOTbjr4WbVg90H21EOLACvtfcHk0lijIVsjOaMpzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlCktLw%253D&md5=8b05bc59535fd156495ef6d47fa16b62</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3892%2For.10.6.1663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.10.6.1663%26sid%3Dliteratum%253Aachs%26aulast%3DBoulikas%26aufirst%3DT.%26aulast%3DVougiouka%26aufirst%3DM.%26atitle%3DCisplatin%2520and%2520platinum%2520drugs%2520at%2520the%2520molecular%2520level%2520%2528Review%2529%26jtitle%3DOncol.%2520Rep.%26date%3D2003%26volume%3D10%26spage%3D1663%26epage%3D1682%26doi%3D10.3892%2For.10.6.1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Gonzalez, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Hernandez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Barriocanal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Novoa, J. M.</span></span> <span> </span><span class="NLM_article-title">Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity</span>. <i>Nephrol., Dial., Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3484</span>– <span class="NLM_lpage">3495</span>, <span class="refDoi"> DOI: 10.1093/ndt/gfr195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1093%2Fndt%2Fgfr195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=21602180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=3484-3495&author=P.+D.+Sanchez-Gonzalezauthor=F.+J.+Lopez-Hernandezauthor=F.+Perez-Barriocanalauthor=A.+I.+Moralesauthor=J.+M.+Lopez-Novoa&title=Quercetin+reduces+cisplatin+nephrotoxicity+in+rats+without+compromising+its+anti-tumour+activity&doi=10.1093%2Fndt%2Fgfr195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity</span></div><div class="casAuthors">Sanchez-Gonzalez, Penelope D.; Lopez-Hernandez, Francisco J.; Perez-Barriocanal, Fernando; Morales, Ana I.; Lopez-Novoa, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3484-3495</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Nephrotoxicity is the major limitation for the clin. use of cisplatin as an anti-tumoral drug.  Our aim was to investigate the protective effect of quercetin on cisplatin nephrotoxicity in a rat tumor model in vivo and to examine the mechanisms of renal protection.  Methods: Breast adenocarcinoma (13762 Mat B-III) cells were inoculated s.c. in male Fischer rats and 7 days later, the rats were administered daily with quercetin [50 mg/kg/day, i.p. (i.p.)] or vehicle.  Four days after that, the rats were given a single dose of cisplatin (4 mg/kg, i.p.) or vehicle.  Tumor growth and renal function were monitored throughout the expt.  Two or 6 days after cisplatin administration, the rats were killed and the kidneys and tumors were removed to examine renal function and toxicity markers in both tissues.  Results: In the kidney, cisplatin treatment induced: (i) a decrease in renal blood flow and glomerular filtration rate, (ii) tubular necrosis/apoptosis, (iii) increased lipid peroxidn. and decreased endogenous antioxidant systems, (iv) increased expression of inflammation markers and (v) increased activity of the apoptosis executioner caspase-3.  Cisplatin effectively reduced tumor size and wt.  Conclusions: Co-treatment with quercetin partially prevented all the renal effects of cisplatin, whereas it did not impair its anti-tumor activity.  In conclusion, in a model of tumor-bearing rats, quercetin prevents the nephrotoxic effect of cisplatin without affecting its anti-tumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPkaWqK0K3wrVg90H21EOLACvtfcHk0lijIVsjOaMpzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtrnN&md5=e9e8bb03a9754d9d926dfc1b77999c31</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfr195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfr195%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Gonzalez%26aufirst%3DP.%2BD.%26aulast%3DLopez-Hernandez%26aufirst%3DF.%2BJ.%26aulast%3DPerez-Barriocanal%26aufirst%3DF.%26aulast%3DMorales%26aufirst%3DA.%2BI.%26aulast%3DLopez-Novoa%26aufirst%3DJ.%2BM.%26atitle%3DQuercetin%2520reduces%2520cisplatin%2520nephrotoxicity%2520in%2520rats%2520without%2520compromising%2520its%2520anti-tumour%2520activity%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2011%26volume%3D26%26spage%3D3484%26epage%3D3495%26doi%3D10.1093%2Fndt%2Fgfr195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadagavadi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, W. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of cisplatin nephrotoxicity</span>. <i>Toxins</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2490</span>– <span class="NLM_lpage">2518</span>, <span class="refDoi"> DOI: 10.3390/toxins2112490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3390%2Ftoxins2112490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22069563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSht7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=2490-2518&author=R.+P.+Millerauthor=R.+K.+Tadagavadiauthor=G.+Rameshauthor=W.+B.+Reeves&title=Mechanisms+of+cisplatin+nephrotoxicity&doi=10.3390%2Ftoxins2112490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cisplatin nephrotoxicity</span></div><div class="casAuthors">Miller, Ronald P.; Tadagavadi, Raghu K.; Ramesh, Ganesan; Reeves, William Brian</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2490-2518</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Cisplatin is a widely used and highly effective cancer chemotherapeutic agent.  One of the limiting side effects of cisplatin use is nephrotoxicity.  Research over the past 10 years has uncovered many of the cellular mechanisms which underlie cisplatin-induced renal cell death.  It has also become apparent that inflammation provoked by injury to renal epithelial cells serves to amplify kidney injury and dysfunction in vivo.  This review summarizes recent advances in our understanding of cisplatin nephrotoxicity and discusses how these advances might lead to more effective prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquPxscC-wQ87Vg90H21EOLACvtfcHk0lijIVsjOaMpzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSht7vJ&md5=7fd6f1103c5e8185eeae1b2d9e9f3969</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Ftoxins2112490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins2112490%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BP.%26aulast%3DTadagavadi%26aufirst%3DR.%2BK.%26aulast%3DRamesh%26aufirst%3DG.%26aulast%3DReeves%26aufirst%3DW.%2BB.%26atitle%3DMechanisms%2520of%2520cisplatin%2520nephrotoxicity%26jtitle%3DToxins%26date%3D2010%26volume%3D2%26spage%3D2490%26epage%3D2518%26doi%3D10.3390%2Ftoxins2112490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">dos
Santos, N. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho Rodrigues, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dos Santos, A. C.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1233</span>– <span class="NLM_lpage">1250</span>, <span class="refDoi"> DOI: 10.1007/s00204-012-0821-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs00204-012-0821-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22382776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC38vltVGltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=1233-1250&author=N.+A.+G.+dos%0ASantosauthor=M.+A.+Carvalho+Rodriguesauthor=N.+M.+Martinsauthor=A.+C.+dos+Santos&title=Cisplatin-induced+nephrotoxicity+and+targets+of+nephroprotection%3A+an+update&doi=10.1007%2Fs00204-012-0821-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update</span></div><div class="casAuthors">dos Santos Neife Aparecida Guinaim; Carvalho Rodrigues Maria Augusta; Martins Nadia Maria; dos Santos Antonio Cardozo</div><div class="citationInfo"><span class="NLM_cas:title">Archives of toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1233-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cisplatin is a highly effective antitumor agent whose clinical application is limited by the inherent nephrotoxicity.  The current measures of nephroprotection used in patients receiving cisplatin are not satisfactory, and studies have focused on the investigation of new possible protective strategies.  Many pathways involved in cisplatin nephrotoxicity have been delineated and proposed as targets for nephroprotection, and many new potentially protective agents have been reported.  The multiple pathways which lead to renal damage and renal cell death have points of convergence and share some common modulators.  The most frequent event among all the described pathways is the oxidative stress that acts as both a trigger and a result.  The most exploited pathways, the proposed protective strategies, the achievements obtained so far as well as conflicting data are summarized and discussed in this review, providing a general view of the knowledge accumulated with past and recent research on this subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvux3PMKPEWvIW7hznt0zpfW6udTcc2eZUd-rbG1fj77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vltVGltQ%253D%253D&md5=6270fa2ce55282ee31669c3c5d39c15c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs00204-012-0821-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-012-0821-7%26sid%3Dliteratum%253Aachs%26aulast%3Ddos%2BSantos%26aufirst%3DN.%2BA.%2BG.%26aulast%3DCarvalho%2BRodrigues%26aufirst%3DM.%2BA.%26aulast%3DMartins%26aufirst%3DN.%2BM.%26aulast%3Ddos%2BSantos%26aufirst%3DA.%2BC.%26atitle%3DCisplatin-induced%2520nephrotoxicity%2520and%2520targets%2520of%2520nephroprotection%253A%2520an%2520update%26jtitle%3DArch.%2520Toxicol.%26date%3D2012%26volume%3D86%26spage%3D1233%26epage%3D1250%26doi%3D10.1007%2Fs00204-012-0821-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chirino, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedraza-Chaverri, J.</span></span> <span> </span><span class="NLM_article-title">Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.etp.2008.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.etp.2008.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18986801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmt1GmtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=223-242&author=Y.+I.+Chirinoauthor=J.+Pedraza-Chaverri&title=Role+of+oxidative+and+nitrosative+stress+in+cisplatin-induced+nephrotoxicity&doi=10.1016%2Fj.etp.2008.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Chirino, Yolanda I.; Pedraza-Chaverri, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-242</span>CODEN:
                <span class="NLM_cas:coden">ETPAEK</span>;
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">A review.  Cis-Diamminedichloroplatinum (II) (cisplatin) is an important chemotherapeutic agent useful in the treatment of several cancers; however, it has several side effects such as nephrotoxicity.  The role of the oxidative and nitrosative stress in cisplatin-induced nephrotoxicity is addnl. supported by the protective effect of several free radical scavengers and antioxidants.  Furthermore, in in vitro expts., antioxidants or reactive oxygen species (ROS) scavengers have a cytoprotective effect on cells exposed to cisplatin.  Recently, the participation of nitrosative stress has been more explored in cisplatin-induced renal damage.  The use of a water-sol. Fe(III) porphyrin complex able to metabolize peroxynitrite (ONOO-) has demonstrated that this anion contributes to both in vivo and in vitro cisplatin-induced toxicity.  ONOO- is produced when nitric oxide (NO·) reacts with superoxide anion (O2·-); currently, there are evidences suggesting alterations in NO· prodn. after cisplatin treatment and the evidence appear to NO· has a toxic effect.  This article goes through current evidence of the mechanism by more than a few compds. have beneficial effects on cisplatin-induced nephrotoxicity, contribute to understanding the role of oxidative and nitrosative stress and suggest several points as part of the mechanism of cisplatin toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YkkrI3WvC7Vg90H21EOLACvtfcHk0lhfGe6BnCi94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmt1GmtL4%253D&md5=59b80730d1ab240bfa2fd44b94108568</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.etp.2008.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.etp.2008.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DChirino%26aufirst%3DY.%2BI.%26aulast%3DPedraza-Chaverri%26aufirst%3DJ.%26atitle%3DRole%2520of%2520oxidative%2520and%2520nitrosative%2520stress%2520in%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2009%26volume%3D61%26spage%3D223%26epage%3D242%26doi%3D10.1016%2Fj.etp.2008.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koyner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher Ali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. T.</span></span> <span> </span><span class="NLM_article-title">Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury?</span>. <i>Nephron Exp. Nephrol</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">e109</span>– <span class="NLM_lpage">e117</span>, <span class="refDoi"> DOI: 10.1159/000142935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1159%2F000142935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18802373" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2008&pages=e109-e117&author=J.+L.+Koynerauthor=R.+Sher+Aliauthor=P.+T.+Murray&title=Antioxidants.+Do+they+have+a+place+in+the+prevention+or+therapy+of+acute+kidney+injury%3F&doi=10.1159%2F000142935"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1159%2F000142935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000142935%26sid%3Dliteratum%253Aachs%26aulast%3DKoyner%26aufirst%3DJ.%2BL.%26aulast%3DSher%2BAli%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DP.%2BT.%26atitle%3DAntioxidants.%2520Do%2520they%2520have%2520a%2520place%2520in%2520the%2520prevention%2520or%2520therapy%2520of%2520acute%2520kidney%2520injury%253F%26jtitle%3DNephron%2520Exp.%2520Nephrol%26date%3D2008%26volume%3D109%26spage%3De109%26epage%3De117%26doi%3D10.1159%2F000142935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span> <span> </span><span class="NLM_article-title">Cisplatin nephrotoxicity: mechanisms and renoprotective strategies</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1038/sj.ki.5002786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fsj.ki.5002786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18272962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12nsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=994-1007&author=N.+Pablaauthor=Z.+Dong&title=Cisplatin+nephrotoxicity%3A+mechanisms+and+renoprotective+strategies&doi=10.1038%2Fsj.ki.5002786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies</span></div><div class="casAuthors">Pabla, N.; Dong, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">994-1007</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin is one of the most widely used and most potent chemotherapy drugs.  However, side effects in normal tissues and organs, notably nephrotoxicity in the kidneys, limit the use of cisplatin and related platinum-based therapeutics.  Recent research has shed significant new lights on the mechanism of cisplatin nephrotoxicity, esp. on the signaling pathways leading to tubular cell death and inflammation.  Renoprotective approaches are being discovered, but the protective effects are mostly partial, suggesting the need for combinatorial strategies.  Importantly, it is unclear whether these approaches would limit the anticancer effects of cisplatin in tumors.  Examn. of tumor-bearing animals and identification of novel renoprotective strategies that do not diminish the anticancer efficacy of cisplatin are essential to the development of clin. applicable interventions.  Kidney International (2008) 73, 994-1007; doi:10.1038/sj.ki.5002786; published online 13 Feb. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSefTtDpSoxbVg90H21EOLACvtfcHk0lhfGe6BnCi94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12nsr8%253D&md5=76caa1316c4d3ac1177446f45bc7de82</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5002786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5002786%26sid%3Dliteratum%253Aachs%26aulast%3DPabla%26aufirst%3DN.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DCisplatin%2520nephrotoxicity%253A%2520mechanisms%2520and%2520renoprotective%2520strategies%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D73%26spage%3D994%26epage%3D1007%26doi%3D10.1038%2Fsj.ki.5002786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2709</span>– <span class="NLM_lpage">2722</span>, <span class="refDoi"> DOI: 10.1172/JCI45586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1172%2FJCI45586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=21633170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2709-2722&author=N.+Pablaauthor=G.+Dongauthor=M.+Jiangauthor=S.+Huangauthor=M.+V.+Kumarauthor=R.+O.+Messingauthor=Z.+Dong&title=Inhibition+of+PKC%CE%B4+reduces+cisplatin-induced+nephrotoxicity+without+blocking+chemotherapeutic+efficacy+in+mouse+models+of+cancer&doi=10.1172%2FJCI45586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer</span></div><div class="casAuthors">Pabla, Navjotsingh; Dong, Guie; Jiang, Man; Huang, Shuang; Kumar, M. Vijay; Messing, Robert O.; Dong, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2709-2722</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Cisplatin is a widely used cancer therapy drug that unfortunately has major side effects in normal tissues, notably nephrotoxicity in kidneys.  Despite intensive research, the mechanism of cisplatin-induced nephrotoxicity remains unclear, and renoprotective approaches during cisplatin-based chemotherapy are lacking.  Here we have identified PKCδ as a crit. regulator of cisplatin nephrotoxicity, which can be effectively targeted for renoprotection during chemotherapy.  We showed that early during cisplatin nephrotoxicity, Src interacted with, phosphorylated, and activated PKCδ in mouse kidney lysates.  After activation, PKCδ regulated MAPKs, but not p53, to induce renal cell apoptosis.  Thus, inhibition of PKCδ pharmacol. or genetically attenuated kidney cell apoptosis and tissue damage, preserving renal function during cisplatin treatment.  Conversely, inhibition of PKCδ enhanced cisplatin-induced cell death in multiple cancer cell lines and, remarkably, enhanced the chemotherapeutic effects of cisplatin in several xenograft and syngeneic mouse tumor models while protecting kidneys from nephrotoxicity.  Together these results demonstrate a role of PKCδ in cisplatin nephrotoxicity and support targeting PKCδ as an effective strategy for renoprotection during cisplatin-based cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriAC370eVshbVg90H21EOLACvtfcHk0lhfGe6BnCi94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgurY%253D&md5=20b50d1d7ac4cd7295a17bfdec34075e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1172%2FJCI45586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45586%26sid%3Dliteratum%253Aachs%26aulast%3DPabla%26aufirst%3DN.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DM.%2BV.%26aulast%3DMessing%26aufirst%3DR.%2BO.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DInhibition%2520of%2520PKC%25CE%25B4%2520reduces%2520cisplatin-induced%2520nephrotoxicity%2520without%2520blocking%2520chemotherapeutic%2520efficacy%2520in%2520mouse%2520models%2520of%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2709%26epage%3D2722%26doi%3D10.1172%2FJCI45586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clerici, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMartino, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, D. A.</span></span> <span> </span><span class="NLM_article-title">Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/0378-5955(96)00075-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2F0378-5955%2896%2900075-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=8880186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK28XmtVSqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1996&pages=116-124&author=W.+J.+Clericiauthor=K.+Hensleyauthor=D.+L.+DiMartinoauthor=D.+A.+Butterfield&title=Direct+detection+of+ototoxicant-induced+reactive+oxygen+species+generation+in+cochlear+explants&doi=10.1016%2F0378-5955%2896%2900075-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants</span></div><div class="casAuthors">Clerici, William J.; Hensley, Kenneth; DiMartino, Debra L.; Butterfield, D. Allan</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">116-124</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The proposal that free-radical generation contributes to the ototoxicities of several chem. agents was studied utilizing ESR (EPR) spectrometry to detect directly ototoxicant-induced reactive oxygen species formation in cochlear tissue.  Guinea pig cochlear explants in chelexed artificial perilymph (AP; 200 μl) were exposed to an ototoxicant or AP for 10 min.  Ototoxic agents included gentamicin sulfate (4.0 mM), kanamycin monosulfate (4.0 mM), ethacrynic acid (0.5 mM), furosemide (0.3 mM), cisplatin (0.1 mM), trimethyltin chloride (0.1 mM), and quinine HCl (3.0 mM).  Following incubation, 20 μl of AP/ototoxicant mixt. was replaced by the filtered spin trap, 5,5-dimethylpyrroline-N-oxide (DMPO).  After 10 min, the EPR spectrum of the mixt. was obtained.  Four line EPR spectra of relative intensities 1:2:2:1, assocd. with hydroxyl radical (OH.)/DMPO adduct formation, were evidenced by reaction mixts. contg. cochlear explants exposed to each ototoxicant.  Cisplatin, quinine and the loop diuretics produced weak OH.-assocd. EPR signals in the absence of a cochlear explant, which were amplified in its presence.  Deferoxamine quenched all OH. spectral peaks.  Peroxide levels, assayed in parallel expts., were diminished by each ototoxicant relative to those seen following AP exposure, suggesting possible H2O2 conversion to OH..  These data support the proposal that various ototoxic agents are capable of reactive oxygen species generation or promotion in cochlear tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzujguZOsDZbVg90H21EOLACvtfcHk0lgOt5TE1vkh5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtVSqsLc%253D&md5=6839be8d17fee5c8927d802a0f34016d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0378-5955%2896%2900075-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-5955%252896%252900075-5%26sid%3Dliteratum%253Aachs%26aulast%3DClerici%26aufirst%3DW.%2BJ.%26aulast%3DHensley%26aufirst%3DK.%26aulast%3DDiMartino%26aufirst%3DD.%2BL.%26aulast%3DButterfield%26aufirst%3DD.%2BA.%26atitle%3DDirect%2520detection%2520of%2520ototoxicant-induced%2520reactive%2520oxygen%2520species%2520generation%2520in%2520cochlear%2520explants%26jtitle%3DHear.%2520Res.%26date%3D1996%26volume%3D98%26spage%3D116%26epage%3D124%26doi%3D10.1016%2F0378-5955%2896%2900075-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L. Q.</span></span> <span> </span><span class="NLM_article-title">Apelin-13 attenuates cisplatin-induced cardiotoxicity through inhibition of ROS-mediated DNA damage and regulation of MAPKs and AKT pathways</span>. <i>Free Radical Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1080/10715762.2017.1313414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1080%2F10715762.2017.1313414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28554248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFCmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2017&pages=449-459&author=P.+Zhangauthor=L.+H.+Yiauthor=G.+Y.+Mengauthor=H.+Y.+Zhangauthor=H.+H.+Sunauthor=L.+Q.+Cui&title=Apelin-13+attenuates+cisplatin-induced+cardiotoxicity+through+inhibition+of+ROS-mediated+DNA+damage+and+regulation+of+MAPKs+and+AKT+pathways&doi=10.1080%2F10715762.2017.1313414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Apelin-13 attenuates cisplatin-induced cardiotoxicity through inhibition of ROS-mediated DNA damage and regulation of MAPKs and AKT pathways</span></div><div class="casAuthors">Zhang, Pu; Yi, Lu-hua; Meng, Guang-yuan; Zhang, Huan-yi; Sun, Hai-hui; Cui, Lian-qun</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-459</span>CODEN:
                <span class="NLM_cas:coden">FRARER</span>;
        ISSN:<span class="NLM_cas:issn">1029-2470</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Platinum-based chemotherapy represents one of the most effective ways in combating human cancers.  However, the cardiotoxicity subsequent severely limited its clin. application.  Increased evidences indicate that oxidative stress plays a crucial role in the pathol. process of platinum-induced cardiotoxicity.  It is reported that apelin-13 a bioactive peptide has the scavenging capacity of free radical, and it has the potential to regulate the cardiovascular system.  Hence, the potential of apelin-13 to antagonize cisplatin-induced cardiotoxicity was evaluated in H9c2 rat myocardial cells in vitro and in C57 mice in vivo.  The results showed that cisplatin indeed caused DNA damage in H9c2 cells by promoting the accumulation of intracellular reactive oxygen species (ROS) and superoxide anion, which led to cell apoptosis and resulted in overt cardiotoxicity.  However, apelin-13 pre-treatment effectively attenuated the cisplatin-induced ROS and superoxide anion generation, inhibited DNA damage, and suppressed the PARP cleavage and caspases activation.  Further investigation revealed that apelin-13 blocked cisplatin-induced H9c2 cells apoptosis involving the regulation of MAPKs and PI3K/Akt signaling pathway.  Importantly, apelin-13 co-treatment also significantly attenuated cisplatin-induced cardiotoxicity in vivo by inhibiting myocardial cells apoptosis and improving angiogenesis in mice heart.  Taken together, our results suggest that the use of apelin-13 may be an effective strategy for antagonizing the cardiotoxicity-induced by platinum-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAWRysC59xuLVg90H21EOLACvtfcHk0lgOt5TE1vkh5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFCmtLY%253D&md5=fd477522eade9b55ab2c11aff87f76eb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F10715762.2017.1313414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10715762.2017.1313414%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYi%26aufirst%3DL.%2BH.%26aulast%3DMeng%26aufirst%3DG.%2BY.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DCui%26aufirst%3DL.%2BQ.%26atitle%3DApelin-13%2520attenuates%2520cisplatin-induced%2520cardiotoxicity%2520through%2520inhibition%2520of%2520ROS-mediated%2520DNA%2520damage%2520and%2520regulation%2520of%2520MAPKs%2520and%2520AKT%2520pathways%26jtitle%3DFree%2520Radical%2520Res.%26date%3D2017%26volume%3D51%26spage%3D449%26epage%3D459%26doi%3D10.1080%2F10715762.2017.1313414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamesdaniel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, W. L.</span></span> <span> </span><span class="NLM_article-title">Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2016.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.redox.2016.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27821327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=257-265&author=S.+Jamesdanielauthor=R.+Rathinamauthor=W.+L.+Neumann&title=Targeting+nitrative+stress+for+attenuating+cisplatin-induced+downregulation+of+cochlear+LIM+domain+only+4+and+ototoxicity&doi=10.1016%2Fj.redox.2016.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity</span></div><div class="casAuthors">Jamesdaniel, Samson; Rathinam, Rajamani; Neumann, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">257-265</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cisplatin-induced ototoxicity remains a primary dose-limiting adverse effect of this highly effective anticancer drug.  The clin. utility of cisplatin could be enhanced if the signaling pathways that regulate the toxic side-effects are delineated.  In previous studies, we reported cisplatin-induced nitration of cochlear proteins and provided the first evidence for nitration and downregulation of cochlear LIM domain only 4 (LMO4) in cisplatin ototoxicity.  Here, we extend these findings to define the crit. role of nitrative stress in cisplatin-induced downregulation of LMO4 and its consequent ototoxic effects in UBOC1 cell cultures derived from sensory epithelial cells of the inner ear and in CBA/J mice.  Cisplatin treatment increased the levels of nitrotyrosine and active caspase 3 in UBOC1 cells, which was detected by immunocytochem. and flow cytometry anal., resp.  The cisplatin-induced nitrative stress and apoptosis were attenuated by co-treatment with SRI110, a peroxynitrite decompn. catalyst (PNDC), which also attenuated the cisplatin-induced downregulation of LMO4 in a dose-dependent manner.  Furthermore, transient overexpression of LMO4 in UBOC1 cells prevented cisplatin-induced cytotoxicity while repression of LMO4 exacerbated cisplatin-induced cell death, indicating a direct link between LMO4 protein levels and cisplatin ototoxicity.  Finally, auditory brainstem responses (ABR) recorded from CBA/J mice indicated that co-treatment with SRI110 mitigated cisplatin-induced hearing loss.  Together, these results suggest that cisplatin-induced nitrative stress leads to a decrease in the levels of LMO4, downregulation of LMO4 is a crit. determinant in cisplatin-induced ototoxicity, and targeting peroxynitrite could be a promising strategy for mitigating cisplatin-induced hearing loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdZhRjHSF0ILVg90H21EOLACvtfcHk0lgOt5TE1vkh5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmtbzK&md5=89f0d6de9aee4b4912a96e45fcee5ae2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2016.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2016.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DJamesdaniel%26aufirst%3DS.%26aulast%3DRathinam%26aufirst%3DR.%26aulast%3DNeumann%26aufirst%3DW.%2BL.%26atitle%3DTargeting%2520nitrative%2520stress%2520for%2520attenuating%2520cisplatin-induced%2520downregulation%2520of%2520cochlear%2520LIM%2520domain%2520only%25204%2520and%2520ototoxicity%26jtitle%3DRedox%2520Biol.%26date%3D2016%26volume%3D10%26spage%3D257%26epage%3D265%26doi%3D10.1016%2Fj.redox.2016.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2009.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.bcp.2009.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20005210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVOhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=1134-1140&author=W.+Wangauthor=Y.+P.+Sunauthor=X.+Z.+Huangauthor=M.+Heauthor=Y.+Y.+Chenauthor=G.+Y.+Shiauthor=H.+Liauthor=J.+Yiauthor=J.+Wang&title=Emodin+enhances+sensitivity+of+gallbladder+cancer+cells+to+platinum+drugs+via+glutathion+depletion+and+MRP1+downregulation&doi=10.1016%2Fj.bcp.2009.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation</span></div><div class="casAuthors">Wang, Wei; Sun, Yue-ping; Huang, Xin-zhi; He, Min; Chen, Yu-ying; Shi, Gui-ying; Li, Hui; Yi, Jing; Wang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1134-1140</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glutathione conjugation and transportation of glutathione conjugates of anticancer drugs out of cells are important for detoxification of many anticancer drugs.  Inhibition of this detoxification system has recently been proposed as a strategy to treat drug-resistant solid tumors.  Gallbladder carcinoma is resistant to many anticancer drugs, therefore, it is needed to develop a novel strategy for cancer therapy.  In the present study, we tested the effect of emodin (1,3,8-trihydroxy-6-methylanthraquinone), a reactive oxygen species (ROS) generator reported by our group previously, in combination with cisplatin (CDDP), carboplatin (CBP) or oxaliplatin in treating the gallbladder carcinoma cell line SGC996.  Our results showed that co-treatment with emodin could remarkably enhance chemosensitivity of SGC996 cells in comparison with cisplatin, carboplatin or oxaliplatin treatment alone.  We found that the mechanisms may be attributed to redn. of glutathione level, and downregulation of multidrug resistance-related protein 1 (MRP1) expression in SGC996 cells.  The expts. on tumor-bearing mice showed that emodin/cisplatin co-treatment inhibited the tumor growth in vivo via increasing tumor cell apoptosis and downregulating MRP1 expression.  In conclusion, emodin can work as an adjunct to enhance the anticancer effect of platinum drugs in gallbladder cancer cells via ROS-related mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqbt3-BVFTErVg90H21EOLACvtfcHk0lgVukAbK3x4ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVOhsbg%253D&md5=18b8229df0bc791a2daebdaa64bfbc79</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2009.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2009.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DY.%2BP.%26aulast%3DHuang%26aufirst%3DX.%2BZ.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DShi%26aufirst%3DG.%2BY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DEmodin%2520enhances%2520sensitivity%2520of%2520gallbladder%2520cancer%2520cells%2520to%2520platinum%2520drugs%2520via%2520glutathion%2520depletion%2520and%2520MRP1%2520downregulation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D79%26spage%3D1134%26epage%3D1140%26doi%3D10.1016%2Fj.bcp.2009.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span> <span> </span><span class="NLM_article-title">Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-2640-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1186%2Fs12885-016-2640-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27485374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaksL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=578-587&author=X.+Liauthor=H.+Wangauthor=J.+Wangauthor=Y.+Chenauthor=X.+Yinauthor=G.+Shiauthor=H.+Liauthor=Z.+Huauthor=X.+Liang&title=Emodin+enhances+cisplatin-induced+cytotoxicity+in+human+bladder+cancer+cells+through+ROS+elevation+and+MRP1+downregulation&doi=10.1186%2Fs12885-016-2640-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation</span></div><div class="casAuthors">Li, Xinxing; Wang, Haolu; Wang, Juan; Chen, Yuying; Yin, Xiaobin; Shi, Guiying; Li, Hui; Hu, Zhiqian; Liang, Xiaowen</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">578/1-578/10</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Chemoresistance is one of the most leading causes for tumor progression and recurrence of bladder cancer.  Reactive oxygen species (ROS) plays a key role in the chemosensitivity of cancer cells.  In the present study, emodin (1,3,8-trihydroxy-6-methylanthraquinone) was applied as a ROS generator in combination with cisplatin in T24 and J82 human bladder cancer cells.  Methods: Cell viability and apoptosis rate of different treatment groups were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry (FCM).  The expression of transporters was measured at both the transcription and translation levels using PCR and western blotting.  In vitro findings were confirmed by in vivo expts. using tumor-bearing mice.  The expression of multidrug resistance-assocd. protein 1 (MRP1) in tumor tissue was measured using immunohistochem. and side effects of the emodin/cisplatin co-treatment were investigated by histol. examn.  Results: Emodin increased the cellular ROS level and effectively enhanced the cisplatin-induced cytotoxicity of T24 and J82 human bladder cancer cells through decreasing glutathione-cisplatin (GSH-cisplatin) conjugates.  It blocked the chemoresistance of T24 and J82 cells to cisplatin through suppressing the expression of MRP1.  This effect was specific in T24 and J82 cells but not in HCV-29 normal bladder epithelial cells.  Consistent with in vitro expts., emodin/cisplatin co-treatment increased the cell apoptosis and repressed the MRP1 expression in xenograft tumors, and without obvious systemic toxicity.  Conclusions: This study revealed that emodin could increase the cisplatin-induced cytotoxicity against T24 and J82 cells via elevating the cellular ROS level and downregulating MRP1 expression.  We suggest that emodin could serve as an effective adjuvant agent for the cisplatin-based chemotherapy of bladder cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUED1VIo2xrrVg90H21EOLACvtfcHk0lgVukAbK3x4ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaksL%252FP&md5=825426bfec12004e60b59ab083b5a492</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-2640-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-2640-3%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DX.%26atitle%3DEmodin%2520enhances%2520cisplatin-induced%2520cytotoxicity%2520in%2520human%2520bladder%2520cancer%2520cells%2520through%2520ROS%2520elevation%2520and%2520MRP1%2520downregulation%26jtitle%3DBMC%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D578%26epage%3D587%26doi%3D10.1186%2Fs12885-016-2640-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohen, R.</span></span> <span> </span><span class="NLM_article-title">The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.redox.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27951496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVOlur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=170-175&author=R.+Sirotaauthor=D.+Gibsonauthor=R.+Kohen&title=The+timing+of+caffeic+acid+treatment+with+cisplatin+determines+sensitization+or+resistance+of+ovarian+carcinoma+cell+lines&doi=10.1016%2Fj.redox.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines</span></div><div class="casAuthors">Sirota, R.; Gibson, D.; Kohen, R.</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">170-175</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cisplatin is a widely used chemotherapeutic drug showing high efficiency in the treatment of primary tumors such as ovarian, testicular and cervical cancers.  The major drawback of cisplatin is tumor resistance either acquired or intrinsic.  Many mechanisms are involved in the resistance, among them is the Nrf2 pathway which regulates glutathione related enzymes.  Caffeic acid, a non-toxic polyphenol which is abundant in many foods modulates glutathione S-transferase (GST) and glutathione reductase (GSR) activity, these enzymes were shown to be involved in resistance of cells towards cisplatin.  Caffeic acid induces the Nrf2 pathway and can also inhibit the activity of GST and GSR.  Our findings demonstrate that the co-treatment of cancer cells with cisplatin and caffeic acid can enhance cisplatin cytotoxicity and increases the amt. of platinum bound to nuclear DNA.  However, 6 h of pre incubation with caffeic acid prior to cisplatin treatment led to acquired resistance to cisplatin and reduced DNA binding.  In conclusion, the enzyme inhibitory action of caffeic acid is dominant when the two agents are co-administered leading to increased cytotoxicity, and the Nrf2 induction is dominant when the cells are treated with caffeic acid prior to cisplatin treatment leading to resistance.  The use of caffeic acid as adjuvant for cisplatin should be carefully examd. due to different pharmacokinetic profiles of caffeic acid and cisplatin.  Thus, it is questionable if the two agents can reach the tumors at the right time frame in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN00ydjn1X0bVg90H21EOLACvtfcHk0lgVukAbK3x4ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVOlur7J&md5=61f8c3e7e9452fd1976b943d82bc2980</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DSirota%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DKohen%26aufirst%3DR.%26atitle%3DThe%2520timing%2520of%2520caffeic%2520acid%2520treatment%2520with%2520cisplatin%2520determines%2520sensitization%2520or%2520resistance%2520of%2520ovarian%2520carcinoma%2520cell%2520lines%26jtitle%3DRedox%2520Biol.%26date%3D2017%26volume%3D11%26spage%3D170%26epage%3D175%26doi%3D10.1016%2Fj.redox.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C. Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, T. T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsim, K. W. K.</span></span> <span> </span><span class="NLM_article-title">Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31926</span>– <span class="NLM_lpage">31939</span>, <span class="refDoi"> DOI: 10.1038/srep31926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fsrep31926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27558312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVantb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=31926-31939&author=J.-S.+Louauthor=L.+Yanauthor=C.+W.+C.+Biauthor=G.+K.+L.+Chanauthor=Q.-Y.+Wuauthor=Y.-L.+Liuauthor=Y.+Huangauthor=P.+Yaoauthor=C.+Y.+Q.+Duauthor=T.+T.+X.+Dongauthor=K.+W.+K.+Tsim&title=Yu+Ping+Feng+San+reverses+cisplatin-induced+multi-drug+resistance+in+lung+cancer+cells+via+regulating+drug+transporters+and+p62%2FTRAF6+signalling&doi=10.1038%2Fsrep31926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling</span></div><div class="casAuthors">Lou, Jian-Shu; Yan, Lu; Bi, Cathy W. C.; Chan, Gallant K. L.; Wu, Qi-Yun; Liu, Yun-Le; Huang, Yun; Yao, Ping; Du, Crystal Y. Q.; Dong, Tina T. X.; Tsim, Karl W. K.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31926</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Yu Ping Feng San (YPFS), an ancient Chinese herbal decoction composed of Astragali Radix, Atractylodis Macrocephalae Rhizoma and Saposhnikoviae Radix, has been used in the clinic for treating immune deficiency.  In cancer therapy, YPFS is being combined with chemotherapy drugs to achieve improved efficacy; however, scientific evidence to illustrate this combination effect is lacking.  The present study aims to demonstrate the anti-drug resistance of YPFS in cisplatin (DDP)-resistant non-small cell lung cancer cells (A549/DDP).  The application of YPFS exhibited a synergistic enhancement of DDP-induced cytotoxicity as well as of the apoptotic signalling mols.  DDP-induced expression of the multi-drug-resistance efflux transporters was markedly reduced in the presence of YPFS, resulting in a higher intracellular concn. of DDP.  In addn., the application of YPFS increased DDP-induced ROS accumulation and MMP depletion, decreased p62/TRAF6 signalling in DDP-treated A549/DDP cells.  The co-treatment of DDP and YPFS in tumor-bearing mice reduced the tumor size robustly (by more than 80%), which was much better than the effect of DDP alone.  These results indicate that YPFS can notably improve the DDP-suppressed cancer effect, which may be a consequence of the elevation of intracellular DDP via the drug transporters as well as the down regulation of p62/TRAF6 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdiIV2RvDQd7Vg90H21EOLACvtfcHk0lhZYMbmB1fieQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVantb%252FL&md5=6333efa4e1da93dccb911514a597f2bc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsrep31926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep31926%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DJ.-S.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DC.%2BW.%2BC.%26aulast%3DChan%26aufirst%3DG.%2BK.%2BL.%26aulast%3DWu%26aufirst%3DQ.-Y.%26aulast%3DLiu%26aufirst%3DY.-L.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DDu%26aufirst%3DC.%2BY.%2BQ.%26aulast%3DDong%26aufirst%3DT.%2BT.%2BX.%26aulast%3DTsim%26aufirst%3DK.%2BW.%2BK.%26atitle%3DYu%2520Ping%2520Feng%2520San%2520reverses%2520cisplatin-induced%2520multi-drug%2520resistance%2520in%2520lung%2520cancer%2520cells%2520via%2520regulating%2520drug%2520transporters%2520and%2520p62%252FTRAF6%2520signalling%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D31926%26epage%3D31939%26doi%3D10.1038%2Fsrep31926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: Glutathione reduction and MRP1 downregulation</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.3892/or.2012.2156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2For.2012.2156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23229154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1CntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=676-684&author=H.+Wangauthor=X.+Liauthor=T.+Chenauthor=W.+Wangauthor=Q.+Liuauthor=H.+Liauthor=J.+Yiauthor=J.+Wang&title=Mechanisms+of+verapamil-enhanced+chemosensitivity+of+gallbladder+cancer+cells+to+platinum+drugs%3A+Glutathione+reduction+and+MRP1+downregulation&doi=10.3892%2For.2012.2156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation</span></div><div class="casAuthors">Wang, Haolu; Li, Xinxing; Chen, Tao; Wang, Wei; Liu, Qiang; Li, Hui; Yi, Jing; Wang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">676-684</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Gallbladder cancer (GBC) is highly malignant with a low response rate after chemotherapy and platinum drugs are currently prominent in the treatment of biliary tract cancers.  Therefore, the development of novel strategies to enhance the sensitivity of GBC to platinum drugs is required.  In the present study, we examd. the effects of verapamil, a classic chemosensitizer whose reported mechanisms of action include inhibiting the transport function of P-glycoprotein (MDR1) or stimulating glutathione (GSH) transport by multidrug resistance-related protein 1 (MRP1), in combination with cisplatin (CDDP), carboplatin (CBP) or oxaliplatin on the GBC cell lines, SGC996 and GBC-SD.  Our results demonstrated that the co-treatment with verapamil markedly enhanced the chemosensitivity of GBC cells in comparison with platinum drug treatment alone.  The mechanisms involved included GSH redn. and MRP1 downregulation.  Verapamil/CDDP co-treatment inhibited tumor xenograft growth via the down-regulation of MRP1 expression.  MRP1 was highly expressed in human GBC tissue compared to non-tumorous gallbladder tissue.  Our data demonstrate that verapamil may be used as a safe chemosensitizer for platinum drugs in the treatment of GBC.  It functions by ROS and ATP-binding cassette transporter-related mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJqXwgBEAAJrVg90H21EOLACvtfcHk0lhZYMbmB1fieQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1CntLg%253D&md5=7ee5566d12fef69e220ce194242a62ca</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3892%2For.2012.2156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2012.2156%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520verapamil-enhanced%2520chemosensitivity%2520of%2520gallbladder%2520cancer%2520cells%2520to%2520platinum%2520drugs%253A%2520Glutathione%2520reduction%2520and%2520MRP1%2520downregulation%26jtitle%3DOncol.%2520Rep.%26date%3D2013%26volume%3D29%26spage%3D676%26epage%3D684%26doi%3D10.3892%2For.2012.2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.bcp.2015.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25801007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=28-37&author=S.-J.+Chenauthor=C.-C.+Kuoauthor=H.-Y.+Panauthor=T.-C.+Tsouauthor=S.-C.+Yehauthor=J.-Y.+Chang&title=Mechanistic+basis+of+a+combination+D-penicillamine+and+platinum+drugs+synergistically+inhibits+tumor+growth+in+oxaliplatin-resistant+human+cervical+cancer+cells+in+vitro+and+in+vivo&doi=10.1016%2Fj.bcp.2015.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo</span></div><div class="casAuthors">Chen, Szu-Jung; Kuo, Ching-Chuan; Pan, Hsin-Yi; Tsou, Tsui-Chun; Yeh, Szu-Ching; Chang, Jang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-37</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The platinum-based regimen is the front-line treatment of chemotherapy.  However, development of platinum resistance often causes therapeutic failure in this disease.  We previously have generated an oxaliplatin-resistant subline, named S3, from human cervical carcinoma SiHa cells, and its resistant phenotype was well-characterized.  In the present study, we aimed to identify the novel therapeutic strategy by combining copper chelator D-penicillamine with oxaliplatin, and to elucidate the underlying mechanisms for overcoming oxaliplatin resistance.  As the result, D-penicillamine exerted synergistic killing effects only in S3 cells when combined with oxaliplatin and cisplatin by using Chou-Talalay method.  Further study showed that the amts. of platinum DNA adduct formed were pos. correlated to the percentage of cell death in S3 cells when co-treated D-penicillamine with oxaliplatin and cisplatin.  D-Penicillamine promoted copper influx transporter hCtr1 expression through upregulation of Sp1.  Sp1 overexpression induced p53 translocation from nucleus to cytosol and caused p53 degrdn. through ubiquitination, which subsequently suppressed the expression of the copper efflux transporter ATP7A.  Importantly, co-treatment of cisplatin with D-penicillamine enhanced oxaliplatin-elicited antitumor effect in the oxalipatin-resistant S3 xenograft tumors, but not found in SiHa xenograft model.  Notably, Mice received D-penicillamine alone or in combination of D-penicillamine ad oxalipatin, increased hCtrl protein level in S3 xenograft tumor, however, the protein level of ATP7A was decreased.  Taken together, this study provides insight into that the co-manipulation of hCtrl and ATP7A by D-penicillamine could increase the therapeutic efficacy of platinum drugs in oxaliplatin resistant tumors, esp. in resistant phenotype with downexpression of hCtrl and overexpression of ATP7A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr964tEXUNUbVg90H21EOLACvtfcHk0lhZYMbmB1fieQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSksr4%253D&md5=718a1ce47b28cd79f73451b1b1718a6c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DKuo%26aufirst%3DC.-C.%26aulast%3DPan%26aufirst%3DH.-Y.%26aulast%3DTsou%26aufirst%3DT.-C.%26aulast%3DYeh%26aufirst%3DS.-C.%26aulast%3DChang%26aufirst%3DJ.-Y.%26atitle%3DMechanistic%2520basis%2520of%2520a%2520combination%2520D-penicillamine%2520and%2520platinum%2520drugs%2520synergistically%2520inhibits%2520tumor%2520growth%2520in%2520oxaliplatin-resistant%2520human%2520cervical%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D95%26spage%3D28%26epage%3D37%26doi%3D10.1016%2Fj.bcp.2015.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2015.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jconrel.2015.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26210439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlektb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2015&pages=82-90&author=J.+H.+Leeauthor=J.+W.+Chaeauthor=J.+K.+Kimauthor=H.+J.+Kimauthor=J.+Y.+Chungauthor=Y.+H.+Kim&title=Inhibition+of+cisplatin-resistance+by+RNA+interference+targeting+metallothionein+using+reducible+oligo-peptoplex&doi=10.1016%2Fj.jconrel.2015.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex</span></div><div class="casAuthors">Lee, Jong-Hwan; Chae, Ji-Won; Kim, Jang Kyoung; Kim, Hyung Jin; Chung, Jee Young; Kim, Yong-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-90</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Effective intracellular level of a platinum anti-cancer drug, cisplatin, following repeated injections can be decreased either by the active efflux via ATP pump or by interactions with glutathione and metallothionein.  Cisplatin in cytoplasm preferably binds to cysteine-rich proteins such as glutathione and metallothionein (MT).  Detoxification of cisplatin by intracellular thiol-contg. proteins has been considered to be major hurdles to overcome.  The short hairpin RNA targeting MT (shMT) was tested to down-regulate MT and recover cisplatin resistance.  A reducible polymer, poly(oligo-D-arginine) (rPOA), formed stable complex with shMT and demonstrated superior transfection efficiency.  Efficient transfection of shMT/rPOA oligo-peptoplexes was found to significantly inhibit MT over-expression, resulting in 45% decrease of cell viability compared to the cisplatin alone group.  This decrease was mediated by the synergistic effect of shMT/rPOA oligo-peptoplex and cisplatin.  Co-administration of shMT/rPOA oligo-peptoplex and cisplatin in in vivo tumor model showed noticeable tumor-suppressing effect by inducing reversal of cisplatin resistance following effective intracellular delivery of shMT by rPOA.  Combination therapy through co-administration of shMT/rPOA oligo-peptoplex and cisplatin was found to effectively reverse cisplatin resistance by RNA interference and consequently improve anti-cancer activity of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVOJc-BHe8kLVg90H21EOLACvtfcHk0limfHY1fjqwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlektb%252FP&md5=696dbb34f1413f66c8fd4033b7f2a953</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DChae%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DChung%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26atitle%3DInhibition%2520of%2520cisplatin-resistance%2520by%2520RNA%2520interference%2520targeting%2520metallothionein%2520using%2520reducible%2520oligo-peptoplex%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D215%26spage%3D82%26epage%3D90%26doi%3D10.1016%2Fj.jconrel.2015.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. Y.</span></span> <span> </span><span class="NLM_article-title">Transplatin enhances effect of cisplatin on both single DNA molecules and live tumor cells</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>536</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2013.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.abb.2013.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23664917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=536&publication_year=2013&pages=12-24&author=Y.+R.+Liuauthor=C.+Jiauthor=H.+Y.+Zhangauthor=S.+X.+Douauthor=P.+Xieauthor=W.+C.+Wangauthor=P.+Y.+Wang&title=Transplatin+enhances+effect+of+cisplatin+on+both+single+DNA+molecules+and+live+tumor+cells&doi=10.1016%2Fj.abb.2013.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Transplatin enhances effect of cisplatin on both single DNA molecules and live tumor cells</span></div><div class="casAuthors">Liu, Yu-Ru; Ji, Chao; Zhang, Hong-Yan; Dou, Shuo-Xing; Xie, Ping; Wang, Wei-Chi; Wang, Peng-Ye</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">536</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-24</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cisplatin is the main platinum antitumor drug applied in clin. settings.  However, its trans isomer, transplatin, is known to have an ineffective antitumor activity.  Despite intensive studies in this field, the structural and biophys. properties of DNA mols. reacting with these two platinum complexes have not been fully elucidated.  In the present study, we obsd. that transplatin made efficient crosslinking of DNA in the vicinity of cisplatin adducts.  High-resoln. at. force microscopy studies revealed that the transplatin-induced cross-linkings of nucleotides flanking cisplatin adducts were characterized by kinked-loop structures with rod-like shapes of nanometer scales (∼10-60 nm).  The results were further confirmed by denaturing gel electrophoresis and single-mol. expt. using magnetic tweezers.  In vivo studies revealed that transplatin and cisplatin co-treatment could induce a considerable amt. of kinked loops with smaller sizes (∼15 nm) in cellular DNA.  Furthermore, compared with cisplatin treatment alone, the co-treatment resulted in enhanced cytotoxicity, increased amt. of interstrand cross-links, and cell lesions more reluctant to cellular repair system.  The results of the present study provide a new clue for understanding the stepwise reactions of DNA with platinum drugs and might serve as a basis for the development of a new antitumor strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwlbQ4aA3-rVg90H21EOLACvtfcHk0limfHY1fjqwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLnL&md5=54aa6f30dc2ee10d6da096724a257fa2</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2013.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2013.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BR.%26aulast%3DJi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26aulast%3DDou%26aufirst%3DS.%2BX.%26aulast%3DXie%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DP.%2BY.%26atitle%3DTransplatin%2520enhances%2520effect%2520of%2520cisplatin%2520on%2520both%2520single%2520DNA%2520molecules%2520and%2520live%2520tumor%2520cells%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2013%26volume%3D536%26spage%3D12%26epage%3D24%26doi%3D10.1016%2Fj.abb.2013.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buquet-Fagot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djelloul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvitkovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louvet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gespach, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1097/00001813-199710000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2F00001813-199710000-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=9402315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK2sXnslehsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=876-885&author=E.+Raymondauthor=C.+Buquet-Fagotauthor=S.+Djelloulauthor=J.+Mesterauthor=E.+Cvitkovicauthor=P.+Allainauthor=C.+Louvetauthor=C.+Gespach&title=Antitumor+activity+of+oxaliplatin+in+combination+with+5-fluorouracil+and+the+thymidylate+synthase+inhibitor+AG337+in+human+colon%2C+breast+and+ovarian+cancers&doi=10.1097%2F00001813-199710000-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers</span></div><div class="casAuthors">Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">876-885</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Rapid Science Publishers</span>)
        </div><div class="casAbstract">Oxaliplatin, classical [5-fluorouracil (5-FU)] and non-classical (AG337) thymidylate synthase inhibitors have shown promising activity in the treatment of cancer.  This study investigates the cytotoxic effects of oxaliplatin in combination with 5-FU and AG337 in cultured human colon (HT29, CaCo2), breast(MCF-7, MDA-MB-231) and ovarian (2008) cancer cell lines, and their derived counterparts selected for their resistance to 5-FU (HT29-5-FU), doxorubicin (MCF-7mdr) or cisplatin (2008C13).  Therapeutic expts. were conducted in mice bearing colon-HT29 xenografts and in the GR hormone-independent mammary carcinoma model.  In vitro, oxaliplatin shows potent cytotoxic activity in colon (IC50 from 2.1 to 5.9 μM), ovarian (IC50 = 10 μM) and breast cancer cells (IC50 from 7.4 to 17.9 μM).  Oxaliplatin was a potent inhibitor of DNA synthesis and bound to cellular DNA.  Surprisingly, the overall amt. of oxaliplatin DNA binding was significantly inferior to that induced by isocytotoxic concns. of cisplatin in HT29.  In vitro, synergistic antiproliferative effects were obsd. when oxaliplatin was added to 5-FU and AG337.  Those synergistic effects of combinations were maintained in colon HT29-5-FU cancer cells.  In vivo, 5-FU increased significantly the antitumor activity of oxaliplatin in HT29 xenografts, and similarly 5-FU and AG337 increased the activity of oxaliplatin in the GR tumor model.  These data may encourage further clin. investigation of oxaliplatin in combination with classical and non-classical thymidylate synthase inhibitors in the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPtoVT4D0AhrVg90H21EOLACvtfcHk0limfHY1fjqwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnslehsb8%253D&md5=db6271193ed47d56b8dbb258c230b129</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1097%2F00001813-199710000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-199710000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DRaymond%26aufirst%3DE.%26aulast%3DBuquet-Fagot%26aufirst%3DC.%26aulast%3DDjelloul%26aufirst%3DS.%26aulast%3DMester%26aufirst%3DJ.%26aulast%3DCvitkovic%26aufirst%3DE.%26aulast%3DAllain%26aufirst%3DP.%26aulast%3DLouvet%26aufirst%3DC.%26aulast%3DGespach%26aufirst%3DC.%26atitle%3DAntitumor%2520activity%2520of%2520oxaliplatin%2520in%2520combination%2520with%25205-fluorouracil%2520and%2520the%2520thymidylate%2520synthase%2520inhibitor%2520AG337%2520in%2520human%2520colon%252C%2520breast%2520and%2520ovarian%2520cancers%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D1997%26volume%3D8%26spage%3D876%26epage%3D885%26doi%3D10.1097%2F00001813-199710000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Caffeine has a synergistic anticancer effect with cisplatin via inhibiting Fanconi anemia group D2 protein monoubiquitination in hepatocellular carcinoma cells</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1248/bpb.b17-00457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1248%2Fbpb.b17-00457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28855448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12lt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2017&pages=2005-2009&author=Y.+Odaauthor=M.+Hidakaauthor=A.+Suzuki&title=Caffeine+has+a+synergistic+anticancer+effect+with+cisplatin+via+inhibiting+Fanconi+anemia+group+D2+protein+monoubiquitination+in+hepatocellular+carcinoma+cells&doi=10.1248%2Fbpb.b17-00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine has a synergistic anticancer effect with cisplatin via inhibiting fanconi anemia group D2 protein monoubiquitination in hepatocellular carcinoma cells</span></div><div class="casAuthors">Oda, Yuichiro; Hidaka, Muneaki; Suzuki, Akito</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2005-2009</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Cisplatin is an anticancer agent and induces DNA interstrand cross-links (ICLs).  ICLs activate various signaling processes and induce DNA repair pathways, including the Fanconi anemia (FA) pathway.  FA complementation group D2 (FANCD2) is monoubiquitinated in response to DNA damage, leading to activation of the DNA double-strand-break repair protein, RAD51.  Caffeine increases the anticancer activity of cisplatin by inhibiting DNA repair; however, details of the mechanism remain unclear.  We investigated the mechanism responsible for the synergistic anticancer effect of cisplatin and caffeine in HepG2 human hepatocellular carcinoma cells, focusing on the FA pathway.  Caffeine (≥100μg/mL) significantly enhanced the antiproliferative activity induced by 3.8μg/mL cisplatin.  Caffeine (200μg/mL) promoted apoptosis and inhibited the increase in the proportion of viable cells in S phase that occurred in the presence of 3.8μg/mL cisplatin.  Both FANCD2 monoubiquitination and RAD51 expression were significantly inhibited by co-treatment with 200μg/mL caffeine and 3.8μg/mL cisplatin compared with cisplatin alone.  In conclusion, caffeine enhances the anticancer effect of cisplatin by inhibiting FANCD2 monoubiquitination.  In HepG2 cells, caffeine might inhibit the FA pathway and thereby regulate DNA damage responses such as DNA repair and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb4TQuJs00T7Vg90H21EOLACvtfcHk0lhfMShCY7hF3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12lt73O&md5=345cc77193fe3eb0dbbdbf3d3e2110c4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b17-00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b17-00457%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DY.%26aulast%3DHidaka%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DCaffeine%2520has%2520a%2520synergistic%2520anticancer%2520effect%2520with%2520cisplatin%2520via%2520inhibiting%2520Fanconi%2520anemia%2520group%2520D2%2520protein%2520monoubiquitination%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2017%26volume%3D40%26spage%3D2005%26epage%3D2009%26doi%3D10.1248%2Fbpb.b17-00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama-Gonda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igawa, M.</span></span> <span> </span><span class="NLM_article-title">Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-α</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1111/j.1464-410X.2007.07256.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1111%2Fj.1464-410X.2007.07256.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=17922863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVagsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=485-491&author=N.+Moriyama-Gondaauthor=H.+Shiinaauthor=M.+Terashimaauthor=K.+Satohauthor=M.+Igawa&title=Rationale+and+clinical+implication+of+combined+chemotherapy+with+cisplatin+and+oestrogen+in+prostate+cancer%3A+primary+evidence+based+on+methylation+analysis+of+oestrogen+receptor-%CE%B1&doi=10.1111%2Fj.1464-410X.2007.07256.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptorα</span></div><div class="casAuthors">Moriyama-Gonda, Nobuko; Shiina, Hiroaki; Terashima, Masaharu; Satoh, Kazumi; Igawa, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">OBJECTIVE: To det. whether estrogen enhances platinum sensitivity, and if promoter CpG methylation of the estrogen receptor-α (ER-α) gene dets. the potential of cisplatin-induced apoptosis in prostate cancer, as the high-mobility group 1 (HMG1) preferentially binds to cisplatin-modified DNA and is up-regulated after estrogen treatment in breast cancer cell line MCF-7.  MATERIALS AND METHODS: The study comprised prostate cancer cell lines (LNCaP and PC-3), 156 pathol. confirmed 156 radical prostatectomy samples and eight hormone-refractory prostate cancer (HRPC) samples (from needle biopsy).  Expression of HMG1 in cell lines was analyzed by Western blotting or differential reverse-transcription-polymerase chain reaction (PCR).  The methylation status of ER-α was analyzed by methylation-specific PCR using bisulfite DNA as a template or bisulfite DNA sequencing.  RESULTS: In LNCaP cells, treatment with estrogen increased HMG1 expression and co-treatment with cisplatin and estrogen reduced cell viability by accelerating apoptosis, compared with cisplatin alone.  However, in PC-3, estrogen did not up-regulate HMG1 or accelerate the cisplatin-induced apoptosis.  Although ER-β was expressed in both LNCaP and PC-3, ER-α was expressed only in LNCaP.  Bisulphite DNA sequencing of the ER-α promoter showed partial methylation in LNCaP but complete methylation in PC-3.  ER-α AS transfection diminished the cisplatin-induced apoptosis in estrogen-treated LNCaP cells.  In clin. samples there was ER-α hypermethylation in 40% of prostate cancers this correlated with Gleason score (GS, 31% for GS < 7, 50% for GS = 7 and 56% for GS > 7).  In addn., five of eight HRPC samples showed ER-α hypermethylation.  CONCLUSION: These findings suggest that HMG1 induction as an enhancer of platinum sensitivity is mediated through interaction between estrogen and ER-α.  As CpG hypermethylation of the ER-α promoter is a frequent event in aggressive prostate cancer, neg. conversion of ER-α methylation is essential to achieve the most beneficial effect when combined chemotherapy of cisplatin with estrogen is used in patients with prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXF_jcr4o67Vg90H21EOLACvtfcHk0lhfMShCY7hF3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVagsb0%253D&md5=b80ddaf3e5da4c3737e04b01bc3be9f2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2007.07256.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2007.07256.x%26sid%3Dliteratum%253Aachs%26aulast%3DMoriyama-Gonda%26aufirst%3DN.%26aulast%3DShiina%26aufirst%3DH.%26aulast%3DTerashima%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DK.%26aulast%3DIgawa%26aufirst%3DM.%26atitle%3DRationale%2520and%2520clinical%2520implication%2520of%2520combined%2520chemotherapy%2520with%2520cisplatin%2520and%2520oestrogen%2520in%2520prostate%2520cancer%253A%2520primary%2520evidence%2520based%2520on%2520methylation%2520analysis%2520of%2520oestrogen%2520receptor-%25CE%25B1%26jtitle%3DBJU%2520Int.%26date%3D2008%26volume%3D101%26spage%3D485%26epage%3D491%26doi%3D10.1111%2Fj.1464-410X.2007.07256.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drost, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Burg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derksen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstege, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Drunen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beverloo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3916</span>– <span class="NLM_lpage">3925</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-07-4953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18559613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlWrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3916-3925&author=B.+Eversauthor=R.+Drostauthor=E.+Schutauthor=M.+de+Bruinauthor=E.+van+der%0ABurgauthor=P.+W.+Derksenauthor=H.+Holstegeauthor=X.+Liuauthor=E.+van+Drunenauthor=H.+B.+Beverlooauthor=G.+C.+Smithauthor=N.+M.+Martinauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=J.+Jonkers&title=Selective+inhibition+of+BRCA2-deficient+mammary+tumor+cell+growth+by+AZD2281+and+cisplatin&doi=10.1158%2F1078-0432.CCR-07-4953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin</span></div><div class="casAuthors">Evers, Bastiaan; Drost, Rinske; Schut, Eva; de Bruin, Michiel; van der Burg, Eline; Derksen, Patrick W. B.; Holstege, Henne; Liu, Xiaoling; van Drunen, Ellen; Beverloo, H. Berna; Smith, Graeme C. M.; Martin, Niall M. B.; Lau, Alan; O'Connor, Mark J.; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3916-3925</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To assess efficacy of the novel, selective poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor AZD2281 against newly established BRCA2-deficient mouse mammary tumor cell lines and to det. potential synergy between AZD2281 and cisplatin.  We established and thoroughly characterized a panel of clonal cell lines from independent BRCA2-deficient mouse mammary tumors and BRCA2-proficient control tumors.  Subsequently, we assessed sensitivity of these lines to conventional cytotoxic drugs and the novel PARP inhibitor AZD2281.  Finally, in vitro combination studies were done to investigate interaction between AZD2281 and cisplatin.  Genetic, transcriptional, and functional analyses confirmed the successful isolation of BRCA2-deficient and BRCA2-proficient mouse mammary tumor cell lines.  Treatment of these cell lines with 11 different anticancer drugs or with γ-irradn. showed that AZD2281, a novel and specific PARP inhibitor, caused the strongest differential growth inhibition of BRCA2-deficient vs. BRCA2-proficient mammary tumor cells.  Finally, drug combination studies showed synergistic cytotoxicity of AZD2281 and cisplatin against BRCA2-deficient cells but not against BRCA2-proficient control cells.  We have successfully established the first set of BRCA2-deficient mammary tumor cell lines, which form an important addn. to the existing preclin. models for BRCA-mutated breast cancer.  The exquisite sensitivity of these cells to the PARP inhibitor AZD2281, alone or in combination with cisplatin, provides strong support for AZD2281 as a novel targeted therapeutic against BRCA-deficient cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxO5G3T8MQobVg90H21EOLACvtfcHk0lhfMShCY7hF3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlWrtb8%253D&md5=a49c338fe283cb28a53fee3be706ca9f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4953%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DDrost%26aufirst%3DR.%26aulast%3DSchut%26aufirst%3DE.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%26aulast%3DHolstege%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3Dvan%2BDrunen%26aufirst%3DE.%26aulast%3DBeverloo%26aufirst%3DH.%2BB.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BRCA2-deficient%2520mammary%2520tumor%2520cell%2520growth%2520by%2520AZD2281%2520and%2520cisplatin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3916%26epage%3D3925%26doi%3D10.1158%2F1078-0432.CCR-07-4953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaspers, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersbergen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Burg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, A. O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, S. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derksen, P. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zevenhoven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">17079</span>– <span class="NLM_lpage">17084</span>, <span class="refDoi"> DOI: 10.1073/pnas.0806092105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1073%2Fpnas.0806092105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18971340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=17079-17084&author=S.+Rottenbergauthor=J.+E.+Jaspersauthor=A.+Kersbergenauthor=E.+van+der+Burgauthor=A.+O.+H.+Nygrenauthor=S.+A.+L.+Zanderauthor=P.+W.+B.+Derksenauthor=M.+de%0ABruinauthor=J.+Zevenhovenauthor=A.+Lauauthor=R.+Boulterauthor=A.+Cranstonauthor=M.+J.+O%27Connorauthor=N.+M.+B.+Martinauthor=P.+Borstauthor=J.+Jonkers&title=High+sensitivity+of+BRCA1-deficient+mammary+tumors+to+the+PARP+inhibitor+AZD2281+alone+and+in+combination+with+platinum+drugs&doi=10.1073%2Fpnas.0806092105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span></div><div class="casAuthors">Rottenberg, Sven; Jaspers, Janneke E.; Kersbergen, Ariena; van der Burg, Eline; Nygren, Anders O. H.; Zander, Serge A. L.; Derksen, Patrick W. B.; de Bruin, Michiel; Zevenhoven, John; Lau, Alan; Boulter, Robert; Cranston, Aaron; O'Connor, Mark J.; Martin, Niall M. B.; Borst, Piet; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17079-17084</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-pos. breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-neg. ("triple-neg.") mammary carcinomas.  Triple-neg. tumors account for 15% of all breast cancers and frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction.  The DNA-repair defects characteristic of BRCA1-deficient cells confer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which could be relevant to treatment of triple-neg. tumors.  To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-assocd. breast cancer.  Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival.  Long-term treatment with AZD2281 in this model did result in the development of drug resistance, caused by up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps.  This resistance to AZD2281 could be reversed by coadministration of the P-glycoprotein inhibitor tariquidar.  Combination of AZD2281 with cisplatin or carboplatin increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.  Our results demonstrate in vivo efficacy of AZD2281 against BRCA1-deficient breast cancer and illustrate how GEMMs of cancer can be used for preclin. evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95zB9OKZ4ObVg90H21EOLACvtfcHk0liZSbg7mRWVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F&md5=788a7d8b5341b731d007753d5a234dec</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0806092105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0806092105%26sid%3Dliteratum%253Aachs%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DNygren%26aufirst%3DA.%2BO.%2BH.%26aulast%3DZander%26aufirst%3DS.%2BA.%2BL.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%2BB.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3DZevenhoven%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DO%2527Connor%26aufirst%3DM.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHigh%2520sensitivity%2520of%2520BRCA1-deficient%2520mammary%2520tumors%2520to%2520the%2520PARP%2520inhibitor%2520AZD2281%2520alone%2520and%2520in%2520combination%2520with%2520platinum%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D17079%26epage%3D17084%26doi%3D10.1073%2Fpnas.0806092105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miknyoczki, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Szanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span> <span> </span><span class="NLM_article-title">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.4161%2Fcbt.2.4.460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12700281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=371-382&author=S.+J.+Miknyoczkiauthor=S.+Jones-Bolinauthor=S.+Pritchardauthor=K.+Hunterauthor=H.+Zhaoauthor=W.+Wanauthor=M.+Atorauthor=R.+Bihovskyauthor=R.+Hudkinsauthor=S.+Chatterjeeauthor=A.+Klein-Szantoauthor=C.+Dionneauthor=B.+Ruggeri&title=Chemopotentiation+of+temozolomide%2C+irinotecan%2C+and+cisplatin+activity+by+CEP-6800%2C+a+poly%28ADP-ribose%29+polymerase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span></div><div class="casAuthors">Miknyoczki, Sheila J.; Jones-Bolin, Susan; Pritchard, Sonya; Hunter, Kathryn; Zhao, Hugh; Wan, Weihua; Ator, Mark; Bihovsky, Ronald; Hudkins, Robert; Chatterjee, Sankar; Klein-Szanto, Andres; Dionne, Craig; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-382</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear zinc finger DNA-binding protein that is implicated in the repair of DNA damage.  Inhibition of PARP-1 through genetic knockouts causes cells to become hypersensitive to various chemotherapeutic agents.  We tested the chemopotentiating ability of the PARP-1 inhibitor, CEP-6800, when used in combination with temozolomide (TMZ), irinotecan (camptothecin or SN38), and cisplatin against U251MG glioblastoma, HT29 colon carcinoma, and Calu-6 non-small cell lung carcinoma xenografts and cell lines, resp.  Exposure of tumor cells to TMZ, camptothecin (or SN38), and cisplatin before, or in the presence of, CEP-6800 significantly increased the onset and the magnitude of DNA damage, the duration for cells to effect repair, and the onset, duration, or fraction of cells arrested at the G2/M boundary.  In addn., in vivo biochem. efficacy studies with CEP-6800 showed that it was able to attenuate irinotecan- and TMZ-induced poly(ADP-ribose) accumulation in LoVo and HT29 xenografts, resp.  Treatment of CEP 6800 (30 mg/kg) with TMZ (17 and 34 mg/kg) resulted in 100% complete regression of U251MG tumors by day 28 vs. 60% complete regression caused by TMZ alone.  CEP-6800 (30 mg/kg) in combination with irinotecan (10 mg/kg) resulted in a 60% inhibition of HT29 tumor growth vs. irinotecan alone by day 33.  The combination therapy of cisplatin (5 mg/kg) with CEP-6800 (30 mg/kg) caused a 35% redn. in Calu-6 tumor growth vs. cisplatin alone by day 28.  These data suggest that CEP-6800 could be used as a chemopotentiating agent with a variety of clin. effective chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiwSIo74c1LVg90H21EOLACvtfcHk0liZSbg7mRWVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D&md5=2c4b1eb96a1b16c44ad15760f5c1f73c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.4161%2Fcbt.2.4.460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.2.4.460%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DChemopotentiation%2520of%2520temozolomide%252C%2520irinotecan%252C%2520and%2520cisplatin%2520activity%2520by%2520CEP-6800%252C%2520a%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D371%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watarai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitanaka, C.</span></span> <span> </span><span class="NLM_article-title">Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.3892/or.2015.4377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2For.2015.4377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26534836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=593-601&author=M.+Seinoauthor=M.+Okadaauthor=H.+Sakakiauthor=H.+Takedaauthor=H.+Wataraiauthor=S.+Suzukiauthor=S.+Seinoauthor=K.+Kuramotoauthor=T.+Ohtaauthor=S.+Nagaseauthor=H.+Kurachiauthor=C.+Kitanaka&title=Time-staggered+inhibition+of+JNK+effectively+sensitizes+chemoresistant+ovarian+cancer+cells+to+cisplatin+and+paclitaxel&doi=10.3892%2For.2015.4377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel</span></div><div class="casAuthors">Seino, Manabu; Okada, Masashi; Sakaki, Hirotsugu; Takeda, Hiroyuki; Watarai, Hikaru; Suzuki, Shuhei; Seino, Shizuka; Kuramoto, Kenta; Ohta, Tsuyoshi; Nagase, Satoru; Kurachi, Hirohisa; Kitanaka, Chifumi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">593-601</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Ovarian cancer is the most lethal gynecol. malignancy, for which platinum- and taxane-based chemotherapy plays a major role.  Chemoresistance of ovarian cancer poses a major obstacle to the successful management of this devastating disease; however, effective measures to overcome platinum and taxane resistance are yet to be established.  In the present study, while investigating the mechanism underlying the chemoresistance of ovarian cancer, we found that JNK may have a key role in the resistance of ovarian cancer cells to cisplatin and paclitaxel.  Importantly, whereas simultaneous application of a JNK inhibitor and either of the chemotherapeutic agents had contrasting effects for cisplatin (enhanced cytotoxicity) and paclitaxel (decreased cytotoxicity), JNK inhibitor treatment prior to chemotherapeutic agent application invariably enhanced the cytotoxicity of both drugs, suggesting that the basal JNK activity is commonly involved in the chemoresistance of ovarian cancer cells to cisplatin and paclitaxel in contrast to drug-induced JNK activity which may have different roles for these two drugs.  Furthermore, we confirmed using non-transformed human and rodent fibroblasts that sequential application of the JNK inhibitor and the chemotherapeutic agents did not augment their toxicity.  Thus, our findings highlight for the first time the possible differential roles of the basal and induced JNK activities in the chemoresistance of ovarian cancer cells and also suggest that time-staggered JNK inhibition may be a rational and promising strategy to overcome the resistance of ovarian cancer to platinum- and taxane-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokT8j1C1XBl7Vg90H21EOLACvtfcHk0liZSbg7mRWVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCisg%253D%253D&md5=31cf8d8ffb47eff759f85a1ccfc5783e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3892%2For.2015.4377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.4377%26sid%3Dliteratum%253Aachs%26aulast%3DSeino%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DSakaki%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DH.%26aulast%3DWatarai%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DSeino%26aufirst%3DS.%26aulast%3DKuramoto%26aufirst%3DK.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DS.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DKitanaka%26aufirst%3DC.%26atitle%3DTime-staggered%2520inhibition%2520of%2520JNK%2520effectively%2520sensitizes%2520chemoresistant%2520ovarian%2520cancer%2520cells%2520to%2520cisplatin%2520and%2520paclitaxel%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D35%26spage%3D593%26epage%3D601%26doi%3D10.3892%2For.2015.4377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziebarth, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steg, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katre, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbin, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landen, C. N.</span></span> <span> </span><span class="NLM_article-title">Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-12-1045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23147994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=170-182&author=A.+J.+Ziebarthauthor=S.+Nowsheenauthor=A.+D.+Stegauthor=M.+M.+Shahauthor=A.+A.+Katreauthor=Z.+C.+Dobbinauthor=H.+D.+Hanauthor=G.+Lopez-Beresteinauthor=A.+K.+Soodauthor=M.+Connerauthor=E.+S.+Yangauthor=C.+N.+Landen&title=Endoglin+%28CD105%29+contributes+to+platinum+resistance+and+is+a+target+for+tumor-specific+therapy+in+epithelial+ovarian+cancer&doi=10.1158%2F1078-0432.CCR-12-1045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer</span></div><div class="casAuthors">Ziebarth, Angela J.; Nowsheen, Somaira; Steg, Adam D.; Shah, Monjri M.; Katre, Ashwini A.; Dobbin, Zachary C.; Han, Hee-Dong; Lopez-Berestein, Gabriel; Sood, Anil K.; Conner, Michael; Yang, Eddy S.; Landen, Charles N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-182</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Endoglin (CD105) is a membranous protein overexpressed in tumor-assocd. endothelial cells, chemoresistant populations of ovarian cancer cells, and potentially stem cells.  Our objective was to evaluate the effects and mechanisms of targeting endoglin in ovarian cancer.  Exptl. Design: Global and membranous endoglin expression was evaluated in multiple ovarian cancer lines.  In vitro, the effects of siRNA-mediated endoglin knockdown with and without chemotherapy were evaluated by MTT assay, cell-cycle anal., alk. comet assay, γ-H2AX foci formation, and quant. PCR.  In an orthotopic mouse model, endoglin was targeted with chitosan-encapsulated siRNA with and without carboplatin.  Results: Endoglin expression was surprisingly predominantly cytoplasmic, with a small population of surface-pos. cells.  Endoglin inhibition decreased cell viability, increased apoptosis, induced double-stranded DNA damage, and increased cisplatin sensitivity.  Targeting endoglin downregulates expression of numerous DNA repair genes, including BARD1, H2AFX, NBN, NTHL1, and SIRT1.  BARD1 was also assocd. with platinum resistance, and was induced by platinum exposure.  In vivo, antiendoglin treatment decreased tumor wt. in both ES2 and HeyA8MDR models when compared with control (35%-41% redn., P < 0.05).  Endoglin inhibition with carboplatin was assocd. with even greater inhibitory effect when compared with control (58%-62% redn., P < 0.001).  Conclusions: Endoglin downregulation promotes apoptosis, induces significant DNA damage through modulation of numerous DNA repair genes, and improves platinum sensitivity both in vivo and in vitro.  Antiendoglin therapy would allow dual treatment of both tumor angiogenesis and a subset of aggressive tumor cells expressing endoglin and is being actively pursued as therapy in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cndPeM7xTbVg90H21EOLACvtfcHk0lhguywiHhcbBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGhug%253D%253D&md5=e71977fceeaf8019eee4fbd637c3ef60</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1045%26sid%3Dliteratum%253Aachs%26aulast%3DZiebarth%26aufirst%3DA.%2BJ.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DSteg%26aufirst%3DA.%2BD.%26aulast%3DShah%26aufirst%3DM.%2BM.%26aulast%3DKatre%26aufirst%3DA.%2BA.%26aulast%3DDobbin%26aufirst%3DZ.%2BC.%26aulast%3DHan%26aufirst%3DH.%2BD.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DConner%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DE.%2BS.%26aulast%3DLanden%26aufirst%3DC.%2BN.%26atitle%3DEndoglin%2520%2528CD105%2529%2520contributes%2520to%2520platinum%2520resistance%2520and%2520is%2520a%2520target%2520for%2520tumor-specific%2520therapy%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D170%26epage%3D182%26doi%3D10.1158%2F1078-0432.CCR-12-1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herůdková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khirsariya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souček, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krkoška, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanářová, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozubík, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaculová, A. H.</span></span> <span> </span><span class="NLM_article-title">Chk1 inhibitor SCH900776 effectively potentiates the cytotoxic effects of platinum-based chemotherapeutic drugs in human colon cancer cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">841</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2017.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.neo.2017.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28888100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlegsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=830-841&author=J.+Her%C5%AFdkov%C3%A1author=K.+Paruchauthor=P.+Khirsariyaauthor=K.+Sou%C4%8Dekauthor=M.+Krko%C5%A1kaauthor=O.+V.+Blan%C3%A1%C5%99ov%C3%A1author=P.+Sovaauthor=A.+Kozub%C3%ADkauthor=A.+H.+Vaculov%C3%A1&title=Chk1+inhibitor+SCH900776+effectively+potentiates+the+cytotoxic+effects+of+platinum-based+chemotherapeutic+drugs+in+human+colon+cancer+cells&doi=10.1016%2Fj.neo.2017.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells</span></div><div class="casAuthors">Herudkova, Jarmila; Paruch, Kamil; Khirsariya, Prashant; Soucek, Karel; Krkoska, Martin; Vondalova Blanarova, Olga; Sova, Petr; Kozubik, Alois; Hyrslova Vaculova, Alena</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">830-841</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Although Chk1 kinase inhibitors are currently under clin. investigation as effective cancer cell sensitizers to the cytotoxic effects of numerous chemotherapeutics, there is still a considerable uncertainty regarding their role in modulation of anticancer potential of platinum-based drugs.  Here we newly demonstrate the ability of one of the most specific Chk1 inhibitors, SCH900776 (MK-8776), to enhance human colon cancer cell sensitivity to the cytotoxic effects of platinum(II) cisplatin and platinum(IV)- LA-12 complexes.  The combined treatment with SCH900776 and cisplatin or LA-12 results in apparent increase in G1/S phase-related apoptosis, stimulation of mitotic slippage, and senescence of HCT116 cells.  We further show that the cancer cell response to the drug combinations is significantly affected by the p21, p53, and PTEN status.  In contrast to their wt counterparts, the p53- or p21-deficient cells treated with SCH900776 and cisplatin or LA-12 enter mitosis and become polyploid, and the senescence phenotype is strongly suppressed.  While the cell death induced by SCH900776 and cisplatin or LA-12 is significantly delayed in the absence of p53, the anticancer action of the drug combinations is significantly accelerated in p21-deficient cells, which is assocd. with stimulation of apoptosis beyond G2/M cell cycle phase.  We also show that cooperative killing action of the drug combinations in HCT116 cells is facilitated in the absence of PTEN.  Our results indicate that SCH900776 may act as an important modulator of cytotoxic response triggered by platinum-based drugs in colon cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtV5iO0XKyUbVg90H21EOLACvtfcHk0lhguywiHhcbBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlegsbrM&md5=0df00cd1990bfafd4036f041f3b1944f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2017.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DHer%25C5%25AFdkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DKhirsariya%26aufirst%3DP.%26aulast%3DSou%25C4%258Dek%26aufirst%3DK.%26aulast%3DKrko%25C5%25A1ka%26aufirst%3DM.%26aulast%3DBlan%25C3%25A1%25C5%2599ov%25C3%25A1%26aufirst%3DO.%2BV.%26aulast%3DSova%26aufirst%3DP.%26aulast%3DKozub%25C3%25ADk%26aufirst%3DA.%26aulast%3DVaculov%25C3%25A1%26aufirst%3DA.%2BH.%26atitle%3DChk1%2520inhibitor%2520SCH900776%2520effectively%2520potentiates%2520the%2520cytotoxic%2520effects%2520of%2520platinum-based%2520chemotherapeutic%2520drugs%2520in%2520human%2520colon%2520cancer%2520cells%26jtitle%3DNeoplasia%26date%3D2017%26volume%3D19%26spage%3D830%26epage%3D841%26doi%3D10.1016%2Fj.neo.2017.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Paris saponin I sensitizes gastric cancer cell lines to cisplatin via cell cycle arrest and apoptosis</span>. <i>Med. Sci. Monit.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3798</span>– <span class="NLM_lpage">3803</span>, <span class="refDoi"> DOI: 10.12659/MSM.898232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.12659%2FMSM.898232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27755523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFGltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=3798-3803&author=S.+Songauthor=L.+Duauthor=H.+Jiangauthor=X.+Zhuauthor=J.+Liauthor=J.+Xu&title=Paris+saponin+I+sensitizes+gastric+cancer+cell+lines+to+cisplatin+via+cell+cycle+arrest+and+apoptosis&doi=10.12659%2FMSM.898232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Paris saponin I sensitizes gastric cancer cell lines to cisplatin via cell cycle arrest and apoptosis</span></div><div class="casAuthors">Song, Shuichuan; Du, Leiwen; Jiang, Hao; Zhu, Xinhai; Li, Jinhui; Xu, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Medical Science Monitor</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3798-3803</span>CODEN:
                <span class="NLM_cas:coden">MSMOFR</span>;
        ISSN:<span class="NLM_cas:issn">1643-3750</span>.
    
            (<span class="NLM_cas:orgname">International Scientific Information, Inc.</span>)
        </div><div class="casAbstract">Background: Dose-related toxicity is the major restriction of cisplatin and cisplatin-combination chemotherapy, and is a challenge for advanced gastric cancer treatment.  We explored the possibility of using Paris saponin I as an agent to sensitize gastric cancer cells to cisplatin, and examd. the underlying mechanism.  Material and Methods: Growth inhibition was detected by MTT assay.  The cell cycle and apoptosis were detected using flow cytometry and Annexin V/PI staining.  The P21waf1/cip1, Bcl-2, Bax, and caspase-3 protein expression were detected using Western blot anal.  Results: The results revealed that PSI sensitized gastric cancer cells to cisplatin, with low toxicity.  The IC50 value of cisplatin in SGC-7901 cell lines was decreased when combined with PSI.  PSI promoted cisplatin-induced G2/M phase arrest and apoptosis in a cisplatin concn.-dependent manner.  Bcl-2 protein expression decreased, but Bax, caspase-3, and P21waf1/cip1 protein expression increased with PSI treatment.  Conclusions: The underlying mechanism of Paris saponin I may be related to targeting the apoptosis pathway and cell cycle blocking, which suggests that PSI is a potential therapeutic sensitizer for cisplatin in treating gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8WMu3qmrqwLVg90H21EOLACvtfcHk0ljOpjzc2o6lhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFGltbk%253D&md5=9f369f63caf32568c0f951fc4c91d898</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.12659%2FMSM.898232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12659%252FMSM.898232%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DParis%2520saponin%2520I%2520sensitizes%2520gastric%2520cancer%2520cell%2520lines%2520to%2520cisplatin%2520via%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%26jtitle%3DMed.%2520Sci.%2520Monit.%26date%3D2016%26volume%3D22%26spage%3D3798%26epage%3D3803%26doi%3D10.12659%2FMSM.898232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span> <span> </span><span class="NLM_article-title">1,25-Dihydroxyvitamin D(3) and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells</span>. <i>Int. J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.3892/ijmm.2014.1664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fijmm.2014.1664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24573222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1177-1184&author=A.+Baoauthor=Y.+Liauthor=Y.+Tongauthor=H.+Zhengauthor=W.+Wuauthor=C.+Wei&title=1%2C25-Dihydroxyvitamin+D%283%29+and+cisplatin+synergistically+induce+apoptosis+and+cell+cycle+arrest+in+gastric+cancer+cells&doi=10.3892%2Fijmm.2014.1664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">1,25-Dihydroxyvitamin D3 and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells</span></div><div class="casAuthors">Bao, Anyu; Li, Yan; Tong, Yongqing; Zheng, Hongyun; Wu, Wei; Wei, Chuandong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1177-1184</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] plays an anticancer role in multiple types of cancer and potentiates the cytotoxic effects of several common chemotherapeutic agents.  The hypercalcemia caused by 1,25(OH)2D3 alone or resistance to cisplatin weaken the anticancer effects of vitamin D.  Thus, in this study, we aimed to investigate the synergistic effects of 1,25(OH)2D3 and cisplatin on the apoptosis and cell cycle progression of gastric cancer cells.  BGC-823 human gastric cancer cells were treated with 1,25(OH)2D3 or cisplatin alone, or a combination of both agents.  Cell apoptosis was assessed by TUNEL assay and flow cytometry.  The expression of the apoptosis-related proteins, poly(ADP-ribose) polymerase (PARP), Bax, Bcl-2, caspase-3 and caspase-8, was examd. using immunoblot anal.  ERK and AKT phosphorylation were examd. by immunoblot anal.  The cell cycle distribution was detd. by propidium iodide staining and flow cytometric anal.  P21 and p27 protein expression was also examd. using immunoblot anal.  Our results revealed that co-treatment with 1,25(OH)2D3 enhanced cisplatin-induced apoptosis and upregulated the expression of Bax, and promoted the cleavage of PARP and caspase-3.  The phosphorylation levels of ERK and AKT were reduced following combined treatment with 1,25(OH)2D3 and cisplatin.  The percentage of cells in the G0/G1 phase was greater in the cells treated with the combined treatment than in those treated with either 1,25(OH)2D3 or cisplatin alone.  P21 and p27 expression was upregulated following co-treatment with both agents.  The results of this study suggest that 1,25(OH)2D3 potentiates cisplatin-mediated cell growth inhibition and cell apoptosis, which involves the upregulation of Bax, a decrease in ERK and AKT phosphorylation levels, and increased p21 and p27 levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLO0mEOiOorVg90H21EOLACvtfcHk0ljOpjzc2o6lhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egtb%252FI&md5=dddedad635f64afe66f5d6eeba5b7d13</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2014.1664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2014.1664%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DC.%26atitle%3D1%252C25-Dihydroxyvitamin%2520D%25283%2529%2520and%2520cisplatin%2520synergistically%2520induce%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520in%2520gastric%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2014%26volume%3D33%26spage%3D1177%26epage%3D1184%26doi%3D10.3892%2Fijmm.2014.1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogosawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowa, Y.</span></span> <span> </span><span class="NLM_article-title">The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.3892/ijo.2014.2703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fijo.2014.2703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25310746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVymtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=389-394&author=Q.+Sunauthor=S.+Yogosawaauthor=Y.+Iizumiauthor=T.+Sakaiauthor=Y.+Sowa&title=The+alkaloid+emetine+sensitizes+ovarian+carcinoma+cells+to+cisplatin+through+downregulation+of+bcl-xL&doi=10.3892%2Fijo.2014.2703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL</span></div><div class="casAuthors">Sun, Qi; Yogosawa, Shingo; Iizumi, Yosuke; Sakai, Toshiyuki; Sowa, Yoshihiro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">389-394</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cisplatin and its platinum derivs. are first-line chemotherapeutic agents in the treatment of ovarian cancer.  However, chemoresistance is the leading cause of therapeutic failure and is responsible for the poor overall survival rate.  Here, we describe that emetine, a natural alkaloid used as an anti-amoebiasis drug, sensitized ovarian carcinoma cells to apoptosis induced by cisplatin.  The single administration of cisplatin or emetine had a weak effect on cell death.  However, co-treatment of cisplatin and emetine remarkably induced apoptosis and reduced the colony formation of ovarian carcinoma cells.  Moreover, we showed that apoptosis induced by the combination of cisplatin and emetine was dependent on the activation of caspases -3, -7 and -8.  As to the mechanism, downregulation of bcl-xL by emetine was shown to be responsible for enhancing the sensitivity of ovarian cancer cells to cisplatin.  These findings suggest that the combination of cisplatin and emetine might be a promising treatment for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-IoLB0ZjncLVg90H21EOLACvtfcHk0ljOpjzc2o6lhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVymtLc%253D&md5=d2dc1ba3988bc6ee00902fd3f49d8712</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2703%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DYogosawa%26aufirst%3DS.%26aulast%3DIizumi%26aufirst%3DY.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DSowa%26aufirst%3DY.%26atitle%3DThe%2520alkaloid%2520emetine%2520sensitizes%2520ovarian%2520carcinoma%2520cells%2520to%2520cisplatin%2520through%2520downregulation%2520of%2520bcl-xL%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2015%26volume%3D46%26spage%3D389%26epage%3D394%26doi%3D10.3892%2Fijo.2014.2703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiourin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memarzadeh, S.</span></span> <span> </span><span class="NLM_article-title">An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7956</span>– <span class="NLM_lpage">7971</span>, <span class="refDoi"> DOI: 10.1038/ncomms8956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fncomms8956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26234182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7956-7971&author=D.+M.+Janzenauthor=E.+Tiourinauthor=J.+A.+Salehiauthor=D.+Y.+Paikauthor=J.+Luauthor=M.+Pellegriniauthor=S.+Memarzadeh&title=An+apoptosis-enhancing+drug+overcomes+platinum+resistance+in+a+tumour-initiating+subpopulation+of+ovarian+cancer&doi=10.1038%2Fncomms8956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer</span></div><div class="casAuthors">Janzen, D. M.; Tiourin, E.; Salehi, J. A.; Paik, D. Y.; Lu, J.; Pellegrini, M.; Memarzadeh, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7956</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">High-grade serous ovarian cancers (HGSCs) are deadly malignancies that relapse despite carboplatin chemotherapy.  Here we show that 16 independent primary HGSC samples contain a CA125-neg. population enriched for carboplatin-resistant cancer initiating cells.  Transcriptome anal. reveals upregulation of homologous recombination DNA repair and anti-apoptotic signals in this population.  While treatment with carboplatin enriches for CA125-neg. cells, co-treatment with carboplatin and birinapant eliminates these cells in HGSCs expressing high levels of the inhibitor of apoptosis protein cIAP in the CA125-neg. population.  Birinapant sensitizes CA125-neg. cells to carboplatin by mediating degrdn. of cIAP causing cleavage of caspase 8 and restoration of apoptosis.  This co-therapy significantly improves disease-free survival in vivo compared with either therapy alone in tumor-bearing mice.  These findings suggest that therapeutic strategies that target CA125-neg. cells may be useful in the treatment of HGSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdyRnR77CebVg90H21EOLACvtfcHk0ljOpjzc2o6lhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrtrbO&md5=bb38a21db055ff90b98599fedf96eba1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fncomms8956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8956%26sid%3Dliteratum%253Aachs%26aulast%3DJanzen%26aufirst%3DD.%2BM.%26aulast%3DTiourin%26aufirst%3DE.%26aulast%3DSalehi%26aufirst%3DJ.%2BA.%26aulast%3DPaik%26aufirst%3DD.%2BY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DPellegrini%26aufirst%3DM.%26aulast%3DMemarzadeh%26aufirst%3DS.%26atitle%3DAn%2520apoptosis-enhancing%2520drug%2520overcomes%2520platinum%2520resistance%2520in%2520a%2520tumour-initiating%2520subpopulation%2520of%2520ovarian%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7956%26epage%3D7971%26doi%3D10.1038%2Fncomms8956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiartivich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiampornkul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2799</span>– <span class="NLM_lpage">2804</span>, <span class="refDoi"> DOI: 10.3892/ol.2017.5746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fol.2017.5746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28454469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVyrsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=2799-2804&author=S.+Kiartivichauthor=Y.+Weiauthor=J.+Liuauthor=R.+Soiampornkulauthor=M.+Liauthor=H.+Zhangauthor=J.+Dong&title=Regulation+of+cytotoxicity+and+apoptosis-associated+pathways+contributes+to+the+enhancement+of+efficacy+of+cisplatin+by+baicalein+adjuvant+in+human+A549+lung+cancer+cells&doi=10.3892%2Fol.2017.5746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells</span></div><div class="casAuthors">Kiartivich, Suparata; Wei, Ying; Liu, Jiaqi; Soiampornkul, Rungtip; Li, Mihui; Zhang, Hongying; Dong, Jingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2799-2804</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Scutellaria baicalensis (SB; Chinese name, huangqin) is widely used in Chinese medicine as a traditional adjuvant in the chemotherapy of lung and liver cancer.  Baicalein is one of the bioactive flavonoid components isolated from the root of SB.  The present study aimed to observe the effect of baicalein, in combination with platin-based systemic chemotherapy (cisplatin), on cytotoxicity and apoptosis of human A549 lung cancer cells.  The cell cultures were treated with baicalein, cisplatin, or a combination of the two.  Cell viability and cytotoxicity was assayed by XTT, and cell apoptosis was measured by flow cytometry.  The apoptosis-assocd. proteins were detected by western blot anal.  The cytokines in the culture supernatant were detected by ELISA.  The present study revealed that cisplatin and the baicalein-cisplatin combination inhibited viability and promoted cytotoxicity of A549 cells.  Cisplatin, baicalein and baicalein-cisplatin combination treatments were effective in the promotion of apoptosis of A549 cells.  Baicalein and baicalein-cisplatin combination treatments also inhibited B cell lymphoma-2 (Bcl-2) and increased Bcl-2-assocd. X protein (Bax) expression.  Addnl., cisplatin, baicalein and the baicalein-cisplatin combination promoted caspase-3 expression.  Furthermore, the baicalein-cisplatin combination suppressed the secretion of interleukin-6, and baicalein and the combination of baicalein cisplatin decreased the secretion of tumor necrosis factor-α of A549 cells.  The present study concluded that baicalein combined with cisplatin induced cytotoxicity and apoptosis of A549 cells, and such activity may be assocd. with the regulation of Bcl-2, Bax and caspase-3, indicating a promising alternative method for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIQ8SKpmuZbLVg90H21EOLACvtfcHk0ljEQSO--XsrXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVyrsr3N&md5=927e6f85acac84fb89bac119ac535ed7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.5746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.5746%26sid%3Dliteratum%253Aachs%26aulast%3DKiartivich%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSoiampornkul%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520cytotoxicity%2520and%2520apoptosis-associated%2520pathways%2520contributes%2520to%2520the%2520enhancement%2520of%2520efficacy%2520of%2520cisplatin%2520by%2520baicalein%2520adjuvant%2520in%2520human%2520A549%2520lung%2520cancer%2520cells%26jtitle%3DOncol.%2520Lett.%26date%3D2017%26volume%3D13%26spage%3D2799%26epage%3D2804%26doi%3D10.3892%2Fol.2017.5746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gornowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryel-Porowska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span> <span> </span><span class="NLM_article-title">Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.3892/ol.2017.7623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fol.2017.7623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29434943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC1MrgslOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=2340-2348&author=A.+Gornowiczauthor=A.+Bielawskaauthor=W.+Szymanowskiauthor=H.+Gabryel-Porowskaauthor=R.+Czarnomysyauthor=K.+Bielawski&title=Mechanism+of+anticancer+action+of+novel+berenil+complex+of+platinum%28II%29+combined+with+anti-MUC1+in+MCF-7+breast+cancer+cells&doi=10.3892%2Fol.2017.7623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells</span></div><div class="casAuthors">Gornowicz Agnieszka; Bielawska Anna; Szymanowski Wojciech; Gabryel-Porowska Halina; Czarnomysy Robert; Bielawski Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2340-2348</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Mucin 1 (MUC1) is a high molecular weight transmembrane glycoprotein, that is overexpressed in >90% of breast cancers.  It serves a crucial role in anti-apoptosis and tumor progression.  MUC1 interacts with proteins in the extracellular matrix, at the cell membrane, in the cytoplasm and in the nucleus.  The aim of the present study was to investigate the mechanism of anticancer action induced by novel berenil complex of platinum(II) (Pt12) together with a monoclonal antibody against MUC1 in breast cancer MCF-7 cells.  The effect of combined treatment on the concentration of selected markers of apoptosis including proapoptotic B-cell lymphoma 2 associated X protein (Bax), caspase-8, cytochrome c and caspase-9, as well as selected proteins involved in intracellular signal transduction pathways including p53, phosphoinositide 3-kinase and phosphorylated protein kinase B (p-Akt) were analyzed.  The results of the present study demonstrated that combined treatment may be a promising strategy in anticancer treatment and represents an alternative to monotherapy.  All compounds used alone (Pt12, cisplatin and the anti-MUC1 antibody) increased the concentration of proapoptotic Bax, cytochrome c and caspase-9 in comparison with control, thus suggesting that they activated the mitochondrial apoptotic pathway.  Pt12 alone significantly increased the concentration of caspase-8, which is responsible for the initiation of the extrinsic apoptotic pathway.  However, the strongest effect was observed following Pt12 (20 μM) treatment combined with the anti-MUC1 antibody (10 μg/ml).  These two compounds together strongly induced apoptosis in MCF-7 breast cancer cells via the external and internal apoptotic pathways.  It was also demonstrated that combined treatment based on Pt12 and the anti-MUC1 antibody significantly reduced p-Akt concentration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhwKE-wGzFGEEgZCMqtRBifW6udTcc2eZLyoViznlQAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrgslOmtw%253D%253D&md5=9008395d8a858eb76104d00da26301a4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.7623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.7623%26sid%3Dliteratum%253Aachs%26aulast%3DGornowicz%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DSzymanowski%26aufirst%3DW.%26aulast%3DGabryel-Porowska%26aufirst%3DH.%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DBielawski%26aufirst%3DK.%26atitle%3DMechanism%2520of%2520anticancer%2520action%2520of%2520novel%2520berenil%2520complex%2520of%2520platinum%2528II%2529%2520combined%2520with%2520anti-MUC1%2520in%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D2340%26epage%3D2348%26doi%3D10.3892%2Fol.2017.7623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Özdemir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apaydin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Önder, N. İ.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Şen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayrim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öǧünç, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">İncesu, Z.</span></span> <span> </span><span class="NLM_article-title">Apoptotic effects of ε-viniferin in combination with cis-platin in C6 cells</span>. <i>Cytotechnology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1007/s10616-018-0197-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs10616-018-0197-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29476302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVyrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=1061-1073&author=F.+%C3%96zdemirauthor=E.+Apaydinauthor=N.+%C4%B0.+%C3%96nderauthor=M.+%C5%9Eenauthor=A.+Ayrimauthor=Y.+%C3%96%C7%A7%C3%BCn%C3%A7author=Z.+%C4%B0ncesu&title=Apoptotic+effects+of+%CE%B5-viniferin+in+combination+with+cis-platin+in+C6+cells&doi=10.1007%2Fs10616-018-0197-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptotic effects of ε-viniferin in combination with cis-platin in C6 cells</span></div><div class="casAuthors">Ozdemir, Filiz; Apaydin, Elif; Onder, Nur Ipek; Sen, Mesut; Ayrim, Aysun; Ogunc, Yuksel; Incesu, Zerrin</div><div class="citationInfo"><span class="NLM_cas:title">Cytotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">CYTOER</span>;
        ISSN:<span class="NLM_cas:issn">0920-9069</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is one of the most common and lethal forms of primary brain tumors in human adults.  Treatment options are limited, and in most cases ineffective.  Natural products are sources of novel compds. endowed with therapeutic properties in many human diseases like cancer. ε-viniferin is a resveratrol dimer and well known for having antiproliferative and apoptotic effects on cancer cells.  Cisplatin is a platinum contg. anti-cancer drug.  In this study, we aimed to investigate antiproliferative and apoptotic effects of using cis-platin and ε-viniferin alone or in combined treatment of C6 cells.  Cell proliferation was detected by WST-1.  Mitochondrial membrane potential changes in the cells (ΔVm) were evaluated using cationic dye JC1.  Apoptotic index which is a hallmark of late apoptosis was detected by using Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method and apoptotic alterations were obsd. by transmission electron microscope (TEM).  Activation of caspase-8, -9, -3 in C6 cells at various incubation periods was measured by flow cytometer.  Apoptotic index increased at highest level in only combined treatment cells (91.6%) after 48 h incubation.  These results were supported by TEM images.  Caspase-8 activation in C6 cells increased to a max. (12.5%) after 6 h by using combined cis-platin/ε-viniferin treatment (13.25/95μM).  Caspase-9 was activated at 44.5% after combined treatment for 24 h.  This rate is higher than using cis-platin (14.2%) or ε-viniferin (43.3%) alone.  The combined 13.25μM/cisplatin and 95μM ε-viniferin treatment caused max. caspase-3 activation in C6 cells (15.5%) at the end of the 72 h incubation.  In conclusion, it was obsd. that caspase-8, -9, -3 activation which was detd. in vitro, triggerred apoptotic mechanism in C6 cells by using low concns. of combined cis-platin and ε-viniferin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0d8gc3ft_PrVg90H21EOLACvtfcHk0ljEQSO--XsrXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVyrurs%253D&md5=e25b62b697ecfa3f11ff39d6086a381e</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs10616-018-0197-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10616-018-0197-5%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596zdemir%26aufirst%3DF.%26aulast%3DApaydin%26aufirst%3DE.%26aulast%3D%25C3%2596nder%26aufirst%3DN.%2B%25C4%25B0.%26aulast%3D%25C5%259Een%26aufirst%3DM.%26aulast%3DAyrim%26aufirst%3DA.%26aulast%3D%25C3%2596%25C7%25A7%25C3%25BCn%25C3%25A7%26aufirst%3DY.%26aulast%3D%25C4%25B0ncesu%26aufirst%3DZ.%26atitle%3DApoptotic%2520effects%2520of%2520%25CE%25B5-viniferin%2520in%2520combination%2520with%2520cis-platin%2520in%2520C6%2520cells%26jtitle%3DCytotechnology%26date%3D2018%26volume%3D70%26spage%3D1061%26epage%3D1073%26doi%3D10.1007%2Fs10616-018-0197-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span> <span> </span><span class="NLM_article-title">Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin</span>. <i>Exp. Biol. Med. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">1416</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.1177/1535370215571881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1177%2F1535370215571881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFajtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2015&pages=1416-1425&author=J.+H.+Kangauthor=H.+S.+Kangauthor=I.+K.+Kimauthor=H.+Y.+Leeauthor=J.+H.+Haauthor=C.+D.+Yeoauthor=H.+H.+Kangauthor=H.+S.+Moonauthor=S.+H.+Lee&title=Curcumin+sensitizes+human+lung+cancer+cells+to+apoptosis+and+metastasis+synergistically+combined+with+carboplatin&doi=10.1177%2F1535370215571881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin</span></div><div class="casAuthors">Kang, Ji Ho; Kang, Hye Seon; Kim, In Kyoung; Lee, Hwa Young; Ha, Jick Hwan; Yeo, Chang Dong; Kang, Hyun Hui; Moon, Hwa Sik; Lee, Sang Haak</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1416-1425</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Although carboplatin is one of the std. chemotherapeutic agents for non-small cell lung cancer (NSCLC), it has limited therapeutic efficacy due to activation of a survival signaling pathway and the induction of multidrug resistance.  Curcumin, a natural compd. isolated from the plant Curcuma longa, is known to sensitize tumors to different chemotherapeutic agents.  The aim of this study is to evaluate whether curcumin can chemosensitize lung cancer cells to carboplatin and to analyze the signaling pathway underlying this synergism.  We investigated the synergistic effect of both agents on cell proliferation, apoptosis, invasion, migration, and expression of related signaling proteins using the human NSCLC cell line, A549.  A549 cell was treated with different concns. of curcumin and carboplatin alone and in combination.  Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone.  Matrix metalloproteinase (MMP)-2 and MMP-9 were more efficiently downregulated by co-treatment than by each treatment alone. mRNA and protein expression of caspase-3 and caspase-9 and proapoptotic genes was increased in cells treated with a combination of curcumin and carboplatin, whereas expression of the antiapoptotic Bcl-2 gene was suppressed.  Co-treatment of both agents substantially suppressed NF-κB activation and increased expression of p53.  Phosphorylation of Akt, a protein upstream of NF-κB, was reduced, resulting in inhibition of the degrdn. of inhibitor of κB(IκBα), whereas the activity of extracellular signal-regulated kinase (ERK1/2) was enhanced.  Our study demonstrated that the synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-κB via inhibition of the Akt/IKKα pathway and enhanced ERK1/2 activity.  Based on this mechanism, curcumin has potential as a chemosensitizer for carboplatin in the treatment of patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5L9IRhbSOmrVg90H21EOLACvtfcHk0liwLONJKrY4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFajtbbI&md5=d1ddb979937767d32ba067968732dc08</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1177%2F1535370215571881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370215571881%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DI.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DHa%26aufirst%3DJ.%2BH.%26aulast%3DYeo%26aufirst%3DC.%2BD.%26aulast%3DKang%26aufirst%3DH.%2BH.%26aulast%3DMoon%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BH.%26atitle%3DCurcumin%2520sensitizes%2520human%2520lung%2520cancer%2520cells%2520to%2520apoptosis%2520and%2520metastasis%2520synergistically%2520combined%2520with%2520carboplatin%26jtitle%3DExp.%2520Biol.%2520Med.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D240%26spage%3D1416%26epage%3D1425%26doi%3D10.1177%2F1535370215571881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">ABT-737 synergizes with cisplatin bypassing aberration of apoptotic pathway in non-small cell lung cancer</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.neo.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28319809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFGqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=354-363&author=E.+Y.+Kimauthor=J.+Y.+Jungauthor=A.+Kimauthor=Y.+S.+Changauthor=S.+K.+Kim&title=ABT-737+synergizes+with+cisplatin+bypassing+aberration+of+apoptotic+pathway+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.neo.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer</span></div><div class="casAuthors">Kim, Eun Young; Jung, Ji Ye; Kim, Arum; Chang, Yoon Soo; Kim, Se Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-363</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A subset of non-small cell lung cancer (NSCLC), which does not have a druggable driver mutation, is treated with platinum-based cytotoxic chemotherapy, but it develops resistance triggered by DNA damage responses.  Here, we investigated the effect of activation of STAT3 by cisplatin on anti-apoptotic proteins and the effectiveness of a co-treatment with cisplatin and a BH3 mimetic, ABT-737.  We analyzed the relationship between cisplatin and STAT3 pathway and effect of ABT-737, when combined with cisplatin in NSCLC cells and K-ras mutant mouse models.  The synergism of this combination was evaluated by the Chou-Talalay Combination Index method.  In vivo activity was evaluated by micro-CT.  In NSCLC cells, there was a time and dose-dependent phosphorylation of SRC-JAK2-STAT3 by cisplatin, followed by increased expression of anti-apoptotic mols.  When the expression of the BCL-2 protein family members was evaluated in clin. samples, BCL-xL was most frequently overexpressed.  Dominant neg. STAT3 suppressed their expression, suggesting that STAT3 mediates cisplatin mediated overexpression of the anti-apoptotic mols.  ABT-737 displaced BCL-xL from mitochondria and induced oligomerization of BAK.  ABT-737 itself showed cytotoxic effects and a combination of ABT-737 with cisplatin showed strong synergistic cytotoxicity.  In a murine lung cancer model, co-treatment with ABT-737 and cisplatin induced significant tumor regression.  These findings reveal a synergistic cytotoxic and anti-tumor activity of ABT-737 and cisplatin co-treatment in preclin. models, and suggest that clin. trials using this strategy may be beneficial in advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbv02CyJXoebVg90H21EOLACvtfcHk0liwLONJKrY4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFGqtbo%253D&md5=556aeb5f043b37886132e6a0cfb6c4c1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BY.%26aulast%3DJung%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DABT-737%2520synergizes%2520with%2520cisplatin%2520bypassing%2520aberration%2520of%2520apoptotic%2520pathway%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNeoplasia%26date%3D2017%26volume%3D19%26spage%3D354%26epage%3D363%26doi%3D10.1016%2Fj.neo.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeon, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandanshive, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. M.</span></span> <span> </span><span class="NLM_article-title">Novel improved synthesis of HSP70 inhibitor, pifithrin-μ. in vitro synergy quantification of pifithrin-μ combined with Pt drugs in prostate and colorectal cancer cells</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.3390/molecules21070949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3390%2Fmolecules21070949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWktLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=949-958&author=A.+M.+McKeonauthor=A.+Eganauthor=J.+Chandanshiveauthor=H.+McMahonauthor=D.+M.+Griffith&title=Novel+improved+synthesis+of+HSP70+inhibitor%2C+pifithrin-%CE%BC.+in+vitro+synergy+quantification+of+pifithrin-%CE%BC+combined+with+Pt+drugs+in+prostate+and+colorectal+cancer+cells&doi=10.3390%2Fmolecules21070949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel improved synthesis of HSP70 inhibitor, pifithrin-μ in vitro synergy quantification of pifithrin-μ combined with pt drugs in prostate and colorectal cancer cells</span></div><div class="casAuthors">McKeon, Aoife M.; Egan, Alan; Chandanshive, Jay; McMahon, Helena; Griffith, Darren M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">949/1-949/10</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A novel improved approach for the synthesis of the important and well-known heat shock protein 70 inhibitor (HSP70), pifithrin-μ, was described with corresponding and previously unreported characterization.  The first example of a combination study comprising HSP70 inhibitor pifithrin-μ and cisplatin or oxaliplatin was reported.  Further, moderate synergistic and synergistic effects in co-treating PC-3 prostate cancer cells with pifithrin-μ and cisplatin and significant synergistic effects including strong synergism in cotreating HT29 colorectal cancer cells with oxaliplatin and pifithrin-μ was also detd. by using the Chou-Talalay method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-EWwYgXnVLrVg90H21EOLACvtfcHk0liwLONJKrY4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWktLjK&md5=0251fc12a8ad117aa1839292d362a80a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21070949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21070949%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeon%26aufirst%3DA.%2BM.%26aulast%3DEgan%26aufirst%3DA.%26aulast%3DChandanshive%26aufirst%3DJ.%26aulast%3DMcMahon%26aufirst%3DH.%26aulast%3DGriffith%26aufirst%3DD.%2BM.%26atitle%3DNovel%2520improved%2520synthesis%2520of%2520HSP70%2520inhibitor%252C%2520pifithrin-%25CE%25BC.%2520in%2520vitro%2520synergy%2520quantification%2520of%2520pifithrin-%25CE%25BC%2520combined%2520with%2520Pt%2520drugs%2520in%2520prostate%2520and%2520colorectal%2520cancer%2520cells%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D949%26epage%3D958%26doi%3D10.3390%2Fmolecules21070949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyula, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newbold, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutting, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, K. J.</span></span> <span> </span><span class="NLM_article-title">HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1186/s12885-017-3084-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1186%2Fs12885-017-3084-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28143445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=86-98&author=M.+McLaughlinauthor=H.+E.+Barkerauthor=A.+A.+Khanauthor=M.+Pedersenauthor=M.+Dillonauthor=D.+C.+Mansfieldauthor=R.+Patelauthor=J.+N.+Kyulaauthor=S.+A.+Bhideauthor=K.+L.+Newboldauthor=C.+M.+Nuttingauthor=K.+J.+Harrington&title=HSP90+inhibition+sensitizes+head+and+neck+cancer+to+platin-based+chemoradiotherapy+by+modulation+of+the+DNA+damage+response+resulting+in+chromosomal+fragmentation&doi=10.1186%2Fs12885-017-3084-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation</span></div><div class="casAuthors">McLaughlin, Martin; Barker, Holly E.; Khan, Aadil A.; Pedersen, Malin; Dillon, Magnus; Mansfield, David C.; Patel, Radhika; Kyula, Joan N.; Bhide, Shreerang A.; Newbold, Kate L.; Nutting, Christopher M.; Harrington, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86/1-86/13</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Concurrent cisplatin radiotherapy (CCRT) is a current std.-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC).  However, CCRT is frequently ineffective in patients with advanced disease.  It has previously been shown that HSP90 inhibitors act as radiosensitizers, but these studies have not focused on CCRT in HNSCC.  Here, we evaluated the HSP90 inhibitor, AUY922, combined with CCRT.  The ability of AUY922 to sensitize to CCRT was assessed in p53 mutant head and neck cell lines by clonogenic assay.  Modulation of the CCRT induced DNA damage response (DDR) by AUY922 was characterized by confocal image anal. of RAD51, BRCA1, 53BP1, ATM and mutant p53 signaling.  The role of FANCA depletion by AUY922 was examd. using shRNA.  Cell cycle checkpoint abrogation and chromosomal fragmentation was assessed by western blot, FACS and confocal.  The role of ATM was also assessed by shRNA.  AUY922 in combination with CCRT was assessed in vivo.  The combination of AUY922 with cisplatin, radiation and CCRT was found to be synergistic in p53 mutant HNSCC.  AUY922 leads to significant alterations to the DDR induced by CCRT.  This comprises inhibition of homologous recombination through decreased RAD51 and pS1524 BRCA1 with a corresponding increase in 53BP1 foci, activation of ATM and signaling into mutant p53.  A shift to more error prone repair combined with a loss of checkpoint function leads to fragmentation of chromosomal material.  The degree of disruption to DDR signalling correlated to chromosomal fragmentation and loss of clonogenicity.  ATM shRNA indicated a possible rationale for the combination of AUY922 and CCRT in cells lacking ATM function.  This study supports future clin. studies combining AUY922 and CCRT in p53 mutant HNSCC.  Modulation of the DDR and chromosomal fragmentation are likely to be anal. points of interest in such trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomzeQvSHIL9rVg90H21EOLACvtfcHk0lg4nkXzEkiA7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12mtb0%253D&md5=b1d0e21fb4055f22e6e9f9d7ca655d15</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3084-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3084-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DKhan%26aufirst%3DA.%2BA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DM.%26aulast%3DMansfield%26aufirst%3DD.%2BC.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DKyula%26aufirst%3DJ.%2BN.%26aulast%3DBhide%26aufirst%3DS.%2BA.%26aulast%3DNewbold%26aufirst%3DK.%2BL.%26aulast%3DNutting%26aufirst%3DC.%2BM.%26aulast%3DHarrington%26aufirst%3DK.%2BJ.%26atitle%3DHSP90%2520inhibition%2520sensitizes%2520head%2520and%2520neck%2520cancer%2520to%2520platin-based%2520chemoradiotherapy%2520by%2520modulation%2520of%2520the%2520DNA%2520damage%2520response%2520resulting%2520in%2520chromosomal%2520fragmentation%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D86%26epage%3D98%26doi%3D10.1186%2Fs12885-017-3084-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1361</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1074/jbc.M509688200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1074%2Fjbc.M509688200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16275646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFOgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=1361-1370&author=Y.+Jungauthor=S.+J.+Lippard&title=RNA+polymerase+II+blockage+by+cisplatin-damaged+DNA.+Stability+and+polyubiquitylation+of+stalled+polymerase&doi=10.1074%2Fjbc.M509688200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">RNA polymerase II blockage by cisplatin-damaged DNA: stability and polyubiquitylation of stalled polymerase</span></div><div class="casAuthors">Jung, Yongwon; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1361-1370</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The consequences of human RNA polymerase II (pol II) arrest at the site of DNA damaged by cisplatin were studied in whole cells and cell exts., with a particular focus on the stability of stalled pol II and its subsequent ubiquitylation.  Site-specifically platinated DNA templates immobilized on a solid support were used to perform in vitro transcription in HeLa nuclear exts.  RNA elongation was completely blocked by a cisplatin intrastrand cross-link.  The stalled polymerase was quite stable, remaining on the DNA template in nuclear exts.  The stability of pol II stalled at the site of cisplatin damage was also obsd. in live cells.  A cell fractionation expt. using cisplatin-treated HeLa cells revealed an increased level of chromatin-assocd. pol II proteins following DNA damage.  The stalled polymerase was transcriptionally active and capable of elongating the transcript following chem. removal of platinum from the template.  Transcription inhibition by α-amanitin in vitro enhanced pol II ubiquitylation at ubiquitin residues Lys-6, Lys-48, and Lys-63.  In live cells expressing epitope-tagged ubiquitin mutants, several ubiquitin lysines also participated in pol II ubiquitylation following DNA damage.  Cisplatin treatment triggered ubiquitylation-mediated pol II degrdn. in HeLa cells, which could be prevented by the proteasomal inhibitor MG132.  Fractionation of pol II from cells co-treated with MG132 and cisplatin indicated that the undegraded ubiquitylated polymerase was mostly unbound or only loosely assocd. with chromatin.  These data are consistent with a model in which only a fraction of pol II, ubiquitylated in response to cisplatin damage of DNA, dissocs. from the sites of platination.  This altered polymerase is rapidly destroyed by proteasomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAVZpbMjVWwbVg90H21EOLACvtfcHk0lgPU94fR7MROA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFOgsA%253D%253D&md5=ae80155af582f77e484b345efd2e5dc1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M509688200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M509688200%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DY.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DRNA%2520polymerase%2520II%2520blockage%2520by%2520cisplatin-damaged%2520DNA.%2520Stability%2520and%2520polyubiquitylation%2520of%2520stalled%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D1361%26epage%3D1370%26doi%3D10.1074%2Fjbc.M509688200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leithner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkoenig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quehenberger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrzenjak, A.</span></span> <span> </span><span class="NLM_article-title">Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-14-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1186%2F1476-4598-14-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25608569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1ejurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=4-19&author=C.+Fischerauthor=K.+Leithnerauthor=C.+Wohlkoenigauthor=F.+Quehenbergerauthor=A.+Bertschauthor=A.+Olschewskiauthor=H.+Olschewskiauthor=A.+Hrzenjak&title=Panobinostat+reduces+hypoxia-induced+cisplatin+resistance+of+non-small+cell+lung+carcinoma+cells+via+HIF-1%CE%B1+destabilization&doi=10.1186%2F1476-4598-14-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization</span></div><div class="casAuthors">Fischer, Carina; Leithner, Katharina; Wohlkoenig, Christoph; Quehenberger, Franz; Bertsch, Alexandra; Olschewski, Andrea; Olschewski, Horst; Hrzenjak, Andelko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Lung cancer is one of the most frequent cancer types and the leading cause of cancer death worldwide.  Cisplatin is a widely used chemotherapeutic for non-small cell lung carcinoma (NSCLC), however, its pos. effects are diminished under hypoxia.  We wanted to det. if co-treatment with cisplatin and histone deacetalyse (HDAC) inhibitor panobinostat can reduce hypoxia-induced cisplatin resistance in NSCLC cells, and to elucidate mechanism involved.  Methods: Expression status of different HDACS was detd. in two cell lines and in tumor tissue from 20 patients.  Cells were treated with cisplatin, panobinostat, or with combination of both under normoxic and hypoxic (1% O2) conditions.  Cell cycle, viability, acetylation of histones, and activation of apoptosis were detd.  HIF-1α stability and its interaction with HDAC4 were analyzed.  Results: Most class I and II HDACs were expressed in NSCLC cells and tumor samples.  Co-treatment of tumor cells with cisplatin and panobinostat decreased cell viability and increased apoptosis more efficiently than in primary, non-malignant bronchial epithelial cells.  Co-treatment induced apoptosis by causing chromatin fragmentation, activation of caspases-3 and 7 and PARP cleavage.  Toxic effects were more pronounced under hypoxic conditions.  Co-treatment resulted in destabilization and degrdn. of HIF-1α and HDAC4, a protein responsible for acetylation and de/stabilization of HIF-1α.  Direct interaction between HDAC4 and HIF-1α proteins in H23 cells was detected.  Conclusions: Here we show that hypoxia-induced cisplatin resistance can be overcome by combining cisplatin with panobinostat, a potent HDAC inhibitor.  These findings may contribute to the development of a new therapeutic strategy for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7oyuVTUGATbVg90H21EOLACvtfcHk0lgPU94fR7MROA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1ejurk%253D&md5=f333d399210ddfcbaa86b2602a80f43c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-14-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-14-4%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DC.%26aulast%3DLeithner%26aufirst%3DK.%26aulast%3DWohlkoenig%26aufirst%3DC.%26aulast%3DQuehenberger%26aufirst%3DF.%26aulast%3DBertsch%26aufirst%3DA.%26aulast%3DOlschewski%26aufirst%3DA.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DHrzenjak%26aufirst%3DA.%26atitle%3DPanobinostat%2520reduces%2520hypoxia-induced%2520cisplatin%2520resistance%2520of%2520non-small%2520cell%2520lung%2520carcinoma%2520cells%2520via%2520HIF-1%25CE%25B1%2520destabilization%26jtitle%3DMol.%2520Cancer%26date%3D2015%26volume%3D14%26spage%3D4%26epage%3D19%26doi%3D10.1186%2F1476-4598-14-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baghai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niknejad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhon, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeneuve, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroulakos, J.</span></span> <span> </span><span class="NLM_article-title">Induction of activating transcription factor 3 is associated with cisplatin responsiveness in non-small cell lung carcinoma cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2016.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.neo.2016.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27659012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Sltb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=525-535&author=J.+Barauthor=M.+S.+Hasimauthor=T.+Baghaiauthor=N.+Niknejadauthor=T.+J.+Perkinsauthor=D.+J.+Stewartauthor=H.+S.+Sekhonauthor=P.+J.+Villeneuveauthor=J.+Dimitroulakos&title=Induction+of+activating+transcription+factor+3+is+associated+with+cisplatin+responsiveness+in+non-small+cell+lung+carcinoma+cells&doi=10.1016%2Fj.neo.2016.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells</span></div><div class="casAuthors">Bar, Jair; Hasim, Mohamed S.; Baghai, Tabassom; Niknejad, Nima; Perkins, Theodore J.; Stewart, David J.; Sekhon, Harmanjatinder S.; Villeneuve, Patrick J.; Dimitroulakos, Jim</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">525-535</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Non-small cell lung carcinoma (NSCLC) is the most common cause of cancer deaths, with platin-based combination chemotherapy the most efficacious therapies.  Gains in overall survival are modest, highlighting the need for novel therapeutic approaches including the development of next-generation platin combination regimens.  The goal of this study was to identify novel regulators of platin-induced cytotoxicity as potential therapeutic targets to further enhance platin cytotoxicity.  Employing RNA-seq transcriptome anal. comparing two parental NSCLC cell lines Calu6 and H23 to their cisplatin-resistant sublines, Calu6cisR1 and H23cisR1, activating transcription factor 3 (ATF3) was robustly induced in cisplatin-treated parental sensitive cell lines but not their resistant sublines, and in three of six tumors evaluated, but not in their corresponding normal adjacent lung tissue (0/6).  Cisplatin-induced JNK activation was a key regulator of this ATF3 induction.  Interestingly, in both resistant sublines, this JNK induction was abrogated, and the expression of an activated JNK construct in these cells enhanced both cisplatin-induced cytotoxicity and ATF3 induction.  An FDA-approved drug compd. screen was employed to identify enhancers of cisplatin cytotoxicity that were dependent on ATF3 gene expression.  Vorinostat, a histone deacetylase inhibitor, was identified in this screen and demonstrated synergistic cytotoxicity with cisplatin in both the parental Calu6 and H23 cell lines and importantly in their resistant sublines as well that was dependent on ATF3 expression.  Thus, we have identified ATF3 as an important regulator of cisplatin cytotoxicity and that ATF3 inducers in combination with platins are a potential novel therapeutic approach for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKamfmozcGeLVg90H21EOLACvtfcHk0lgPU94fR7MROA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Sltb3K&md5=265ec1ea01d8fc97d62b25508d8a9018</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2016.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2016.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DBar%26aufirst%3DJ.%26aulast%3DHasim%26aufirst%3DM.%2BS.%26aulast%3DBaghai%26aufirst%3DT.%26aulast%3DNiknejad%26aufirst%3DN.%26aulast%3DPerkins%26aufirst%3DT.%2BJ.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DSekhon%26aufirst%3DH.%2BS.%26aulast%3DVilleneuve%26aufirst%3DP.%2BJ.%26aulast%3DDimitroulakos%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520activating%2520transcription%2520factor%25203%2520is%2520associated%2520with%2520cisplatin%2520responsiveness%2520in%2520non-small%2520cell%2520lung%2520carcinoma%2520cells%26jtitle%3DNeoplasia%26date%3D2016%26volume%3D18%26spage%3D525%26epage%3D535%26doi%3D10.1016%2Fj.neo.2016.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tzeng, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W. H.</span></span> <span> </span><span class="NLM_article-title">Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e101664</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0101664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1371%2Fjournal.pone.0101664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25010594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ersb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=T.+J.+Tzengauthor=L.+Caoauthor=Y.+Fuauthor=H.+Zengauthor=W.+H.+Cheng&title=Methylseleninic+acid+sensitizes+Notch3-activated+OVCA429+ovarian+cancer+cells+to+carboplatin&doi=10.1371%2Fjournal.pone.0101664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin</span></div><div class="casAuthors">Tzeng, Tiffany J.; Cao, Lei; Fu, YangXin; Zeng, Huawei; Cheng, Wen-Hsing</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e101664/1-e101664/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Ovarian cancer, the deadliest of gynecol. cancers, is usually not diagnosed until advanced stages.  Although carboplatin has been popular for treating ovarian cancer for decades, patients eventually develop resistance to this platinum-contg. drug.  Expression of neurogenic locus notch homolog 3 (Notch3) is assocd. with chemoresistance and poor overall survival in ovarian cancer patients.  Overexpression of NICD3 (the constitutively active form of Notch3) in OVCA429 ovarian cancer cells (OVCA429/NICD3) renders them resistance to carboplatin treatment compared to OVCA429/pCEG cells expressing an empty vector.  We have previously shown that methylseleninic acid (MSeA) induces oxidative stress and activates ataxia-telangiectasia mutated and DNA-dependent protein kinase in cancer cells.  Here we tested the hypothesis that MSeA and carboplatin exerted a synthetic lethal effect on OVCA429/NICD3 cells.  Co-treatment with MSeA synergistically sensitized OVCA429/NICD3 but not OVCA429/pCEG cells to the killing by carboplatin.  This synergism was assocd. with a cell cycle exit at the G2/M phase and the induction of NICD3 target gene HES1.  Treatment of N-acetyl cysteine or inhibitors of the above two kinases did not directly impact on the synergism in OVCA429/NICD3 cells.  Taken together, these results suggest that the efficacy of carboplatin in the treatment of high grade ovarian carcinoma can be enhanced by a combinational therapy with MSeA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqRsrVnamU5bVg90H21EOLACvtfcHk0li2RHOvCZs0mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ersb7L&md5=272d64385a39bd79cda33e00a3fb7f6b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0101664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0101664%26sid%3Dliteratum%253Aachs%26aulast%3DTzeng%26aufirst%3DT.%2BJ.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DW.%2BH.%26atitle%3DMethylseleninic%2520acid%2520sensitizes%2520Notch3-activated%2520OVCA429%2520ovarian%2520cancer%2520cells%2520to%2520carboplatin%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0101664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Circu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Osta, H.</span></span> <span> </span><span class="NLM_article-title">Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0184922</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0184922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1371%2Fjournal.pone.0184922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28945807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+Circuauthor=J.+Cardelliauthor=M.+P.+Barrauthor=K.+O%E2%80%99Byrneauthor=G.+Millsauthor=H.+El-Osta&title=Modulating+lysosomal+function+through+lysosome+membrane+permeabilization+or+autophagy+suppression+restores+sensitivity+to+cisplatin+in+refractory+non-small-cell+lung+cancer+cells&doi=10.1371%2Fjournal.pone.0184922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells</span></div><div class="casAuthors">Circu, Magdalena; Cardelli, James; Barr, Martin; O'Byrne, Kenneth; Mills, Glenn; El-Osta, Hazem</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0184922/1-e0184922/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Lung cancer is the leading cause of cancer-related deaths.  Most patients develop resistance to platinum within several months of treatment.  We investigated whether triggering lysosomal membrane permeabilization (LMP) or suppressing autophagy can restore cisplatin susceptibility in lung cancer with acquired chemoresistance.  Cisplatin IC50 in A549Pt (parental) and A549cisR (cisplatin resistant) cells was 13 μM and 47 μM, resp.  Following cisplatin exposure, A549cisR cells failed to elicit an apoptotic response.  This was manifested by diminished Annexin±V staining, caspase 3 and 9, BAX and BAK activation in resistant but not in parental cells.  Chloroquine preferentially promoted LMP in A549cisR cells, revealed by leakage of FITC-dextran into the cytosol as detected by immunofluorescence microscopy.  This was confirmed by increased cytosolic cathepsin D signal on Immunoblot.  Cell viability of cisplatin-treated A549cisR cells was decreased when co-treated with chloroquine, corresponding to a combination index below 0.8, suggesting synergism between the two drugs.  Notably, chloroquine activated the mitochondrial cell death pathway as indicated by increase in caspase 9 activity.  Interestingly, inhibition of lysosomal proteases using E64 conferred cytoprotection against cisplatin and chloroquine co-treatment, suggesting that chloroquine-induced cell death occurred in a cathepsin-mediated mechanism.  Likewise, blockage of caspases partially rescued A549cisR cells against the cytotoxicity of cisplatin and chloroquine combination.  Cisplatin promoted a dose-dependent autophagic flux induction preferentially in A549cisR cells, as evidenced by a surge in LC3-II/ α-tubulin following pre-treatment with E64 and increase in p62 degrdn.  Compared to untreated cells, cisplatin induced an increase in cyto-ID-loaded autophagosomes in A549cisR cells that was further amplified by chloroquine, pointing toward autophagic flux activation by cisplatin.  Interestingly, this effect was less pronounced in A549Pt cells.  Blocking autophagy by ATG5 depletion using siRNA markedly enhances susceptibility to cisplatin in A549cisR cells.  Taken together, our results underscore the utility of targeting lysosomal function in overcoming acquired cisplatin refractoriness in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLEMt4g6rOwLVg90H21EOLACvtfcHk0li2RHOvCZs0mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFCgsbc%253D&md5=c457697a0d6a4affef9489554c1222bd</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0184922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0184922%26sid%3Dliteratum%253Aachs%26aulast%3DCircu%26aufirst%3DM.%26aulast%3DCardelli%26aufirst%3DJ.%26aulast%3DBarr%26aufirst%3DM.%2BP.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DMills%26aufirst%3DG.%26aulast%3DEl-Osta%26aufirst%3DH.%26atitle%3DModulating%2520lysosomal%2520function%2520through%2520lysosome%2520membrane%2520permeabilization%2520or%2520autophagy%2520suppression%2520restores%2520sensitivity%2520to%2520cisplatin%2520in%2520refractory%2520non-small-cell%2520lung%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0184922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreaden, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadir, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberio, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberlton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shopsowitz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, P. T.</span></span> <span> </span><span class="NLM_article-title">RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors</span>. <i>Bioeng. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1002/btm2.10086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fbtm2.10086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29376131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=26-36&author=E.+C.+Dreadenauthor=Y.+W.+Kongauthor=M.+A.+Quadirauthor=S.+Correaauthor=L.+Suarez-Lopezauthor=A.+E.+Barberioauthor=M.+K.+Hwangauthor=A.+C.+Shiauthor=B.+Oberltonauthor=P.+N.+Gallagherauthor=K.+E.+Shopsowitzauthor=K.+M.+Eliasauthor=M.+B.+Yaffeauthor=P.+T.+Hammond&title=RNA-Peptide+nanoplexes+drug+DNA+damage+pathways+in+high-grade+serous+ovarian+tumors&doi=10.1002%2Fbtm2.10086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors</span></div><div class="casAuthors">Dreaden, Erik C.; Kong, Yi Wen; Quadir, Mohiuddin A.; Correa, Santiago; Suarez-Lopez, Lucia; Barberio, Antonio E.; Hwang, Mun Kyung; Shi, Aria C.; Oberlton, Benjamin; Gallagher, Paige N.; Shopsowitz, Kevin E.; Elias, Kevin M.; Yaffe, Michael B.; Hammond, Paula T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioengineering & Translational Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-36</span>CODEN:
                <span class="NLM_cas:coden">BTMIAQ</span>;
        ISSN:<span class="NLM_cas:issn">2380-6761</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">DNA damaging chemotherapy is a cornerstone of current front-line treatments for advanced ovarian cancer (OC).  Despite the fact that a majority of these patients initially respond to therapy, most will relapse with chemo-resistant disease; therefore, adjuvant treatments that synergize with DNA-damaging chemotherapy could improve treatment outcomes and survival in patients with this deadly disease.  Here, we report the development of a nanoscale peptide-nucleic acid complex that facilitates tumor-specific RNA interference therapy to chemosensitize advanced ovarian tumors to frontline platinum/taxane therapy.  We found that the nanoplex-mediated silencing of the protein kinase, MK2, profoundly sensitized mouse models of high-grade serous OC to cytotoxic chemotherapy by blocking p38/MK2-dependent cell cycle checkpoint maintenance.  Combined RNAi therapy improved overall survival by 37% compared with platinum/taxane chemotherapy alone and decreased metastatic spread to the lungs without observable toxic side effects.  These findings suggest (a) that peptide nanoplexes can serve as safe and effective delivery vectors for siRNA and (b) that combined inhibition of MK2 could improve treatment outcomes in patients currently receiving frontline chemotherapy for advanced OC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPPQh0tegq7Vg90H21EOLACvtfcHk0li2RHOvCZs0mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKjur4%253D&md5=0d2ddfa17618bb37c2ddcc02b3748e2a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fbtm2.10086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbtm2.10086%26sid%3Dliteratum%253Aachs%26aulast%3DDreaden%26aufirst%3DE.%2BC.%26aulast%3DKong%26aufirst%3DY.%2BW.%26aulast%3DQuadir%26aufirst%3DM.%2BA.%26aulast%3DCorrea%26aufirst%3DS.%26aulast%3DSuarez-Lopez%26aufirst%3DL.%26aulast%3DBarberio%26aufirst%3DA.%2BE.%26aulast%3DHwang%26aufirst%3DM.%2BK.%26aulast%3DShi%26aufirst%3DA.%2BC.%26aulast%3DOberlton%26aufirst%3DB.%26aulast%3DGallagher%26aufirst%3DP.%2BN.%26aulast%3DShopsowitz%26aufirst%3DK.%2BE.%26aulast%3DElias%26aufirst%3DK.%2BM.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DHammond%26aufirst%3DP.%2BT.%26atitle%3DRNA-Peptide%2520nanoplexes%2520drug%2520DNA%2520damage%2520pathways%2520in%2520high-grade%2520serous%2520ovarian%2520tumors%26jtitle%3DBioeng.%2520Transl.%2520Med.%26date%3D2018%26volume%3D3%26spage%3D26%26epage%3D36%26doi%3D10.1002%2Fbtm2.10086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.3892/ol.2020.11905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fol.2020.11905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=32802168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BB38fmtFKltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=46-52&author=X.+Songauthor=W.+Qiauthor=J.+Guoauthor=L.+Sunauthor=A.+Dingauthor=G.+Zhaoauthor=H.+Liauthor=W.+Qiuauthor=J.+Lv&title=Immune+checkpoint+inhibitor+combination+therapy+for+gastric+cancer%3A+Research+progress&doi=10.3892%2Fol.2020.11905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress</span></div><div class="casAuthors">Song Xiaoxu; Qi Weiwei; Guo Jing; Sun Libin; Ding Aiping; Zhao Guanghui; Li Hui; Qiu Wensheng; Lv Jing</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">46</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Gastric cancer is one of the most common types of cancer; notably, gastric cancer is one of the top five malignancies with regards to incidence and mortality rates.  The symptoms of early gastric cancer are not typical, exhibiting only slight upper abdominal discomfort.  When the symptoms become more obvious, the lesion has usually progressed to an advanced stage.  Notably, >90% of inpatients already have locally advanced or metastatic gastric cancer at the time of initial diagnosis, with limited treatment options for advanced gastric cancer.  These options include chemotherapy, targeted therapy and immune checkpoint inhibitors (ICIs).  With regards to ICIs, the clinical benefit of monotherapy for advanced gastric cancer is limited; however, combinations of ICIs and other therapies may have clinical benefit.  Relevant clinical studies have demonstrated that combinations of ICIs with chemotherapy, anti-vascular targeted therapy or other molecular targeted therapies, and the use of two ICIs, improve outcomes for patients with advanced gastric cancer.  This article is a review of progress in the use of ICIs in combination with other therapies for the treatment of gastric cancer.  The purpose of this article was to advance gastric cancer immunotherapy and to improve the overall therapeutic benefit for patients with advanced gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMGL-IdhhnmacY7HFp97qMfW6udTcc2eYcx3Hk0zfqHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38fmtFKltw%253D%253D&md5=421d54ea061bbf044ed3c404792a156a</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3892%2Fol.2020.11905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2020.11905%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DJ.%26atitle%3DImmune%2520checkpoint%2520inhibitor%2520combination%2520therapy%2520for%2520gastric%2520cancer%253A%2520Research%2520progress%26jtitle%3DOncol.%2520Lett.%26date%3D2020%26volume%3D20%26spage%3D46%26epage%3D52%26doi%3D10.3892%2Fol.2020.11905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasaturo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Blasio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figdor, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hato, S. V.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2013.00417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3389%2Ffimmu.2013.00417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24348481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsVCgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=417-430&author=A.+Vasaturoauthor=S.+Di+Blasioauthor=D.+G.+Peetersauthor=C.+C.+de+Koningauthor=J.+M.+de+Vriesauthor=C.+G.+Figdorauthor=S.+V.+Hato&title=Clinical+implications+of+co-inhibitory+molecule+expression+in+the+tumor+microenvironment+for+DC+vaccination%3A+a+game+of+stop+and+go&doi=10.3389%2Ffimmu.2013.00417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go</span></div><div class="casAuthors">Vasaturo Angela; Di Blasio Stefania; Peeters Deborah G A; de Koning Coco C H; Figdor Carl G; Hato Stanleyson V; de Vries Jolanda M</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">The aim of therapeutic dendritic cell (DC) vaccines in cancer immunotherapy is to activate cytotoxic T cells to recognize and attack the tumor.  T cell activation requires the interaction of the T cell receptor with a cognate major-histocompatibility complex-peptide complex.  Although initiated by antigen engagement, it is the complex balance between co-stimulatory and co-inhibitory signals on DCs that results in T cell activation or tolerance.  Even when already activated, tumor-specific T cells can be neutralized by the expression of co-inhibitory molecules on tumor cells.  These and other immunosuppressive cues in the tumor microenvironment are major factors currently hampering the application of DC vaccination.  In this review, we discuss recent data regarding the essential and complex role of co-inhibitory molecules in regulating the immune response within the tumor microenvironment.  In particular, possible therapeutic intervention strategies aimed at reversing or neutralizing suppressive networks within the tumor microenvironment will be emphasized.  Importantly, blocking co-inhibitory molecule signaling, often referred to as immune checkpoint blockade, does not necessarily lead to an effective activation of tumor-specific T cells.  Therefore, combination of checkpoint blockade with other immune potentiating therapeutic strategies, such as DC vaccination, might serve as a synergistic combination, capable of reversing effector T cells immunosuppression while at the same time increasing the efficacy of T cell-mediated immunotherapies.  This will ultimately result in long-term anti-tumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNtZ9JYMnH-K69lAbTj9rGfW6udTcc2eYcx3Hk0zfqHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsVCgsQ%253D%253D&md5=6c033e0abf9d40edb924c2c469067ce6</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00417%26sid%3Dliteratum%253Aachs%26aulast%3DVasaturo%26aufirst%3DA.%26aulast%3DDi%2BBlasio%26aufirst%3DS.%26aulast%3DPeeters%26aufirst%3DD.%2BG.%26aulast%3Dde%2BKoning%26aufirst%3DC.%2BC.%26aulast%3Dde%2BVries%26aufirst%3DJ.%2BM.%26aulast%3DFigdor%26aufirst%3DC.%2BG.%26aulast%3DHato%26aufirst%3DS.%2BV.%26atitle%3DClinical%2520implications%2520of%2520co-inhibitory%2520molecule%2520expression%2520in%2520the%2520tumor%2520microenvironment%2520for%2520DC%2520vaccination%253A%2520a%2520game%2520of%2520stop%2520and%2520go%26jtitle%3DFront.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D417%26epage%3D430%26doi%3D10.3389%2Ffimmu.2013.00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grabosch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulatovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brozick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambotto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elishaev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlad, A. M.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2393</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0581-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fs41388-018-0581-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30518877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2380-2393&author=S.+Graboschauthor=M.+Bulatovicauthor=F.+Zengauthor=T.+Maauthor=L.+Zhangauthor=M.+Rossauthor=J.+Brozickauthor=Y.+Fangauthor=G.+Tsengauthor=E.+Kimauthor=A.+Gambottoauthor=E.+Elishaevauthor=R.+P.+Edwardsauthor=A.+M.+Vlad&title=Cisplatin-induced+immune+modulation+in+ovarian+cancer+mouse+models+with+distinct+inflammation+profiles&doi=10.1038%2Fs41388-018-0581-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles</span></div><div class="casAuthors">Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Ma, Tianzhou; Zhang, Lixin; Ross, Malcolm; Brozick, Joan; Fang, YuSi; Tseng, George; Kim, Eun; Gambotto, Andrea; Elishaev, Esther; P. Edwards, Robert; Vlad, Anda M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2380-2393</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking.  New therapeutic approaches using immunotherapy via immune checkpoint blockade, which have demonstrated clin. efficacy in other tumor types, have been less promising in ovarian cancer.  To increase their clin. efficacy, checkpoint inhibitors are now being tested in clin. trials in combination with chemotherapy.  Here, we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1, in two novel murine ovarian cancer cell models.  The 2F8 and its platinum-resistant deriv. 2F8cis model, display distinct inflammatory profiles and chemotherapy sensitivities, and mirror the primary and recurrent human disease, resp.  Acute and chronic exposure to cisplatin enhances tumor immunogenicity by increasing calreticulin, MHC class I, antigen presentation and T-cell infiltration.  Cisplatin also upregulates PD-L1 expression in vitro and in vivo, demonstrating a dual, paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade.  One of the pathways activated by cisplatin treatment is the cGAS/STING pathway.  Chronic cisplatin treatment led to upregulation of cGAS and STING proteins in 2F8cis compared to parental 2F8 cells, while acute exposure to cisplatin further increases cGAS and STING levels in both 2F8 and 2F8cis cells.  Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1, MHC I and calreticulin in tumor cells.  Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival.  These studies have high translational potential in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZIZzCpm2HLVg90H21EOLACvtfcHk0li7nqXrSpaYtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWkt7vK&md5=dab087745abb955a114017f47fd48b5f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0581-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0581-9%26sid%3Dliteratum%253Aachs%26aulast%3DGrabosch%26aufirst%3DS.%26aulast%3DBulatovic%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DRoss%26aufirst%3DM.%26aulast%3DBrozick%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DTseng%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DGambotto%26aufirst%3DA.%26aulast%3DElishaev%26aufirst%3DE.%26aulast%3DEdwards%26aufirst%3DR.%2BP.%26aulast%3DVlad%26aufirst%3DA.%2BM.%26atitle%3DCisplatin-induced%2520immune%2520modulation%2520in%2520ovarian%2520cancer%2520mouse%2520models%2520with%2520distinct%2520inflammation%2520profiles%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D2380%26epage%3D2393%26doi%3D10.1038%2Fs41388-018-0581-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-McIntyre, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Perrot, M.</span></span> <span> </span><span class="NLM_article-title">CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1809</span>– <span class="NLM_lpage">1819</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1535-7163.MCT-11-1014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22584123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1809-1819&author=L.+Wuauthor=Z.+Yunauthor=T.+Tagawaauthor=K.+Rey-McIntyreauthor=M.+de+Perrot&title=CTLA-4+blockade+expands+infiltrating+T+cells+and+inhibits+cancer+cell+repopulation+during+the+intervals+of+chemotherapy+in+murine+mesothelioma&doi=10.1158%2F1535-7163.MCT-11-1014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma</span></div><div class="casAuthors">Wu, Licun; Yun, Zhihong; Tagawa, Tetsuzo; Rey-McIntyre, Katrina; de Perrot, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1809-1819</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer immunotherapy has shown promising results when combined with chemotherapy.  Blocking CTLA-4 signaling by monoclonal antibody between cycles of chemotherapy may inhibit cancer cell repopulation and enhance the antitumoral immune reaction, thus improve the efficacy of chemotherapy in mesothelioma.  The impact of CTLA-4 blockade on the early stage of tumor development was evaluated in a s.c. murine mesothelioma model.  CTLA-4 blocking antibody was administered following each cycle of chemotherapy, and monotherapy was included as controls.  Antitumor effect was evaluated by tumor growth delay and survival of the animals.  Tumor cell repopulation was quantified by bromodeoxyuridine incorporation and Ki67 by immunohistochem. and/or flow cytometry.  In vitro cell killing was detd. by classic chromium-released assay, and reverse transcription PCR (RT-PCR) was carried out to det. the gene expression of assocd. cytokines.  Anti-CTLA-4 monoclonal antibody was able to inhibit tumor growth at early stage of tumor development.  Antitumor effect was achieved by administration of CTLA-4 blockade between cycles of chemotherapy.  Tumor cell repopulation during the intervals of cisplatin was inhibited by CTLA-4 blockade.  Anti-CTLA-4 therapy gave rise to an increased no. of CD4 and CD8 T cells infiltrating the tumor.  RT-PCR showed that the gene expression of interleukin IL-2, IFN-γ, granzyme B, and perforin increased in the tumor milieu.  Blockade of CTLA-4 signaling showed effective anticancer effect, correlating with inhibiting cancer cell repopulation between cycles of chemotherapy and upregulating tumor-infiltrating T lymphocytes, cytokines, and cytolytic enzymes in a murine mesothelioma model.  Mol Cancer Ther; 11(8); 1809-19. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN5maekd_K1rVg90H21EOLACvtfcHk0lipRo2ome9Mvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrK&md5=0869285e2f11dbc076b9596680d42084</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DZ.%26aulast%3DTagawa%26aufirst%3DT.%26aulast%3DRey-McIntyre%26aufirst%3DK.%26aulast%3Dde%2BPerrot%26aufirst%3DM.%26atitle%3DCTLA-4%2520blockade%2520expands%2520infiltrating%2520T%2520cells%2520and%2520inhibits%2520cancer%2520cell%2520repopulation%2520during%2520the%2520intervals%2520of%2520chemotherapy%2520in%2520murine%2520mesothelioma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1809%26epage%3D1819%26doi%3D10.1158%2F1535-7163.MCT-11-1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulgrew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodorge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcook, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCourt, M.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-14-0191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F2326-6066.CIR-14-0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25943534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFartL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=1052-1062&author=R.+Stewartauthor=M.+Morrowauthor=S.+A.+Hammondauthor=K.+Mulgrewauthor=D.+Marcusauthor=E.+Poonauthor=A.+Watkinsauthor=S.+Mullinsauthor=M.+Chodorgeauthor=J.+Andrewsauthor=D.+Bannisterauthor=E.+Dickauthor=N.+Crawfordauthor=J.+Parmentierauthor=M.+Alimzhanovauthor=J.+S.+Babcookauthor=I.+N.+Foltzauthor=A.+Buchananauthor=V.+Bedianauthor=R.+W.+Wilkinsonauthor=M.+McCourt&title=Identification+and+characterization+of+MEDI4736%2C+an+antagonistic+anti-PD-L1+monoclonal+antibody&doi=10.1158%2F2326-6066.CIR-14-0191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody</span></div><div class="casAuthors">Stewart, Ross; Morrow, Michelle; Hammond, Scott A.; Mulgrew, Kathy; Marcus, Danielle; Poon, Edmund; Watkins, Amanda; Mullins, Stefanie; Chodorge, Matthieu; Andrews, John; Bannister, David; Dick, Emily; Crawford, Nicola; Parmentier, Julie; Alimzhanov, Marat; Babcook, John S.; Foltz, Ian N.; Buchanan, Andrew; Bedian, Vahe; Wilkinson, Robert W.; McCourt, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1052-1062</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Programmed cell-death 1 ligand 1 (PD-L1) is a member of the B7/CD28 family of proteins that control T-cell activation.  Many tumors can upregulate expression of PD-L1, inhibiting antitumor T-cell responses and avoiding immune surveillance and elimination.  We have identified and characterized MEDI4736, a human IgG1 monoclonal antibody that binds with high affinity and specificity to PD-L1 and is uniquely engineered to prevent antibody-dependent cell-mediated cytotoxicity.  In vitro assays demonstrate that MEDI4736 is a potent antagonist of PD-L1 function, blocking interaction with PD-1 and CD80 to overcome inhibition of primary human T-cell activation.  In vivo MEDI4736 significantly inhibits the growth of human tumors in a novel xenograft model contg. coimplanted human T cells.  This activity is entirely dependent on the presence of transplanted T cells, supporting the immunol. mechanism of action for MEDI4736.  To further det. the utility of PD-L1 blockade, an anti-mouse PD-L1 antibody was investigated in immunocompetent mice.  Here, anti-mouse PD-L1 significantly improved survival of mice implanted with CT26 colorectal cancer cells.  The antitumor activity of anti-PD-L1 was enhanced by combination with oxaliplatin, which resulted in increased release of HMGB1 within CT26 tumors.  Taken together, our results demonstrate that inhibition of PD-L1 function can have potent antitumor activity when used as monotherapy or in combination in preclin. models, and suggest it may be a promising therapeutic approach for the treatment of cancer.  MEDI4736 is currently in several clin. trials both alone and in combination with other agents, including anti-CTLA-4, anti-PD-1, and inhibitors of IDO, MEK, BRAF, and EGFR.  Cancer Immunol Res; 3(9); 1052-62. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0trbhV8xu_7Vg90H21EOLACvtfcHk0lipRo2ome9Mvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFartL%252FN&md5=af677d33c3446f209eeac3219dea5513</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-14-0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-14-0191%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DR.%26aulast%3DMorrow%26aufirst%3DM.%26aulast%3DHammond%26aufirst%3DS.%2BA.%26aulast%3DMulgrew%26aufirst%3DK.%26aulast%3DMarcus%26aufirst%3DD.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DA.%26aulast%3DMullins%26aufirst%3DS.%26aulast%3DChodorge%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DJ.%26aulast%3DBannister%26aufirst%3DD.%26aulast%3DDick%26aufirst%3DE.%26aulast%3DCrawford%26aufirst%3DN.%26aulast%3DParmentier%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBabcook%26aufirst%3DJ.%2BS.%26aulast%3DFoltz%26aufirst%3DI.%2BN.%26aulast%3DBuchanan%26aufirst%3DA.%26aulast%3DBedian%26aufirst%3DV.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DMcCourt%26aufirst%3DM.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520MEDI4736%252C%2520an%2520antagonistic%2520anti-PD-L1%2520monoclonal%2520antibody%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D1052%26epage%3D1062%26doi%3D10.1158%2F2326-6066.CIR-14-0191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosheva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span> <span> </span><span class="NLM_article-title">Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04605-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fs41467-018-04605-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29884866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC1MblsFKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2237-2247&author=W.+Songauthor=L.+Shenauthor=Y.+Wangauthor=Q.+Liuauthor=T.+J.+Goodwinauthor=J.+Liauthor=O.+Doroshevaauthor=T.+Liuauthor=R.+Liuauthor=L.+Huang&title=Synergistic+and+low+adverse+effect+cancer+immunotherapy+by+immunogenic+chemotherapy+and+locally+expressed+PD-L1+trap&doi=10.1038%2Fs41467-018-04605-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap</span></div><div class="casAuthors">Song Wantong; Shen Limei; Wang Ying; Liu Qi; Goodwin Tyler J; Huang Leaf; Song Wantong; Li Jingjing; Dorosheva Olekasandra; Liu Rihe; Liu Tianzhou; Liu Rihe</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2237</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although great success has been obtained in the clinic, the current immune checkpoint inhibitors still face two challenging problems: low response rate and immune-related adverse effects (irAEs).  Here we report the combination of immunogenic chemotherapy and locally expressed PD-L1 trap fusion protein for efficacious and safe cancer immunotherapy.  We demonstrate that oxaliplatin (OxP) boosts anti-PD-L1 mAb therapy against murine colorectal cancer.  By design of a PD-L1 trap and loading its coding plasmid DNA into a lipid-protamine-DNA nanoparticle, PD-L1 trap is produced transiently and locally in the tumor microenvironment, and synergizes with OxP for tumor inhibition.  Significantly, unlike the combination of OxP and anti-PD-L1 mAb, the combination of OxP and PD-L1 trap does not induce obvious Th17 cells accumulation in the spleen, indicating better tolerance and lower tendency to irAEs.  The reports here may highlight the potential of applying PD-L1 inhibitor, especially locally expressed PD-L1 trap, in cancer therapy following OxP-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZUVp89Gd1Zi86Js-BCLiifW6udTcc2eY04KsVpRrBSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MblsFKltg%253D%253D&md5=4f5f6a692814f6ffeaab32034db3f006</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04605-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04605-x%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGoodwin%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDorosheva%26aufirst%3DO.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DSynergistic%2520and%2520low%2520adverse%2520effect%2520cancer%2520immunotherapy%2520by%2520immunogenic%2520chemotherapy%2520and%2520locally%2520expressed%2520PD-L1%2520trap%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2237%26epage%3D2247%26doi%3D10.1038%2Fs41467-018-04605-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Za’abi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoj, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waly, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemmar, A.</span></span> <span> </span><span class="NLM_article-title">The effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particles</span>. <i>Exp. Biol. Med. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">1698</span>– <span class="NLM_lpage">1707</span>, <span class="refDoi"> DOI: 10.1177/1535370215579013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1177%2F1535370215579013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVamtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2015&pages=1698-1707&author=B.+H.+Aliauthor=M.+Al+Za%E2%80%99abiauthor=A.+Shalabyauthor=P.+Manojauthor=M.+I.+Walyauthor=J.+Yasinauthor=M.+Fahimauthor=A.+Nemmar&title=The+effect+of+thymoquinone+treatment+on+the+combined+renal+and+pulmonary+toxicity+of+cisplatin+and+diesel+exhaust+particles&doi=10.1177%2F1535370215579013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particles</span></div><div class="casAuthors">Ali, Badreldin H.; Al Za'abi, Mohammed; Shalaby, Asem; Manoj, Priyadarsini; Waly, Mostafa I.; Yasin, Javed; Fahim, Mohamed; Nemmar, Abderrahim</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1698-1707</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Particulate air pollution (PAP) exposure is assocd. with increased morbidity and mortality, particularly in patients with renal disease.  However, there are only a few studies on the interaction between PAP and renal injury, and none on agents that may ameliorate it.  We studied the interaction between cisplatin (CP) nephrotoxicity and a single exposure to diesel exhaust particle (DEP) in rats 24 h before sacrifice, and assessed the effect of co-treatment with the active ingredient in Nigella Sativa seed oil, thymoquinone (TQ) thereon.  Rats were injected i.p. with CP (6mg/kg) and four days later, they were exposed intratracheally to DEP (0.5mg/kg), and were sacrificed 24 h later.  Oral TQ (20mg/kg) was given daily throughout the exptl. period.  CP alone caused several physiol., biochem., and histopathol. changes that included reduced growth and creatinine clearance, and raised plasma neutrophil gelatinase-assocd. lipocalin (NGAL), interleukin 6 (IL-6) and C-reactive protein (CRP), creatinine and urea concns., and urinary N-acetyl-b-D-glucosaminidase (NAG) activities.  It adversely affected several indexes of oxidative damage in the kidneys, and induced renal tubular necrosis.  Most of these actions were significantly potentiated in rats given both CP and DEP.  TQ significantly abrogated many of the effects of CP and DEP, given alone and in combination.  These results provide exptl. evidence that subjects with renal diseases can be at higher risk from PAP, and that TQ, pending further pharmacol. and toxicol. studies, can be considered a useful agent in patients with renal diseases and exposed to PAP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQUHppuhzuWLVg90H21EOLACvtfcHk0lhR_ocfyVN-uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVamtLfK&md5=7c45f2bbcb4e272e18043a9e8f196f3d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1177%2F1535370215579013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370215579013%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DB.%2BH.%26aulast%3DAl%2BZa%25E2%2580%2599abi%26aufirst%3DM.%26aulast%3DShalaby%26aufirst%3DA.%26aulast%3DManoj%26aufirst%3DP.%26aulast%3DWaly%26aufirst%3DM.%2BI.%26aulast%3DYasin%26aufirst%3DJ.%26aulast%3DFahim%26aufirst%3DM.%26aulast%3DNemmar%26aufirst%3DA.%26atitle%3DThe%2520effect%2520of%2520thymoquinone%2520treatment%2520on%2520the%2520combined%2520renal%2520and%2520pulmonary%2520toxicity%2520of%2520cisplatin%2520and%2520diesel%2520exhaust%2520particles%26jtitle%3DExp.%2520Biol.%2520Med.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D240%26spage%3D1698%26epage%3D1707%26doi%3D10.1177%2F1535370215579013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atasayar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürer-Orhan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orhan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özgüneş, H.</span></span> <span> </span><span class="NLM_article-title">Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.etp.2008.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.etp.2008.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18684602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlygurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=23-32&author=S.+Atasayarauthor=H.+G%C3%BCrer-Orhanauthor=H.+Orhanauthor=B.+G%C3%BCrelauthor=G.+Girginauthor=H.+%C3%96zg%C3%BCne%C5%9F&title=Preventive+effect+of+aminoguanidine+compared+to+vitamin+E+and+C+on+cisplatin-induced+nephrotoxicity+in+rats&doi=10.1016%2Fj.etp.2008.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats</span></div><div class="casAuthors">Atasayar, S.; Gurer-Orhan, H.; Orhan, H.; Gurel, B.; Girgin, G.; Ozgunes, H.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-32</span>CODEN:
                <span class="NLM_cas:coden">ETPAEK</span>;
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">In this study, the antioxidant effect of aminoguanidine on nephrotoxicity of a single dose of cisplatin is investigated and compared with the effects of well-known antioxidants vitamin C and E combination.  Tubular damage and perivascular inflammation were obsd. in kidney samples of the cisplatin-administered groups.  Aminoguanidine and vitamin C-E combination are found to be capable of preventing these effects of cisplatin.  Liver tissues of all groups were intact.  Cisplatin-induced oxidative stress was evidenced by significant decrease in glutathione and significant increase in malondialdehyde levels in kidney samples.  Antioxidants with cisplatin decreased malondialdehyde levels.  Antioxidants with cisplatin prevented the decrease in liver glutathione levels.  The nephrotoxicity was confirmed biochem. by significant elevation of serum urea and creatinine levels.  Both vitamin C-E combination and aminoguanidine prevented the increase in serum urea levels according to the cisplatin group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoln5vA1W76iLVg90H21EOLACvtfcHk0lhR_ocfyVN-uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlygurw%253D&md5=8b7a8716f07dae3af007c139fd1b0477</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.etp.2008.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.etp.2008.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DAtasayar%26aufirst%3DS.%26aulast%3DG%25C3%25BCrer-Orhan%26aufirst%3DH.%26aulast%3DOrhan%26aufirst%3DH.%26aulast%3DG%25C3%25BCrel%26aufirst%3DB.%26aulast%3DGirgin%26aufirst%3DG.%26aulast%3D%25C3%2596zg%25C3%25BCne%25C5%259F%26aufirst%3DH.%26atitle%3DPreventive%2520effect%2520of%2520aminoguanidine%2520compared%2520to%2520vitamin%2520E%2520and%2520C%2520on%2520cisplatin-induced%2520nephrotoxicity%2520in%2520rats%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2009%26volume%3D61%26spage%3D23%26epage%3D32%26doi%3D10.1016%2Fj.etp.2008.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deegan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basinger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hande, K. R.</span></span> <span> </span><span class="NLM_article-title">Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/0300-483X(95)03182-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2F0300-483X%2895%2903182-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=8571387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK2MXpvV2nsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1996&pages=159-166&author=P.+M.+Deeganauthor=M.+A.+Basingerauthor=M.+M.+Jonesauthor=K.+R.+Hande&title=Prevention+of+cisplatin+nephrotoxicity+by+exogenous+atrial+natriuretic+peptide&doi=10.1016%2F0300-483X%2895%2903182-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide</span></div><div class="casAuthors">Deegan, Patricia M.; Basinger, Mark A.; Jones, Mark M.; Hande, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">159-66</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The ability of atrial natriuretic peptide (ANP) to prevent cisplatin-induced nephrotoxicity was compared to the protective effect of 3% NaCl.  ANP (1 μg/kg/min), 3% NaCl or peptide buffer vehicle (50 μl/min) were infused for 45 min to conscious unrestrained rats immediately after cisplatin administration (5 mg/kg i.v.).  Measurements taken 72 h after drug treatment indicated that compared to animals receiving cisplatin only, ANP co-treated rats had lower post- treatment plasma creatinine concns. (0.70 vs. 1.3 mg/dL), blood urea nitrogen (BUN) concns. (44.2 vs. 65.5 mg/dL) and higher post-treatment glomerular filtration rates (GFR) (0.71 vs. 0.14 mL/min).  ANP was as effective as 3% NaCl in preventing cisplatin nephrotoxicity in this model.  The effect of ANP co-treatment on the anti-tumor activity of cisplatin was also examd. using the Walker 256 carcinosarcoma model.  ANP treatment did not result in any observable loss in anti-tumor activity.  When ANP was administered 72 h after cisplatin treatment, improvement in GFR was obsd. for the duration of the infusion, confirming the beneficial effect of ANP on cisplatin-damaged kidneys.  ANP may have a role in the treatment and prevention of cisplatin nephrotoxicity esp. in clin. situations where treatment with a large fluid vol. is contraindicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqngvHz2DU6rLVg90H21EOLACvtfcHk0lhR_ocfyVN-uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpvV2nsb0%253D&md5=a9c19f1589b46335c856d6016c72c7c2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0300-483X%2895%2903182-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0300-483X%252895%252903182-F%26sid%3Dliteratum%253Aachs%26aulast%3DDeegan%26aufirst%3DP.%2BM.%26aulast%3DBasinger%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DM.%2BM.%26aulast%3DHande%26aufirst%3DK.%2BR.%26atitle%3DPrevention%2520of%2520cisplatin%2520nephrotoxicity%2520by%2520exogenous%2520atrial%2520natriuretic%2520peptide%26jtitle%3DToxicology%26date%3D1996%26volume%3D106%26spage%3D159%26epage%3D166%26doi%3D10.1016%2F0300-483X%2895%2903182-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekborn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnström, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksborg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrsson, H.</span></span> <span> </span><span class="NLM_article-title">D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(02)00277-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2802%2900277-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12031515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2002&pages=53-61&author=A.+Ekbornauthor=G.+Laurellauthor=P.+Johnstr%C3%B6mauthor=I.+Wallinauthor=S.+Eksborgauthor=H.+Ehrsson&title=D-Methionine+and+cisplatin+ototoxicity+in+the+guinea+pig%3A+D-methionine+influences+cisplatin+pharmacokinetics&doi=10.1016%2FS0378-5955%2802%2900277-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics</span></div><div class="casAuthors">Ekborn, Andreas; Laurell, Goran; Johnstrom, Peter; Wallin, Inger; Eksborg, Staffan; Ehrsson, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-61</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The use of systemic D-methionine as a protector against cisplatin ototoxicity was studied in guinea pigs.  The kinetics and distribution of [11CH3]D-methionine were analyzed by PET.  Cisplatin and the monohydrated complex of cisplatin were quantified in the blood ultrafiltrate by using reversed-phase liq. chromatog. with postcolumn derivatization.  Administration of 300 mg D-methionine/kg caused a 30% decrease in the area under the concn.-time curve (AUC) of cisplatin.  The ototoxic effect of cisplatin was studied after dose adjustment of cisplatin, i.e., with similar cisplatin AUC in the group receiving D-methionine and the saline control group.  A significant ototoxic effect, measured as difference in pre- and 96-h post-treatment electrophysiol. hearing threshold (auditory brainstem response), was obsd. at stimulus frequencies of 30 and 20 kHz.  There was no difference between the groups in the extent of threshold shift.  Quant. outer hair cell counts showed a similar loss of cells in the two groups.  All the animals had an increase in plasma creatinine but there was no difference between the groups.  The results indicate that protection from cisplatin ototoxicity by systemic D-methionine can be explained by a lowered systemic exposure to the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3gmhj7fvRDLVg90H21EOLACvtfcHk0lgrB-RXs4AMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVWjtrk%253D&md5=b34abe89edf9850ece17ed5c37edb5ef</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2802%2900277-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252802%252900277-0%26sid%3Dliteratum%253Aachs%26aulast%3DEkborn%26aufirst%3DA.%26aulast%3DLaurell%26aufirst%3DG.%26aulast%3DJohnstr%25C3%25B6m%26aufirst%3DP.%26aulast%3DWallin%26aufirst%3DI.%26aulast%3DEksborg%26aufirst%3DS.%26aulast%3DEhrsson%26aufirst%3DH.%26atitle%3DD-Methionine%2520and%2520cisplatin%2520ototoxicity%2520in%2520the%2520guinea%2520pig%253A%2520D-methionine%2520influences%2520cisplatin%2520pharmacokinetics%26jtitle%3DHear.%2520Res.%26date%3D2002%26volume%3D165%26spage%3D53%26epage%3D61%26doi%3D10.1016%2FS0378-5955%2802%2900277-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serpeloni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcelos, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann Angeli, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercadante, A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lourdes Pires Bianchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antunes, L. M. G.</span></span> <span> </span><span class="NLM_article-title">Dietary carotenoid lutein protects against DNA damage and alterations of the redox status induced by cisplatin in human derived HepG2 cells</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2011.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.tiv.2011.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22138568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVOls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=288-294&author=J.+M.+Serpeloniauthor=G.+R.+Barcelosauthor=J.+P.+Friedmann+Angeliauthor=A.+Z.+Mercadanteauthor=M.+Lourdes+Pires+Bianchiauthor=L.+M.+G.+Antunes&title=Dietary+carotenoid+lutein+protects+against+DNA+damage+and+alterations+of+the+redox+status+induced+by+cisplatin+in+human+derived+HepG2+cells&doi=10.1016%2Fj.tiv.2011.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary carotenoid lutein protects against DNA damage and alterations of the redox status induced by cisplatin in human derived HepG2 cells</span></div><div class="casAuthors">Serpeloni, Juliana Mara; Barcelos, Gustavo Rafael Mazzaron; Angeli, Jose Pedro Friedmann; Mercadante, Adriana Zerlotti; Bianchi, Maria Lourdes Pires; Antunes, Lusania Maria Greggi</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-294</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Several epidemiol. and exptl. studies has been reported that lutein (LT) presents antioxidant properties.  Aim of the present study was to investigate the protective effects of LT against oxidative stress and DNA damage induced by cisplatin (cDDP) in a human derived liver cell line (HepG2).  Cell viability and DNA-damage was monitored by MTT and comet assays.  Moreover, different biochem. parameters related to redox status (glutathione, cytochrome-c and intracellular ROS) were also evaluated.  A clear DNA-damage was seen with cDDP (1.0 μM) treatment.  In combination with the carotenoid, redn. of DNA damage was obsd. after pre- and simultaneous treatment of the cells, but not when the carotenoid was added to the cells after the exposure to cDDP.  Exposure of the cells to cDDP also caused significant changes of all biochem. parameters and in co-treatment of the cells with LT, the carotenoid reverted these alterations.  The results indicate that cDDP induces pronounced oxidative stress in HepG2 cells that is related to DNA damage and that the supplementation with the antioxidant LT may protect these adverse effects caused by the exposure of the cells to platinum compd., which can be a good predict for chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFyt97pXSbDLVg90H21EOLACvtfcHk0lgrB-RXs4AMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVOls7k%253D&md5=fc6b40da2da1a2960db5ebe2e7250811</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2011.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2011.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DSerpeloni%26aufirst%3DJ.%2BM.%26aulast%3DBarcelos%26aufirst%3DG.%2BR.%26aulast%3DFriedmann%2BAngeli%26aufirst%3DJ.%2BP.%26aulast%3DMercadante%26aufirst%3DA.%2BZ.%26aulast%3DLourdes%2BPires%2BBianchi%26aufirst%3DM.%26aulast%3DAntunes%26aufirst%3DL.%2BM.%2BG.%26atitle%3DDietary%2520carotenoid%2520lutein%2520protects%2520against%2520DNA%2520damage%2520and%2520alterations%2520of%2520the%2520redox%2520status%2520induced%2520by%2520cisplatin%2520in%2520human%2520derived%2520HepG2%2520cells%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2012%26volume%3D26%26spage%3D288%26epage%3D294%26doi%3D10.1016%2Fj.tiv.2011.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishijima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokosuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iigo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani-Kaneko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span> <span> </span><span class="NLM_article-title">Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1034/j.1600-079X.2001.300301.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1034%2Fj.1600-079X.2001.300301.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=11316323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2001&pages=129-138&author=M.+Haraauthor=M.+Yoshidaauthor=H.+Nishijimaauthor=M.+Yokosukaauthor=M.+Iigoauthor=R.+Ohtani-Kanekoauthor=A.+Shimadaauthor=T.+Hasegawaauthor=Y.+Akamaauthor=K.+Hirata&title=Melatonin%2C+a+pineal+secretory+product+with+antioxidant+properties%2C+protects+against+cisplatin-induced+nephrotoxicity+in+rats&doi=10.1034%2Fj.1600-079X.2001.300301.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats</span></div><div class="casAuthors">Hara, Masayuki; Yoshida, Minoru; Nishijima, Hironori; Yokosuka, Makoto; Iigo, Masayuki; Ohtani-Kaneko, Ritsuko; Shimada, Akinori; Hasegawa, Tatsuya; Akama, Yoshifumi; Hirata, Kazuaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pineal Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">JPRSE9</span>;
        ISSN:<span class="NLM_cas:issn">0742-3098</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">To define the role of the pineal secretory melatonin and an analog, 6-hydroxymelatonin (6-Ω), in limiting oxidative stress, the present study investigated the cisplatin (CP)-induced alteration in the renal antioxidant system and nephroprotection with the two indolamines.  Melatonin (5 mg/kg), 6-Ω (5 mg/kg), or an equal vol. of saline were administered i.p. to male Sprague-Dawley rats 30 min prior to an i.p. injection of CP (7 mg/kg).  After CP treatment, the animals each received indolamine or saline every day and were sacrificed 3 or 5 days later and plasma as well as kidney were collected.  Both plasma creatinine and blood urea nitrogen increased significantly following CP administration alone; these values decreased significantly with melatonin co-treatment of CP-treated rats.  In the kidney, CP decreased the levels of GSH (reduced glutathione)/GSSG (oxidized glutathione) ratio, an index directly related to oxidative stress.  When animals were treated with melatonin, the redn. in the GSH/GSSG ratio was prevented.  Treatment of CP-enhanced lipid peroxidn. in the kidney was again prevented in animals treated with melatonin.  The activity of the antioxidant enzyme, glutathione peroxidase (GSH-Px), decreased as a result of CP administration, which was restored to control levels with melatonin co-treatment.  Upon histol. anal., damage to the proximal tubular cells was seen in the kidneys of CP-treated rats; these changes were prevented by melatonin treatment.  6-Ω Has been shown to have some antioxidative capacity, however, the protective effects of 6-Ω against CP-induced nephrotoxicity were less than those of melatonin.  The residual platinum concn. in the kidney of melatonin co-treated rats was significantly lower than that of rats treated with CP alone.  It is concluded that administration of CP imposes a severe oxidative stress to renal tissue and melatonin confers protection against the oxidative damage assocd. with CP.  This mechanism may be reasonably attributed to its radical scavenging activity, to its GSH-Px activating property, and/or to its regulatory activity for renal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFrovCvIp9rVg90H21EOLACvtfcHk0lgrB-RXs4AMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLs%253D&md5=f06ca3aaa0659f73cf4aa6d66f1e9a1f</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-079X.2001.300301.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-079X.2001.300301.x%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DNishijima%26aufirst%3DH.%26aulast%3DYokosuka%26aufirst%3DM.%26aulast%3DIigo%26aufirst%3DM.%26aulast%3DOhtani-Kaneko%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DA.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DAkama%26aufirst%3DY.%26aulast%3DHirata%26aufirst%3DK.%26atitle%3DMelatonin%252C%2520a%2520pineal%2520secretory%2520product%2520with%2520antioxidant%2520properties%252C%2520protects%2520against%2520cisplatin-induced%2520nephrotoxicity%2520in%2520rats%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D2001%26volume%3D30%26spage%3D129%26epage%3D138%26doi%3D10.1034%2Fj.1600-079X.2001.300301.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sridevi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhiayi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fcdd.2013.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23660976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlCmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=953-962&author=P.+Srideviauthor=M.+Nhiayiauthor=J.+Wang&title=Genetic+disruption+of+Abl+nuclear+import+reduces+renal+apoptosis+in+a+mouse+model+of+cisplatin-induced+nephrotoxicity&doi=10.1038%2Fcdd.2013.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Sridevi, P.; Nhiayi, M. K.; Wang, J. Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-962</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNA damage activates nuclear Abl tyrosine kinase to stimulate intrinsic apoptosis in cancer cell lines and mouse embryonic stem cells.  To examine the in vivo function of nuclear Abl in apoptosis, we generated Abl-μNLS (μ, mutated in nuclear localization signals) mice.  We show here that cisplatin-induced apoptosis is defective in the renal proximal tubule cells (RPTC) from the Ablμ/μ mice.  When injected with cisplatin, we found similar levels of platinum in the Abl+/+ and the Ablμ/μ kidneys, as well as similar initial inductions of p53 and PUMAα expression.  However, the accumulation of p53 and PUMAα could not be sustained in the Ablμ/μ kidneys, leading to redns. in renal apoptosis and tubule damage.  Co-treatment of cisplatin with the Abl kinase inhibitor, imatinib, reduced the accumulation of p53 and PUMAα in the Abl+/+ but not in the Ablμ/μ kidneys.  The residual apoptosis in the Ablμ/μ mice was not further reduced in the Ablμ/μ; p53-/- double-mutant mice, suggesting that nuclear Abl and p53 are epistatic to each other in this apoptosis response.  Although apoptosis and tubule damage were reduced, cisplatin-induced increases in phospho-Stat-1 and blood urea nitrogen were similar between the Abl+/+ and the Ablμ/μ kidneys, indicating that RPTC apoptosis is not the only factor in cisplatin-induced nephrotoxicity.  These results provide in vivo evidence for the pro-apoptotic function of Abl, and show that its nuclear localization and tyrosine kinase activity are both required for the sustained expression of p53 and PUMAα in cisplatin-induced renal apoptosis.  Cell Death and Differentiation (2013) 20, 953-962; doi:10.1038/cdd.2013.42; published online 10 May 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0JvLU9rcGNLVg90H21EOLACvtfcHk0lhywsSLvMCHYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlCmtr8%253D&md5=3d255e7d832da0373082d199b035cfcd</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.42%26sid%3Dliteratum%253Aachs%26aulast%3DSridevi%26aufirst%3DP.%26aulast%3DNhiayi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DGenetic%2520disruption%2520of%2520Abl%2520nuclear%2520import%2520reduces%2520renal%2520apoptosis%2520in%2520a%2520mouse%2520model%2520of%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2013%26volume%3D20%26spage%3D953%26epage%3D962%26doi%3D10.1038%2Fcdd.2013.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waissbluth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinpelu, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, S. J.</span></span> <span> </span><span class="NLM_article-title">The impact of erdosteine on cisplatin-induced ototoxicity: a proteomics approach</span>. <i>Eur. Arch. Oto-Rhino-L</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1007/s00405-016-4399-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs00405-016-4399-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2017&pages=1365-1374&author=S.+Waissbluthauthor=D.+Garnierauthor=O.+V.+Akinpeluauthor=P.+Salehiauthor=S.+J.+Daniel&title=The+impact+of+erdosteine+on+cisplatin-induced+ototoxicity%3A+a+proteomics+approach&doi=10.1007%2Fs00405-016-4399-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs00405-016-4399-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00405-016-4399-1%26sid%3Dliteratum%253Aachs%26aulast%3DWaissbluth%26aufirst%3DS.%26aulast%3DGarnier%26aufirst%3DD.%26aulast%3DAkinpelu%26aufirst%3DO.%2BV.%26aulast%3DSalehi%26aufirst%3DP.%26aulast%3DDaniel%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520impact%2520of%2520erdosteine%2520on%2520cisplatin-induced%2520ototoxicity%253A%2520a%2520proteomics%2520approach%26jtitle%3DEur.%2520Arch.%2520Oto-Rhino-L%26date%3D2017%26volume%3D274%26spage%3D1365%26epage%3D1374%26doi%3D10.1007%2Fs00405-016-4399-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gispen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G.</span></span> <span> </span><span class="NLM_article-title">Application of a neuroprotective ACTH (4–9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs</span>. <i>Eur. Arch. Oto-Rhino-L</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1007/BF00175953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2FBF00175953" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1994&pages=23-29&author=F.+Hamersauthor=S.+Klisauthor=W.+Gispenauthor=G.+Smoorenburg&title=Application+of+a+neuroprotective+ACTH+%284%E2%80%939%29+analog+to+affect+cisplatin+ototoxicity%3A+an+electrocochleographic+study+in+guinea+pigs&doi=10.1007%2FBF00175953"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2FBF00175953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00175953%26sid%3Dliteratum%253Aachs%26aulast%3DHamers%26aufirst%3DF.%26aulast%3DKlis%26aufirst%3DS.%26aulast%3DGispen%26aufirst%3DW.%26aulast%3DSmoorenburg%26aufirst%3DG.%26atitle%3DApplication%2520of%2520a%2520neuroprotective%2520ACTH%2520%25284%25E2%2580%25939%2529%2520analog%2520to%2520affect%2520cisplatin%2520ototoxicity%253A%2520an%2520electrocochleographic%2520study%2520in%2520guinea%2520pigs%26jtitle%3DEur.%2520Arch.%2520Oto-Rhino-L%26date%3D1994%26volume%3D251%26spage%3D23%26epage%3D29%26doi%3D10.1007%2FBF00175953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gispen, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Co-administration of the neurotrophic ACTH (4–9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(96)00213-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2896%2900213-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=9112103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK2sXislGiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1997&pages=9-19&author=J.+C.+M.+J.+de%0AGrootauthor=F.+P.+T.+Hamersauthor=W.-H.+Gispenauthor=G.+F.+Smoorenburg&title=Co-administration+of+the+neurotrophic+ACTH+%284%E2%80%939%29+analogue%2C+ORG+2766%2C+may+reduce+the+cochleotoxic+effects+of+cisplatin&doi=10.1016%2FS0378-5955%2896%2900213-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Co-administration of the neurotrophic ACTH(4-9) analog, ORG 2766, may reduce the cochleotoxic effects of cisplatin</span></div><div class="casAuthors">De Groot, John C.M.J.; Hamers, Frank P.T.; Gispen, Willem-Hendrik; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">9-19</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study the effect of the neurotrophic ACTH(4-9) analog, ORG 2766, on cisplatin cochleotoxicity was investigated with both light- and TEM microscopy.  Guinea pigs were treated with either cisplatin+ORG 2766 or cisplatin+physiol. saline.  All animals treated with cisplatin+physiol. saline showed complete loss of outer hair cells (OHC) and degeneration of the organ of Corti in the basal cochlear turns, while partial OHC loss was found in the middle and apical turns.  The inner hair cells (IHC) and other cochlear tissues were not affected.  Eight animals from the group treated with cisplatin+ORG 2766 demonstrated similar pathol. changes, but to a lesser degree, esp. in the middle turns.  The three remaining animals demonstrated no cochlear alterations at all, light-microscopically, and only minor subcellular changes in the OHCs at the ultrastructural level.  Electrophysiol., these three animals showed normal compd. action potential (CAP) amplitudes at stimulus frequencies from 0.5 to 16 kHz and normal cochlear microphonics (CM) in the frequency range from 0.5 to 8 kHz.  The other animals treated with cisplatin+ORG 2766 showed a severe loss in their CAPs and CM, except for one showing intermediate loss.  All animals from the group treated with cisplatin alone showed a severe loss in their CAPs and CM.  Endolymphatic hydrops was present in all animals from the cisplatin- and the cisplatin+ORG 2766-treated groups.  These data indicate that daily, concomitant administration of ORG 2766 may reduce OHC loss and subsequent degeneration of the organ of Corti in cisplatin-treated guinea pig cochleas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ZyUBazD8Y7Vg90H21EOLACvtfcHk0lhywsSLvMCHYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislGiu7o%253D&md5=1daeb257d7db00719aee94e5c3783483</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2896%2900213-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252896%252900213-4%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DHamers%26aufirst%3DF.%2BP.%2BT.%26aulast%3DGispen%26aufirst%3DW.-H.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DCo-administration%2520of%2520the%2520neurotrophic%2520ACTH%2520%25284%25E2%2580%25939%2529%2520analogue%252C%2520ORG%25202766%252C%2520may%2520reduce%2520the%2520cochleotoxic%2520effects%2520of%2520cisplatin%26jtitle%3DHear.%2520Res.%26date%3D1997%26volume%3D106%26spage%3D9%26epage%3D19%26doi%3D10.1016%2FS0378-5955%2896%2900213-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijbenga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, F. L.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S. F.L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluyter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Cisplatin ototoxicity involves organ of Corti, Stria vascularis and Spiral ganglion: modulation by αMSH and ORG 2766</span>. <i>Audiol. Neuro-Otol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1159/000073515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1159%2F000073515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14566101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=305-315&author=F.+P.T.+Hamersauthor=J.+Wijbengaauthor=F.+L.C.+Woltersauthor=S.+F.L.+Klisauthor=S.+Sluyterauthor=G.+F.+Smoorenburg&title=Cisplatin+ototoxicity+involves+organ+of+Corti%2C+Stria+vascularis+and+Spiral+ganglion%3A+modulation+by+%CE%B1MSH+and+ORG+2766&doi=10.1159%2F000073515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin ototoxicity involves organ of corti, stria vascularis and spiral ganglion: modulation by αMSH and ORG 2766</span></div><div class="casAuthors">Hamers, Frank P. T.; Wijbenga, Jeroen; Wolters, Francisca L. C.; Klis, Sjaak F. L.; Sluyter, Steven; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Audiology & Neuro-Otology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">305-315</span>CODEN:
                <span class="NLM_cas:coden">ANEOFO</span>;
        ISSN:<span class="NLM_cas:issn">1420-3030</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">It has been shown that αMSH and the nonmelanotropic ACTH/MSH(4-9) analog ORG 2766 can ameliorate cisplatin-induced neurotoxicity and ototoxicity.  Here, we investigated whether these peptides delay the occurrence of the cisplatin-induced shift in auditory threshold, and whether they affect the subsequent recovery of cochlear potentials.  Chronically implanted round window electrodes were used to obtain daily recordings of auditory nerve compd. action potentials (CAP) and cochlear microphonics at frequencies ranging from 2 to 16 kHz.  Cisplatin (1.5 mg/kg i.p.) plus αMSH, ORG 2766 (75 μg/kg s.c.), or saline were injected daily until the 40-dB CAP threshold shift at 8 kHz was reached.  Endocochlear potential (EP) was measured either 1-2 days or 28 days later, followed by morphometric anal. of the cochlea.  Peptide cotreatment did not consistently delay the threshold shift; however, the CAP threshold recovered faster and to a greater extent, with the potency order being αMSH > ORG 2766 > saline.  Significant recovery at the 2 highest frequencies was seen in the αMSH-treated animals only.  CAP amplitude at high sound pressures, which depends more on nerve function than on outer hair cell (OHC) function, decreased severely in all groups but recovered significantly in the αMSH- and completely in the ORG-2766-cotreated group.  EP was significantly lower in the first days after the threshold shift but had completely recovered at 28 days.  Morphometric anal. of the spiral ganglion also indicated involvement of ganglion cells.  OHC loss was most severe in the basal turn of saline-cotreated animals.  These data suggest that the cisplatin-induced acute threshold shift might be due to reversible strial failure, whereas subsequent OHC survival dets. the final degree of functional recovery.  Both OHC loss and neuronal function were ameliorated by peptide cotreatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmbYQqfAYhLVg90H21EOLACvtfcHk0lhywsSLvMCHYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFertLc%253D&md5=358a389020cb9809d6f32a79e208682c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1159%2F000073515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000073515%26sid%3Dliteratum%253Aachs%26aulast%3DHamers%26aufirst%3DF.%2BP.T.%26aulast%3DWijbenga%26aufirst%3DJ.%26aulast%3DWolters%26aufirst%3DF.%2BL.C.%26aulast%3DKlis%26aufirst%3DS.%2BF.L.%26aulast%3DSluyter%26aufirst%3DS.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DCisplatin%2520ototoxicity%2520involves%2520organ%2520of%2520Corti%252C%2520Stria%2520vascularis%2520and%2520Spiral%2520ganglion%253A%2520modulation%2520by%2520%25CE%25B1MSH%2520and%2520ORG%25202766%26jtitle%3DAudiol.%2520Neuro-Otol.%26date%3D2003%26volume%3D8%26spage%3D305%26epage%3D315%26doi%3D10.1159%2F000073515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinaal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huizing, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Histological effects of co-administration of an ACTH (4–9) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(00)00061-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2800%2900061-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10831874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsVGitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2000&pages=157-167&author=R.+M.+Cardinaalauthor=J.+C.+M.+J.+de+Grootauthor=E.+H.+Huizingauthor=J.+E.+Veldmanauthor=G.+F.+Smoorenburg&title=Histological+effects+of+co-administration+of+an+ACTH+%284%E2%80%939%29+analogue%2C+ORG+2766%2C+on+cisplatin+ototoxicity+in+the+albino+guinea+pig&doi=10.1016%2FS0378-5955%2800%2900061-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Histological effects of co-administration of an ACTH(4-9) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig</span></div><div class="casAuthors">Cardinaal, R. M.; de Groot, J. C. M. J.; Huizing, E. H.; Veldman, J. E.; Smoorenburg, G. F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">157-167</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Cisplatin is one of the most potent antineoplastic drugs presently known, but its therapeutic efficacy is seriously limited by several side effects such as ototoxicity.  Several compds. that are known for their nephroprotective effects also seem to reduce the incidence and severity of cisplatin-induced ototoxicity.  Hamers et al. (1994) and De Groot et al. (1997) investigated the possibly protective effect of concomitant administration of the ACTH(4-9) analog ORG 2766 upon cisplatin ototoxicity in guinea pigs.  Animals were treated with cisplatin at a daily dose of 2.0 mg/kg for 8 consecutive days and ORG 2766 at a daily dose of 75 μg/kg for 9 days.  Concomitant administration of cisplatin plus ORG 2766 resulted in a bimodal distribution of the electrophysiol. data (compd. action potential and cochlear microphonics amplitudes) and the histol. data (outer hair cell (OHC) counts).  It was surmised that this dichotomy might occur at a certain cisplatin dose.  We investigated whether this protective effect of ORG 2766 could be enhanced by reducing the daily dose of cisplatin while maintaining the same dose of ORG 2766.  Thirty-six animals were treated with daily i.p. injections of cisplatin at a dose of 1.0 mg/kg (n=18) or 1.5 mg/kg (n=18) for 8 consecutive days.  When comparing the mean OHC counts of the different exptl. groups, treatment with cisplatin at a daily dose of 1.5 mg/kg for 8 consecutive days resulted in a considerable loss of OHCs, which was significantly reduced after co-administration of ORG 2766.  Co-treatment with ORG 2766 did not result in a change in the vol. of the scala media.  The present results are in agreement with electrophysiol. results published earlier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd3-Mu4H4RBbVg90H21EOLACvtfcHk0lgMj_rl1YRiXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsVGitb0%253D&md5=4357ff502787a54baa4f8d50ec87a801</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2800%2900061-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252800%252900061-7%26sid%3Dliteratum%253Aachs%26aulast%3DCardinaal%26aufirst%3DR.%2BM.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DHuizing%26aufirst%3DE.%2BH.%26aulast%3DVeldman%26aufirst%3DJ.%2BE.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DHistological%2520effects%2520of%2520co-administration%2520of%2520an%2520ACTH%2520%25284%25E2%2580%25939%2529%2520analogue%252C%2520ORG%25202766%252C%2520on%2520cisplatin%2520ototoxicity%2520in%2520the%2520albino%2520guinea%2520pig%26jtitle%3DHear.%2520Res.%26date%3D2000%26volume%3D144%26spage%3D157%26epage%3D167%26doi%3D10.1016%2FS0378-5955%2800%2900061-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, F. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S. F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(03)00396-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2803%2900396-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14987750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVKhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2004&pages=31-40&author=F.+L.+C.+Woltersauthor=S.+F.+L.+Klisauthor=F.+P.+T.+Hamersauthor=J.+C.+M.+J.+de%0AGrootauthor=G.+F.+Smoorenburg&title=Perilymphatic+application+of+%CE%B1-melanocyte+stimulating+hormone+ameliorates+hearing+loss+caused+by+systemic+administration+of+cisplatin&doi=10.1016%2FS0378-5955%2803%2900396-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin</span></div><div class="casAuthors">Wolters, Francisca L. C.; Klis, Sjaak F. L.; Hamers, Frank P. T.; de Groot, John C. M. J.; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">It has previously been demonstrated that ototoxicity induced by systemic administration of cisplatin is reduced by concomitant systemic administration of α-MSH.  In this study the authors investigated the effects of cochlear, perilymphatic application of α-MSH during i.p. administration of cisplatin.  Guinea pigs, implanted with a round-window electrode, allowing daily monitoring of the compd. action potential (CAP), and also implanted with a mini-osmotic pump, pumping at a rate of 0.25 μl/h either physiol. saline or α-MSH soln. (0.02, 2, and 20 μg/mL), were treated daily with a bolus injection of cisplatin (2 mg/kg) until the electrocochleogram showed a persistent decrease in CAP amplitude (≥40 dB threshold shift at 8 kHz).  Then, cisplatin treatment was stopped, but intracochlear perfusion of α-MSH or physiol. saline was continued for 10 days to evaluate possible effects of α-MSH on the expected recovery.  On day 10, the animals were killed and the cochleas were fixed and processed for histol. anal.  All groups required 6-7 days of cisplatin to reach the criterion CAP threshold shift.  Ten days after cessation of the cisplatin treatment, recovery of the CAP was obsd. in all groups and at all frequencies, although it was more pronounced at the lower frequencies.  With respect to recovery, small statistically significant differences were found between the saline and the α-MSH co-treated groups.  Histol. results showed significantly less outer hair cell (OHC) loss in the group co-treated with 2 μg/mL α-MSH as compared to the group co-treated with saline.  Since α-MSH was directly delivered to the cochlea, the ameliorating effect of α-MSH on OHC survival is likely to involve a cochlear target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJpw2ntAtR7Vg90H21EOLACvtfcHk0lgMj_rl1YRiXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVKhsrw%253D&md5=83418183c2169f34f83aa361a4045e92</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2803%2900396-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252803%252900396-4%26sid%3Dliteratum%253Aachs%26aulast%3DWolters%26aufirst%3DF.%2BL.%2BC.%26aulast%3DKlis%26aufirst%3DS.%2BF.%2BL.%26aulast%3DHamers%26aufirst%3DF.%2BP.%2BT.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DPerilymphatic%2520application%2520of%2520%25CE%25B1-melanocyte%2520stimulating%2520hormone%2520ameliorates%2520hearing%2520loss%2520caused%2520by%2520systemic%2520administration%2520of%2520cisplatin%26jtitle%3DHear.%2520Res.%26date%3D2004%26volume%3D189%26spage%3D31%26epage%3D40%26doi%3D10.1016%2FS0378-5955%2803%2900396-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, F. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S. F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieskorn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Systemic co-treatment with α-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(03)00080-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2803%2900080-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12742238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2003&pages=53-61&author=F.+L.+C.+Woltersauthor=S.+F.+L.+Klisauthor=J.+C.+M.+J.+de%0AGrootauthor=F.+P.+T.+Hamersauthor=D.+M.+Prieskornauthor=J.+M.+Millerauthor=G.+F.+Smoorenburg&title=Systemic+co-treatment+with+%CE%B1-melanocyte+stimulating+hormone+delays+hearing+loss+caused+by+local+cisplatin+administration+in+guinea+pigs&doi=10.1016%2FS0378-5955%2803%2900080-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic co-treatment with α-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs</span></div><div class="casAuthors">Wolters, Francisca L. C.; Klis, Sjaak F. L.; de Groot, John C. M. J.; Hamers, Frank P. T.; Prieskorn, Diane M.; Miller, Josef M.; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-61</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">It has previously been demonstrated that ototoxicity induced by systemic administration of cisplatin is reduced by concomitant administration of melanocortins, like α-MSH.  However, these expts. were hampered by large interanimal variability.  Therefore, we re-investigated the effects of systemically administered α-MSH during local (intracochlear) administration of cisplatin.  Guinea pigs, implanted with a round-window electrode, allowing daily monitoring of the compd. action potentials (CAPs), and a mini-osmotic pump, pumping either 0.5 μL/h physiol. saline or cisplatin soln. (15 μg/mL), were cotreated daily with a s.c. bolus injection of either α-MSH (75 μg/kg) or physiol. saline for 1 wk or until the electrocochleogram showed a persistent decrease in CAP amplitude (40 dB threshold shift at 8 kHz).  Next, the animals were sacrificed and the cochleas were processed for histol.  After 2-3 days, cisplatin alone caused a threshold shift at all frequencies (2-16 kHz).  Co-administration with α-MSH consistently delayed the criterion threshold shift by 1 day.  When the 40 dB criterion had been reached, similar outer hair cell losses in both the cisplatin/α-MSH- and cisplatin/saline-treated groups were obsd.  This expt. confirms that direct administration of cisplatin into the cochlea results in considerably less interanimal variability than systemic administration and that co-treatment with α-MSH delays cisplatin ototoxicity.  Since cisplatin was delivered directly to the cochlea, the ameliorating effect of α-MSH probably involves a cochlear target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9QM7-CPTLLLVg90H21EOLACvtfcHk0lgMj_rl1YRiXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWks7Y%253D&md5=1182c8b4035785950e5333c1de133849</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2803%2900080-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252803%252900080-7%26sid%3Dliteratum%253Aachs%26aulast%3DWolters%26aufirst%3DF.%2BL.%2BC.%26aulast%3DKlis%26aufirst%3DS.%2BF.%2BL.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DHamers%26aufirst%3DF.%2BP.%2BT.%26aulast%3DPrieskorn%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DJ.%2BM.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DSystemic%2520co-treatment%2520with%2520%25CE%25B1-melanocyte%2520stimulating%2520hormone%2520delays%2520hearing%2520loss%2520caused%2520by%2520local%2520cisplatin%2520administration%2520in%2520guinea%2520pigs%26jtitle%3DHear.%2520Res.%26date%3D2003%26volume%3D179%26spage%3D53%26epage%3D61%26doi%3D10.1016%2FS0378-5955%2803%2900080-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">Platinum(IV) anticancer prodrugs - hypotheses and facts</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">12983</span>– <span class="NLM_lpage">12991</span>, <span class="refDoi"> DOI: 10.1039/C6DT01414C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC6DT01414C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27214873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XotlCruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=12983-12991&author=D.+Gibson&title=Platinum%28IV%29+anticancer+prodrugs+-+hypotheses+and+facts&doi=10.1039%2FC6DT01414C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) anticancer prodrugs - hypotheses and facts</span></div><div class="casAuthors">Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">12983-12991</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In this manuscript we focus on Pt(IV) anticancer prodrugs.  We explore the main working hypotheses for the design of effective Pt(IV) prodrugs and note the exceptions to the common assumptions that are prevalent in the field.  Special attention was devoted to the emerging class of "dual action" Pt(IV) prodrugs, where bioactive ligands are conjugated to the axial positions of platinum in order to obtain orthogonal or complementary effects that will increase the efficacy of killing the cancer cells.  We discuss the rationale behind the design of the "dual action" prodrugs and the results of the pharmacol. studies obtained.  Simultaneous release of two bioactive moieties inside the cancer cells often triggers several processes that together det. the fate of the cell.  Pt(IV) complexes provide many opportunities for applying new concepts in targeting, synergistic cell killing and exploiting novel nanodelivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN31ie6PsEtLVg90H21EOLACvtfcHk0ljyPF_hXhF2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotlCruro%253D&md5=99fca9a3216d25087a0b565f8997c3ae</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1039%2FC6DT01414C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01414C%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DPlatinum%2528IV%2529%2520anticancer%2520prodrugs%2520-%2520hypotheses%2520and%2520facts%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D12983%26epage%3D12991%26doi%3D10.1039%2FC6DT01414C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Current developments in Pt(IV) prodrugs conjugated with bioactive ligands</span>. <i>Bioinorg. Chem. Appl.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">8276139</span>, <span class="refDoi"> DOI: 10.1155/2018/8276139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1155%2F2018%2F8276139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30402082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BB3cvntl2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=8276139&author=X.+Liauthor=Y.+Liuauthor=H.+Tian&title=Current+developments+in+Pt%28IV%29+prodrugs+conjugated+with+bioactive+ligands&doi=10.1155%2F2018%2F8276139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands</span></div><div class="casAuthors">Li Xuejiao; Tian Hongqi; Liu Yahong</div><div class="citationInfo"><span class="NLM_cas:title">Bioinorganic chemistry and applications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8276139</span>
        ISSN:<span class="NLM_cas:issn">1565-3633</span>.
    </div><div class="casAbstract">To overcome the side effects of and resistance to cisplatin, a variety of Pt(IV) prodrugs were designed and synthesized via different modifications including combination with lipid chains to increase hydrophobicity, conjugation with short peptide chains or nanoparticles to improve drug delivery, or addition of bioactive ligands to the axial positions of Pt(IV) complexes to exert dual-function effects.  This review summarizes the recent progress in the development of Pt(IV) prodrugs conjugated with bioactive-targeting ligands, including histone deacetylase inhibitors, p53 agonists, alkylating agents, and nonsteroidal anti-inflammatory agents.  Although Pt(IV) complexes that conjugated with bioactive ligands show satisfactory anticancer effects, none has been approved for clinical use.  Therefore, we hope that this review will contribute to further study and development of Pt(IV) complexes conjugated with bioactive and other ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyKq5BuXOBhwaK-_ZudimnfW6udTcc2eayM_8gYpKKILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvntl2rtw%253D%253D&md5=93dd0f70da754552be3a890d8fa7ae05</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1155%2F2018%2F8276139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F8276139%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DCurrent%2520developments%2520in%2520Pt%2528IV%2529%2520prodrugs%2520conjugated%2520with%2520bioactive%2520ligands%26jtitle%3DBioinorg.%2520Chem.%2520Appl.%26date%3D2018%26volume%3D2018%26spage%3D8276139%26doi%3D10.1155%2F2018%2F8276139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Rational design of anticancer platinum(IV) prodrugs</span>. <i>Adv. Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/bs.adioch.2019.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fbs.adioch.2019.10.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2020&pages=149-182&author=S.+Zhangauthor=X.+Wangauthor=Z.+Guo&title=Rational+design+of+anticancer+platinum%28IV%29+prodrugs&doi=10.1016%2Fbs.adioch.2019.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fbs.adioch.2019.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.adioch.2019.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DRational%2520design%2520of%2520anticancer%2520platinum%2528IV%2529%2520prodrugs%26jtitle%3DAdv.%2520Inorg.%2520Chem.%26date%3D2020%26volume%3D75%26spage%3D149%26epage%3D182%26doi%3D10.1016%2Fbs.adioch.2019.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalaila, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allardyce, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, P. J.</span></span> <span> </span><span class="NLM_article-title">Rational design of platinum(IV) compounds to overcome glutathione-s-transferase mediated drug resistance</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1382</span>– <span class="NLM_lpage">1383</span>, <span class="refDoi"> DOI: 10.1021/ja0432618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0432618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=1382-1383&author=W.+H.+Angauthor=I.+Khalailaauthor=C.+S.+Allardyceauthor=L.+Juillerat-Jeanneretauthor=P.+J.+Dyson&title=Rational+design+of+platinum%28IV%29+compounds+to+overcome+glutathione-s-transferase+mediated+drug+resistance&doi=10.1021%2Fja0432618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Platinum(IV) Compounds to Overcome Glutathione-S-Transferase Mediated Drug Resistance</span></div><div class="casAuthors">Ang, Wee Han; Khalaila, Isam; Allardyce, Claire S.; Juillerat-Jeanneret, Lucienne; Dyson, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1382-1383</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A rationally designed Pt(IV) anticancer compd. is described, employing the novel concept of tethering an inhibitor of glutathione-S-transferase, an enzyme assocd. with Pt-based drug-resistance, to cisplatin.  Its enzyme inhibition activity, investigated using spectrophotometric and mass spectrometry-based techniques, and cytotoxic profile in resistant cancer cells are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7VgXIgOAQKLVg90H21EOLACvtfcHk0ljyPF_hXhF2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGmsA%253D%253D&md5=814c125e4c704b8b1a3811f1e01eedfd</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fja0432618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0432618%26sid%3Dliteratum%253Aachs%26aulast%3DAng%26aufirst%3DW.%2BH.%26aulast%3DKhalaila%26aufirst%3DI.%26aulast%3DAllardyce%26aufirst%3DC.%2BS.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DDyson%26aufirst%3DP.%2BJ.%26atitle%3DRational%2520design%2520of%2520platinum%2528IV%2529%2520compounds%2520to%2520overcome%2520glutathione-s-transferase%2520mediated%2520drug%2520resistance%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D1382%26epage%3D1383%26doi%3D10.1021%2Fja0432618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2019.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jinorgbio.2019.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30731264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2019&pages=133-142&author=H.+Chenauthor=X.+Wangauthor=S.+Gou&title=A+cisplatin-based+platinum%28IV%29+prodrug+containing+a+glutathione+s-transferase+inhibitor+to+reverse+cisplatin-resistance+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.jinorgbio.2019.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer</span></div><div class="casAuthors">Chen, Hong; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A Pt(IV) prodrug of cisplatin contg. a glutathione s-transferase (GSTs) inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), complex 1, was designed and studied aiming to overcome cisplatin-resistance and reduce its toxicity by inhibiting GSTs overexpressed in cancer cells.  The complex could be reduced to release its active Pt(II) species and axial ligand in the presence of ascorbic acid.  In cytotoxicity study, complex 1 showed more potent anticancer activity than cisplatin and NBDHEX against all the tested cancer cells, esp. toward cisplatin resistant A549/DDP cells with a resistance factor value of 0.37.  By effectively inhibiting GSTs, complex 1 was found to be able to promote higher platinum uptake and cause more severe DNA damage in both A549 cells and A549/DDP cells as compared with cisplatin.  Further mechanism study indicated that it could trigger cell death via an apoptotic pathway.  In vivo tests on A549 xenograft tumor mice model showed that complex 1 presented higher tumor inhibiting rate and lower toxicity than cisplatin as well.  In all, the Pt(IV) prodrug has potential to be developed as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjC9GD7aCddbVg90H21EOLACvtfcHk0lgY1orogvy20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWntr8%253D&md5=601a07727f245c505bb4d1e41657ca3b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2019.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2019.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DA%2520cisplatin-based%2520platinum%2528IV%2529%2520prodrug%2520containing%2520a%2520glutathione%2520s-transferase%2520inhibitor%2520to%2520reverse%2520cisplatin-resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2019%26volume%3D193%26spage%3D133%26epage%3D142%26doi%3D10.1016%2Fj.jinorgbio.2019.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid of DNA-targeting chlorambucil with Pt(IV) species to reverse drug resistance</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.243451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1124%2Fjpet.117.243451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28916659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=221-239&author=F.+Chenauthor=G.+Xuauthor=X.+Qinauthor=X.+Jinauthor=S.+Gou&title=Hybrid+of+DNA-targeting+chlorambucil+with+Pt%28IV%29+species+to+reverse+drug+resistance&doi=10.1124%2Fjpet.117.243451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid of DNA-targeting chlorambucil with Pt(IV) species to reverse drug resistance</span></div><div class="casAuthors">Chen, Feihong; Xu, Gang; Qin, Xiaodong; Jin, Xiufeng; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-239</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Two hybrids of Pt(IV) species were designed and prepd. by addn. of a chlorambucil unit to the axial positions of the Pt(IV) complexes derived from DN603 and DN604.  In vitro studies of two hybrids against two pairs of cisplatin sensitive and resistant cancer cell lines indicated that compd. 5 had superior antitumor activity to cisplatin and chlorambucil via suppressing DNA damage repair to reverse drug resistance.  Mechanistic investigation suggested that the potent antitumor activity of compd. 5 arose from its major suppression of CK2-mediated MRE11-RAD50-NBS1(MRN) complex promotion of DNA double strand break (DSB) repair.  In nude mice with A549/CDDP xenografts, compd. 5 exhibited higher anticancer efficacy than cisplatin and chlorambucil by reversing drug resistance, displayed improved effectiveness, and had no toxicity effects.  Overall, compd. 5 is a promising drug candidate, which could promote the anticancer activity and reverse drug resistance by attenuating CK2-induced MRN-dependent DSB repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFlzpA5Kf6rVg90H21EOLACvtfcHk0lgY1orogvy20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrbJ&md5=d69a3c10dff340fa5b99ef54ad21067d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.243451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.243451%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DHybrid%2520of%2520DNA-targeting%2520chlorambucil%2520with%2520Pt%2528IV%2529%2520species%2520to%2520reverse%2520drug%2520resistance%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D221%26epage%3D239%26doi%3D10.1124%2Fjpet.117.243451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">A platinum(IV) anticancer prodrug targeting nucleotide excision repair to overcome cisplatin resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">15564</span>– <span class="NLM_lpage">15568</span>, <span class="refDoi"> DOI: 10.1002/anie.201608936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fanie.201608936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=15564-15568&author=Z.+Wangauthor=Z.+Xuauthor=G.+Zhu&title=A+platinum%28IV%29+anticancer+prodrug+targeting+nucleotide+excision+repair+to+overcome+cisplatin+resistance&doi=10.1002%2Fanie.201608936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance</span></div><div class="casAuthors">Wang, Zhigang; Xu, Zoufeng; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">15564-15568</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">DNA damage response plays a key role not only in maintaining genome integrity but also in mediating the antitumor efficacy of DNA-damaging antineoplastic drugs.  Herein, we report the rational design and evaluation of a PtIV anticancer prodrug inhibiting nucleotide excision repair (NER), one of the most pivotal processes after the formation of cisplatin-induced DNA damage that deactivates the drug and leads to drug resistance in the clinic.  This dual-action prodrug enters cells efficiently and causes DNA damage while simultaneously inhibiting NER to promote apoptotic response.  The prodrug is strongly active against the proliferation of cisplatin-resistant human cancer cells with an up to 88-fold increase in growth inhibition compared with cisplatin, and the prodrug is much more active than a mixt. of cisplatin and an NER inhibitor.  Our study highlights the importance of targeting downstream pathways after the formation of Pt-induced DNA damage as a novel strategy to conquer cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5lc5oE4qMXrVg90H21EOLACvtfcHk0lgY1orogvy20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK&md5=551b6004833ce071b79c923cdf9483ca</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1002%2Fanie.201608936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201608936%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DA%2520platinum%2528IV%2529%2520anticancer%2520prodrug%2520targeting%2520nucleotide%2520excision%2520repair%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D15564%26epage%3D15568%26doi%3D10.1002%2Fanie.201608936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2465</span>– <span class="NLM_lpage">2468</span>, <span class="refDoi"> DOI: 10.1039/c3cc48740g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2Fc3cc48740g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24452361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVygsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=2465-2468&author=K.+Suntharalingamauthor=Y.+Songauthor=S.+J.+Lippard&title=Conjugation+of+vitamin+E+analog+%CE%B1-TOS+to+Pt%28IV%29+complexes+for+dual-targeting+anticancer+therapy&doi=10.1039%2Fc3cc48740g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy</span></div><div class="casAuthors">Suntharalingam, Kogularamanan; Song, Ying; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2465-2468</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The authors report two platinum(IV) complexes conjugated with a vitamin E analog, α-tocopherol succinate (α-TOS).  One of the conjugates displays the activity of both cisplatin and α-TOS in cancer cells, causing damage to DNA and mitochondria simultaneously.  Accordingly, it serves as a promising dual-targeting anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruxZumJGIJpbVg90H21EOLACvtfcHk0li7mhc3TTIV_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVygsLY%253D&md5=dc381d990f2afa1e349752f4e81976ba</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1039%2Fc3cc48740g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc48740g%26sid%3Dliteratum%253Aachs%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DConjugation%2520of%2520vitamin%2520E%2520analog%2520%25CE%25B1-TOS%2520to%2520Pt%2528IV%2529%2520complexes%2520for%2520dual-targeting%2520anticancer%2520therapy%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D2465%26epage%3D2468%26doi%3D10.1039%2Fc3cc48740g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2793</span>– <span class="NLM_lpage">2800</span>, <span class="refDoi"> DOI: 10.1021/mp200597r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200597r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2793-2800&author=J.+Yangauthor=X.+Sunauthor=W.+Maoauthor=M.+Suiauthor=J.+Tangauthor=Y.+Shen&title=Conjugate+of+Pt%28IV%29-histone+deacetylase+inhibitor+as+a+prodrug+for+cancer+chemotherapy&doi=10.1021%2Fmp200597r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugate of Pt(IV)-Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy</span></div><div class="casAuthors">Yang, Jun; Sun, Xuanrong; Mao, Weiwei; Sui, Meihua; Tang, Jianbin; Shen, Youqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2793-2800</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixt. with VA, against various human carcinoma cell lines.  VAAP could be quickly absorbed in the cell membrane and diffused into the cytosol.  VAAP loaded in polyethylene glycol-polycaprolactone micelles (PEG-PCL) was taken up via endocytosis.  The cytosolic VAAP was intracellular reduced to Pt(II) and released VA eliciting a HDAC inhibitory effect and subsequently induced cell cycle arrest at the S phase in 24 h and cell apoptosis in a time-dependent manner.  The in vivo antitumor expt. on A549-xenograft tumor model showed that VAAP dispersed in Tween 80 or loaded in PEG-PCL nanoparticles had long blood circulation times and thereby high accumulation in tumors and exerted a significant in vivo inhibitory effect on tumor growth with low systemic toxicity.  Therefore, this novel conjugate is very promising for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeW1MFD6bedbVg90H21EOLACvtfcHk0li7mhc3TTIV_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrK&md5=838e90dcb852b4dddeb424832f46ab15</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fmp200597r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200597r%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DSui%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DConjugate%2520of%2520Pt%2528IV%2529-histone%2520deacetylase%2520inhibitor%2520as%2520a%2520prodrug%2520for%2520cancer%2520chemotherapy%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2793%26epage%3D2800%26doi%3D10.1021%2Fmp200597r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrache, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berding, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The prodrug platin-A: simultaneous release of cisplatin and aspirin</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/anie.201308899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fanie.201308899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1963-1967&author=R.+K.+Pathakauthor=S.+Marracheauthor=J.+H.+Choiauthor=T.+B.+Berdingauthor=S.+Dhar&title=The+prodrug+platin-A%3A+simultaneous+release+of+cisplatin+and+aspirin&doi=10.1002%2Fanie.201308899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span></div><div class="casAuthors">Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer-assocd. inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers.  The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin.  Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin.  These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIPcwRalkB7Vg90H21EOLACvtfcHk0li7mhc3TTIV_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D&md5=d40b197ee5448e5a64a60c656eb0fde9</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1002%2Fanie.201308899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201308899%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DMarrache%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DBerding%26aufirst%3DT.%2BB.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520prodrug%2520platin-A%253A%2520simultaneous%2520release%2520of%2520cisplatin%2520and%2520aspirin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fanie.201308899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">7427</span>– <span class="NLM_lpage">7430</span>, <span class="refDoi"> DOI: 10.1039/C4CC00419A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC4CC00419A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24777030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=7427-7430&author=Q.+Chengauthor=H.+Shiauthor=H.+Wangauthor=Y.+Minauthor=J.+Wangauthor=Y.+Liu&title=The+ligation+of+aspirin+to+cisplatin+demonstrates+significant+synergistic+effects+on+tumor+cells&doi=10.1039%2FC4CC00419A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span></div><div class="casAuthors">Cheng, Qinqin; Shi, Hongdong; Wang, Hongxia; Min, Yuanzeng; Wang, Jun; Liu, Yangzhong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">7427-7430</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells.  Asplatin is highly accumulated in cancer cells and is activated upon the redn. by ascorbic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT52MltZpsqbVg90H21EOLACvtfcHk0li7mhc3TTIV_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO&md5=5679afe1ad21bd6c6181aa0bd6d1f2fe</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1039%2FC4CC00419A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC00419A%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DThe%2520ligation%2520of%2520aspirin%2520to%2520cisplatin%2520demonstrates%2520significant%2520synergistic%2520effects%2520on%2520tumor%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D7427%26epage%3D7430%26doi%3D10.1039%2FC4CC00419A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jinorgbio.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28700961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCltrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2017&pages=47-57&author=W.+Huauthor=L.+Fangauthor=W.+Huaauthor=S.+Gou&title=Biotin-Pt+%28IV%29-indomethacin+hybrid%3A+A+targeting+anticancer+prodrug+providing+enhanced+cancer+cellular+uptake+and+reversing+cisplatin+resistance&doi=10.1016%2Fj.jinorgbio.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance</span></div><div class="casAuthors">Hu, Weiwei; Fang, Lei; Hua, Wuyang; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-57</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A Pt(IV) prodrug (2) composed of cancer-targeting biotin and nonsteroidal anti-inflammatory drug indomethacin in the axial positions of the six-coordinated octahedral geometry derived from cisplatin was developed, which could be highly accumulated in cancer cells more than normal ones and activated by endogenous reducing mols. to release cisplatin and indomethacin moieties simultaneously to inhibit tumor progression synergistically.  In vitro assays revealed that 2 exhibited significantly selective inhibition to the tested cancer cell lines and sensitivity to cisplatin resistant cancer cells.  Moreover, 2 presented cyclooxygenases inhibition properties to reduce tumor-assocd. inflammation, reduced the invasiveness of the highly aggressive PC-3 cells, and disrupted capillary-like tube formation in EA.hy926 cells.  In all, this study offers a new strategy to enhance sensitivity and reduce toxicity of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwSqdeg6RZY7Vg90H21EOLACvtfcHk0lg9kIl8e57-6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCltrfP&md5=fc6c894c081b68804819dead13f16cc7</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DHua%26aufirst%3DW.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DBiotin-Pt%2520%2528IV%2529-indomethacin%2520hybrid%253A%2520A%2520targeting%2520anticancer%2520prodrug%2520providing%2520enhanced%2520cancer%2520cellular%2520uptake%2520and%2520reversing%2520cisplatin%2520resistance%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2017%26volume%3D175%26spage%3D47%26epage%3D57%26doi%3D10.1016%2Fj.jinorgbio.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(IV) prodrugs</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3829</span>– <span class="NLM_lpage">3835</span>, <span class="refDoi"> DOI: 10.1039/D0SC00197J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FD0SC00197J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFegt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=3829-3835&author=S.+Zhangauthor=X.+Zhongauthor=H.+Yuanauthor=Y.+Guoauthor=D.+Songauthor=F.+Qiauthor=Z.+Zhuauthor=X.+Wangauthor=Z.+Guo&title=Interfering+in+apoptosis+and+DNA+repair+of+cancer+cells+to+conquer+cisplatin+resistance+by+platinum%28IV%29+prodrugs&doi=10.1039%2FD0SC00197J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(IV) prodrugs</span></div><div class="casAuthors">Zhang, Shuren; Zhong, Xuanmeng; Yuan, Hao; Guo, Yan; Song, Dongfan; Qi, Fen; Zhu, Zhenzhu; Wang, Xiaoyong; Guo, Zijian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3829-3835</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Two anticancer PtIV prodrugs with the formulas [Pt(NH3)2Cl2(L1)2] (1, L1 = 3-chloro-benzo[b]thiophene-2-carboxylic acid) and [Pt(NH3)2Cl2(L2)2] (2, L2 = 3-chloro-6-methylbenzo[b]thiophene-2-carboxylic acid) were designed to target Mcl-1, a protein responsible for inhibiting apoptosis and promoting DNA damage repair.  Both 1 and 2 could enter cancer cells effectively and cause DNA damage while simultaneously downregulating Mcl-1 to prompt a conspicuous apoptotic response.  Complex 2 also downregulated the DNA damage repair proteins RAD51 and BRCA2 as well as inhibited the formation of RAD51 foci, which is regarded as a crit. step and functional biomarker in homologous recombination.  The acute toxicity of 1 and 2 to mice is lower than that of cisplatin, and more importantly, they show much stronger inhibition towards the growth of non-small-cell lung cancer in nude mice than cisplatin.  Complexes 1 and 2 are the first Mcl-1-targeted PtIV prodrugs, and the latter could synchronously inhibit apoptosis and DNA repair related proteins in cisplatin-resistant cancer cells.  The strategy of tuning both apoptosis and DNA repair pathways opens a promising window to overcoming resistance to cisplatin in anticancer chemotherapy, and is also a breakthrough in the design of multitalented platinum-based anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV_cxH8CGc2rVg90H21EOLACvtfcHk0lg9kIl8e57-6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFegt78%253D&md5=28565813ce600fc6973282acf98109a1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1039%2FD0SC00197J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0SC00197J%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DQi%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DInterfering%2520in%2520apoptosis%2520and%2520DNA%2520repair%2520of%2520cancer%2520cells%2520to%2520conquer%2520cisplatin%2520resistance%2520by%2520platinum%2528IV%2529%2520prodrugs%26jtitle%3DChem.%2520Sci.%26date%3D2020%26volume%3D11%26spage%3D3829%26epage%3D3835%26doi%3D10.1039%2FD0SC00197J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.-R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immuno-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0lg9kIl8e57-6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.-R.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immuno-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">9971</span>– <span class="NLM_lpage">9974</span>, <span class="refDoi"> DOI: 10.1039/C7CC05311H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC7CC05311H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28831477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=9971-9974&author=N.+Muhammadauthor=N.+Sadiaauthor=C.+Zhuauthor=C.+Luoauthor=Z.+Guoauthor=X.+Wang&title=Biotin-tagged+platinum%28IV%29+complexes+as+targeted+cytostatic+agents+against+breast+cancer+cells&doi=10.1039%2FC7CC05311H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells</span></div><div class="casAuthors">Muhammad, Nafees; Sadia, Nasreen; Zhu, Chengcheng; Luo, Cheng; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">72</span>),
    <span class="NLM_cas:pages">9971-9974</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A biotin-guided platinumIV complex is highly cytotoxic against breast cancer cells but hypotoxic against mammary epithelial cells.  The mono-biotinylated PtIV complex is superior to the di-biotinylated one and hence a promising drug candidate for the targeted therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojsf_nE7HGsrVg90H21EOLACvtfcHk0li6VVIweVuHJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO&md5=e0003ab9a6a3ef976136f8ea223433e5</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2FC7CC05311H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC05311H%26sid%3Dliteratum%253Aachs%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DSadia%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DBiotin-tagged%2520platinum%2528IV%2529%2520complexes%2520as%2520targeted%2520cytostatic%2520agents%2520against%2520breast%2520cancer%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D9971%26epage%3D9974%26doi%3D10.1039%2FC7CC05311H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">8790</span>– <span class="NLM_lpage">8798</span>, <span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.-R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+prodrugs+designed+to+bind+non-covalently+to+human+serum+albumin+for+drug+delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0li6VVIweVuHJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.-R.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520designed%2520to%2520bind%2520non-covalently%2520to%2520human%2520serum%2520albumin%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laws, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span> <span> </span><span class="NLM_article-title">The next generation of anticancer metallopharmaceuticals: cancer stem cell-active inorganics</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2246</span>– <span class="NLM_lpage">2253</span>, <span class="refDoi"> DOI: 10.1002/cbic.201800358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fcbic.201800358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30109911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2nsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2246-2253&author=K.+Lawsauthor=K.+Suntharalingam&title=The+next+generation+of+anticancer+metallopharmaceuticals%3A+cancer+stem+cell-active+inorganics&doi=10.1002%2Fcbic.201800358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Anticancer Metallopharmaceuticals: Cancer Stem Cell-Active Inorganics</span></div><div class="casAuthors">Laws, Kristine; Suntharalingam, Kogularamanan</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2246-2253</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are heavily linked to fatal incidences of cancer relapse and metastasis.  Conventional cancer therapies such as surgery, chemotherapy and radiation are largely futile against CSCs.  Therefore, highly original approaches are needed to overcome CSCs and to provide durable, long-term clin. outcomes.  Many academia- and pharmaceutical-led studies aimed at developing chem. or biol. anti-CSC agents are ongoing; however, the application of inorg. compds. is rare.  In this minireview, we discuss how the chem. diversity and versatility offered by metals has been harnessed to develop an unprecedented, emerging class of metallopharmaceuticals: CSC-active inorgs.  A detailed account of their mechanism(s) of action is provided, and possible future directions for exploration are also put forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2ekH5pCdv7Vg90H21EOLACvtfcHk0li6VVIweVuHJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2nsb%252FM&md5=4c0ad667b145406a5861cafe9e01a81c</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201800358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201800358%26sid%3Dliteratum%253Aachs%26aulast%3DLaws%26aufirst%3DK.%26aulast%3DSuntharalingam%26aufirst%3DK.%26atitle%3DThe%2520next%2520generation%2520of%2520anticancer%2520metallopharmaceuticals%253A%2520cancer%2520stem%2520cell-active%2520inorganics%26jtitle%3DChemBioChem%26date%3D2018%26volume%3D19%26spage%3D2246%26epage%3D2253%26doi%3D10.1002%2Fcbic.201800358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonagh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ffrench, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, M. P.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">72544</span>– <span class="NLM_lpage">72563</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.18632%2Foncotarget.19881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29069808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ksVKmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=72544-72563&author=L.+MacDonaghauthor=M.+F.+Gallagherauthor=B.+Ffrenchauthor=C.+Gaschauthor=E.+Breenauthor=S.+G.+Grayauthor=S.+Nicholsonauthor=N.+Leonardauthor=R.+Ryanauthor=V.+Youngauthor=J.+J.+O%E2%80%99Learyauthor=S.+Cuffeauthor=S.+P.+Finnauthor=K.+J.+O%E2%80%99Byrneauthor=M.+P.+Barr&title=Targeting+the+cancer+stem+cell+marker%2C+aldehyde+dehydrogenase+1%2C+to+circumvent+cisplatin+resistance+in+NSCLC&doi=10.18632%2Foncotarget.19881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC</span></div><div class="casAuthors">MacDonagh Lauren; Gray Steven G; Cuffe Sinead; Finn Stephen P; O'Byrne Kenneth J; Barr Martin P; Gallagher Michael F; Ffrench Brendan; Gasch Claudia; O'Leary John J; Breen Eamon; Nicholson Siobhan; Leonard Niamh; Finn Stephen P; Ryan Ronan; Young Vincent; O'Byrne Kenneth J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">72544-72563</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) accounts for a large proportion of cancer deaths and is characterized by low treatment response rates and poor overall prognosis.  In the absence of specific treatable mutations, cisplatin-based chemotherapy plays an important role in the treatment of this disease.  Unfortunately, the development of resistance has become a major therapeutic challenge in the use of this cytotoxic drug.  Elucidating the mechanisms underlying this resistance phenotype, may result in the development of novel agents that enhance sensitivity to cisplatin in lung cancer patients.  In this study, targeting the cancer stem cell activity of aldehyde dehydrogenase 1 (ALDH1) was investigated as a strategy to overcome chemoresistance in NSCLC.  Tumors from NSCLC patients showed an increase in their profile of pluripotent stemness genes.  Cisplatin exposure induced the emergence or expansion of an ALDH1-positive subpopulation in cisplatin sensitive and resistant NSCLC cell lines, respectively, further enhancing cisplatin resistance.  Using the Aldefluor assay and FACS analysis, ALDH1 subpopulations were isolated and evaluated in terms of stem cell characteristics.  Only ALDH1-positive cells exhibited asymmetric division, cisplatin resistance and increased expression of stem cell factors in vitro.  Xenograft studies in NOD/SCID mice demonstrated efficient tumorigenesis from low cell numbers of ALDH1-positive and ALDH1-negative subpopulations.  Targeting ALDH1 with Diethylaminobenzaldehyde (DEAB) and Disulfiram, significantly re-sensitized resistant lung cancer cells to the cytotoxic effects of cisplatin.  Our data demonstrate the existence of a lung CSC population and suggest a role for targeting ALDH1 as a potential therapeutic strategy in re-sensitizing NSCLC cells to the cytotoxic effects of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnxbjAjsdnFMjl5L8hwNX0fW6udTcc2ebn59SyEe96ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ksVKmsA%253D%253D&md5=b7536b1fc32fd80effce42d222a1f285</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19881%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonagh%26aufirst%3DL.%26aulast%3DGallagher%26aufirst%3DM.%2BF.%26aulast%3DFfrench%26aufirst%3DB.%26aulast%3DGasch%26aufirst%3DC.%26aulast%3DBreen%26aufirst%3DE.%26aulast%3DGray%26aufirst%3DS.%2BG.%26aulast%3DNicholson%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DCuffe%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DBarr%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520the%2520cancer%2520stem%2520cell%2520marker%252C%2520aldehyde%2520dehydrogenase%25201%252C%2520to%2520circumvent%2520cisplatin%2520resistance%2520in%2520NSCLC%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D72544%26epage%3D72563%26doi%3D10.18632%2Foncotarget.19881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, E. J.</span></span> <span> </span><span class="NLM_article-title">Ru(II) compounds: next-generation anticancer metallotherapeutics?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5805</span>– <span class="NLM_lpage">5821</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01689</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01689" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5805-5821&author=S.+Thotaauthor=D.+A.+Rodriguesauthor=D.+C.+Cransauthor=E.+J.+Barreiro&title=Ru%28II%29+compounds%3A+next-generation+anticancer+metallotherapeutics%3F&doi=10.1021%2Facs.jmedchem.7b01689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?</span></div><div class="casAuthors">Thota, Sreekanth; Rodrigues, Daniel A.; Crans, Debbie C.; Barreiro, Eliezer J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5805-5821</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metal based therapeutics are a precious class of drugs in oncol. research that include examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and therapeutics applications.  Ruthenium compds. have shown selective bioactivity and the ability to overcome the resistance that platinum-based therapeutics face, making them effective oncotherapeutic competitors in rational drug invention approaches.  The development of antineoplastic ruthenium therapeutics is of particular interest because ruthenium contg. complexes NAMI-A, KP1019, and KP1339 entered clin. trials and DW1/2 is in preclin. levels.  The very robust, conformationally rigid organometallic Ru(II) compd. DW1/2 is a protein kinase inhibitor and presents new Ru(II) compd. designs as anticancer agents.  Over the recent years, numerous strategies have been used to encapsulate Ru(II) derived compds. in a nanomaterial system, improving their targeting and delivery into neoplastic cells.  A new photodynamic therapy based Ru(II) therapeutic, TLD-1433, has also entered clin. trials.  Ru(II)-based compds. can also be photosensitizers for photodynamic therapy, which has proven to be an effective new, alternative, and noninvasive oncotherapy modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpCNrozZw4y7Vg90H21EOLACvtfcHk0lj2KMbpQBvw2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgsbc%253D&md5=2b539999f1e68e2ea1369b8f8ff9c719</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01689%26sid%3Dliteratum%253Aachs%26aulast%3DThota%26aufirst%3DS.%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26aulast%3DCrans%26aufirst%3DD.%2BC.%26aulast%3DBarreiro%26aufirst%3DE.%2BJ.%26atitle%3DRu%2528II%2529%2520compounds%253A%2520next-generation%2520anticancer%2520metallotherapeutics%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5805%26epage%3D5821%26doi%3D10.1021%2Facs.jmedchem.7b01689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, R.</span></span> <span> </span><span class="NLM_article-title">The status of platinum anticancer drugs in the clinic and in clinical trials</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">8113</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+status+of+platinum+anticancer+drugs+in+the+clinic+and+in+clinical+trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0lj2KMbpQBvw2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520status%2520of%2520platinum%2520anticancer%2520drugs%2520in%2520the%2520clinic%2520and%2520in%2520clinical%2520trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, R. G.</span></span> <span> </span><span class="NLM_article-title">Advances in drug delivery system for platinum agents based combination therapy</span>. <i>Cancer Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.7497/j.issn.2095-3941.2015.0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.7497%2Fj.issn.2095-3941.2015.0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26779373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=362-374&author=X.+Kangauthor=H.+H.+Xiaoauthor=H.+Q.+Songauthor=X.+B.+Jingauthor=L.+S.+Yanauthor=R.+G.+Qi&title=Advances+in+drug+delivery+system+for+platinum+agents+based+combination+therapy&doi=10.7497%2Fj.issn.2095-3941.2015.0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug delivery system for platinum agents based combination therapy</span></div><div class="casAuthors">Kang, Xiang; Xiao, Hai-Hua; Song, Hai-Qin; Jing, Xia-Bin; Yan, Le-San; Qi, Ruo-Gu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4Spec.Iss.</span>),
    <span class="NLM_cas:pages">362-374</span>CODEN:
                <span class="NLM_cas:coden">CBMADQ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Tianjin Medical University Cancer Institute and Hospital</span>)
        </div><div class="casAbstract">Platinum-based anticancer agents are widely used as first-line drugs in cancer chemotherapy for various solid tumors.  However, great side effects and occurrence of resistance remain as the major drawbacks for almost all the platinum drugs developed.  To conquer these problems, new strategies should be adopted for platinum drug based chemotherapy.  Modern nanotechnol. has been widely employed in the delivery of various therapeutics and diagnostic.  It provides the possibility of targeted delivery of a certain anticancer drug to the tumor site, which could minimize toxicity and optimize the drug efficacy.  Here, in this review, we focused on the recent progress in polymer based drug delivery systems for platinum-based combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6c7l6YI7qmbVg90H21EOLACvtfcHk0lgrWEq_1besqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D&md5=086ed651b447b0d2563c81c555c26702</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.7497%2Fj.issn.2095-3941.2015.0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7497%252Fj.issn.2095-3941.2015.0063%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DH.%2BH.%26aulast%3DSong%26aufirst%3DH.%2BQ.%26aulast%3DJing%26aufirst%3DX.%2BB.%26aulast%3DYan%26aufirst%3DL.%2BS.%26aulast%3DQi%26aufirst%3DR.%2BG.%26atitle%3DAdvances%2520in%2520drug%2520delivery%2520system%2520for%2520platinum%2520agents%2520based%2520combination%2520therapy%26jtitle%3DCancer%2520Biol.%2520Med.%26date%3D2015%26volume%3D12%26spage%3D362%26epage%3D374%26doi%3D10.7497%2Fj.issn.2095-3941.2015.0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daruwalla, J.</span></span> <span> </span><span class="NLM_article-title">Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect</span>. <i>Eur. J. Pharm. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.ejpb.2008.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.ejpb.2008.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=19070661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2009&pages=409-419&author=H.+Maedaauthor=G.+Y.+Bharateauthor=J.+Daruwalla&title=Polymeric+drugs+for+efficient+tumor-targeted+drug+delivery+based+on+EPR-effect&doi=10.1016%2Fj.ejpb.2008.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect</span></div><div class="casAuthors">Maeda, H.; Bharate, G. Y.; Daruwalla, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-419</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  For over half a century extensive research has been undertaken for the control of cancer.  However, success has been limited to certain malignancies, and surgical intervention is potentially curative for early stage patients.  For the majority of patients with advanced stage of cancer, the treatment is limited to chemotherapy or radiation.  Chemotherapy in particular has limitations due to the lack of selectivity with severe toxicity.  Under these circumstances tumor-targeted delivery of anticancer drugs is perhaps one of the most important steps for cancer chemotherapy.  We reported such a drug for the first time, styrene-maleic acid copolymer-conjugated neocarzinostatin (SMANCS) in 1979, and it eventually led to formulate the concept of the enhanced permeability and retention (EPR) effect of solid tumors in 1986.  Monoclonal antibody conjugates are another direction, of which interest is increasing recently though with limited success.  The EPR-effect appears as a universal phenomenon in solid tumors which warrants the development of other polymeric drugs or nanomedicine.  EPR-effect is applicable for any biocompatible macromol. compds. above 40 kDa, even larger than 800 kDa, or of the size of bacteria; thus complexed mols. like micelles and liposomes contg. anticancer drugs are hallmark examples.  The drug concn. in tumor compared to that of the blood (T/B ratio) can be usually as high as 10-30 times.  In case of SMANCS/Lipiodol given via tumor feeding artery, the T/B ratio can be as high as 2000, a real pin-point targeting.  EPR-effect is not just passive targeting for momentary tumor delivery, but it means prolonged drug retention for more than several weeks or longer.  This review describes the pathophysiol. mechanisms of the EPR-effect, architectural difference of tumor blood vessel, various factors involved and artificial augmentation of EPR-effect with respect to tumor-selective delivery, and then advantages and problems of macromol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS--P962B5eLVg90H21EOLACvtfcHk0lgrWEq_1besqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFWgt78%253D&md5=a385460578d0a3722f9f51d7c7ca5abd</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2008.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2008.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DBharate%26aufirst%3DG.%2BY.%26aulast%3DDaruwalla%26aufirst%3DJ.%26atitle%3DPolymeric%2520drugs%2520for%2520efficient%2520tumor-targeted%2520drug%2520delivery%2520based%2520on%2520EPR-effect%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2009%26volume%3D71%26spage%3D409%26epage%3D419%26doi%3D10.1016%2Fj.ejpb.2008.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novohradsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span> <span> </span><span class="NLM_article-title">Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28456</span>– <span class="NLM_lpage">28473</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.18632%2Foncotarget.25466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29983873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FlvFWlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=28456-28473&author=V.+Novohradskyauthor=J.+Zajacauthor=O.+Vranaauthor=J.+Kasparkovaauthor=V.+Brabec&title=Simultaneous+delivery+of+olaparib+and+carboplatin+in+PEGylated+liposomes+imparts+this+drug+combination+hypersensitivity+and+selectivity+for+breast+tumor+cells&doi=10.18632%2Foncotarget.25466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells</span></div><div class="casAuthors">Novohradsky Vojtech; Zajac Juraj; Vrana Oldrich; Kasparkova Jana; Brabec Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">28456-28473</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Combination regiments involving platinum anticancer drugs and agents with unrelated mechanisms of action are a subject of widespread interest.  Here, we show that synergistic toxic action in cancer cells of combinations of antitumor platinum drug carboplatin and effective PARP inhibitor olaparib is considerably improved if these combined drugs are encapsulated into liposomes.  Notably, the formation of such nano-formulations, called OLICARB, leads to a marked enhancement of activity in human cancer cell lines (including those resistant to conventional platinum antitumor drugs) and selectivity towards tumor cells.  We used immunofluorescence analysis of γH2AX expression and examined DNA damage in cancerous cells treated with the investigated compounds.  We find that the synergistic toxic effects in cancer cells of both drugs used in combination, nonencapsulated or embedded in the OLICARB nanoparticles, positively correlates with DNA damage.  These results also suggest that the enhancement of the toxic effects of carboplatin by olaparib in cancer cells is a consequence of an accumulation of cytotoxic lesions in DNA due to the inhibition of repair of platinated DNA augmented by the synergistic action of olaparib as an effective PARP inhibitor.  Our findings also reveal that the combination of olaparib with carboplatin encapsulated in the OLICARB nanoparticles is particularly effective to inhibit the growth of 3D mammospheres.  Collectively, the data provide convincing evidence that the encapsulation of carboplatin and olaparib into liposomal constructs to form the OLICARB nanoparticles may represent the viable approach for the treatment of tumors with the aim to eliminate the possible effects of acquired resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9NFGEnVFtt1QKX3ooHxWjfW6udTcc2eZr2h1x3LApW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FlvFWlsw%253D%253D&md5=2c5ca718f535de0e39c8f5308d1090a3</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25466%26sid%3Dliteratum%253Aachs%26aulast%3DNovohradsky%26aufirst%3DV.%26aulast%3DZajac%26aufirst%3DJ.%26aulast%3DVrana%26aufirst%3DO.%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DBrabec%26aufirst%3DV.%26atitle%3DSimultaneous%2520delivery%2520of%2520olaparib%2520and%2520carboplatin%2520in%2520PEGylated%2520liposomes%2520imparts%2520this%2520drug%2520combination%2520hypersensitivity%2520and%2520selectivity%2520for%2520breast%2520tumor%2520cells%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D28456%26epage%3D28473%26doi%3D10.18632%2Foncotarget.25466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lorenzo Biancalana, Hana Kostrhunova, Lucinda K. Batchelor, Mouna Hadiji, Ilaria Degano, Guido Pampaloni, Stefano Zacchini, Paul J. Dyson, Viktor Brabec, <span class="NLM_string-name hlFld-ContribAuthor">Fabio Marchetti</span>. </span><span class="cited-content_cbyCitation_article-title">Hetero-Bis-Conjugation of Bioactive Molecules to Half-Sandwich Ruthenium(II) and Iridium(III) Complexes Provides Synergic Effects in Cancer Cell Cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2021,</strong> <em>60 </em>
                                    (13)
                                     , 9529-9541. <a href="https://doi.org/10.1021/acs.inorgchem.1c00641" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.1c00641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.1c00641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.1c00641%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DHetero-Bis-Conjugation%252Bof%252BBioactive%252BMolecules%252Bto%252BHalf-Sandwich%252BRuthenium%252528II%252529%252Band%252BIridium%252528III%252529%252BComplexes%252BProvides%252BSynergic%252BEffects%252Bin%252BCancer%252BCell%252BCytotoxicity%26aulast%3DBiancalana%26aufirst%3DLorenzo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03032021%26date%3D22062021%26volume%3D60%26issue%3D13%26spage%3D9529%26epage%3D9541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simona  Braccini</span>, <span class="hlFld-ContribAuthor ">Giorgia  Rizzi</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Biancalana</span>, <span class="hlFld-ContribAuthor ">Alessandro  Pratesi</span>, <span class="hlFld-ContribAuthor ">Stefano  Zacchini</span>, <span class="hlFld-ContribAuthor ">Guido  Pampaloni</span>, <span class="hlFld-ContribAuthor ">Federica  Chiellini</span>, <span class="hlFld-ContribAuthor ">Fabio  Marchetti</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Diiron Vinyliminium Complexes: A Structure–Activity Relationship Study. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (8)
                                     , 1158. <a href="https://doi.org/10.3390/pharmaceutics13081158" title="DOI URL">https://doi.org/10.3390/pharmaceutics13081158</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13081158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13081158%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DAnticancer%252BDiiron%252BVinyliminium%252BComplexes%25253A%252BA%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudy%26aulast%3DBraccini%26aufirst%3DSimona%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D8%26spage%3D1158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruizheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chao  Du</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Li</span>, <span class="hlFld-ContribAuthor ">Yanhong  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei  Xiong</span>, <span class="hlFld-ContribAuthor ">Juanjuan  Xiang</span>, <span class="hlFld-ContribAuthor ">Jiheng  Liu</span>, <span class="hlFld-ContribAuthor ">Zhigang  Xiao</span>, <span class="hlFld-ContribAuthor ">Li  Fang</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Investigation of DNA Methylation Associated With Platinum Chemotherapy Resistance Across 13 Cancer Types. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.616529" title="DOI URL">https://doi.org/10.3389/fphar.2021.616529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.616529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.616529%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DSystematic%252BInvestigation%252Bof%252BDNA%252BMethylation%252BAssociated%252BWith%252BPlatinum%252BChemotherapy%252BResistance%252BAcross%252B13%252BCancer%252BTypes%26aulast%3DSun%26aufirst%3DRuizheng%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Lang</span>, <span class="hlFld-ContribAuthor ">Nuannuan  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Rong</span>, <span class="hlFld-ContribAuthor ">Yuanlei  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin
              in vivo
              and
              in vitro. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery</span><span> <strong>2021,</strong> <em>28 </em>
                                    (1)
                                     , 1272-1280. <a href="https://doi.org/10.1080/10717544.2021.1938754" title="DOI URL">https://doi.org/10.1080/10717544.2021.1938754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10717544.2021.1938754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10717544.2021.1938754%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%26atitle%3DProdrug-based%252Bnano-delivery%252Bstrategy%252Bto%252Bimprove%252Bthe%252Bantitumor%252Bability%252Bof%252Bcarboplatin%252Bin%2525C2%2525A0vivo%252Band%252Bin%2525C2%2525A0vitro%26aulast%3DLang%26aufirst%3DTingting%26date%3D2021%26date%3D2021%26volume%3D28%26issue%3D1%26spage%3D1272%26epage%3D1280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of clinically used platinum drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Number of clinical trials investigating direct platinum-based combination therapy started each year over past 5 years (the data were collected from <a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a> on April 21, 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Main mechanisms of anticancer action and drug resistance of cisplatin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modulation of the immune system by cisplatin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of platinum(IV) complexes overcoming resistance of platinum drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of platinum(IV) complexes targeting tumor microenvironment or reducing toxicities of platinum drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/medium/jm0c00950_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Number of clinical trials investigating platinum-based combinations containing checkpoint inhibitors started over the past 10 years (the data were collected from <a href="https://clinicaltrials.gov/" class="extLink">https://clinicaltrials.gov/</a> on May 3, 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00950/20201120/images/large/jm0c00950_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00950&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46384" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46384" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 119 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Camp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krigas, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1038/205698a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2F205698a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14287410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaF2MXns1aruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=1965&pages=698-699&author=B.+Rosenbergauthor=L.+Van+Campauthor=T.+Krigas&title=Inhibition+of+cell+division+in+Escherichia+coli+by+electrolysis+products+from+a+platinum+electrode&doi=10.1038%2F205698a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode</span></div><div class="casAuthors">Rosenberg, Barnett; Van Camp, Loretta; Krigas, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">4972</span>),
    <span class="NLM_cas:pages">698-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">E. coli cells grown in a continuous culture app. with an esp. designed chamber contg. 2 Pt electrodes were subjected to an elec. field in an O atm.  With an applied voltage of 500 to 6000 cycles/sec., cell division ceased and filamentous growth occurred.  A similar effect was shown with a soln. of 10 ppm. (NH4)2PtCl6.  Pt(IV) was found in the electrolyzed medium in concns. of 8 ppm.  Other transition metal ions, including Rh, in concns. of 1-10 ppm. inhibited cell division in E. coli while not interfering with growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDyKBEDeGaCrVg90H21EOLACvtfcHk0lhoZFZUaDZpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXns1aruw%253D%253D&md5=2d2e79bfe93d202de21a43b131ea95b2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F205698a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F205698a0%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DB.%26aulast%3DVan%2BCamp%26aufirst%3DL.%26aulast%3DKrigas%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520cell%2520division%2520in%2520Escherichia%2520coli%2520by%2520electrolysis%2520products%2520from%2520a%2520platinum%2520electrode%26jtitle%3DNature%26date%3D1965%26volume%3D205%26spage%3D698%26epage%3D699%26doi%3D10.1038%2F205698a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilruba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalayda, G. V.</span></span> <span> </span><span class="NLM_article-title">Platinum-based drugs: past, present and future</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-2976-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs00280-016-2976-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26886018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2016&pages=1103-1124&author=S.+Dilrubaauthor=G.+V.+Kalayda&title=Platinum-based+drugs%3A+past%2C+present+and+future&doi=10.1007%2Fs00280-016-2976-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum-based drugs: past, present and future</span></div><div class="casAuthors">Dilruba, Shahana; Kalayda, Ganna V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1103-1124</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms.  Their clin. success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment.  Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clin. application so far.  Nedaplatin, lobaplatin and heptaplatin received only regional approval.  Some new platinum complexes and platinum drug formulations are undergoing clin. trials.  Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biol. active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems.  For each class of compds., a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clin. used platinum drugs, and the clin. perspectives are discussed.  A crit. anal. of lessons to be learned is presented.  Finally, a general outlook regarding future directions in the field of new platinum drugs is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfV4v-5JjduLVg90H21EOLACvtfcHk0li3ZFv7Vw2Zxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFOqs7k%253D&md5=1e1882f631ad56ef1a07b2075b1faa5e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-2976-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-2976-z%26sid%3Dliteratum%253Aachs%26aulast%3DDilruba%26aufirst%3DS.%26aulast%3DKalayda%26aufirst%3DG.%2BV.%26atitle%3DPlatinum-based%2520drugs%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D77%26spage%3D1103%26epage%3D1124%26doi%3D10.1007%2Fs00280-016-2976-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular processing of platinum anticancer drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=15789122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+processing+of+platinum+anticancer+drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular processing of platinum anticancer drugs</span></div><div class="casAuthors">Wang, Dong; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy.  Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs.  This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signaling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death.  Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJfZNaqwy67Vg90H21EOLACvtfcHk0lgy2qCFXCUYJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D&md5=e44a8e87683ba5cfe3e165f9f4229fee</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520processing%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-prodrug-constructed liposomes as a versatile theranostic nanoplatform for bimodal imaging guided combination cancer therapy</span>. <i>Adv. Funct. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2207</span>– <span class="NLM_lpage">2217</span>, <span class="refDoi"> DOI: 10.1002/adfm.201504899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fadfm.201504899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2207-2217&author=L.+Fengauthor=M.+Gaoauthor=D.+Taoauthor=Q.+Chenauthor=H.+Wangauthor=Z.+Dongauthor=M.+Chenauthor=Z.+Liu&title=Cisplatin-prodrug-constructed+liposomes+as+a+versatile+theranostic+nanoplatform+for+bimodal+imaging+guided+combination+cancer+therapy&doi=10.1002%2Fadfm.201504899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-Prodrug-Constructed Liposomes as a Versatile Theranostic Nanoplatform for Bimodal Imaging Guided Combination Cancer Therapy</span></div><div class="casAuthors">Feng, Liangzhu; Gao, Min; Tao, Danlei; Chen, Qian; Wang, Hairong; Dong, Ziliang; Chen, Meiwan; Liu, Zhuang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Functional Materials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2207-2217</span>CODEN:
                <span class="NLM_cas:coden">AFMDC6</span>;
        ISSN:<span class="NLM_cas:issn">1616-301X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Up to date, a large variety of liposomal nanodrugs have been explored for cancer nanomedicine, showing encouraging results in both preclin. animal expts. and clin. treatment of cancer patients.  Herein, a phospholipid conjugated with a cisplatin prodrug is used as the major structure component of liposomes together with other com. lipids via self-assembling.  By doping with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR), a lipophilic dye with strong near IR (NIR) absorbance and fluorescence, the obtained DiR-Pt(IV)-liposome is found to be an effective probe for in vivo NIR fluorescence and photoacoustic bimodal imaging.  Attributing to its intrinsically doped cis-Pt(IV) prodrug, efficient photothermal conversion ability, and excellent tumor homing ability, DiR-Pt(IV)-liposome confers greatly enhanced therapeutic outcomes in the combined photothermal-chemotherapy.  Moreover, Pt(IV)-liposome is also demonstrated to be an efficient carrier for both small hydrophilic mols. and proteins, which are encapsulated inside the water-cavity of liposomes, further demonstrating the versatile functions of this nanoplatform.  This study develops a unique type of liposomal nanomedicine with a prodrug conjugated phospholipid as the major structure component.  Such Pt(IV)-liposome is featured with advantages including precisely defined/easily tunable drug compns., stealth-like pharmacokinetics, efficient tumor passive uptake, and the capabilities to simultaneously load with various types of imaging or therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Zlhkd_J0E7Vg90H21EOLACvtfcHk0lgy2qCFXCUYJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCls7o%253D&md5=897cc57ee8a6149233004a1c58a3a237</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fadfm.201504899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadfm.201504899%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DCisplatin-prodrug-constructed%2520liposomes%2520as%2520a%2520versatile%2520theranostic%2520nanoplatform%2520for%2520bimodal%2520imaging%2520guided%2520combination%2520cancer%2520therapy%26jtitle%3DAdv.%2520Funct.%2520Mater.%26date%3D2016%26volume%3D26%26spage%3D2207%26epage%3D2217%26doi%3D10.1002%2Fadfm.201504899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stathopoulos, G. P.</span></span> <span> </span><span class="NLM_article-title">Liposomal cisplatin: a new cisplatin formulation</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1097/CAD.0b013e32833d9adf</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2FCAD.0b013e32833d9adf" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20671511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=732-736&author=G.+P.+Stathopoulos&title=Liposomal+cisplatin%3A+a+new+cisplatin+formulation&doi=10.1097%2FCAD.0b013e32833d9adf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Liposomal cisplatin: a new cisplatin formulation</span></div><div class="casAuthors">Stathopoulos, George P.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Over the last three decades, cisplatin has been one of the most effective cytotoxic agents, but its administration has been hindered by its nephrotoxicity, neurotoxicity and myelo toxicity.  Recently, liposomal cisplatin, lipoplatin, has been formulated and tested thoroughly in preclin. (in vitro) and phase I, II and III trials, as documented in the literature.  Expts. in animals showed that lipoplatin is less toxic than cisplatin and that it produces tumor redn.  The histol. examn. of treated tumors from mouse xenografts was consistent with apoptosis in the tumor cells in a mechanism similar to that of cisplatin.  Lipoplatin infusion in patients and measurements of platinum levels in tumor specimens showed 10-50 times higher levels in tumors and metastases than in the adjacent normal specimens.  A phase I-II study using a combination of lipoplatin and gemcitabine in pretreated patients (with disease progression or stable disease) with advanced pancreatic cancer was conducted.  No nephrotoxicity was obsd.  With lipoplatin monotherapy the dose-limiting toxicity was detd. to be 350 mg/m and the max. tolerated dose 300 mg/m; when used in combination with paclitaxel the dose-limiting toxicity for lipoplatin was 250 mg/m and for paclitaxel 175 mg/m, and the max. tolerated dose was 200 and 175 mg/m, resp.  In two phase II randomized studies comparing the lipoplatin combination vs. the cisplatin combination, it was found that the former was statistically significantly less toxic than the latter, whereas the response rate and survival were similar.  Up to now, the data on lipoplatin treatment in malignant tumors are quite impressive, because of the negligible toxicity and because it is equal if not superior to cisplatin with regard to response rate.  This review aims to chronol. document publications relevant to liposomal cisplatin to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprIdRClLKAibVg90H21EOLACvtfcHk0li2SL5QdfR8Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCmsr8%253D&md5=e47a8de4563457e9b9bd7b513743422a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e32833d9adf&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e32833d9adf%26sid%3Dliteratum%253Aachs%26aulast%3DStathopoulos%26aufirst%3DG.%2BP.%26atitle%3DLiposomal%2520cisplatin%253A%2520a%2520new%2520cisplatin%2520formulation%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2010%26volume%3D21%26spage%3D732%26epage%3D736%26doi%3D10.1097%2FCAD.0b013e32833d9adf" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulikas, T.</span></span> <span> </span><span class="NLM_article-title">Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1517/13543780903114168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1517%2F13543780903114168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=19604121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1197-1218&author=T.+Boulikas&title=Clinical+overview+on+Lipoplatin%3A+a+successful+liposomal+formulation+of+cisplatin&doi=10.1517%2F13543780903114168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin</span></div><div class="casAuthors">Boulikas, Teni</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1197-1218</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Nanoparticle formulations for packaging existing drugs have been used to treat cancer.  Lipoplatin is a liposomal cisplatin encapsulated into liposome nanoparticles of an av. diam. of 110 nm.  Lipoplatin has substantially reduced the renal toxicity, peripheral neuropathy, ototoxicity, myelotoxicity as well as nausea/vomiting and asthenia of cisplatin in Phase I, II and III clin. studies with enhanced or similar efficacy to cisplatin.  During clin. development, 10- to 200-fold higher accumulation of Lipoplatin in solid tumors compared to adjacent normal tissue was found in patients.  Targeting of tumor vasculature by Lipoplatin in animals suggested its antiangiogenesis potential and Lipoplatin was proposed to act like a double-sword: as chemotherapy and an antiangiogenesis drug.  Lipoplatin has finished successfully one Phase III non-inferiority clin. study as first-line against NSCLC in its combination with paclitaxel showing statistically significant redn. in nephrotoxicity; two more Phase III studies are in progress, one in NSCLC with gemcitabine also showing noninferiority with reduced toxicity and another in squamous cell carcinoma of the head and neck with 5-fluorouracil.  A registrational Phase II/III study against pancreatic cancer is in progress under the orphan drug status granted to Lipoplatin by the European Medicines Agency.  Phase II studies are continuing in advanced breast cancer with vinorelbine and gastrointestinal cancers with radiotherapy and 5-fluorouracil.  The highlights of the clin. development of Lipoplatin are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_giP1ppFTrVg90H21EOLACvtfcHk0li2SL5QdfR8Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCmtb4%253D&md5=3e7d4f4710792af5700e2b24a9627837</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543780903114168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903114168%26sid%3Dliteratum%253Aachs%26aulast%3DBoulikas%26aufirst%3DT.%26atitle%3DClinical%2520overview%2520on%2520Lipoplatin%253A%2520a%2520successful%2520liposomal%2520formulation%2520of%2520cisplatin%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1197%26epage%3D1218%26doi%3D10.1517%2F13543780903114168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oberoi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nukolova, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabanov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronich, T. K.</span></span> <span> </span><span class="NLM_article-title">Nanocarriers for delivery of platinum anticancer drugs</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1667</span>– <span class="NLM_lpage">1685</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2013.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.addr.2013.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24113520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1667-1685&author=H.+S.+Oberoiauthor=N.+V.+Nukolovaauthor=A.+V.+Kabanovauthor=T.+K.+Bronich&title=Nanocarriers+for+delivery+of+platinum+anticancer+drugs&doi=10.1016%2Fj.addr.2013.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers for delivery of platinum anticancer drugs</span></div><div class="casAuthors">Oberoi, Hardeep S.; Nukolova, Natalia V.; Kabanov, Alexander V.; Bronich, Tatiana K.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">1667-1685</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clin. use esp. for management of tumors of the ovary, testes, and the head and neck.  However, several dose limiting toxicities assocd. with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life.  These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy.  Nanocarrier-based delivery of platinum compds. is one such area of intense research effort beginning to provide encouraging preclin. and clin. results and may allow the development of the next generation of platinum chemotherapy.  This review highlights current understanding on the pharmacol. and limitations of platinum compds. in clin. use, and provides a comprehensive anal. of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9t-JIgD2CMrVg90H21EOLACvtfcHk0ljHO_eAh77VtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO&md5=25ea0f4f9f5f2712c294c8f37bb541ce</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DOberoi%26aufirst%3DH.%2BS.%26aulast%3DNukolova%26aufirst%3DN.%2BV.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26aulast%3DBronich%26aufirst%3DT.%2BK.%26atitle%3DNanocarriers%2520for%2520delivery%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1667%26epage%3D1685%26doi%3D10.1016%2Fj.addr.2013.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazarević, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rilak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugarčić, Ž. D.</span></span> <span> </span><span class="NLM_article-title">Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.ejmech.2017.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28442170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFelur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=8-31&author=T.+Lazarevi%C4%87author=A.+Rilakauthor=%C5%BD.+D.+Bugar%C4%8Di%C4%87&title=Platinum%2C+palladium%2C+gold+and+ruthenium+complexes+as+anticancer+agents%3A+Current+clinical+uses%2C+cytotoxicity+studies+and+future+perspectives&doi=10.1016%2Fj.ejmech.2017.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives</span></div><div class="casAuthors">Lazarevic, Tatjana; Rilak, Ana; Bugarcic, Zivadin D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-31</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidn. state, the types and no. of coordinated ligands and the coordination geometry.  This review illustrates notable recent progress in the field of medicinal bioinorg. chem. as many new approaches to the design of innovative metal-based anticancer drugs are emerging.  Current research addressing the problems assocd. with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy.  Examples of metal compds. and chelating agents currently in clin. use, clin. trials or preclin. development are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzaU1RDFb8E7Vg90H21EOLACvtfcHk0ljHO_eAh77VtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFelur8%253D&md5=4fd6838043aff980baa053436e87219a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DLazarevi%25C4%2587%26aufirst%3DT.%26aulast%3DRilak%26aufirst%3DA.%26aulast%3DBugar%25C4%258Di%25C4%2587%26aufirst%3D%25C5%25BD.%2BD.%26atitle%3DPlatinum%252C%2520palladium%252C%2520gold%2520and%2520ruthenium%2520complexes%2520as%2520anticancer%2520agents%253A%2520Current%2520clinical%2520uses%252C%2520cytotoxicity%2520studies%2520and%2520future%2520perspectives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D8%26epage%3D31%26doi%3D10.1016%2Fj.ejmech.2017.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The Platin-X series: activation, targeting, and delivery</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">12992</span>– <span class="NLM_lpage">13004</span>, <span class="refDoi"> DOI: 10.1039/C6DT01738J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC6DT01738J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27493131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=12992-13004&author=U.+Basuauthor=B.+Banikauthor=R.+Wenauthor=R.+K.+Pathakauthor=S.+Dhar&title=The+Platin-X+series%3A+activation%2C+targeting%2C+and+delivery&doi=10.1039%2FC6DT01738J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Platin-X series: activation, targeting, and delivery</span></div><div class="casAuthors">Basu, Uttara; Banik, Bhabatosh; Wen, Ru; Pathak, Rakesh K.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">12992-13004</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorg. chem.  Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation.  Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append addnl. functional groups/ligands for prodrug activation, tumor targeting, or drug delivery.  The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs.  Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery.  In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnol.-based delivery platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYcK59HMDWBbVg90H21EOLACvtfcHk0liQHbo7zx10ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCiur7J&md5=3d4894b6935545dceab775c94b75d38c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1039%2FC6DT01738J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01738J%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DU.%26aulast%3DBanik%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DR.%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520Platin-X%2520series%253A%2520activation%252C%2520targeting%252C%2520and%2520delivery%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D12992%26epage%3D13004%26doi%3D10.1039%2FC6DT01738J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3486</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+next+generation+of+platinum+drugs%3A+targeted+Pt%28II%29+agents%2C+nanoparticle+delivery%2C+and+Pt%28IV%29+prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0liQHbo7zx10ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520next%2520generation%2520of%2520platinum%2520drugs%253A%2520targeted%2520Pt%2528II%2529%2520agents%252C%2520nanoparticle%2520delivery%252C%2520and%2520Pt%2528IV%2529%2520prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babkov, A. V.</span></span> <span> </span><span class="NLM_article-title">The mechanical nature of the trans-effect in ligand substitution reactions of square-planar complexes</span>. <i>Polyhedron</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1016/S0277-5387(00)81209-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0277-5387%2800%2981209-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaL1cXltlGrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1988&pages=1203-1206&author=A.+V.+Babkov&title=The+mechanical+nature+of+the+trans-effect+in+ligand+substitution+reactions+of+square-planar+complexes&doi=10.1016%2FS0277-5387%2800%2981209-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanical nature of the trans-effect in ligand substitution reactions of square-planar complexes</span></div><div class="casAuthors">Babkov, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Polyhedron</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1203-6</span>CODEN:
                <span class="NLM_cas:coden">PLYHDE</span>;
        ISSN:<span class="NLM_cas:issn">0277-5387</span>.
    </div><div class="casAbstract">The kinetic trans-effect in associative ligand substitution reactions of square-planar complexes is explained theor. on the basis of the angular deformability of the bond in the trans-activating ligands.  The ability of these ligands, under the condition of low energy input, to leave the plane of the complex dets. the ease with which the transition of the complex into the pentacoordinate state takes place in the substitution process.  The most general property of ligands exhibiting a strong trans-effect is the large angular unfolding of the donor orbital in the direction of the central atom.  This facilitates coordination between the bond-cleaving process and the formation of chem. bonds in the intermediate compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_lArySZoXA7Vg90H21EOLACvtfcHk0lhyUUG_vLvGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltlGrtrc%253D&md5=93a3494d80aa67a0ca023225f222a28e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0277-5387%2800%2981209-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0277-5387%252800%252981209-7%26sid%3Dliteratum%253Aachs%26aulast%3DBabkov%26aufirst%3DA.%2BV.%26atitle%3DThe%2520mechanical%2520nature%2520of%2520the%2520trans-effect%2520in%2520ligand%2520substitution%2520reactions%2520of%2520square-planar%2520complexes%26jtitle%3DPolyhedron%26date%3D1988%26volume%3D7%26spage%3D1203%26epage%3D1206%26doi%3D10.1016%2FS0277-5387%2800%2981209-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Third row transition metals for the treatment of cancer</span>. <i>Philos. Trans. R. Soc., A</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">2037</span>),  <span class="NLM_fpage">20140185</span>, <span class="refDoi"> DOI: 10.1098/rsta.2014.0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1098%2Frsta.2014.0185" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=20140185&issue=2037&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=Third+row+transition+metals+for+the+treatment+of+cancer&doi=10.1098%2Frsta.2014.0185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1098%2Frsta.2014.0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsta.2014.0185%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThird%2520row%2520transition%2520metals%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520A%26date%3D2015%26volume%3D373%26issue%3D2037%26spage%3D20140185%26doi%3D10.1098%2Frsta.2014.0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, K. G.K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prives, C.</span></span> <span> </span><span class="NLM_article-title">High mobility group protein-1 (HMG-1) is a unique activator of p53</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1101/gad.12.4.462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1101%2Fgad.12.4.462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=9472015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=462-472&author=L.+Jayaramanauthor=N.+C.+Moorthyauthor=K.+G.K.+Murthyauthor=J.+L.+Manleyauthor=M.+Bustinauthor=C.+Prives&title=High+mobility+group+protein-1+%28HMG-1%29+is+a+unique+activator+of+p53&doi=10.1101%2Fgad.12.4.462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">High mobility group protein-1 (HMG-1) is a unique activator of p53</span></div><div class="casAuthors">Jayaraman, Lata; Moorthy, Narayani Chandra; Murthy, Kanneganti G. K.; Manley, James L.; Bustin, Michael; Prives, Carol</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-472</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The binding of p53 protein to DNA is stimulated by its interaction with covalent as well as noncovalent modifiers.  The authors report the identification of a factor from HeLa nuclear exts. that activates p53 DNA binding.  This factor was purified to homogeneity and identified as the high mobility group protein, HMG-1.  HMG-1 belongs to a family of highly conserved chromatin-assocd. nucleoproteins that bend DNA and facilitate the binding of various transcription factors to their cognate DNA sequences.  The authors demonstrate that recombinant His-tagged HMG-1 enhances p53 DNA binding in vitro and also that HMG-1 and p53 can interact directly in vitro.  Unexpectedly, HMG-1 also stimulates DNA binding by p53Δ30, a carboxy-terminally deleted form of the protein that is considered to be constitutively active, suggesting that HMG-1 stimulates p53 by a mechanism that is distinct from other known activators of p53.  Finally, using transient transfection assays the authors show that HMG-1 can increase p53 and p53Δ30-mediated transactivation in vivo.  HMG-1 promotes the assembly of higher order p53 nucleoprotein structures, and these data, along with the fact that HMG-1 is capable of bending DNA, suggest that HMG-1 may activate p53 DNA binding by a novel mechanism involving a structural change in the target DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJiVQXNeAsNbVg90H21EOLACvtfcHk0lhyUUG_vLvGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlShsbY%253D&md5=a2b2b9628bca1b06ff2958ed621c2c86</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.4.462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.4.462%26sid%3Dliteratum%253Aachs%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DMoorthy%26aufirst%3DN.%2BC.%26aulast%3DMurthy%26aufirst%3DK.%2BG.K.%26aulast%3DManley%26aufirst%3DJ.%2BL.%26aulast%3DBustin%26aufirst%3DM.%26aulast%3DPrives%26aufirst%3DC.%26atitle%3DHigh%2520mobility%2520group%2520protein-1%2520%2528HMG-1%2529%2520is%2520a%2520unique%2520activator%2520of%2520p53%26jtitle%3DGenes%2520Dev.%26date%3D1998%26volume%3D12%26spage%3D462%26epage%3D472%26doi%3D10.1101%2Fgad.12.4.462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span> <span> </span><span class="NLM_article-title">Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2005.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.drup.2005.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=15894512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVSlsr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=131-146&author=V.+Brabecauthor=J.+Kasparkova&title=Modifications+of+DNA+by+platinum+complexes.+Relation+to+resistance+of+tumors+to+platinum+antitumor+drugs&doi=10.1016%2Fj.drup.2005.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Modifications of DNA by platinum complexes</span></div><div class="casAuthors">Brabec, Viktor; Kasparkova, Jana</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-146</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The importance of platinum drugs in cancer chemotherapy is underscored by the clin. success of cisplatin [cis-diamminedichloroplatinum(II)] and its analogs and by clin. trials of other, less toxic platinum complexes that are active against resistant tumors.  The antitumor effect of platinum complexes is believed to result from their ability to form various types of adducts with DNA.  Nevertheless, drug resistance can occur by several ways: increased drug efflux, drug inactivation, alterations in drug target, processing of drug-induced damage, and evasion of apoptosis.  This review focuses on mechanisms of resistance and sensitivity of tumors to conventional cisplatin assocd. with DNA modifications.  We also discuss mol. mechanisms underlying resistance and sensitivity of tumors to the new platinum compds. synthesized with the goal to overcome resistance of tumors to established platinum drugs.  Importantly, a no. of new platinum compds. were designed to test the hypothesis that there is a correlation between the extent of resistance of tumors to these agents and their ability to induce a certain kind of damage or conformational change in DNA.  Hence, information on DNA-binding modes, as well as recognition and repair of DNA damage is discussed, since this information may be exploited for improved structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoliOk5cSz47LVg90H21EOLACvtfcHk0lhvx9Ws73xJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVSlsr7K&md5=0b2aedfc594780c9727404fce1b1669d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2005.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2005.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrabec%26aufirst%3DV.%26aulast%3DKasparkova%26aufirst%3DJ.%26atitle%3DModifications%2520of%2520DNA%2520by%2520platinum%2520complexes.%2520Relation%2520to%2520resistance%2520of%2520tumors%2520to%2520platinum%2520antitumor%2520drugs%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2005%26volume%3D8%26spage%3D131%26epage%3D146%26doi%3D10.1016%2Fj.drup.2005.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Regulation of cell death by the Abl tyrosine kinase</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5643</span>– <span class="NLM_lpage">5650</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fsj.onc.1203878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=11114745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2nurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5643-5650&author=J.+Y.+Wang&title=Regulation+of+cell+death+by+the+Abl+tyrosine+kinase&doi=10.1038%2Fsj.onc.1203878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell death by the Abl tyrosine kinase</span></div><div class="casAuthors">Wang, Jean Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5643-5650</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with ∼72 refs.  The c-abl proto-oncogene encodes a protein tyrosine kinase that is distributed in the nucleus and the cytoplasm of proliferating cells.  In the nucleus, c-Abl activity is neg. regulated by the retinoblastoma protein (RB) and pos. regulated by DNA damage signals.  Activation of the c-Abl kinase by DNA damage requires the function of ATM, which regulates cell cycle checkpoint, DNA repair and apoptosis in response to DNA damage.  Cells lacking c-Abl can activate cell cycle checkpoints and DNA repair, but show defects in apoptosis.  The apoptosis defect of c-Abl deficient cells is correlated with a defect in the induction and activation of p73, which is a functional homolog of the p53 tumor suppressor protein and has pro-apoptotic activity.  The inhibition of c-Abl by RB is consistent with RB's ability to block apoptosis; while the activation of c-Abl by ATM is consistent with ATM's ability to activate cell death.  The oncogenic Bcr-Abl tyrosine kinase is a potent inhibitor of apoptosis, and it is retained exclusively in the cytoplasm of transformed cells.  Interestingly, when Bcr-Abl is trapped inside of the nucleus through a combined disruption of its cytoplasmic retention and its nuclear export, this oncogenic Abl kinase induces apoptosis.  Taken together, the current results support a role for the nuclear c-Abl tyrosine kinase in the regulation of apoptosis.  Whether the cytoplasmic c-Abl kinase can actively inhibit apoptosis remains to be detd.; however, a deliberate retention of c-Abl in the cytoplasm could potentially contribute to the attenuation of apoptosis response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkGJbCJsFvBLVg90H21EOLACvtfcHk0lhvx9Ws73xJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2nurg%253D&md5=46b8a4dd07791d0209b219af768a6aa9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203878%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BY.%26atitle%3DRegulation%2520of%2520cell%2520death%2520by%2520the%2520Abl%2520tyrosine%2520kinase%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5643%26epage%3D5650%26doi%3D10.1038%2Fsj.onc.1203878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Englinger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffeter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terenzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span> <span> </span><span class="NLM_article-title">Metal drugs and the anticancer immune response</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1519-1624&author=B.+Englingerauthor=C.+Pirkerauthor=P.+Heffeterauthor=A.+Terenziauthor=C.+R.+Kowolauthor=B.+K.+Kepplerauthor=W.+Berger&title=Metal+drugs+and+the+anticancer+immune+response&doi=10.1021%2Facs.chemrev.8b00396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Metal drugs and the anticancer immune response</span></div><div class="casAuthors">Englinger, Bernhard; Pirker, Christine; Heffeter, Petra; Terenzi, Alessio; Kowol, Christian R.; Keppler, Bernhard K.; Berger, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1519-1624</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance").  Hence, a clin. apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion").  Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion.  This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clin. settings.  This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects.  It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses.  Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment.  On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpduZa3EdGgurVg90H21EOLACvtfcHk0lgNMXLtxayWIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO&md5=9cf67c2ef463cd26be88b178b5b6534a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00396%26sid%3Dliteratum%253Aachs%26aulast%3DEnglinger%26aufirst%3DB.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DTerenzi%26aufirst%3DA.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DBerger%26aufirst%3DW.%26atitle%3DMetal%2520drugs%2520and%2520the%2520anticancer%2520immune%2520response%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1519%26epage%3D1624%26doi%3D10.1021%2Facs.chemrev.8b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hato, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesterhuis, W. J.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2831</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-13-3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24879823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Kks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2831-2837&author=S.+V.+Hatoauthor=A.+Khongauthor=I.+J.+de+Vriesauthor=W.+J.+Lesterhuis&title=Molecular+pathways%3A+the+immunogenic+effects+of+platinum-based+chemotherapeutics&doi=10.1158%2F1078-0432.CCR-13-3141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics</span></div><div class="casAuthors">Hato, Stanleyson V.; Khong, Andrea; de Vries, I. Jolanda M.; Lesterhuis, W. Joost</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2831-2837</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The platinum-based drugs cisplatin, carboplatin, and oxaliplatin belong to the most widely used chemotherapeutics in oncol., showing clin. efficacy against many solid tumors.  Their main mechanism of action is believed to be the induction of cancer cell apoptosis as a response to their covalent binding to DNA.  In recent years, this picture has increased in complexity, based on studies indicating that cellular mols. other than DNA may potentially act as targets, and that part of the antitumor effects of platinum drugs occurs through modulation of the immune system.  These immunogenic effects include modulation of STAT signaling; induction of an immunogenic type of cancer cell death through exposure of calreticulin and release of ATP and high-mobility group protein box-1 (HMGB-1); and enhancement of the effector immune response through modulation of programmed death receptor 1-ligand and mannose-6-phosphate receptor expression.  Both basic and clin. studies indicate that at least part of the antitumor efficacy of platinum chemotherapeutics may be due to immune potentiating mechanisms.  Clin. studies exploiting this novel mechanism of action of these old cancer drugs were initiated.  Here, we review the literature on the immunogenic effects of platinum, summarize the clin. advances using platinum as a cytotoxic compd. with immune adjuvant properties, and discuss the limitations to these studies and the gaps in our understanding of the immunol. effects of these drugs.  Clin Cancer Res; 20(11); 2831-7. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW0TjczqF-MbVg90H21EOLACvtfcHk0lgNMXLtxayWIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Kks7g%253D&md5=87b6f62ab4e87dfb208c8b827370b608</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3141%26sid%3Dliteratum%253Aachs%26aulast%3DHato%26aufirst%3DS.%2BV.%26aulast%3DKhong%26aufirst%3DA.%26aulast%3Dde%2BVries%26aufirst%3DI.%2BJ.%26aulast%3DLesterhuis%26aufirst%3DW.%2BJ.%26atitle%3DMolecular%2520pathways%253A%2520the%2520immunogenic%2520effects%2520of%2520platinum-based%2520chemotherapeutics%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2831%26epage%3D2837%26doi%3D10.1158%2F1078-0432.CCR-13-3141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Biasi, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villena-Vargas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adusumilli, P. S.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5384</span>– <span class="NLM_lpage">5391</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-14-1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25204552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5384-5391&author=A.+R.+de%0ABiasiauthor=J.+Villena-Vargasauthor=P.+S.+Adusumilli&title=Cisplatin-induced+antitumor+immunomodulation%3A+a+review+of+preclinical+and+clinical+evidence&doi=10.1158%2F1078-0432.CCR-14-1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence</span></div><div class="casAuthors">de Biasi, Andreas R.; Villena-Vargas, Jonathan; Adusumilli, Prasad S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5384-5391</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Contrary to the long held belief that chemotherapy is immunosuppressive, emerging evidence indicates that the anticancer activity of cisplatin is not limited to its ability to inhibit mitosis, but that cisplatin also has important immunomodulatory effects.  We therefore methodically examd. the relevant preclin. literature and identified four main mechanisms of cisplatin-induced antitumor immunomodulation: (i) MHC class I expression upregulation; (ii) recruitment and proliferation of effector cells; (iii) upregulation of the lytic activity of cytotoxic effectors; and (iv) downregulation of the immunosuppressive microenvironment.  Cisplatin-based combination chemotherapy's antitumor immunomodulatory effects are also beginning to be harnessed in the clinic; we therefore addnl. reviewed the applicable clin. literature and discussed how monitoring various components of the immune system (and their responses to cisplatin) can add new levels of sophistication to disease monitoring and prognostication.  In summation, this growing body of literature on cisplatin-induced antitumor immunomodulation ultimately highlights the therapeutic potential of synergistic strategies that combine traditional chemotherapy with immunotherapy.  Clin Cancer Res; 20(21); 5384-91. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiV10JQeEbqrVg90H21EOLACvtfcHk0lgNMXLtxayWIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOgu7rI&md5=f62672b07b6156ff3b13844d34d83089</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1298%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBiasi%26aufirst%3DA.%2BR.%26aulast%3DVillena-Vargas%26aufirst%3DJ.%26aulast%3DAdusumilli%26aufirst%3DP.%2BS.%26atitle%3DCisplatin-induced%2520antitumor%2520immunomodulation%253A%2520a%2520review%2520of%2520preclinical%2520and%2520clinical%2520evidence%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5384%26epage%3D5391%26doi%3D10.1158%2F1078-0432.CCR-14-1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manorek, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, S. B.</span></span> <span> </span><span class="NLM_article-title">Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1390</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1124/mol.106.022624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1124%2Fmol.106.022624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16847145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOjtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=1390-1394&author=A.+K.+Holzerauthor=G.+H.+Manorekauthor=S.+B.+Howell&title=Contribution+of+the+major+copper+influx+transporter+CTR1+to+the+cellular+accumulation+of+cisplatin%2C+carboplatin%2C+and+oxaliplatin&doi=10.1124%2Fmol.106.022624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin</span></div><div class="casAuthors">Holzer, Alison K.; Manorek, Gerald H.; Howell, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1390-1394</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The goal of this study was to det. the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP).  Wild-type murine embryonic fibroblasts (CTR1+/+) and a subline in which both alleles of CTR1 were deleted (CTR1-/-) were tested for their ability to accumulate platinum when exposed to increasing concns. of DDP, CBDCA, or L-OHP for 1 h.  They were also tested for their sensitivity to the growth-inhibitory effect of each drug.  Platinum content was measured by ion-coupled plasmon mass spectroscopy.  The exptl. model was validated by measuring copper accumulation and cytotoxicity.  CTR1-/- cells accumulated only 5.7% as much copper as CTR1+/+ cells during a 1-h exposure to 2 μM copper.  When exposed to DDP, CBDCA, or L-OHP at 2 μM, accumulation in the CTR1-/- cells was only 35 to 36% of that in the CTR1+/+ cells.  When tested at a 5-fold higher concn., this deficit remained for DDP and CBDCA, but accumulation of L-OHP was no longer CTR1-dependent.  There was an assocn. between the effect of loss of CTR1 function on uptake of the platinum drugs and their cytotoxicity.  The CTR1-/- cells were 3.2-fold resistant to DDP, 2.0-fold resistant to CBDCA, but only 1.7-fold resistant to L-OHP.  Thus, whereas CTR1 controls the cellular accumulation of all three drugs at low concns., accumulation of L-OHP is not dependent on CTR1 at higher concns.  The authors conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clin. spectrum of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXnxzqXfOgNbVg90H21EOLACvtfcHk0linLumvP8aOJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOjtL7O&md5=5c59b1c5c2b70ed0a2a300fd2c510b6d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.022624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.022624%26sid%3Dliteratum%253Aachs%26aulast%3DHolzer%26aufirst%3DA.%2BK.%26aulast%3DManorek%26aufirst%3DG.%2BH.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26atitle%3DContribution%2520of%2520the%2520major%2520copper%2520influx%2520transporter%2520CTR1%2520to%2520the%2520cellular%2520accumulation%2520of%2520cisplatin%252C%2520carboplatin%252C%2520and%2520oxaliplatin%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D1390%26epage%3D1394%26doi%3D10.1124%2Fmol.106.022624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safaei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samimi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochdi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, S. B.</span></span> <span> </span><span class="NLM_article-title">Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6559</span>– <span class="NLM_lpage">6565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12438251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFOks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6559-6565&author=K.+Katanoauthor=A.+Kondoauthor=R.+Safaeiauthor=A.+Holzerauthor=G.+Samimiauthor=M.+Mishimaauthor=Y.-M.+Kuoauthor=M.+Rochdiauthor=S.+B.+Howell&title=Acquisition+of+resistance+to+cisplatin+is+accompanied+by+changes+in+the+cellular+pharmacology+of+copper"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper</span></div><div class="casAuthors">Katano, Kuniyuki; Kondo, Akira; Safaei, Roohangiz; Holzer, Alison; Samimi, Goli; Mishima, Misako; Kuo, Yien-Ming; Rochdi, Myriam; Howell, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6559-6565</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Impaired uptake of cisplatin (DDP) consistently accompanies the acquisition of resistance to the platinum drugs.  The pathways by which DDP enters or exits from cells remain poorly defined.  Using three pairs of human ovarian carcinoma cell lines, each consisting of a sensitive parental line and a stably DDP-resistant subline derived by in vitro selection, resistance to DDP was found to be accompanied by cross-resistance to Cu.  Accumulation of DDP in the resistant sublines ranged from 38 to 67% of that in the parental line at 1 h, and DNA adduct formation varied from 10 to 38% of that in the sensitive cells.  The DDP-resistant cells had 22-56% lower basal levels of copper, and the copper levels were only 27-46% of those obsd. in the sensitive parental lines after a 24-h exposure to medium supplemented with copper.  The initial influx rate for DDP in the three resistant cell lines ranged from 23 to 55% of that in the sensitive cells of each pair; the initial influx rate for copper in the resistant cells varied from 56 to 75% of control.  Studies performed using one pair of cell lines demonstrated that for both copper and DDP the initial efflux rate was lower, whereas the terminal efflux rate was higher in the resistant cells.  On Western blot anal. all three resistant lines exhibited increased expression of one or the other of the two copper export pumps (ATP7A or ATP7B) with no change in the HAH1 chaperone.  We conclude that the acquisition of DDP resistance in ovarian carcinoma is accompanied by alterations in the cellular pharmacol. of DDP that are paralleled by similar changes in the uptake and efflux of copper.  These results are consistent with the concept that DDP enters and exits from the cell via transporters that normally mediate copper homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnqIiTYYPGbVg90H21EOLACvtfcHk0linLumvP8aOJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFOks74%253D&md5=5697c2f333988b90acdfe44a5144e279</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatano%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DA.%26aulast%3DSafaei%26aufirst%3DR.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DSamimi%26aufirst%3DG.%26aulast%3DMishima%26aufirst%3DM.%26aulast%3DKuo%26aufirst%3DY.-M.%26aulast%3DRochdi%26aufirst%3DM.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26atitle%3DAcquisition%2520of%2520resistance%2520to%2520cisplatin%2520is%2520accompanied%2520by%2520changes%2520in%2520the%2520cellular%2520pharmacology%2520of%2520copper%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6559%26epage%3D6565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safaei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samimi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, S. B.</span></span> <span> </span><span class="NLM_article-title">The role of copper transporters in the development of resistance to Pt drugs</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2004.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jinorgbio.2004.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=15458823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2mtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2004&pages=1607-1613&author=R.+Safaeiauthor=A.+K.+Holzerauthor=K.+Katanoauthor=G.+Samimiauthor=S.+B.+Howell&title=The+role+of+copper+transporters+in+the+development+of+resistance+to+Pt+drugs&doi=10.1016%2Fj.jinorgbio.2004.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of copper transporters in the development of resistance to Pt drugs</span></div><div class="casAuthors">Safaei, Roohangiz; Holzer, Alison K.; Katano, Kuniyuki; Samimi, Goli; Howell, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1607-1613</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent studies in yeast, mouse and human cells suggest that the conserved metal binding transporters of the Cu homeostasis pathway can mediate resistance to Pt drugs in cancer cells.  This review summarizes the data available from these studies.  The observation that cells selected for resistance to Cu or the Pt drugs display bidirectional cross-resistance, parallel defects in the transport of Cu and the Pt drugs and altered expression of Cu transporters is consistent with the concept that the Cu homeostasis proteins regulate sensitivity to the Pt drugs by influencing their uptake, efflux and intracellular distribution.  This model is supported by the finding that when mammalian and yeast cells are genetically engineered to express altered levels of the Cu transporters they exhibit altered sensitivity to Pt drugs and are defective in intracellular Pt accumulation due to altered uptake and/or efflux rates.  Neg. assocns. between the expression of ATP7A and ATP7B and the outcome of Pt therapy further support the significance of the Cu homeostasis proteins as both markers of and contributors to Pt resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS2olePtMTlLVg90H21EOLACvtfcHk0lgB9kbryIxwaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2mtbo%253D&md5=d6ce56766a657676bea1ddd6ea367925</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2004.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2004.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DSafaei%26aufirst%3DR.%26aulast%3DHolzer%26aufirst%3DA.%2BK.%26aulast%3DKatano%26aufirst%3DK.%26aulast%3DSamimi%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26atitle%3DThe%2520role%2520of%2520copper%2520transporters%2520in%2520the%2520development%2520of%2520resistance%2520to%2520Pt%2520drugs%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2004%26volume%3D98%26spage%3D1607%26epage%3D1613%26doi%3D10.1016%2Fj.jinorgbio.2004.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planells-Cases, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyader, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhards, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucukosmanoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reincke, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummelkamp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jentsch, T. J.</span></span> <span> </span><span class="NLM_article-title">Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2993</span>– <span class="NLM_lpage">3008</span>, <span class="refDoi"> DOI: 10.15252/embj.201592409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.15252%2Fembj.201592409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26530471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGitbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=2993-3008&author=R.+Planells-Casesauthor=D.+Lutterauthor=C.+Guyaderauthor=N.+M.+Gerhardsauthor=F.+Ullrichauthor=D.+A.+Elgerauthor=A.+Kucukosmanogluauthor=G.+Xuauthor=F.+K.+Vossauthor=S.+M.+Reinckeauthor=T.+Stauberauthor=V.+A.+Blomenauthor=D.+J.+Visauthor=L.+F.+Wesselsauthor=T.+R.+Brummelkampauthor=P.+Borstauthor=S.+Rottenbergauthor=T.+J.+Jentsch&title=Subunit+composition+of+VRAC+channels+determines+substrate+specificity+and+cellular+resistance+to+Pt-based+anti-cancer+drugs&doi=10.15252%2Fembj.201592409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs</span></div><div class="casAuthors">Planells-Cases, Rosa; Lutter, Darius; Guyader, Charlotte; Gerhards, Nora M.; Ullrich, Florian; Elger, Deborah A.; Kucukosmanoglu, Asli; Xu, Guotai; Voss, Felizia K.; Reincke, S. Momsen; Stauber, Tobias; Blomen, Vincent A.; Vis, Daniel J.; Wessels, Lodewyk F.; Brummelkamp, Thijn R.; Borst, Piet; Rottenberg, Sven; Jentsch, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2993-3008</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although platinum-based drugs are widely used chemotherapeutics for cancer treatment, the determinants of tumor cell responsiveness remain poorly understood.  The authors show that the loss of subunits LRRC8A and LRRC8D of the heteromeric LRRC8 vol.-regulated anion channels (VRACs) increased resistance to clin. relevant cisplatin/carboplatin concns.  Under isotonic conditions, about 50% of cisplatin uptake depended on LRRC8A and LRRC8D, but neither on LRRC8C nor on LRRC8E.  Cell swelling strongly enhanced LRRC8-dependent cisplatin uptake, bolstering the notion that cisplatin enters cells through VRAC.  LRRC8A disruption also suppressed drug-induced apoptosis independently from drug uptake, possibly by impairing VRAC-dependent apoptotic cell vol. decrease.  Hence, by mediating cisplatin uptake and facilitating apoptosis, VRAC plays a dual role in the cellular drug response.  Incorporation of the LRRC8D subunit into VRAC substantially increased its permeability for cisplatin and the cellular osmolyte taurine, indicating that LRRC8 proteins form the channel pore.  The authors' work suggests that LRRC8D-contg. VRACs are crucial for cell vol. regulation by an important org. osmolyte and may influence cisplatin/carboplatin responsiveness of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMK0m-YSkAN7Vg90H21EOLACvtfcHk0lgB9kbryIxwaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGitbrM&md5=0560c891ce3b7b49b84d80c105152375</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.15252%2Fembj.201592409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201592409%26sid%3Dliteratum%253Aachs%26aulast%3DPlanells-Cases%26aufirst%3DR.%26aulast%3DLutter%26aufirst%3DD.%26aulast%3DGuyader%26aufirst%3DC.%26aulast%3DGerhards%26aufirst%3DN.%2BM.%26aulast%3DUllrich%26aufirst%3DF.%26aulast%3DElger%26aufirst%3DD.%2BA.%26aulast%3DKucukosmanoglu%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DVoss%26aufirst%3DF.%2BK.%26aulast%3DReincke%26aufirst%3DS.%2BM.%26aulast%3DStauber%26aufirst%3DT.%26aulast%3DBlomen%26aufirst%3DV.%2BA.%26aulast%3DVis%26aufirst%3DD.%2BJ.%26aulast%3DWessels%26aufirst%3DL.%2BF.%26aulast%3DBrummelkamp%26aufirst%3DT.%2BR.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJentsch%26aufirst%3DT.%2BJ.%26atitle%3DSubunit%2520composition%2520of%2520VRAC%2520channels%2520determines%2520substrate%2520specificity%2520and%2520cellular%2520resistance%2520to%2520Pt-based%2520anti-cancer%2520drugs%26jtitle%3DEMBO%2520J.%26date%3D2015%26volume%3D34%26spage%3D2993%26epage%3D3008%26doi%3D10.15252%2Fembj.201592409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashikata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobiume, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetsuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takechi, M.</span></span> <span> </span><span class="NLM_article-title">Snail-induced CD44<sup>high</sup> cells in HNSCC with high ABC transporter capacity exhibit potent resistance to cisplatin and docetaxel</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7908</span>– <span class="NLM_lpage">7918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotl2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=7908-7918&author=M.+Hashikataauthor=H.+Shigeishiauthor=G.+Okuiauthor=K.+Yamamotoauthor=K.+Tobiumeauthor=S.+Seinoauthor=R.+Uetsukiauthor=H.+Katoauthor=Y.+Ishiokaauthor=S.+Onoauthor=K.+Ohtaauthor=K.+Higashikawaauthor=M.+Sugiyamaauthor=M.+Takechi&title=Snail-induced+CD44high+cells+in+HNSCC+with+high+ABC+transporter+capacity+exhibit+potent+resistance+to+cisplatin+and+docetaxel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Snail-induced CD44high cells in HNSCC with high ABC transporter capacity exhibit potent resistance to cisplatin and docetaxel</span></div><div class="casAuthors">Hashikata, Miho; Shigeishi, Hideo; Okui, Gaku; Yamamoto, Kazuhiro; Tobiume, Kei; Seino, Sayaka; Uetsuki, Ryo; Kato, Hiroki; Ishioka, Yasuki; Ono, Shigehiro; Ohta, Kouji; Higashikawa, Koichiro; Sugiyama, Masaru; Takechi, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">7908-7918</span>CODEN:
                <span class="NLM_cas:coden">IJCEC7</span>;
        ISSN:<span class="NLM_cas:issn">1936-2625</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">CD44high head and neck squamous cell carcinoma (HNSCC) cells with cancer stem cell (CSC)-like properties have been speculated to be involved in resistance to apoptosis induced by anti-cancer drugs and thereby assocd. with tumor recurrence.  To clarify the chemotherapeutic resistance of CD44high HNSCC cells, we examd. the apoptotic effects of cisplatin and docetaxel in sorted populations (i.e., CD44high/ESAlow, CD44high/ESAhigh and CD44low cells) from the HNSCC cell line HTB-41.  Furthermore, we examd. whether Snail, which leads to the epithelial to mesenchymal transition (EMT) program, can induce formation of CD44high/ESAlow cells in an HNSCC cell population.  CD44high/ESAlow cells showed mesenchymal features and potent resistance to both cisplatin- and docetaxel-induced apoptosis. siRNA knockdown of ABCC2 significantly induced apoptosis of CD44high/ESAlow cells in the presence of cisplatin, while ABCG2 knockdown induced apoptosis of those cells in the presence of docetaxel.  These findings suggest that strong resistance to cisplatin by CD44high/ESAlow cells may be attributable to a high level of ABC transporter activity.  Furthermore, development of CD44high/ESAlow cells was induced in the HNSCC cell line OM-1 by Snail transfection and those sorted from OM-1 cells harboring a Snail-transgene showed strong resistance to cisplatin- and docetaxel-induced apoptosis.  Our results indicate that CD44high/ESAlow HNSCC cells play important roles in cisplatin and docetaxel resistance caused by high drug efflux activity.  Furthermore, Snail may be involved in induction of both mesenchymal characteristics and CSC-like properties of HNSCC cells.  A better understanding of the phenotypic plasticity of HNSCC cells is necessary to improve the results of chemotherapy with cisplatin and docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjJux65nkjbVg90H21EOLACvtfcHk0lheXdUGWlsM8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotl2qsrY%253D&md5=ded73771328b77b4f06528623b59bc9c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHashikata%26aufirst%3DM.%26aulast%3DShigeishi%26aufirst%3DH.%26aulast%3DOkui%26aufirst%3DG.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTobiume%26aufirst%3DK.%26aulast%3DSeino%26aufirst%3DS.%26aulast%3DUetsuki%26aufirst%3DR.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DIshioka%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DHigashikawa%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTakechi%26aufirst%3DM.%26atitle%3DSnail-induced%2520CD44high%2520cells%2520in%2520HNSCC%2520with%2520high%2520ABC%2520transporter%2520capacity%2520exhibit%2520potent%2520resistance%2520to%2520cisplatin%2520and%2520docetaxel%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2016%26volume%3D9%26spage%3D7908%26epage%3D7918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of cisplatin resistance</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1883</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+mechanisms+of+cisplatin+resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0lheXdUGWlsM8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520of%2520cisplatin%2520resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M. T.</span></span> <span> </span><span class="NLM_article-title">Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy</span>. <i>Met.-Based Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">430939</span>, <span class="refDoi"> DOI: 10.1155/2010/430939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1155%2F2010%2F430939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20885916" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=430939&author=H.+H.+W.+Chenauthor=M.+T.+Kuo&title=Role+of+glutathione+in+the+regulation+of+cisplatin+resistance+in+cancer+chemotherapy&doi=10.1155%2F2010%2F430939"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2010%2F430939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2010%252F430939%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BH.%2BW.%26aulast%3DKuo%26aufirst%3DM.%2BT.%26atitle%3DRole%2520of%2520glutathione%2520in%2520the%2520regulation%2520of%2520cisplatin%2520resistance%2520in%2520cancer%2520chemotherapy%26jtitle%3DMet.-Based%2520Drugs%26date%3D2010%26volume%3D2010%26spage%3D430939%26doi%3D10.1155%2F2010%2F430939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olaussen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountzios, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer</span>. <i>Curr. Opin. Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1097/MCP.0b013e32816b5c63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2FMCP.0b013e32816b5c63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=17534174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVajur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=284-289&author=K.+A.+Olaussenauthor=G.+Mountziosauthor=J.-C.+Soria&title=ERCC1+as+a+risk+stratifier+in+platinum-based+chemotherapy+for+nonsmall-cell+lung+cancer&doi=10.1097%2FMCP.0b013e32816b5c63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer</span></div><div class="casAuthors">Olaussen, Ken Andre; Mountzios, Giannis; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">284-289</span>CODEN:
                <span class="NLM_cas:coden">COPMFY</span>;
        ISSN:<span class="NLM_cas:issn">1070-5287</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  High ERCC1 expression is predictive of resistance to platinum-based therapy.  Thus, there is solid evidence to support ERCC1 as a useful marker of clin. resistance to platinum-based chemotherapy in the adjuvant setting of nonsmall-cell lung cancer.  Meanwhile, optimization of methodol. and standardization of tech. procedures seem necessary before larger prospective studies can address the same question.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruNAbPz6aB6rVg90H21EOLACvtfcHk0liK4ZzME3ULBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVajur0%253D&md5=743b4f9b02e1b1eb88190ab6a372755e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e32816b5c63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e32816b5c63%26sid%3Dliteratum%253Aachs%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DMountzios%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DERCC1%2520as%2520a%2520risk%2520stratifier%2520in%2520platinum-based%2520chemotherapy%2520for%2520nonsmall-cell%2520lung%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D284%26epage%3D289%26doi%3D10.1097%2FMCP.0b013e32816b5c63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enot, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaussen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.4161/cc.24034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.4161%2Fcc.24034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23428903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFegs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=877-883&author=J.+Michelsauthor=I.+Vitaleauthor=L.+Senovillaauthor=D.+P.+Enotauthor=P.+Garciaauthor=D.+Lissaauthor=K.+A.+Olaussenauthor=C.+Brennerauthor=J.+C.+Soriaauthor=M.+Castedoauthor=G.+Kroemer&title=Synergistic+interaction+between+cisplatin+and+PARP+inhibitors+in+non-small+cell+lung+cancer&doi=10.4161%2Fcc.24034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Michels, Judith; Vitale, Ilio; Senovilla, Laura; Enot, David P.; Garcia, Pauline; Lissa, Delphine; Olaussen, Ken A.; Brenner, Catherine; Soria, Jean-Charles; Castedo, Maria; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">877-883</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective std. treatment of non-small cell lung carcinoma (NSCLC).  Here, we report a novel strategy to improve the efficacy of CDDP.  In conditions in which CDDP alone or either of two PARP inhibitors, PJ34 hydrochloride hydrate or CEP 8983, used as standalone treatments were inefficient in killing NSCLC cells, the combination of CDDP plus PJ34 or that of CDDP plus CEP 8983 were found to kill a substantial fraction of the cells.  This cytotoxic synergy could be recapitulated by combining CDDP and the siRNA-mediated depletion of the principal PARP isoform, PARP1, indicating that it is mediated by on-target effects of PJ34 or CEP 8983.  CDDP and PARP inhibitors synergized in inducing DNA damage foci, mitochondrial membrane permeabilization leading to cytochrome c release, and dissipation of the inner transmembrane potential, caspase activation, plasma membrane rupture and loss of clonogenic potential in NSCLC cells.  Collectively, our results indicate that CDDP can be advantageously combined with PARP inhibitors to kill several NSCLC cell lines, independently from their p53 status.  Combined treatment with CDDP and PARP inhibitors elicits the intrinsic pathway of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvs-_LhEGU-LVg90H21EOLACvtfcHk0lgTluO52Gvx5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFegs7c%253D&md5=1b4e720bd82ae15ac0d8363aaf4ee994</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4161%2Fcc.24034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.24034%26sid%3Dliteratum%253Aachs%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DEnot%26aufirst%3DD.%2BP.%26aulast%3DGarcia%26aufirst%3DP.%26aulast%3DLissa%26aufirst%3DD.%26aulast%3DOlaussen%26aufirst%3DK.%2BA.%26aulast%3DBrenner%26aufirst%3DC.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DSynergistic%2520interaction%2520between%2520cisplatin%2520and%2520PARP%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCell%2520Cycle%26date%3D2013%26volume%3D12%26spage%3D877%26epage%3D883%26doi%3D10.4161%2Fcc.24034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span> <span> </span><span class="NLM_article-title">DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3799</span>– <span class="NLM_lpage">3808</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.05.4171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1200%2FJCO.2005.05.4171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16896009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVaqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=3799-3808&author=R.+D.+Kennedyauthor=A.+D.+D%E2%80%99Andrea&title=DNA+repair+pathways+in+clinical+practice%3A+lessons+from+pediatric+cancer+susceptibility+syndromes&doi=10.1200%2FJCO.2005.05.4171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes</span></div><div class="casAuthors">Kennedy, Richard D.; D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3799-3808</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair.  Cancer cells are often defective in one of six major DNA repair pathways, namely: mismatch repair, base excision repair, nucleotide excision repair, homologous recombination, nonhomologous endjoining and translesion synthesis.  The specific DNA repair pathway affected is predictive of the kinds of mutations, the tumor drug sensitivity, and the treatment outcome.  The study of rare inherited DNA repair disorders, such as Fanconi anemia, has yielded new insights to drug sensitivity and treatment of sporadic cancers, such as breast or ovarian epithelial tumors, in the general population.  The Fanconi anemia pathway is an example of how DNA repair pathways can be deregulated in cancer cells and how biomarkers of the integrity of these pathways could be useful as a guide to cancer management and may be used in the development of novel therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUIOsyxbFHCrVg90H21EOLACvtfcHk0lgTluO52Gvx5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVaqsLw%253D&md5=c4e88a82fe518518dea05a7791d6558d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.05.4171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.05.4171%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DR.%2BD.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DDNA%2520repair%2520pathways%2520in%2520clinical%2520practice%253A%2520lessons%2520from%2520pediatric%2520cancer%2520susceptibility%2520syndromes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D3799%26epage%3D3808%26doi%3D10.1200%2FJCO.2005.05.4171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fijołek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiatr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowińska-Zakrzewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giedronowicz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langfort, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orłowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszkowski, K.</span></span> <span> </span><span class="NLM_article-title">p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer</span>. <i>Int. J. Biol. Markers</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1177/172460080602100203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1177%2F172460080602100203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16847810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFWktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=81-87&author=J.+Fijo%C5%82ekauthor=E.+Wiatrauthor=E.+Rowi%C5%84ska-Zakrzewskaauthor=D.+Giedronowiczauthor=R.+Langfortauthor=M.+Chabowskiauthor=T.+Or%C5%82owskiauthor=K.+Roszkowski&title=p53+and+HER2%2Fneu+expression+in+relation+to+chemotherapy+response+in+patients+with+non-small+cell+lung+cancer&doi=10.1177%2F172460080602100203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer</span></div><div class="casAuthors">Fijolek, J.; Wiatr, E.; Rowinska-Zakrzewska, E.; Giedronowicz, D.; Langfort, R.; Chabowski, M.; Orlowski, T.; Roszkowski, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Markers</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-87</span>CODEN:
                <span class="NLM_cas:coden">IBMAEP</span>;
        ISSN:<span class="NLM_cas:issn">0393-6155</span>.
    
            (<span class="NLM_cas:orgname">Wichtig Editore</span>)
        </div><div class="casAbstract">The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy.  The study population included 67 consecutive patients with non-small cell lung cancer (NSCLC) in stage II or III who were operated on at the Institute of Tuberculosis, Warsaw, Poland, between 20 Apr. 2001 and 10 Mar. 2003.  All patients received two cycles of chemotherapy consisting of cisplatin and vinorelbine prior to the operation.  The response to therapy was assessed as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), on the basis of CT scans performed before and after neoadjuvant chemotherapy.  P53 and HER2/neu protein expression were evaluated by immunohistochem. (IHC) using antibodies against p53 (clone PAb 1801, Novocastra) and against HER2/neu (Dako) in paraffin-embedded specimens of tumors.  A response to therapy (CR+PR) was obsd. in 27 patients, while 40 patients (SD+PD) were regarded as resistant to therapy.  Resistance was obsd. significantly more often in tumors above 3 cm in diam.  P53 expression was found in 16 tumors (23.9%) and HER2/neu in 26 tumors (38.8%).  We obsd. a nonsignificant tendency to chemoresistance in tumors with HER-2/neu overexpression and also in tumors with p53 overexpression.  If we consider HER-2/neu and p53 together, chemoresistance was obsd. statistically significantly more often when one or both markers were pos. (p<0.05).  This significance was independent of tumor size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5IyIFPHMLhLVg90H21EOLACvtfcHk0lhXvDGehkYLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFWktLs%253D&md5=22f6fdbad1bc9c2a5e7c59a12a5293b6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F172460080602100203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F172460080602100203%26sid%3Dliteratum%253Aachs%26aulast%3DFijo%25C5%2582ek%26aufirst%3DJ.%26aulast%3DWiatr%26aufirst%3DE.%26aulast%3DRowi%25C5%2584ska-Zakrzewska%26aufirst%3DE.%26aulast%3DGiedronowicz%26aufirst%3DD.%26aulast%3DLangfort%26aufirst%3DR.%26aulast%3DChabowski%26aufirst%3DM.%26aulast%3DOr%25C5%2582owski%26aufirst%3DT.%26aulast%3DRoszkowski%26aufirst%3DK.%26atitle%3Dp53%2520and%2520HER2%252Fneu%2520expression%2520in%2520relation%2520to%2520chemotherapy%2520response%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DInt.%2520J.%2520Biol.%2520Markers%26date%3D2006%26volume%3D21%26spage%3D81%26epage%3D87%26doi%3D10.1177%2F172460080602100203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, P.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.-I.</span></span> <span> </span><span class="NLM_article-title">Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2005.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.bcp.2005.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16004971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=658-667&author=J.+Linauthor=P.-W.+Hsiaoauthor=T.+H.+Chiuauthor=J.-I.+Chao&title=Combination+of+cyclooxygenase-2+inhibitors+and+oxaliplatin+increases+the+growth+inhibition+and+death+in+human+colon+cancer+cells&doi=10.1016%2Fj.bcp.2005.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells</span></div><div class="casAuthors">Lin, Johnson; Hsiao, Po-Wen; Chiu, Ted H.; Chao, Jui-I.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">658-667</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cyclooxygenase-2 (COX-2) protein is highly expressed in a variety of human cancers and has been reported to promote tumor growth.  Non-steroidal anti-inflammatory drugs such as etodolac and celecoxib have been shown to inhibit COX-2 activity and may play a role in the chemoprevention of cancer.  Oxaliplatin is a third-generation platinum compd. that exhibits a different spectrum of activity compared with cisplatin.  Other cisplatin-resistant tumors can still respond to oxaliplatin.  However, the anticancer ability of the combination of COX-2 inhibitors and oxaliplatin is still unknown.  In this study, we investigated the effects of combination of COX-2 inhibitors and oxaliplatin on the cell growth and survival in human colon cancer cells.  Treatments with etodolac (0.3-0.5 mM) or celecoxib (20-80 μM) for 24 h concn.-dependently induced the cytotoxicity in the RKO colon carcinoma cells.  Etodolac and celecoxib did not alter the COX-2 protein levels but inhibited its enzyme activity to reduce prostaglandin E2 prodn.  Furthermore, the cell survival was concn.-dependently decreased following oxaliplatin (1-100 μM, 24 h) treatment.  Combination of oxaliplatin and etodolac additively increased the death and growth inhibition of RKO cells.  Survivin, an inhibitor protein of apoptosis, mediates anti-apoptosis and promotes cell division in cancer cells.  Oxaliplatin or COX-2 inhibitors significantly decreased the levels of survivin proteins.  Moreover, survivin proteins were markedly diminished following co-treatment with oxaliplatin and etodolac.  Together, this is the first report that combination of COX-2 inhibitors and oxaliplatin can increase the redn. of survivin protein expression, growth inhibition, and death in human colon cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAfA_FTW3tP7Vg90H21EOLACvtfcHk0lhXvDGehkYLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrs%253D&md5=a4e3c4b0af0d01a1d3fb8624103c1410</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2005.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2005.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHsiao%26aufirst%3DP.-W.%26aulast%3DChiu%26aufirst%3DT.%2BH.%26aulast%3DChao%26aufirst%3DJ.-I.%26atitle%3DCombination%2520of%2520cyclooxygenase-2%2520inhibitors%2520and%2520oxaliplatin%2520increases%2520the%2520growth%2520inhibition%2520and%2520death%2520in%2520human%2520colon%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2005%26volume%3D70%26spage%3D658%26epage%3D667%26doi%3D10.1016%2Fj.bcp.2005.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panichpisal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtzman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, K.</span></span> <span> </span><span class="NLM_article-title">Cisplatin nephrotoxicity: a review</span>. <i>Am. J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1097/MAJ.0b013e31812dfe1e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2FMAJ.0b013e31812dfe1e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=17700201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BD2svot1Gqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2007&pages=115-124&author=X.+Yaoauthor=K.+Panichpisalauthor=N.+Kurtzmanauthor=K.+Nugent&title=Cisplatin+nephrotoxicity%3A+a+review&doi=10.1097%2FMAJ.0b013e31812dfe1e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin nephrotoxicity: a review</span></div><div class="casAuthors">Yao Xin; Panichpisal Kessarin; Kurtzman Neil; Nugent Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of the medical sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-24</span>
        ISSN:<span class="NLM_cas:issn">0002-9629</span>.
    </div><div class="casAbstract">BACKGROUND:  Cisplatin is a major antineoplastic drug for the treatment of solid tumors, but it has dose-dependent renal toxicity.  METHODS:  We reviewed clinical and experimental literature on cisplatin nephrotoxicity to identify new information on the mechanism of injury and potential approaches to prevention and/or treatment.  RESULTS:  Unbound cisplatin is freely filtered at the glomerulus and taken up into renal tubular cells mainly by a transport-mediated process.  The drug is at least partially metabolized into toxic species.  Cisplatin has multiple intracellular effects, including regulating genes, causing direct cytotoxicity with reactive oxygen species, activating mitogen-activated protein kinases, inducing apoptosis, and stimulating inflammation and fibrogenesis.  These events cause tubular damage and tubular dysfunction with sodium, potassium, and magnesium wasting.  Most patients have a reversible decrease in glomerular filtration, but some have an irreversible decrease in glomerular filtration.  Volume expansion and saline diuresis remain the most effective preventive strategies.  CONCLUSIONS:  Understanding the mechanisms of injury has led to multiple approaches to prevention.  Furthermore, the experimental approaches in these studies with cisplatin are potentially applicable to other drugs causing renal dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTPybNzmIWpnthwrmtH4OBfW6udTcc2ebpYJJpHIhDr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svot1Gqsw%253D%253D&md5=200e6829fafd9fe4b941ee5f387412e6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FMAJ.0b013e31812dfe1e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMAJ.0b013e31812dfe1e%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DX.%26aulast%3DPanichpisal%26aufirst%3DK.%26aulast%3DKurtzman%26aufirst%3DN.%26aulast%3DNugent%26aufirst%3DK.%26atitle%3DCisplatin%2520nephrotoxicity%253A%2520a%2520review%26jtitle%3DAm.%2520J.%2520Med.%2520Sci.%26date%3D2007%26volume%3D334%26spage%3D115%26epage%3D124%26doi%3D10.1097%2FMAJ.0b013e31812dfe1e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vougiouka, M.</span></span> <span> </span><span class="NLM_article-title">Cisplatin and platinum drugs at the molecular level (Review)</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1663</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.3892/or.10.6.1663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2For.10.6.1663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14534679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlCktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=1663-1682&author=T.+Boulikasauthor=M.+Vougiouka&title=Cisplatin+and+platinum+drugs+at+the+molecular+level+%28Review%29&doi=10.3892%2For.10.6.1663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin and platinum drugs at the molecular level (review)</span></div><div class="casAuthors">Boulikas, Teni; Vougiouka, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1663-1682</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review.  Over twenty years of intensive work toward improvement of cisplatin, and with hundreds of platinum drugs tested, has resulted in the introduction of the widely used carboplatin and of oxaliplatin used only for a very narrow spectrum of cancers.  A no. of interesting platinum compds. including the orally administered platinum drug JM216, nedaplatin, the sterically hindered platinum(II) complex ZD0473, the trinuclear platinum complex BBR3464, and the liposomal forms Lipoplatin and SPI-77 are under clin. evaluation.  This review summarizes the mol. mechanisms of platinum compds. for DNA damage, DNA repair and induction of apoptosis via activation or modulation of signaling pathways and explores the basis of platinum resistance.  Cisplatin, carboplatin, oxaliplatin and most other platinum compds. induce damage to tumors via induction of apoptosis; this is mediated by activation of signal transduction leading to the death receptor mechanisms as well as mitochondrial pathways.  Apoptosis is responsible for the characteristic nephrotoxicity, ototoxicity and most other toxicities of the drugs.  The major limitation in the clin. applications of cisplatin has been the development of cisplatin resistance by tumors.  Mechanisms explaining cisplatin resistance include the redn. in cisplatin accumulation inside cancer cells because of barriers across the cell membrane, the faster repair of cisplatin adducts, the modulation of apoptotic pathways in various cells, the upregulation in transcription factors, the loss of p53 and other protein functions and a higher concn. of glutathione and metallothioneins in some type of tumors.  A no. of exptl. strategies to overcome cisplatin resistance are at the preclin. or clin. level such as introduction of the bax gene, inhibition of the JNK pathway, introduction of a functional p53 gene, treatment of tumors with aldose reductase inhibitors and others.  Particularly important are combinations of platinum drug treatments with other drugs, radiation and the emerging gene therapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOSyOTbjr4WbVg90H21EOLACvtfcHk0ljpfEXsQSqHHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlCktLw%253D&md5=8b05bc59535fd156495ef6d47fa16b62</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3892%2For.10.6.1663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.10.6.1663%26sid%3Dliteratum%253Aachs%26aulast%3DBoulikas%26aufirst%3DT.%26aulast%3DVougiouka%26aufirst%3DM.%26atitle%3DCisplatin%2520and%2520platinum%2520drugs%2520at%2520the%2520molecular%2520level%2520%2528Review%2529%26jtitle%3DOncol.%2520Rep.%26date%3D2003%26volume%3D10%26spage%3D1663%26epage%3D1682%26doi%3D10.3892%2For.10.6.1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Gonzalez, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Hernandez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Barriocanal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Novoa, J. M.</span></span> <span> </span><span class="NLM_article-title">Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity</span>. <i>Nephrol., Dial., Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3484</span>– <span class="NLM_lpage">3495</span>, <span class="refDoi"> DOI: 10.1093/ndt/gfr195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1093%2Fndt%2Fgfr195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=21602180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=3484-3495&author=P.+D.+Sanchez-Gonzalezauthor=F.+J.+Lopez-Hernandezauthor=F.+Perez-Barriocanalauthor=A.+I.+Moralesauthor=J.+M.+Lopez-Novoa&title=Quercetin+reduces+cisplatin+nephrotoxicity+in+rats+without+compromising+its+anti-tumour+activity&doi=10.1093%2Fndt%2Fgfr195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity</span></div><div class="casAuthors">Sanchez-Gonzalez, Penelope D.; Lopez-Hernandez, Francisco J.; Perez-Barriocanal, Fernando; Morales, Ana I.; Lopez-Novoa, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3484-3495</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Nephrotoxicity is the major limitation for the clin. use of cisplatin as an anti-tumoral drug.  Our aim was to investigate the protective effect of quercetin on cisplatin nephrotoxicity in a rat tumor model in vivo and to examine the mechanisms of renal protection.  Methods: Breast adenocarcinoma (13762 Mat B-III) cells were inoculated s.c. in male Fischer rats and 7 days later, the rats were administered daily with quercetin [50 mg/kg/day, i.p. (i.p.)] or vehicle.  Four days after that, the rats were given a single dose of cisplatin (4 mg/kg, i.p.) or vehicle.  Tumor growth and renal function were monitored throughout the expt.  Two or 6 days after cisplatin administration, the rats were killed and the kidneys and tumors were removed to examine renal function and toxicity markers in both tissues.  Results: In the kidney, cisplatin treatment induced: (i) a decrease in renal blood flow and glomerular filtration rate, (ii) tubular necrosis/apoptosis, (iii) increased lipid peroxidn. and decreased endogenous antioxidant systems, (iv) increased expression of inflammation markers and (v) increased activity of the apoptosis executioner caspase-3.  Cisplatin effectively reduced tumor size and wt.  Conclusions: Co-treatment with quercetin partially prevented all the renal effects of cisplatin, whereas it did not impair its anti-tumor activity.  In conclusion, in a model of tumor-bearing rats, quercetin prevents the nephrotoxic effect of cisplatin without affecting its anti-tumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPkaWqK0K3wrVg90H21EOLACvtfcHk0ljedddcA58z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtrnN&md5=e9e8bb03a9754d9d926dfc1b77999c31</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfr195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfr195%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Gonzalez%26aufirst%3DP.%2BD.%26aulast%3DLopez-Hernandez%26aufirst%3DF.%2BJ.%26aulast%3DPerez-Barriocanal%26aufirst%3DF.%26aulast%3DMorales%26aufirst%3DA.%2BI.%26aulast%3DLopez-Novoa%26aufirst%3DJ.%2BM.%26atitle%3DQuercetin%2520reduces%2520cisplatin%2520nephrotoxicity%2520in%2520rats%2520without%2520compromising%2520its%2520anti-tumour%2520activity%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2011%26volume%3D26%26spage%3D3484%26epage%3D3495%26doi%3D10.1093%2Fndt%2Fgfr195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadagavadi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, W. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of cisplatin nephrotoxicity</span>. <i>Toxins</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2490</span>– <span class="NLM_lpage">2518</span>, <span class="refDoi"> DOI: 10.3390/toxins2112490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3390%2Ftoxins2112490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22069563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSht7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=2490-2518&author=R.+P.+Millerauthor=R.+K.+Tadagavadiauthor=G.+Rameshauthor=W.+B.+Reeves&title=Mechanisms+of+cisplatin+nephrotoxicity&doi=10.3390%2Ftoxins2112490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cisplatin nephrotoxicity</span></div><div class="casAuthors">Miller, Ronald P.; Tadagavadi, Raghu K.; Ramesh, Ganesan; Reeves, William Brian</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2490-2518</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Cisplatin is a widely used and highly effective cancer chemotherapeutic agent.  One of the limiting side effects of cisplatin use is nephrotoxicity.  Research over the past 10 years has uncovered many of the cellular mechanisms which underlie cisplatin-induced renal cell death.  It has also become apparent that inflammation provoked by injury to renal epithelial cells serves to amplify kidney injury and dysfunction in vivo.  This review summarizes recent advances in our understanding of cisplatin nephrotoxicity and discusses how these advances might lead to more effective prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquPxscC-wQ87Vg90H21EOLACvtfcHk0ljedddcA58z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSht7vJ&md5=7fd6f1103c5e8185eeae1b2d9e9f3969</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Ftoxins2112490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins2112490%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BP.%26aulast%3DTadagavadi%26aufirst%3DR.%2BK.%26aulast%3DRamesh%26aufirst%3DG.%26aulast%3DReeves%26aufirst%3DW.%2BB.%26atitle%3DMechanisms%2520of%2520cisplatin%2520nephrotoxicity%26jtitle%3DToxins%26date%3D2010%26volume%3D2%26spage%3D2490%26epage%3D2518%26doi%3D10.3390%2Ftoxins2112490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">dos
Santos, N. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho Rodrigues, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dos Santos, A. C.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1233</span>– <span class="NLM_lpage">1250</span>, <span class="refDoi"> DOI: 10.1007/s00204-012-0821-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs00204-012-0821-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22382776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC38vltVGltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=1233-1250&author=N.+A.+G.+dos%0ASantosauthor=M.+A.+Carvalho+Rodriguesauthor=N.+M.+Martinsauthor=A.+C.+dos+Santos&title=Cisplatin-induced+nephrotoxicity+and+targets+of+nephroprotection%3A+an+update&doi=10.1007%2Fs00204-012-0821-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update</span></div><div class="casAuthors">dos Santos Neife Aparecida Guinaim; Carvalho Rodrigues Maria Augusta; Martins Nadia Maria; dos Santos Antonio Cardozo</div><div class="citationInfo"><span class="NLM_cas:title">Archives of toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1233-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cisplatin is a highly effective antitumor agent whose clinical application is limited by the inherent nephrotoxicity.  The current measures of nephroprotection used in patients receiving cisplatin are not satisfactory, and studies have focused on the investigation of new possible protective strategies.  Many pathways involved in cisplatin nephrotoxicity have been delineated and proposed as targets for nephroprotection, and many new potentially protective agents have been reported.  The multiple pathways which lead to renal damage and renal cell death have points of convergence and share some common modulators.  The most frequent event among all the described pathways is the oxidative stress that acts as both a trigger and a result.  The most exploited pathways, the proposed protective strategies, the achievements obtained so far as well as conflicting data are summarized and discussed in this review, providing a general view of the knowledge accumulated with past and recent research on this subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvux3PMKPEWvIW7hznt0zpfW6udTcc2eZ0zAklKcDwmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vltVGltQ%253D%253D&md5=6270fa2ce55282ee31669c3c5d39c15c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs00204-012-0821-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-012-0821-7%26sid%3Dliteratum%253Aachs%26aulast%3Ddos%2BSantos%26aufirst%3DN.%2BA.%2BG.%26aulast%3DCarvalho%2BRodrigues%26aufirst%3DM.%2BA.%26aulast%3DMartins%26aufirst%3DN.%2BM.%26aulast%3Ddos%2BSantos%26aufirst%3DA.%2BC.%26atitle%3DCisplatin-induced%2520nephrotoxicity%2520and%2520targets%2520of%2520nephroprotection%253A%2520an%2520update%26jtitle%3DArch.%2520Toxicol.%26date%3D2012%26volume%3D86%26spage%3D1233%26epage%3D1250%26doi%3D10.1007%2Fs00204-012-0821-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chirino, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedraza-Chaverri, J.</span></span> <span> </span><span class="NLM_article-title">Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.etp.2008.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.etp.2008.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18986801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmt1GmtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=223-242&author=Y.+I.+Chirinoauthor=J.+Pedraza-Chaverri&title=Role+of+oxidative+and+nitrosative+stress+in+cisplatin-induced+nephrotoxicity&doi=10.1016%2Fj.etp.2008.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Chirino, Yolanda I.; Pedraza-Chaverri, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-242</span>CODEN:
                <span class="NLM_cas:coden">ETPAEK</span>;
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">A review.  Cis-Diamminedichloroplatinum (II) (cisplatin) is an important chemotherapeutic agent useful in the treatment of several cancers; however, it has several side effects such as nephrotoxicity.  The role of the oxidative and nitrosative stress in cisplatin-induced nephrotoxicity is addnl. supported by the protective effect of several free radical scavengers and antioxidants.  Furthermore, in in vitro expts., antioxidants or reactive oxygen species (ROS) scavengers have a cytoprotective effect on cells exposed to cisplatin.  Recently, the participation of nitrosative stress has been more explored in cisplatin-induced renal damage.  The use of a water-sol. Fe(III) porphyrin complex able to metabolize peroxynitrite (ONOO-) has demonstrated that this anion contributes to both in vivo and in vitro cisplatin-induced toxicity.  ONOO- is produced when nitric oxide (NO·) reacts with superoxide anion (O2·-); currently, there are evidences suggesting alterations in NO· prodn. after cisplatin treatment and the evidence appear to NO· has a toxic effect.  This article goes through current evidence of the mechanism by more than a few compds. have beneficial effects on cisplatin-induced nephrotoxicity, contribute to understanding the role of oxidative and nitrosative stress and suggest several points as part of the mechanism of cisplatin toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YkkrI3WvC7Vg90H21EOLACvtfcHk0lglOeyahU0ZCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmt1GmtL4%253D&md5=59b80730d1ab240bfa2fd44b94108568</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.etp.2008.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.etp.2008.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DChirino%26aufirst%3DY.%2BI.%26aulast%3DPedraza-Chaverri%26aufirst%3DJ.%26atitle%3DRole%2520of%2520oxidative%2520and%2520nitrosative%2520stress%2520in%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2009%26volume%3D61%26spage%3D223%26epage%3D242%26doi%3D10.1016%2Fj.etp.2008.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koyner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher Ali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. T.</span></span> <span> </span><span class="NLM_article-title">Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury?</span>. <i>Nephron Exp. Nephrol</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">e109</span>– <span class="NLM_lpage">e117</span>, <span class="refDoi"> DOI: 10.1159/000142935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1159%2F000142935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18802373" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2008&pages=e109-e117&author=J.+L.+Koynerauthor=R.+Sher+Aliauthor=P.+T.+Murray&title=Antioxidants.+Do+they+have+a+place+in+the+prevention+or+therapy+of+acute+kidney+injury%3F&doi=10.1159%2F000142935"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1159%2F000142935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000142935%26sid%3Dliteratum%253Aachs%26aulast%3DKoyner%26aufirst%3DJ.%2BL.%26aulast%3DSher%2BAli%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DP.%2BT.%26atitle%3DAntioxidants.%2520Do%2520they%2520have%2520a%2520place%2520in%2520the%2520prevention%2520or%2520therapy%2520of%2520acute%2520kidney%2520injury%253F%26jtitle%3DNephron%2520Exp.%2520Nephrol%26date%3D2008%26volume%3D109%26spage%3De109%26epage%3De117%26doi%3D10.1159%2F000142935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span> <span> </span><span class="NLM_article-title">Cisplatin nephrotoxicity: mechanisms and renoprotective strategies</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1038/sj.ki.5002786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fsj.ki.5002786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18272962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12nsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=994-1007&author=N.+Pablaauthor=Z.+Dong&title=Cisplatin+nephrotoxicity%3A+mechanisms+and+renoprotective+strategies&doi=10.1038%2Fsj.ki.5002786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies</span></div><div class="casAuthors">Pabla, N.; Dong, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">994-1007</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin is one of the most widely used and most potent chemotherapy drugs.  However, side effects in normal tissues and organs, notably nephrotoxicity in the kidneys, limit the use of cisplatin and related platinum-based therapeutics.  Recent research has shed significant new lights on the mechanism of cisplatin nephrotoxicity, esp. on the signaling pathways leading to tubular cell death and inflammation.  Renoprotective approaches are being discovered, but the protective effects are mostly partial, suggesting the need for combinatorial strategies.  Importantly, it is unclear whether these approaches would limit the anticancer effects of cisplatin in tumors.  Examn. of tumor-bearing animals and identification of novel renoprotective strategies that do not diminish the anticancer efficacy of cisplatin are essential to the development of clin. applicable interventions.  Kidney International (2008) 73, 994-1007; doi:10.1038/sj.ki.5002786; published online 13 Feb. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSefTtDpSoxbVg90H21EOLACvtfcHk0lizjJd1kKqAEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12nsr8%253D&md5=76caa1316c4d3ac1177446f45bc7de82</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5002786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5002786%26sid%3Dliteratum%253Aachs%26aulast%3DPabla%26aufirst%3DN.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DCisplatin%2520nephrotoxicity%253A%2520mechanisms%2520and%2520renoprotective%2520strategies%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D73%26spage%3D994%26epage%3D1007%26doi%3D10.1038%2Fsj.ki.5002786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2709</span>– <span class="NLM_lpage">2722</span>, <span class="refDoi"> DOI: 10.1172/JCI45586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1172%2FJCI45586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=21633170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2709-2722&author=N.+Pablaauthor=G.+Dongauthor=M.+Jiangauthor=S.+Huangauthor=M.+V.+Kumarauthor=R.+O.+Messingauthor=Z.+Dong&title=Inhibition+of+PKC%CE%B4+reduces+cisplatin-induced+nephrotoxicity+without+blocking+chemotherapeutic+efficacy+in+mouse+models+of+cancer&doi=10.1172%2FJCI45586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer</span></div><div class="casAuthors">Pabla, Navjotsingh; Dong, Guie; Jiang, Man; Huang, Shuang; Kumar, M. Vijay; Messing, Robert O.; Dong, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2709-2722</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Cisplatin is a widely used cancer therapy drug that unfortunately has major side effects in normal tissues, notably nephrotoxicity in kidneys.  Despite intensive research, the mechanism of cisplatin-induced nephrotoxicity remains unclear, and renoprotective approaches during cisplatin-based chemotherapy are lacking.  Here we have identified PKCδ as a crit. regulator of cisplatin nephrotoxicity, which can be effectively targeted for renoprotection during chemotherapy.  We showed that early during cisplatin nephrotoxicity, Src interacted with, phosphorylated, and activated PKCδ in mouse kidney lysates.  After activation, PKCδ regulated MAPKs, but not p53, to induce renal cell apoptosis.  Thus, inhibition of PKCδ pharmacol. or genetically attenuated kidney cell apoptosis and tissue damage, preserving renal function during cisplatin treatment.  Conversely, inhibition of PKCδ enhanced cisplatin-induced cell death in multiple cancer cell lines and, remarkably, enhanced the chemotherapeutic effects of cisplatin in several xenograft and syngeneic mouse tumor models while protecting kidneys from nephrotoxicity.  Together these results demonstrate a role of PKCδ in cisplatin nephrotoxicity and support targeting PKCδ as an effective strategy for renoprotection during cisplatin-based cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriAC370eVshbVg90H21EOLACvtfcHk0lizjJd1kKqAEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgurY%253D&md5=20b50d1d7ac4cd7295a17bfdec34075e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1172%2FJCI45586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45586%26sid%3Dliteratum%253Aachs%26aulast%3DPabla%26aufirst%3DN.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DM.%2BV.%26aulast%3DMessing%26aufirst%3DR.%2BO.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DInhibition%2520of%2520PKC%25CE%25B4%2520reduces%2520cisplatin-induced%2520nephrotoxicity%2520without%2520blocking%2520chemotherapeutic%2520efficacy%2520in%2520mouse%2520models%2520of%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2709%26epage%3D2722%26doi%3D10.1172%2FJCI45586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clerici, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMartino, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, D. A.</span></span> <span> </span><span class="NLM_article-title">Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1016/0378-5955(96)00075-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2F0378-5955%2896%2900075-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=8880186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK28XmtVSqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1996&pages=116-124&author=W.+J.+Clericiauthor=K.+Hensleyauthor=D.+L.+DiMartinoauthor=D.+A.+Butterfield&title=Direct+detection+of+ototoxicant-induced+reactive+oxygen+species+generation+in+cochlear+explants&doi=10.1016%2F0378-5955%2896%2900075-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants</span></div><div class="casAuthors">Clerici, William J.; Hensley, Kenneth; DiMartino, Debra L.; Butterfield, D. Allan</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">116-124</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The proposal that free-radical generation contributes to the ototoxicities of several chem. agents was studied utilizing ESR (EPR) spectrometry to detect directly ototoxicant-induced reactive oxygen species formation in cochlear tissue.  Guinea pig cochlear explants in chelexed artificial perilymph (AP; 200 μl) were exposed to an ototoxicant or AP for 10 min.  Ototoxic agents included gentamicin sulfate (4.0 mM), kanamycin monosulfate (4.0 mM), ethacrynic acid (0.5 mM), furosemide (0.3 mM), cisplatin (0.1 mM), trimethyltin chloride (0.1 mM), and quinine HCl (3.0 mM).  Following incubation, 20 μl of AP/ototoxicant mixt. was replaced by the filtered spin trap, 5,5-dimethylpyrroline-N-oxide (DMPO).  After 10 min, the EPR spectrum of the mixt. was obtained.  Four line EPR spectra of relative intensities 1:2:2:1, assocd. with hydroxyl radical (OH.)/DMPO adduct formation, were evidenced by reaction mixts. contg. cochlear explants exposed to each ototoxicant.  Cisplatin, quinine and the loop diuretics produced weak OH.-assocd. EPR signals in the absence of a cochlear explant, which were amplified in its presence.  Deferoxamine quenched all OH. spectral peaks.  Peroxide levels, assayed in parallel expts., were diminished by each ototoxicant relative to those seen following AP exposure, suggesting possible H2O2 conversion to OH..  These data support the proposal that various ototoxic agents are capable of reactive oxygen species generation or promotion in cochlear tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzujguZOsDZbVg90H21EOLACvtfcHk0lizjJd1kKqAEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtVSqsLc%253D&md5=6839be8d17fee5c8927d802a0f34016d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0378-5955%2896%2900075-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-5955%252896%252900075-5%26sid%3Dliteratum%253Aachs%26aulast%3DClerici%26aufirst%3DW.%2BJ.%26aulast%3DHensley%26aufirst%3DK.%26aulast%3DDiMartino%26aufirst%3DD.%2BL.%26aulast%3DButterfield%26aufirst%3DD.%2BA.%26atitle%3DDirect%2520detection%2520of%2520ototoxicant-induced%2520reactive%2520oxygen%2520species%2520generation%2520in%2520cochlear%2520explants%26jtitle%3DHear.%2520Res.%26date%3D1996%26volume%3D98%26spage%3D116%26epage%3D124%26doi%3D10.1016%2F0378-5955%2896%2900075-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, L. Q.</span></span> <span> </span><span class="NLM_article-title">Apelin-13 attenuates cisplatin-induced cardiotoxicity through inhibition of ROS-mediated DNA damage and regulation of MAPKs and AKT pathways</span>. <i>Free Radical Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1080/10715762.2017.1313414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1080%2F10715762.2017.1313414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28554248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFCmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2017&pages=449-459&author=P.+Zhangauthor=L.+H.+Yiauthor=G.+Y.+Mengauthor=H.+Y.+Zhangauthor=H.+H.+Sunauthor=L.+Q.+Cui&title=Apelin-13+attenuates+cisplatin-induced+cardiotoxicity+through+inhibition+of+ROS-mediated+DNA+damage+and+regulation+of+MAPKs+and+AKT+pathways&doi=10.1080%2F10715762.2017.1313414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Apelin-13 attenuates cisplatin-induced cardiotoxicity through inhibition of ROS-mediated DNA damage and regulation of MAPKs and AKT pathways</span></div><div class="casAuthors">Zhang, Pu; Yi, Lu-hua; Meng, Guang-yuan; Zhang, Huan-yi; Sun, Hai-hui; Cui, Lian-qun</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-459</span>CODEN:
                <span class="NLM_cas:coden">FRARER</span>;
        ISSN:<span class="NLM_cas:issn">1029-2470</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Platinum-based chemotherapy represents one of the most effective ways in combating human cancers.  However, the cardiotoxicity subsequent severely limited its clin. application.  Increased evidences indicate that oxidative stress plays a crucial role in the pathol. process of platinum-induced cardiotoxicity.  It is reported that apelin-13 a bioactive peptide has the scavenging capacity of free radical, and it has the potential to regulate the cardiovascular system.  Hence, the potential of apelin-13 to antagonize cisplatin-induced cardiotoxicity was evaluated in H9c2 rat myocardial cells in vitro and in C57 mice in vivo.  The results showed that cisplatin indeed caused DNA damage in H9c2 cells by promoting the accumulation of intracellular reactive oxygen species (ROS) and superoxide anion, which led to cell apoptosis and resulted in overt cardiotoxicity.  However, apelin-13 pre-treatment effectively attenuated the cisplatin-induced ROS and superoxide anion generation, inhibited DNA damage, and suppressed the PARP cleavage and caspases activation.  Further investigation revealed that apelin-13 blocked cisplatin-induced H9c2 cells apoptosis involving the regulation of MAPKs and PI3K/Akt signaling pathway.  Importantly, apelin-13 co-treatment also significantly attenuated cisplatin-induced cardiotoxicity in vivo by inhibiting myocardial cells apoptosis and improving angiogenesis in mice heart.  Taken together, our results suggest that the use of apelin-13 may be an effective strategy for antagonizing the cardiotoxicity-induced by platinum-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAWRysC59xuLVg90H21EOLACvtfcHk0liRxMVss6bTqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFCmtLY%253D&md5=fd477522eade9b55ab2c11aff87f76eb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F10715762.2017.1313414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10715762.2017.1313414%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYi%26aufirst%3DL.%2BH.%26aulast%3DMeng%26aufirst%3DG.%2BY.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26aulast%3DSun%26aufirst%3DH.%2BH.%26aulast%3DCui%26aufirst%3DL.%2BQ.%26atitle%3DApelin-13%2520attenuates%2520cisplatin-induced%2520cardiotoxicity%2520through%2520inhibition%2520of%2520ROS-mediated%2520DNA%2520damage%2520and%2520regulation%2520of%2520MAPKs%2520and%2520AKT%2520pathways%26jtitle%3DFree%2520Radical%2520Res.%26date%3D2017%26volume%3D51%26spage%3D449%26epage%3D459%26doi%3D10.1080%2F10715762.2017.1313414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamesdaniel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, W. L.</span></span> <span> </span><span class="NLM_article-title">Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2016.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.redox.2016.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27821327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=257-265&author=S.+Jamesdanielauthor=R.+Rathinamauthor=W.+L.+Neumann&title=Targeting+nitrative+stress+for+attenuating+cisplatin-induced+downregulation+of+cochlear+LIM+domain+only+4+and+ototoxicity&doi=10.1016%2Fj.redox.2016.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity</span></div><div class="casAuthors">Jamesdaniel, Samson; Rathinam, Rajamani; Neumann, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">257-265</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cisplatin-induced ototoxicity remains a primary dose-limiting adverse effect of this highly effective anticancer drug.  The clin. utility of cisplatin could be enhanced if the signaling pathways that regulate the toxic side-effects are delineated.  In previous studies, we reported cisplatin-induced nitration of cochlear proteins and provided the first evidence for nitration and downregulation of cochlear LIM domain only 4 (LMO4) in cisplatin ototoxicity.  Here, we extend these findings to define the crit. role of nitrative stress in cisplatin-induced downregulation of LMO4 and its consequent ototoxic effects in UBOC1 cell cultures derived from sensory epithelial cells of the inner ear and in CBA/J mice.  Cisplatin treatment increased the levels of nitrotyrosine and active caspase 3 in UBOC1 cells, which was detected by immunocytochem. and flow cytometry anal., resp.  The cisplatin-induced nitrative stress and apoptosis were attenuated by co-treatment with SRI110, a peroxynitrite decompn. catalyst (PNDC), which also attenuated the cisplatin-induced downregulation of LMO4 in a dose-dependent manner.  Furthermore, transient overexpression of LMO4 in UBOC1 cells prevented cisplatin-induced cytotoxicity while repression of LMO4 exacerbated cisplatin-induced cell death, indicating a direct link between LMO4 protein levels and cisplatin ototoxicity.  Finally, auditory brainstem responses (ABR) recorded from CBA/J mice indicated that co-treatment with SRI110 mitigated cisplatin-induced hearing loss.  Together, these results suggest that cisplatin-induced nitrative stress leads to a decrease in the levels of LMO4, downregulation of LMO4 is a crit. determinant in cisplatin-induced ototoxicity, and targeting peroxynitrite could be a promising strategy for mitigating cisplatin-induced hearing loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdZhRjHSF0ILVg90H21EOLACvtfcHk0liRxMVss6bTqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmtbzK&md5=89f0d6de9aee4b4912a96e45fcee5ae2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2016.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2016.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DJamesdaniel%26aufirst%3DS.%26aulast%3DRathinam%26aufirst%3DR.%26aulast%3DNeumann%26aufirst%3DW.%2BL.%26atitle%3DTargeting%2520nitrative%2520stress%2520for%2520attenuating%2520cisplatin-induced%2520downregulation%2520of%2520cochlear%2520LIM%2520domain%2520only%25204%2520and%2520ototoxicity%26jtitle%3DRedox%2520Biol.%26date%3D2016%26volume%3D10%26spage%3D257%26epage%3D265%26doi%3D10.1016%2Fj.redox.2016.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2009.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.bcp.2009.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20005210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVOhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=1134-1140&author=W.+Wangauthor=Y.+P.+Sunauthor=X.+Z.+Huangauthor=M.+Heauthor=Y.+Y.+Chenauthor=G.+Y.+Shiauthor=H.+Liauthor=J.+Yiauthor=J.+Wang&title=Emodin+enhances+sensitivity+of+gallbladder+cancer+cells+to+platinum+drugs+via+glutathion+depletion+and+MRP1+downregulation&doi=10.1016%2Fj.bcp.2009.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation</span></div><div class="casAuthors">Wang, Wei; Sun, Yue-ping; Huang, Xin-zhi; He, Min; Chen, Yu-ying; Shi, Gui-ying; Li, Hui; Yi, Jing; Wang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1134-1140</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glutathione conjugation and transportation of glutathione conjugates of anticancer drugs out of cells are important for detoxification of many anticancer drugs.  Inhibition of this detoxification system has recently been proposed as a strategy to treat drug-resistant solid tumors.  Gallbladder carcinoma is resistant to many anticancer drugs, therefore, it is needed to develop a novel strategy for cancer therapy.  In the present study, we tested the effect of emodin (1,3,8-trihydroxy-6-methylanthraquinone), a reactive oxygen species (ROS) generator reported by our group previously, in combination with cisplatin (CDDP), carboplatin (CBP) or oxaliplatin in treating the gallbladder carcinoma cell line SGC996.  Our results showed that co-treatment with emodin could remarkably enhance chemosensitivity of SGC996 cells in comparison with cisplatin, carboplatin or oxaliplatin treatment alone.  We found that the mechanisms may be attributed to redn. of glutathione level, and downregulation of multidrug resistance-related protein 1 (MRP1) expression in SGC996 cells.  The expts. on tumor-bearing mice showed that emodin/cisplatin co-treatment inhibited the tumor growth in vivo via increasing tumor cell apoptosis and downregulating MRP1 expression.  In conclusion, emodin can work as an adjunct to enhance the anticancer effect of platinum drugs in gallbladder cancer cells via ROS-related mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqbt3-BVFTErVg90H21EOLACvtfcHk0lhGUvKWoFW-ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVOhsbg%253D&md5=18b8229df0bc791a2daebdaa64bfbc79</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2009.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2009.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DY.%2BP.%26aulast%3DHuang%26aufirst%3DX.%2BZ.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DShi%26aufirst%3DG.%2BY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DEmodin%2520enhances%2520sensitivity%2520of%2520gallbladder%2520cancer%2520cells%2520to%2520platinum%2520drugs%2520via%2520glutathion%2520depletion%2520and%2520MRP1%2520downregulation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D79%26spage%3D1134%26epage%3D1140%26doi%3D10.1016%2Fj.bcp.2009.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span> <span> </span><span class="NLM_article-title">Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-2640-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1186%2Fs12885-016-2640-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27485374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaksL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=578-587&author=X.+Liauthor=H.+Wangauthor=J.+Wangauthor=Y.+Chenauthor=X.+Yinauthor=G.+Shiauthor=H.+Liauthor=Z.+Huauthor=X.+Liang&title=Emodin+enhances+cisplatin-induced+cytotoxicity+in+human+bladder+cancer+cells+through+ROS+elevation+and+MRP1+downregulation&doi=10.1186%2Fs12885-016-2640-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation</span></div><div class="casAuthors">Li, Xinxing; Wang, Haolu; Wang, Juan; Chen, Yuying; Yin, Xiaobin; Shi, Guiying; Li, Hui; Hu, Zhiqian; Liang, Xiaowen</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">578/1-578/10</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Chemoresistance is one of the most leading causes for tumor progression and recurrence of bladder cancer.  Reactive oxygen species (ROS) plays a key role in the chemosensitivity of cancer cells.  In the present study, emodin (1,3,8-trihydroxy-6-methylanthraquinone) was applied as a ROS generator in combination with cisplatin in T24 and J82 human bladder cancer cells.  Methods: Cell viability and apoptosis rate of different treatment groups were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry (FCM).  The expression of transporters was measured at both the transcription and translation levels using PCR and western blotting.  In vitro findings were confirmed by in vivo expts. using tumor-bearing mice.  The expression of multidrug resistance-assocd. protein 1 (MRP1) in tumor tissue was measured using immunohistochem. and side effects of the emodin/cisplatin co-treatment were investigated by histol. examn.  Results: Emodin increased the cellular ROS level and effectively enhanced the cisplatin-induced cytotoxicity of T24 and J82 human bladder cancer cells through decreasing glutathione-cisplatin (GSH-cisplatin) conjugates.  It blocked the chemoresistance of T24 and J82 cells to cisplatin through suppressing the expression of MRP1.  This effect was specific in T24 and J82 cells but not in HCV-29 normal bladder epithelial cells.  Consistent with in vitro expts., emodin/cisplatin co-treatment increased the cell apoptosis and repressed the MRP1 expression in xenograft tumors, and without obvious systemic toxicity.  Conclusions: This study revealed that emodin could increase the cisplatin-induced cytotoxicity against T24 and J82 cells via elevating the cellular ROS level and downregulating MRP1 expression.  We suggest that emodin could serve as an effective adjuvant agent for the cisplatin-based chemotherapy of bladder cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUED1VIo2xrrVg90H21EOLACvtfcHk0lhGUvKWoFW-ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaksL%252FP&md5=825426bfec12004e60b59ab083b5a492</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-2640-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-2640-3%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DX.%26atitle%3DEmodin%2520enhances%2520cisplatin-induced%2520cytotoxicity%2520in%2520human%2520bladder%2520cancer%2520cells%2520through%2520ROS%2520elevation%2520and%2520MRP1%2520downregulation%26jtitle%3DBMC%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D578%26epage%3D587%26doi%3D10.1186%2Fs12885-016-2640-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohen, R.</span></span> <span> </span><span class="NLM_article-title">The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.redox.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27951496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVOlur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=170-175&author=R.+Sirotaauthor=D.+Gibsonauthor=R.+Kohen&title=The+timing+of+caffeic+acid+treatment+with+cisplatin+determines+sensitization+or+resistance+of+ovarian+carcinoma+cell+lines&doi=10.1016%2Fj.redox.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines</span></div><div class="casAuthors">Sirota, R.; Gibson, D.; Kohen, R.</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">170-175</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cisplatin is a widely used chemotherapeutic drug showing high efficiency in the treatment of primary tumors such as ovarian, testicular and cervical cancers.  The major drawback of cisplatin is tumor resistance either acquired or intrinsic.  Many mechanisms are involved in the resistance, among them is the Nrf2 pathway which regulates glutathione related enzymes.  Caffeic acid, a non-toxic polyphenol which is abundant in many foods modulates glutathione S-transferase (GST) and glutathione reductase (GSR) activity, these enzymes were shown to be involved in resistance of cells towards cisplatin.  Caffeic acid induces the Nrf2 pathway and can also inhibit the activity of GST and GSR.  Our findings demonstrate that the co-treatment of cancer cells with cisplatin and caffeic acid can enhance cisplatin cytotoxicity and increases the amt. of platinum bound to nuclear DNA.  However, 6 h of pre incubation with caffeic acid prior to cisplatin treatment led to acquired resistance to cisplatin and reduced DNA binding.  In conclusion, the enzyme inhibitory action of caffeic acid is dominant when the two agents are co-administered leading to increased cytotoxicity, and the Nrf2 induction is dominant when the cells are treated with caffeic acid prior to cisplatin treatment leading to resistance.  The use of caffeic acid as adjuvant for cisplatin should be carefully examd. due to different pharmacokinetic profiles of caffeic acid and cisplatin.  Thus, it is questionable if the two agents can reach the tumors at the right time frame in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN00ydjn1X0bVg90H21EOLACvtfcHk0li5ppeTXQ6_ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVOlur7J&md5=61f8c3e7e9452fd1976b943d82bc2980</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DSirota%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DKohen%26aufirst%3DR.%26atitle%3DThe%2520timing%2520of%2520caffeic%2520acid%2520treatment%2520with%2520cisplatin%2520determines%2520sensitization%2520or%2520resistance%2520of%2520ovarian%2520carcinoma%2520cell%2520lines%26jtitle%3DRedox%2520Biol.%26date%3D2017%26volume%3D11%26spage%3D170%26epage%3D175%26doi%3D10.1016%2Fj.redox.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C. Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, T. T. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsim, K. W. K.</span></span> <span> </span><span class="NLM_article-title">Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31926</span>– <span class="NLM_lpage">31939</span>, <span class="refDoi"> DOI: 10.1038/srep31926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fsrep31926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27558312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVantb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=31926-31939&author=J.-S.+Louauthor=L.+Yanauthor=C.+W.+C.+Biauthor=G.+K.+L.+Chanauthor=Q.-Y.+Wuauthor=Y.-L.+Liuauthor=Y.+Huangauthor=P.+Yaoauthor=C.+Y.+Q.+Duauthor=T.+T.+X.+Dongauthor=K.+W.+K.+Tsim&title=Yu+Ping+Feng+San+reverses+cisplatin-induced+multi-drug+resistance+in+lung+cancer+cells+via+regulating+drug+transporters+and+p62%2FTRAF6+signalling&doi=10.1038%2Fsrep31926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling</span></div><div class="casAuthors">Lou, Jian-Shu; Yan, Lu; Bi, Cathy W. C.; Chan, Gallant K. L.; Wu, Qi-Yun; Liu, Yun-Le; Huang, Yun; Yao, Ping; Du, Crystal Y. Q.; Dong, Tina T. X.; Tsim, Karl W. K.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31926</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Yu Ping Feng San (YPFS), an ancient Chinese herbal decoction composed of Astragali Radix, Atractylodis Macrocephalae Rhizoma and Saposhnikoviae Radix, has been used in the clinic for treating immune deficiency.  In cancer therapy, YPFS is being combined with chemotherapy drugs to achieve improved efficacy; however, scientific evidence to illustrate this combination effect is lacking.  The present study aims to demonstrate the anti-drug resistance of YPFS in cisplatin (DDP)-resistant non-small cell lung cancer cells (A549/DDP).  The application of YPFS exhibited a synergistic enhancement of DDP-induced cytotoxicity as well as of the apoptotic signalling mols.  DDP-induced expression of the multi-drug-resistance efflux transporters was markedly reduced in the presence of YPFS, resulting in a higher intracellular concn. of DDP.  In addn., the application of YPFS increased DDP-induced ROS accumulation and MMP depletion, decreased p62/TRAF6 signalling in DDP-treated A549/DDP cells.  The co-treatment of DDP and YPFS in tumor-bearing mice reduced the tumor size robustly (by more than 80%), which was much better than the effect of DDP alone.  These results indicate that YPFS can notably improve the DDP-suppressed cancer effect, which may be a consequence of the elevation of intracellular DDP via the drug transporters as well as the down regulation of p62/TRAF6 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdiIV2RvDQd7Vg90H21EOLACvtfcHk0li5ppeTXQ6_ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVantb%252FL&md5=6333efa4e1da93dccb911514a597f2bc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsrep31926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep31926%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DJ.-S.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DC.%2BW.%2BC.%26aulast%3DChan%26aufirst%3DG.%2BK.%2BL.%26aulast%3DWu%26aufirst%3DQ.-Y.%26aulast%3DLiu%26aufirst%3DY.-L.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DDu%26aufirst%3DC.%2BY.%2BQ.%26aulast%3DDong%26aufirst%3DT.%2BT.%2BX.%26aulast%3DTsim%26aufirst%3DK.%2BW.%2BK.%26atitle%3DYu%2520Ping%2520Feng%2520San%2520reverses%2520cisplatin-induced%2520multi-drug%2520resistance%2520in%2520lung%2520cancer%2520cells%2520via%2520regulating%2520drug%2520transporters%2520and%2520p62%252FTRAF6%2520signalling%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D31926%26epage%3D31939%26doi%3D10.1038%2Fsrep31926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: Glutathione reduction and MRP1 downregulation</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.3892/or.2012.2156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2For.2012.2156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23229154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1CntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=676-684&author=H.+Wangauthor=X.+Liauthor=T.+Chenauthor=W.+Wangauthor=Q.+Liuauthor=H.+Liauthor=J.+Yiauthor=J.+Wang&title=Mechanisms+of+verapamil-enhanced+chemosensitivity+of+gallbladder+cancer+cells+to+platinum+drugs%3A+Glutathione+reduction+and+MRP1+downregulation&doi=10.3892%2For.2012.2156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation</span></div><div class="casAuthors">Wang, Haolu; Li, Xinxing; Chen, Tao; Wang, Wei; Liu, Qiang; Li, Hui; Yi, Jing; Wang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">676-684</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Gallbladder cancer (GBC) is highly malignant with a low response rate after chemotherapy and platinum drugs are currently prominent in the treatment of biliary tract cancers.  Therefore, the development of novel strategies to enhance the sensitivity of GBC to platinum drugs is required.  In the present study, we examd. the effects of verapamil, a classic chemosensitizer whose reported mechanisms of action include inhibiting the transport function of P-glycoprotein (MDR1) or stimulating glutathione (GSH) transport by multidrug resistance-related protein 1 (MRP1), in combination with cisplatin (CDDP), carboplatin (CBP) or oxaliplatin on the GBC cell lines, SGC996 and GBC-SD.  Our results demonstrated that the co-treatment with verapamil markedly enhanced the chemosensitivity of GBC cells in comparison with platinum drug treatment alone.  The mechanisms involved included GSH redn. and MRP1 downregulation.  Verapamil/CDDP co-treatment inhibited tumor xenograft growth via the down-regulation of MRP1 expression.  MRP1 was highly expressed in human GBC tissue compared to non-tumorous gallbladder tissue.  Our data demonstrate that verapamil may be used as a safe chemosensitizer for platinum drugs in the treatment of GBC.  It functions by ROS and ATP-binding cassette transporter-related mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJqXwgBEAAJrVg90H21EOLACvtfcHk0lj0WmgsM3YhIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1CntLg%253D&md5=7ee5566d12fef69e220ce194242a62ca</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3892%2For.2012.2156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2012.2156%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520verapamil-enhanced%2520chemosensitivity%2520of%2520gallbladder%2520cancer%2520cells%2520to%2520platinum%2520drugs%253A%2520Glutathione%2520reduction%2520and%2520MRP1%2520downregulation%26jtitle%3DOncol.%2520Rep.%26date%3D2013%26volume%3D29%26spage%3D676%26epage%3D684%26doi%3D10.3892%2For.2012.2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.bcp.2015.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25801007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=28-37&author=S.-J.+Chenauthor=C.-C.+Kuoauthor=H.-Y.+Panauthor=T.-C.+Tsouauthor=S.-C.+Yehauthor=J.-Y.+Chang&title=Mechanistic+basis+of+a+combination+D-penicillamine+and+platinum+drugs+synergistically+inhibits+tumor+growth+in+oxaliplatin-resistant+human+cervical+cancer+cells+in+vitro+and+in+vivo&doi=10.1016%2Fj.bcp.2015.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo</span></div><div class="casAuthors">Chen, Szu-Jung; Kuo, Ching-Chuan; Pan, Hsin-Yi; Tsou, Tsui-Chun; Yeh, Szu-Ching; Chang, Jang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-37</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The platinum-based regimen is the front-line treatment of chemotherapy.  However, development of platinum resistance often causes therapeutic failure in this disease.  We previously have generated an oxaliplatin-resistant subline, named S3, from human cervical carcinoma SiHa cells, and its resistant phenotype was well-characterized.  In the present study, we aimed to identify the novel therapeutic strategy by combining copper chelator D-penicillamine with oxaliplatin, and to elucidate the underlying mechanisms for overcoming oxaliplatin resistance.  As the result, D-penicillamine exerted synergistic killing effects only in S3 cells when combined with oxaliplatin and cisplatin by using Chou-Talalay method.  Further study showed that the amts. of platinum DNA adduct formed were pos. correlated to the percentage of cell death in S3 cells when co-treated D-penicillamine with oxaliplatin and cisplatin.  D-Penicillamine promoted copper influx transporter hCtr1 expression through upregulation of Sp1.  Sp1 overexpression induced p53 translocation from nucleus to cytosol and caused p53 degrdn. through ubiquitination, which subsequently suppressed the expression of the copper efflux transporter ATP7A.  Importantly, co-treatment of cisplatin with D-penicillamine enhanced oxaliplatin-elicited antitumor effect in the oxalipatin-resistant S3 xenograft tumors, but not found in SiHa xenograft model.  Notably, Mice received D-penicillamine alone or in combination of D-penicillamine ad oxalipatin, increased hCtrl protein level in S3 xenograft tumor, however, the protein level of ATP7A was decreased.  Taken together, this study provides insight into that the co-manipulation of hCtrl and ATP7A by D-penicillamine could increase the therapeutic efficacy of platinum drugs in oxaliplatin resistant tumors, esp. in resistant phenotype with downexpression of hCtrl and overexpression of ATP7A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr964tEXUNUbVg90H21EOLACvtfcHk0lhoAbWHyJVyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSksr4%253D&md5=718a1ce47b28cd79f73451b1b1718a6c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DKuo%26aufirst%3DC.-C.%26aulast%3DPan%26aufirst%3DH.-Y.%26aulast%3DTsou%26aufirst%3DT.-C.%26aulast%3DYeh%26aufirst%3DS.-C.%26aulast%3DChang%26aufirst%3DJ.-Y.%26atitle%3DMechanistic%2520basis%2520of%2520a%2520combination%2520D-penicillamine%2520and%2520platinum%2520drugs%2520synergistically%2520inhibits%2520tumor%2520growth%2520in%2520oxaliplatin-resistant%2520human%2520cervical%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D95%26spage%3D28%26epage%3D37%26doi%3D10.1016%2Fj.bcp.2015.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2015.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jconrel.2015.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26210439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlektb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2015&pages=82-90&author=J.+H.+Leeauthor=J.+W.+Chaeauthor=J.+K.+Kimauthor=H.+J.+Kimauthor=J.+Y.+Chungauthor=Y.+H.+Kim&title=Inhibition+of+cisplatin-resistance+by+RNA+interference+targeting+metallothionein+using+reducible+oligo-peptoplex&doi=10.1016%2Fj.jconrel.2015.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex</span></div><div class="casAuthors">Lee, Jong-Hwan; Chae, Ji-Won; Kim, Jang Kyoung; Kim, Hyung Jin; Chung, Jee Young; Kim, Yong-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-90</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Effective intracellular level of a platinum anti-cancer drug, cisplatin, following repeated injections can be decreased either by the active efflux via ATP pump or by interactions with glutathione and metallothionein.  Cisplatin in cytoplasm preferably binds to cysteine-rich proteins such as glutathione and metallothionein (MT).  Detoxification of cisplatin by intracellular thiol-contg. proteins has been considered to be major hurdles to overcome.  The short hairpin RNA targeting MT (shMT) was tested to down-regulate MT and recover cisplatin resistance.  A reducible polymer, poly(oligo-D-arginine) (rPOA), formed stable complex with shMT and demonstrated superior transfection efficiency.  Efficient transfection of shMT/rPOA oligo-peptoplexes was found to significantly inhibit MT over-expression, resulting in 45% decrease of cell viability compared to the cisplatin alone group.  This decrease was mediated by the synergistic effect of shMT/rPOA oligo-peptoplex and cisplatin.  Co-administration of shMT/rPOA oligo-peptoplex and cisplatin in in vivo tumor model showed noticeable tumor-suppressing effect by inducing reversal of cisplatin resistance following effective intracellular delivery of shMT by rPOA.  Combination therapy through co-administration of shMT/rPOA oligo-peptoplex and cisplatin was found to effectively reverse cisplatin resistance by RNA interference and consequently improve anti-cancer activity of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVOJc-BHe8kLVg90H21EOLACvtfcHk0lhoAbWHyJVyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlektb%252FP&md5=696dbb34f1413f66c8fd4033b7f2a953</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DChae%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DChung%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26atitle%3DInhibition%2520of%2520cisplatin-resistance%2520by%2520RNA%2520interference%2520targeting%2520metallothionein%2520using%2520reducible%2520oligo-peptoplex%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D215%26spage%3D82%26epage%3D90%26doi%3D10.1016%2Fj.jconrel.2015.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. Y.</span></span> <span> </span><span class="NLM_article-title">Transplatin enhances effect of cisplatin on both single DNA molecules and live tumor cells</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>536</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2013.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.abb.2013.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23664917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=536&publication_year=2013&pages=12-24&author=Y.+R.+Liuauthor=C.+Jiauthor=H.+Y.+Zhangauthor=S.+X.+Douauthor=P.+Xieauthor=W.+C.+Wangauthor=P.+Y.+Wang&title=Transplatin+enhances+effect+of+cisplatin+on+both+single+DNA+molecules+and+live+tumor+cells&doi=10.1016%2Fj.abb.2013.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Transplatin enhances effect of cisplatin on both single DNA molecules and live tumor cells</span></div><div class="casAuthors">Liu, Yu-Ru; Ji, Chao; Zhang, Hong-Yan; Dou, Shuo-Xing; Xie, Ping; Wang, Wei-Chi; Wang, Peng-Ye</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">536</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-24</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cisplatin is the main platinum antitumor drug applied in clin. settings.  However, its trans isomer, transplatin, is known to have an ineffective antitumor activity.  Despite intensive studies in this field, the structural and biophys. properties of DNA mols. reacting with these two platinum complexes have not been fully elucidated.  In the present study, we obsd. that transplatin made efficient crosslinking of DNA in the vicinity of cisplatin adducts.  High-resoln. at. force microscopy studies revealed that the transplatin-induced cross-linkings of nucleotides flanking cisplatin adducts were characterized by kinked-loop structures with rod-like shapes of nanometer scales (∼10-60 nm).  The results were further confirmed by denaturing gel electrophoresis and single-mol. expt. using magnetic tweezers.  In vivo studies revealed that transplatin and cisplatin co-treatment could induce a considerable amt. of kinked loops with smaller sizes (∼15 nm) in cellular DNA.  Furthermore, compared with cisplatin treatment alone, the co-treatment resulted in enhanced cytotoxicity, increased amt. of interstrand cross-links, and cell lesions more reluctant to cellular repair system.  The results of the present study provide a new clue for understanding the stepwise reactions of DNA with platinum drugs and might serve as a basis for the development of a new antitumor strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwlbQ4aA3-rVg90H21EOLACvtfcHk0ljtxXotylGJbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLnL&md5=54aa6f30dc2ee10d6da096724a257fa2</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2013.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2013.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BR.%26aulast%3DJi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26aulast%3DDou%26aufirst%3DS.%2BX.%26aulast%3DXie%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DP.%2BY.%26atitle%3DTransplatin%2520enhances%2520effect%2520of%2520cisplatin%2520on%2520both%2520single%2520DNA%2520molecules%2520and%2520live%2520tumor%2520cells%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2013%26volume%3D536%26spage%3D12%26epage%3D24%26doi%3D10.1016%2Fj.abb.2013.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buquet-Fagot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djelloul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvitkovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louvet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gespach, C.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1097/00001813-199710000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1097%2F00001813-199710000-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=9402315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK2sXnslehsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=876-885&author=E.+Raymondauthor=C.+Buquet-Fagotauthor=S.+Djelloulauthor=J.+Mesterauthor=E.+Cvitkovicauthor=P.+Allainauthor=C.+Louvetauthor=C.+Gespach&title=Antitumor+activity+of+oxaliplatin+in+combination+with+5-fluorouracil+and+the+thymidylate+synthase+inhibitor+AG337+in+human+colon%2C+breast+and+ovarian+cancers&doi=10.1097%2F00001813-199710000-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers</span></div><div class="casAuthors">Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">876-885</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Rapid Science Publishers</span>)
        </div><div class="casAbstract">Oxaliplatin, classical [5-fluorouracil (5-FU)] and non-classical (AG337) thymidylate synthase inhibitors have shown promising activity in the treatment of cancer.  This study investigates the cytotoxic effects of oxaliplatin in combination with 5-FU and AG337 in cultured human colon (HT29, CaCo2), breast(MCF-7, MDA-MB-231) and ovarian (2008) cancer cell lines, and their derived counterparts selected for their resistance to 5-FU (HT29-5-FU), doxorubicin (MCF-7mdr) or cisplatin (2008C13).  Therapeutic expts. were conducted in mice bearing colon-HT29 xenografts and in the GR hormone-independent mammary carcinoma model.  In vitro, oxaliplatin shows potent cytotoxic activity in colon (IC50 from 2.1 to 5.9 μM), ovarian (IC50 = 10 μM) and breast cancer cells (IC50 from 7.4 to 17.9 μM).  Oxaliplatin was a potent inhibitor of DNA synthesis and bound to cellular DNA.  Surprisingly, the overall amt. of oxaliplatin DNA binding was significantly inferior to that induced by isocytotoxic concns. of cisplatin in HT29.  In vitro, synergistic antiproliferative effects were obsd. when oxaliplatin was added to 5-FU and AG337.  Those synergistic effects of combinations were maintained in colon HT29-5-FU cancer cells.  In vivo, 5-FU increased significantly the antitumor activity of oxaliplatin in HT29 xenografts, and similarly 5-FU and AG337 increased the activity of oxaliplatin in the GR tumor model.  These data may encourage further clin. investigation of oxaliplatin in combination with classical and non-classical thymidylate synthase inhibitors in the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPtoVT4D0AhrVg90H21EOLACvtfcHk0ljtxXotylGJbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnslehsb8%253D&md5=db6271193ed47d56b8dbb258c230b129</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1097%2F00001813-199710000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-199710000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DRaymond%26aufirst%3DE.%26aulast%3DBuquet-Fagot%26aufirst%3DC.%26aulast%3DDjelloul%26aufirst%3DS.%26aulast%3DMester%26aufirst%3DJ.%26aulast%3DCvitkovic%26aufirst%3DE.%26aulast%3DAllain%26aufirst%3DP.%26aulast%3DLouvet%26aufirst%3DC.%26aulast%3DGespach%26aufirst%3DC.%26atitle%3DAntitumor%2520activity%2520of%2520oxaliplatin%2520in%2520combination%2520with%25205-fluorouracil%2520and%2520the%2520thymidylate%2520synthase%2520inhibitor%2520AG337%2520in%2520human%2520colon%252C%2520breast%2520and%2520ovarian%2520cancers%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D1997%26volume%3D8%26spage%3D876%26epage%3D885%26doi%3D10.1097%2F00001813-199710000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Caffeine has a synergistic anticancer effect with cisplatin via inhibiting Fanconi anemia group D2 protein monoubiquitination in hepatocellular carcinoma cells</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1248/bpb.b17-00457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1248%2Fbpb.b17-00457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28855448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12lt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2017&pages=2005-2009&author=Y.+Odaauthor=M.+Hidakaauthor=A.+Suzuki&title=Caffeine+has+a+synergistic+anticancer+effect+with+cisplatin+via+inhibiting+Fanconi+anemia+group+D2+protein+monoubiquitination+in+hepatocellular+carcinoma+cells&doi=10.1248%2Fbpb.b17-00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine has a synergistic anticancer effect with cisplatin via inhibiting fanconi anemia group D2 protein monoubiquitination in hepatocellular carcinoma cells</span></div><div class="casAuthors">Oda, Yuichiro; Hidaka, Muneaki; Suzuki, Akito</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2005-2009</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Cisplatin is an anticancer agent and induces DNA interstrand cross-links (ICLs).  ICLs activate various signaling processes and induce DNA repair pathways, including the Fanconi anemia (FA) pathway.  FA complementation group D2 (FANCD2) is monoubiquitinated in response to DNA damage, leading to activation of the DNA double-strand-break repair protein, RAD51.  Caffeine increases the anticancer activity of cisplatin by inhibiting DNA repair; however, details of the mechanism remain unclear.  We investigated the mechanism responsible for the synergistic anticancer effect of cisplatin and caffeine in HepG2 human hepatocellular carcinoma cells, focusing on the FA pathway.  Caffeine (≥100μg/mL) significantly enhanced the antiproliferative activity induced by 3.8μg/mL cisplatin.  Caffeine (200μg/mL) promoted apoptosis and inhibited the increase in the proportion of viable cells in S phase that occurred in the presence of 3.8μg/mL cisplatin.  Both FANCD2 monoubiquitination and RAD51 expression were significantly inhibited by co-treatment with 200μg/mL caffeine and 3.8μg/mL cisplatin compared with cisplatin alone.  In conclusion, caffeine enhances the anticancer effect of cisplatin by inhibiting FANCD2 monoubiquitination.  In HepG2 cells, caffeine might inhibit the FA pathway and thereby regulate DNA damage responses such as DNA repair and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb4TQuJs00T7Vg90H21EOLACvtfcHk0likIcZDGAv0fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12lt73O&md5=345cc77193fe3eb0dbbdbf3d3e2110c4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b17-00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b17-00457%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DY.%26aulast%3DHidaka%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DCaffeine%2520has%2520a%2520synergistic%2520anticancer%2520effect%2520with%2520cisplatin%2520via%2520inhibiting%2520Fanconi%2520anemia%2520group%2520D2%2520protein%2520monoubiquitination%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2017%26volume%3D40%26spage%3D2005%26epage%3D2009%26doi%3D10.1248%2Fbpb.b17-00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama-Gonda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igawa, M.</span></span> <span> </span><span class="NLM_article-title">Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-α</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1111/j.1464-410X.2007.07256.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1111%2Fj.1464-410X.2007.07256.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=17922863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVagsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=485-491&author=N.+Moriyama-Gondaauthor=H.+Shiinaauthor=M.+Terashimaauthor=K.+Satohauthor=M.+Igawa&title=Rationale+and+clinical+implication+of+combined+chemotherapy+with+cisplatin+and+oestrogen+in+prostate+cancer%3A+primary+evidence+based+on+methylation+analysis+of+oestrogen+receptor-%CE%B1&doi=10.1111%2Fj.1464-410X.2007.07256.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptorα</span></div><div class="casAuthors">Moriyama-Gonda, Nobuko; Shiina, Hiroaki; Terashima, Masaharu; Satoh, Kazumi; Igawa, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">OBJECTIVE: To det. whether estrogen enhances platinum sensitivity, and if promoter CpG methylation of the estrogen receptor-α (ER-α) gene dets. the potential of cisplatin-induced apoptosis in prostate cancer, as the high-mobility group 1 (HMG1) preferentially binds to cisplatin-modified DNA and is up-regulated after estrogen treatment in breast cancer cell line MCF-7.  MATERIALS AND METHODS: The study comprised prostate cancer cell lines (LNCaP and PC-3), 156 pathol. confirmed 156 radical prostatectomy samples and eight hormone-refractory prostate cancer (HRPC) samples (from needle biopsy).  Expression of HMG1 in cell lines was analyzed by Western blotting or differential reverse-transcription-polymerase chain reaction (PCR).  The methylation status of ER-α was analyzed by methylation-specific PCR using bisulfite DNA as a template or bisulfite DNA sequencing.  RESULTS: In LNCaP cells, treatment with estrogen increased HMG1 expression and co-treatment with cisplatin and estrogen reduced cell viability by accelerating apoptosis, compared with cisplatin alone.  However, in PC-3, estrogen did not up-regulate HMG1 or accelerate the cisplatin-induced apoptosis.  Although ER-β was expressed in both LNCaP and PC-3, ER-α was expressed only in LNCaP.  Bisulphite DNA sequencing of the ER-α promoter showed partial methylation in LNCaP but complete methylation in PC-3.  ER-α AS transfection diminished the cisplatin-induced apoptosis in estrogen-treated LNCaP cells.  In clin. samples there was ER-α hypermethylation in 40% of prostate cancers this correlated with Gleason score (GS, 31% for GS < 7, 50% for GS = 7 and 56% for GS > 7).  In addn., five of eight HRPC samples showed ER-α hypermethylation.  CONCLUSION: These findings suggest that HMG1 induction as an enhancer of platinum sensitivity is mediated through interaction between estrogen and ER-α.  As CpG hypermethylation of the ER-α promoter is a frequent event in aggressive prostate cancer, neg. conversion of ER-α methylation is essential to achieve the most beneficial effect when combined chemotherapy of cisplatin with estrogen is used in patients with prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXF_jcr4o67Vg90H21EOLACvtfcHk0likIcZDGAv0fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVagsb0%253D&md5=b80ddaf3e5da4c3737e04b01bc3be9f2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2007.07256.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2007.07256.x%26sid%3Dliteratum%253Aachs%26aulast%3DMoriyama-Gonda%26aufirst%3DN.%26aulast%3DShiina%26aufirst%3DH.%26aulast%3DTerashima%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DK.%26aulast%3DIgawa%26aufirst%3DM.%26atitle%3DRationale%2520and%2520clinical%2520implication%2520of%2520combined%2520chemotherapy%2520with%2520cisplatin%2520and%2520oestrogen%2520in%2520prostate%2520cancer%253A%2520primary%2520evidence%2520based%2520on%2520methylation%2520analysis%2520of%2520oestrogen%2520receptor-%25CE%25B1%26jtitle%3DBJU%2520Int.%26date%3D2008%26volume%3D101%26spage%3D485%26epage%3D491%26doi%3D10.1111%2Fj.1464-410X.2007.07256.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drost, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Burg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derksen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstege, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Drunen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beverloo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3916</span>– <span class="NLM_lpage">3925</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-07-4953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18559613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlWrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3916-3925&author=B.+Eversauthor=R.+Drostauthor=E.+Schutauthor=M.+de+Bruinauthor=E.+van+der%0ABurgauthor=P.+W.+Derksenauthor=H.+Holstegeauthor=X.+Liuauthor=E.+van+Drunenauthor=H.+B.+Beverlooauthor=G.+C.+Smithauthor=N.+M.+Martinauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=J.+Jonkers&title=Selective+inhibition+of+BRCA2-deficient+mammary+tumor+cell+growth+by+AZD2281+and+cisplatin&doi=10.1158%2F1078-0432.CCR-07-4953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin</span></div><div class="casAuthors">Evers, Bastiaan; Drost, Rinske; Schut, Eva; de Bruin, Michiel; van der Burg, Eline; Derksen, Patrick W. B.; Holstege, Henne; Liu, Xiaoling; van Drunen, Ellen; Beverloo, H. Berna; Smith, Graeme C. M.; Martin, Niall M. B.; Lau, Alan; O'Connor, Mark J.; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3916-3925</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To assess efficacy of the novel, selective poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor AZD2281 against newly established BRCA2-deficient mouse mammary tumor cell lines and to det. potential synergy between AZD2281 and cisplatin.  We established and thoroughly characterized a panel of clonal cell lines from independent BRCA2-deficient mouse mammary tumors and BRCA2-proficient control tumors.  Subsequently, we assessed sensitivity of these lines to conventional cytotoxic drugs and the novel PARP inhibitor AZD2281.  Finally, in vitro combination studies were done to investigate interaction between AZD2281 and cisplatin.  Genetic, transcriptional, and functional analyses confirmed the successful isolation of BRCA2-deficient and BRCA2-proficient mouse mammary tumor cell lines.  Treatment of these cell lines with 11 different anticancer drugs or with γ-irradn. showed that AZD2281, a novel and specific PARP inhibitor, caused the strongest differential growth inhibition of BRCA2-deficient vs. BRCA2-proficient mammary tumor cells.  Finally, drug combination studies showed synergistic cytotoxicity of AZD2281 and cisplatin against BRCA2-deficient cells but not against BRCA2-proficient control cells.  We have successfully established the first set of BRCA2-deficient mammary tumor cell lines, which form an important addn. to the existing preclin. models for BRCA-mutated breast cancer.  The exquisite sensitivity of these cells to the PARP inhibitor AZD2281, alone or in combination with cisplatin, provides strong support for AZD2281 as a novel targeted therapeutic against BRCA-deficient cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxO5G3T8MQobVg90H21EOLACvtfcHk0lhtIzT_CACciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlWrtb8%253D&md5=a49c338fe283cb28a53fee3be706ca9f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4953%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DDrost%26aufirst%3DR.%26aulast%3DSchut%26aufirst%3DE.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%26aulast%3DHolstege%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3Dvan%2BDrunen%26aufirst%3DE.%26aulast%3DBeverloo%26aufirst%3DH.%2BB.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BRCA2-deficient%2520mammary%2520tumor%2520cell%2520growth%2520by%2520AZD2281%2520and%2520cisplatin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3916%26epage%3D3925%26doi%3D10.1158%2F1078-0432.CCR-07-4953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaspers, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersbergen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Burg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nygren, A. O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, S. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derksen, P. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zevenhoven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span> <span> </span><span class="NLM_article-title">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">17079</span>– <span class="NLM_lpage">17084</span>, <span class="refDoi"> DOI: 10.1073/pnas.0806092105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1073%2Fpnas.0806092105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18971340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=17079-17084&author=S.+Rottenbergauthor=J.+E.+Jaspersauthor=A.+Kersbergenauthor=E.+van+der+Burgauthor=A.+O.+H.+Nygrenauthor=S.+A.+L.+Zanderauthor=P.+W.+B.+Derksenauthor=M.+de%0ABruinauthor=J.+Zevenhovenauthor=A.+Lauauthor=R.+Boulterauthor=A.+Cranstonauthor=M.+J.+O%27Connorauthor=N.+M.+B.+Martinauthor=P.+Borstauthor=J.+Jonkers&title=High+sensitivity+of+BRCA1-deficient+mammary+tumors+to+the+PARP+inhibitor+AZD2281+alone+and+in+combination+with+platinum+drugs&doi=10.1073%2Fpnas.0806092105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</span></div><div class="casAuthors">Rottenberg, Sven; Jaspers, Janneke E.; Kersbergen, Ariena; van der Burg, Eline; Nygren, Anders O. H.; Zander, Serge A. L.; Derksen, Patrick W. B.; de Bruin, Michiel; Zevenhoven, John; Lau, Alan; Boulter, Robert; Cranston, Aaron; O'Connor, Mark J.; Martin, Niall M. B.; Borst, Piet; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17079-17084</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-pos. breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-neg. ("triple-neg.") mammary carcinomas.  Triple-neg. tumors account for 15% of all breast cancers and frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction.  The DNA-repair defects characteristic of BRCA1-deficient cells confer sensitivity to poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which could be relevant to treatment of triple-neg. tumors.  To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-assocd. breast cancer.  Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival.  Long-term treatment with AZD2281 in this model did result in the development of drug resistance, caused by up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps.  This resistance to AZD2281 could be reversed by coadministration of the P-glycoprotein inhibitor tariquidar.  Combination of AZD2281 with cisplatin or carboplatin increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.  Our results demonstrate in vivo efficacy of AZD2281 against BRCA1-deficient breast cancer and illustrate how GEMMs of cancer can be used for preclin. evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr95zB9OKZ4ObVg90H21EOLACvtfcHk0lhtIzT_CACciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlKlsr7F&md5=788a7d8b5341b731d007753d5a234dec</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0806092105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0806092105%26sid%3Dliteratum%253Aachs%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DJaspers%26aufirst%3DJ.%2BE.%26aulast%3DKersbergen%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BBurg%26aufirst%3DE.%26aulast%3DNygren%26aufirst%3DA.%2BO.%2BH.%26aulast%3DZander%26aufirst%3DS.%2BA.%2BL.%26aulast%3DDerksen%26aufirst%3DP.%2BW.%2BB.%26aulast%3Dde%2BBruin%26aufirst%3DM.%26aulast%3DZevenhoven%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DO%2527Connor%26aufirst%3DM.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DHigh%2520sensitivity%2520of%2520BRCA1-deficient%2520mammary%2520tumors%2520to%2520the%2520PARP%2520inhibitor%2520AZD2281%2520alone%2520and%2520in%2520combination%2520with%2520platinum%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D17079%26epage%3D17084%26doi%3D10.1073%2Fpnas.0806092105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miknyoczki, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones-Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Szanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dionne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span> <span> </span><span class="NLM_article-title">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.4161%2Fcbt.2.4.460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12700281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=371-382&author=S.+J.+Miknyoczkiauthor=S.+Jones-Bolinauthor=S.+Pritchardauthor=K.+Hunterauthor=H.+Zhaoauthor=W.+Wanauthor=M.+Atorauthor=R.+Bihovskyauthor=R.+Hudkinsauthor=S.+Chatterjeeauthor=A.+Klein-Szantoauthor=C.+Dionneauthor=B.+Ruggeri&title=Chemopotentiation+of+temozolomide%2C+irinotecan%2C+and+cisplatin+activity+by+CEP-6800%2C+a+poly%28ADP-ribose%29+polymerase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor</span></div><div class="casAuthors">Miknyoczki, Sheila J.; Jones-Bolin, Susan; Pritchard, Sonya; Hunter, Kathryn; Zhao, Hugh; Wan, Weihua; Ator, Mark; Bihovsky, Ronald; Hudkins, Robert; Chatterjee, Sankar; Klein-Szanto, Andres; Dionne, Craig; Ruggeri, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-382</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear zinc finger DNA-binding protein that is implicated in the repair of DNA damage.  Inhibition of PARP-1 through genetic knockouts causes cells to become hypersensitive to various chemotherapeutic agents.  We tested the chemopotentiating ability of the PARP-1 inhibitor, CEP-6800, when used in combination with temozolomide (TMZ), irinotecan (camptothecin or SN38), and cisplatin against U251MG glioblastoma, HT29 colon carcinoma, and Calu-6 non-small cell lung carcinoma xenografts and cell lines, resp.  Exposure of tumor cells to TMZ, camptothecin (or SN38), and cisplatin before, or in the presence of, CEP-6800 significantly increased the onset and the magnitude of DNA damage, the duration for cells to effect repair, and the onset, duration, or fraction of cells arrested at the G2/M boundary.  In addn., in vivo biochem. efficacy studies with CEP-6800 showed that it was able to attenuate irinotecan- and TMZ-induced poly(ADP-ribose) accumulation in LoVo and HT29 xenografts, resp.  Treatment of CEP 6800 (30 mg/kg) with TMZ (17 and 34 mg/kg) resulted in 100% complete regression of U251MG tumors by day 28 vs. 60% complete regression caused by TMZ alone.  CEP-6800 (30 mg/kg) in combination with irinotecan (10 mg/kg) resulted in a 60% inhibition of HT29 tumor growth vs. irinotecan alone by day 33.  The combination therapy of cisplatin (5 mg/kg) with CEP-6800 (30 mg/kg) caused a 35% redn. in Calu-6 tumor growth vs. cisplatin alone by day 28.  These data suggest that CEP-6800 could be used as a chemopotentiating agent with a variety of clin. effective chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiwSIo74c1LVg90H21EOLACvtfcHk0lhZMi3TOc4DNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVyktbY%253D&md5=2c4b1eb96a1b16c44ad15760f5c1f73c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.4161%2Fcbt.2.4.460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.2.4.460%26sid%3Dliteratum%253Aachs%26aulast%3DMiknyoczki%26aufirst%3DS.%2BJ.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAtor%26aufirst%3DM.%26aulast%3DBihovsky%26aufirst%3DR.%26aulast%3DHudkins%26aufirst%3DR.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DRuggeri%26aufirst%3DB.%26atitle%3DChemopotentiation%2520of%2520temozolomide%252C%2520irinotecan%252C%2520and%2520cisplatin%2520activity%2520by%2520CEP-6800%252C%2520a%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D371%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watarai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitanaka, C.</span></span> <span> </span><span class="NLM_article-title">Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.3892/or.2015.4377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2For.2015.4377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26534836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=593-601&author=M.+Seinoauthor=M.+Okadaauthor=H.+Sakakiauthor=H.+Takedaauthor=H.+Wataraiauthor=S.+Suzukiauthor=S.+Seinoauthor=K.+Kuramotoauthor=T.+Ohtaauthor=S.+Nagaseauthor=H.+Kurachiauthor=C.+Kitanaka&title=Time-staggered+inhibition+of+JNK+effectively+sensitizes+chemoresistant+ovarian+cancer+cells+to+cisplatin+and+paclitaxel&doi=10.3892%2For.2015.4377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel</span></div><div class="casAuthors">Seino, Manabu; Okada, Masashi; Sakaki, Hirotsugu; Takeda, Hiroyuki; Watarai, Hikaru; Suzuki, Shuhei; Seino, Shizuka; Kuramoto, Kenta; Ohta, Tsuyoshi; Nagase, Satoru; Kurachi, Hirohisa; Kitanaka, Chifumi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">593-601</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Ovarian cancer is the most lethal gynecol. malignancy, for which platinum- and taxane-based chemotherapy plays a major role.  Chemoresistance of ovarian cancer poses a major obstacle to the successful management of this devastating disease; however, effective measures to overcome platinum and taxane resistance are yet to be established.  In the present study, while investigating the mechanism underlying the chemoresistance of ovarian cancer, we found that JNK may have a key role in the resistance of ovarian cancer cells to cisplatin and paclitaxel.  Importantly, whereas simultaneous application of a JNK inhibitor and either of the chemotherapeutic agents had contrasting effects for cisplatin (enhanced cytotoxicity) and paclitaxel (decreased cytotoxicity), JNK inhibitor treatment prior to chemotherapeutic agent application invariably enhanced the cytotoxicity of both drugs, suggesting that the basal JNK activity is commonly involved in the chemoresistance of ovarian cancer cells to cisplatin and paclitaxel in contrast to drug-induced JNK activity which may have different roles for these two drugs.  Furthermore, we confirmed using non-transformed human and rodent fibroblasts that sequential application of the JNK inhibitor and the chemotherapeutic agents did not augment their toxicity.  Thus, our findings highlight for the first time the possible differential roles of the basal and induced JNK activities in the chemoresistance of ovarian cancer cells and also suggest that time-staggered JNK inhibition may be a rational and promising strategy to overcome the resistance of ovarian cancer to platinum- and taxane-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokT8j1C1XBl7Vg90H21EOLACvtfcHk0ljolG5xjDF4RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCisg%253D%253D&md5=31cf8d8ffb47eff759f85a1ccfc5783e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3892%2For.2015.4377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.4377%26sid%3Dliteratum%253Aachs%26aulast%3DSeino%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DSakaki%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DH.%26aulast%3DWatarai%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DSeino%26aufirst%3DS.%26aulast%3DKuramoto%26aufirst%3DK.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DS.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DKitanaka%26aufirst%3DC.%26atitle%3DTime-staggered%2520inhibition%2520of%2520JNK%2520effectively%2520sensitizes%2520chemoresistant%2520ovarian%2520cancer%2520cells%2520to%2520cisplatin%2520and%2520paclitaxel%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D35%26spage%3D593%26epage%3D601%26doi%3D10.3892%2For.2015.4377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziebarth, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steg, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katre, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbin, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landen, C. N.</span></span> <span> </span><span class="NLM_article-title">Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1078-0432.CCR-12-1045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23147994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=170-182&author=A.+J.+Ziebarthauthor=S.+Nowsheenauthor=A.+D.+Stegauthor=M.+M.+Shahauthor=A.+A.+Katreauthor=Z.+C.+Dobbinauthor=H.+D.+Hanauthor=G.+Lopez-Beresteinauthor=A.+K.+Soodauthor=M.+Connerauthor=E.+S.+Yangauthor=C.+N.+Landen&title=Endoglin+%28CD105%29+contributes+to+platinum+resistance+and+is+a+target+for+tumor-specific+therapy+in+epithelial+ovarian+cancer&doi=10.1158%2F1078-0432.CCR-12-1045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer</span></div><div class="casAuthors">Ziebarth, Angela J.; Nowsheen, Somaira; Steg, Adam D.; Shah, Monjri M.; Katre, Ashwini A.; Dobbin, Zachary C.; Han, Hee-Dong; Lopez-Berestein, Gabriel; Sood, Anil K.; Conner, Michael; Yang, Eddy S.; Landen, Charles N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-182</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Endoglin (CD105) is a membranous protein overexpressed in tumor-assocd. endothelial cells, chemoresistant populations of ovarian cancer cells, and potentially stem cells.  Our objective was to evaluate the effects and mechanisms of targeting endoglin in ovarian cancer.  Exptl. Design: Global and membranous endoglin expression was evaluated in multiple ovarian cancer lines.  In vitro, the effects of siRNA-mediated endoglin knockdown with and without chemotherapy were evaluated by MTT assay, cell-cycle anal., alk. comet assay, γ-H2AX foci formation, and quant. PCR.  In an orthotopic mouse model, endoglin was targeted with chitosan-encapsulated siRNA with and without carboplatin.  Results: Endoglin expression was surprisingly predominantly cytoplasmic, with a small population of surface-pos. cells.  Endoglin inhibition decreased cell viability, increased apoptosis, induced double-stranded DNA damage, and increased cisplatin sensitivity.  Targeting endoglin downregulates expression of numerous DNA repair genes, including BARD1, H2AFX, NBN, NTHL1, and SIRT1.  BARD1 was also assocd. with platinum resistance, and was induced by platinum exposure.  In vivo, antiendoglin treatment decreased tumor wt. in both ES2 and HeyA8MDR models when compared with control (35%-41% redn., P < 0.05).  Endoglin inhibition with carboplatin was assocd. with even greater inhibitory effect when compared with control (58%-62% redn., P < 0.001).  Conclusions: Endoglin downregulation promotes apoptosis, induces significant DNA damage through modulation of numerous DNA repair genes, and improves platinum sensitivity both in vivo and in vitro.  Antiendoglin therapy would allow dual treatment of both tumor angiogenesis and a subset of aggressive tumor cells expressing endoglin and is being actively pursued as therapy in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cndPeM7xTbVg90H21EOLACvtfcHk0ljolG5xjDF4RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGhug%253D%253D&md5=e71977fceeaf8019eee4fbd637c3ef60</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1045%26sid%3Dliteratum%253Aachs%26aulast%3DZiebarth%26aufirst%3DA.%2BJ.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DSteg%26aufirst%3DA.%2BD.%26aulast%3DShah%26aufirst%3DM.%2BM.%26aulast%3DKatre%26aufirst%3DA.%2BA.%26aulast%3DDobbin%26aufirst%3DZ.%2BC.%26aulast%3DHan%26aufirst%3DH.%2BD.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DConner%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DE.%2BS.%26aulast%3DLanden%26aufirst%3DC.%2BN.%26atitle%3DEndoglin%2520%2528CD105%2529%2520contributes%2520to%2520platinum%2520resistance%2520and%2520is%2520a%2520target%2520for%2520tumor-specific%2520therapy%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D170%26epage%3D182%26doi%3D10.1158%2F1078-0432.CCR-12-1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herůdková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khirsariya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souček, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krkoška, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanářová, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozubík, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaculová, A. H.</span></span> <span> </span><span class="NLM_article-title">Chk1 inhibitor SCH900776 effectively potentiates the cytotoxic effects of platinum-based chemotherapeutic drugs in human colon cancer cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">841</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2017.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.neo.2017.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28888100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlegsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=830-841&author=J.+Her%C5%AFdkov%C3%A1author=K.+Paruchauthor=P.+Khirsariyaauthor=K.+Sou%C4%8Dekauthor=M.+Krko%C5%A1kaauthor=O.+V.+Blan%C3%A1%C5%99ov%C3%A1author=P.+Sovaauthor=A.+Kozub%C3%ADkauthor=A.+H.+Vaculov%C3%A1&title=Chk1+inhibitor+SCH900776+effectively+potentiates+the+cytotoxic+effects+of+platinum-based+chemotherapeutic+drugs+in+human+colon+cancer+cells&doi=10.1016%2Fj.neo.2017.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells</span></div><div class="casAuthors">Herudkova, Jarmila; Paruch, Kamil; Khirsariya, Prashant; Soucek, Karel; Krkoska, Martin; Vondalova Blanarova, Olga; Sova, Petr; Kozubik, Alois; Hyrslova Vaculova, Alena</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">830-841</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Although Chk1 kinase inhibitors are currently under clin. investigation as effective cancer cell sensitizers to the cytotoxic effects of numerous chemotherapeutics, there is still a considerable uncertainty regarding their role in modulation of anticancer potential of platinum-based drugs.  Here we newly demonstrate the ability of one of the most specific Chk1 inhibitors, SCH900776 (MK-8776), to enhance human colon cancer cell sensitivity to the cytotoxic effects of platinum(II) cisplatin and platinum(IV)- LA-12 complexes.  The combined treatment with SCH900776 and cisplatin or LA-12 results in apparent increase in G1/S phase-related apoptosis, stimulation of mitotic slippage, and senescence of HCT116 cells.  We further show that the cancer cell response to the drug combinations is significantly affected by the p21, p53, and PTEN status.  In contrast to their wt counterparts, the p53- or p21-deficient cells treated with SCH900776 and cisplatin or LA-12 enter mitosis and become polyploid, and the senescence phenotype is strongly suppressed.  While the cell death induced by SCH900776 and cisplatin or LA-12 is significantly delayed in the absence of p53, the anticancer action of the drug combinations is significantly accelerated in p21-deficient cells, which is assocd. with stimulation of apoptosis beyond G2/M cell cycle phase.  We also show that cooperative killing action of the drug combinations in HCT116 cells is facilitated in the absence of PTEN.  Our results indicate that SCH900776 may act as an important modulator of cytotoxic response triggered by platinum-based drugs in colon cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtV5iO0XKyUbVg90H21EOLACvtfcHk0lhegvCKEk4AYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlegsbrM&md5=0df00cd1990bfafd4036f041f3b1944f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2017.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DHer%25C5%25AFdkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DKhirsariya%26aufirst%3DP.%26aulast%3DSou%25C4%258Dek%26aufirst%3DK.%26aulast%3DKrko%25C5%25A1ka%26aufirst%3DM.%26aulast%3DBlan%25C3%25A1%25C5%2599ov%25C3%25A1%26aufirst%3DO.%2BV.%26aulast%3DSova%26aufirst%3DP.%26aulast%3DKozub%25C3%25ADk%26aufirst%3DA.%26aulast%3DVaculov%25C3%25A1%26aufirst%3DA.%2BH.%26atitle%3DChk1%2520inhibitor%2520SCH900776%2520effectively%2520potentiates%2520the%2520cytotoxic%2520effects%2520of%2520platinum-based%2520chemotherapeutic%2520drugs%2520in%2520human%2520colon%2520cancer%2520cells%26jtitle%3DNeoplasia%26date%3D2017%26volume%3D19%26spage%3D830%26epage%3D841%26doi%3D10.1016%2Fj.neo.2017.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Paris saponin I sensitizes gastric cancer cell lines to cisplatin via cell cycle arrest and apoptosis</span>. <i>Med. Sci. Monit.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3798</span>– <span class="NLM_lpage">3803</span>, <span class="refDoi"> DOI: 10.12659/MSM.898232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.12659%2FMSM.898232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27755523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFGltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=3798-3803&author=S.+Songauthor=L.+Duauthor=H.+Jiangauthor=X.+Zhuauthor=J.+Liauthor=J.+Xu&title=Paris+saponin+I+sensitizes+gastric+cancer+cell+lines+to+cisplatin+via+cell+cycle+arrest+and+apoptosis&doi=10.12659%2FMSM.898232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Paris saponin I sensitizes gastric cancer cell lines to cisplatin via cell cycle arrest and apoptosis</span></div><div class="casAuthors">Song, Shuichuan; Du, Leiwen; Jiang, Hao; Zhu, Xinhai; Li, Jinhui; Xu, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Medical Science Monitor</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3798-3803</span>CODEN:
                <span class="NLM_cas:coden">MSMOFR</span>;
        ISSN:<span class="NLM_cas:issn">1643-3750</span>.
    
            (<span class="NLM_cas:orgname">International Scientific Information, Inc.</span>)
        </div><div class="casAbstract">Background: Dose-related toxicity is the major restriction of cisplatin and cisplatin-combination chemotherapy, and is a challenge for advanced gastric cancer treatment.  We explored the possibility of using Paris saponin I as an agent to sensitize gastric cancer cells to cisplatin, and examd. the underlying mechanism.  Material and Methods: Growth inhibition was detected by MTT assay.  The cell cycle and apoptosis were detected using flow cytometry and Annexin V/PI staining.  The P21waf1/cip1, Bcl-2, Bax, and caspase-3 protein expression were detected using Western blot anal.  Results: The results revealed that PSI sensitized gastric cancer cells to cisplatin, with low toxicity.  The IC50 value of cisplatin in SGC-7901 cell lines was decreased when combined with PSI.  PSI promoted cisplatin-induced G2/M phase arrest and apoptosis in a cisplatin concn.-dependent manner.  Bcl-2 protein expression decreased, but Bax, caspase-3, and P21waf1/cip1 protein expression increased with PSI treatment.  Conclusions: The underlying mechanism of Paris saponin I may be related to targeting the apoptosis pathway and cell cycle blocking, which suggests that PSI is a potential therapeutic sensitizer for cisplatin in treating gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8WMu3qmrqwLVg90H21EOLACvtfcHk0lhegvCKEk4AYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFGltbk%253D&md5=9f369f63caf32568c0f951fc4c91d898</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.12659%2FMSM.898232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12659%252FMSM.898232%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DParis%2520saponin%2520I%2520sensitizes%2520gastric%2520cancer%2520cell%2520lines%2520to%2520cisplatin%2520via%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%26jtitle%3DMed.%2520Sci.%2520Monit.%26date%3D2016%26volume%3D22%26spage%3D3798%26epage%3D3803%26doi%3D10.12659%2FMSM.898232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span> <span> </span><span class="NLM_article-title">1,25-Dihydroxyvitamin D(3) and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells</span>. <i>Int. J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.3892/ijmm.2014.1664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fijmm.2014.1664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24573222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1177-1184&author=A.+Baoauthor=Y.+Liauthor=Y.+Tongauthor=H.+Zhengauthor=W.+Wuauthor=C.+Wei&title=1%2C25-Dihydroxyvitamin+D%283%29+and+cisplatin+synergistically+induce+apoptosis+and+cell+cycle+arrest+in+gastric+cancer+cells&doi=10.3892%2Fijmm.2014.1664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">1,25-Dihydroxyvitamin D3 and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells</span></div><div class="casAuthors">Bao, Anyu; Li, Yan; Tong, Yongqing; Zheng, Hongyun; Wu, Wei; Wei, Chuandong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1177-1184</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] plays an anticancer role in multiple types of cancer and potentiates the cytotoxic effects of several common chemotherapeutic agents.  The hypercalcemia caused by 1,25(OH)2D3 alone or resistance to cisplatin weaken the anticancer effects of vitamin D.  Thus, in this study, we aimed to investigate the synergistic effects of 1,25(OH)2D3 and cisplatin on the apoptosis and cell cycle progression of gastric cancer cells.  BGC-823 human gastric cancer cells were treated with 1,25(OH)2D3 or cisplatin alone, or a combination of both agents.  Cell apoptosis was assessed by TUNEL assay and flow cytometry.  The expression of the apoptosis-related proteins, poly(ADP-ribose) polymerase (PARP), Bax, Bcl-2, caspase-3 and caspase-8, was examd. using immunoblot anal.  ERK and AKT phosphorylation were examd. by immunoblot anal.  The cell cycle distribution was detd. by propidium iodide staining and flow cytometric anal.  P21 and p27 protein expression was also examd. using immunoblot anal.  Our results revealed that co-treatment with 1,25(OH)2D3 enhanced cisplatin-induced apoptosis and upregulated the expression of Bax, and promoted the cleavage of PARP and caspase-3.  The phosphorylation levels of ERK and AKT were reduced following combined treatment with 1,25(OH)2D3 and cisplatin.  The percentage of cells in the G0/G1 phase was greater in the cells treated with the combined treatment than in those treated with either 1,25(OH)2D3 or cisplatin alone.  P21 and p27 expression was upregulated following co-treatment with both agents.  The results of this study suggest that 1,25(OH)2D3 potentiates cisplatin-mediated cell growth inhibition and cell apoptosis, which involves the upregulation of Bax, a decrease in ERK and AKT phosphorylation levels, and increased p21 and p27 levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLO0mEOiOorVg90H21EOLACvtfcHk0lhWKEqkugaIAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egtb%252FI&md5=dddedad635f64afe66f5d6eeba5b7d13</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2014.1664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2014.1664%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DC.%26atitle%3D1%252C25-Dihydroxyvitamin%2520D%25283%2529%2520and%2520cisplatin%2520synergistically%2520induce%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520in%2520gastric%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2014%26volume%3D33%26spage%3D1177%26epage%3D1184%26doi%3D10.3892%2Fijmm.2014.1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogosawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowa, Y.</span></span> <span> </span><span class="NLM_article-title">The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.3892/ijo.2014.2703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fijo.2014.2703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25310746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVymtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=389-394&author=Q.+Sunauthor=S.+Yogosawaauthor=Y.+Iizumiauthor=T.+Sakaiauthor=Y.+Sowa&title=The+alkaloid+emetine+sensitizes+ovarian+carcinoma+cells+to+cisplatin+through+downregulation+of+bcl-xL&doi=10.3892%2Fijo.2014.2703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL</span></div><div class="casAuthors">Sun, Qi; Yogosawa, Shingo; Iizumi, Yosuke; Sakai, Toshiyuki; Sowa, Yoshihiro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">389-394</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cisplatin and its platinum derivs. are first-line chemotherapeutic agents in the treatment of ovarian cancer.  However, chemoresistance is the leading cause of therapeutic failure and is responsible for the poor overall survival rate.  Here, we describe that emetine, a natural alkaloid used as an anti-amoebiasis drug, sensitized ovarian carcinoma cells to apoptosis induced by cisplatin.  The single administration of cisplatin or emetine had a weak effect on cell death.  However, co-treatment of cisplatin and emetine remarkably induced apoptosis and reduced the colony formation of ovarian carcinoma cells.  Moreover, we showed that apoptosis induced by the combination of cisplatin and emetine was dependent on the activation of caspases -3, -7 and -8.  As to the mechanism, downregulation of bcl-xL by emetine was shown to be responsible for enhancing the sensitivity of ovarian cancer cells to cisplatin.  These findings suggest that the combination of cisplatin and emetine might be a promising treatment for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-IoLB0ZjncLVg90H21EOLACvtfcHk0lhWKEqkugaIAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVymtLc%253D&md5=d2dc1ba3988bc6ee00902fd3f49d8712</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2703%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DYogosawa%26aufirst%3DS.%26aulast%3DIizumi%26aufirst%3DY.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DSowa%26aufirst%3DY.%26atitle%3DThe%2520alkaloid%2520emetine%2520sensitizes%2520ovarian%2520carcinoma%2520cells%2520to%2520cisplatin%2520through%2520downregulation%2520of%2520bcl-xL%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2015%26volume%3D46%26spage%3D389%26epage%3D394%26doi%3D10.3892%2Fijo.2014.2703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiourin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memarzadeh, S.</span></span> <span> </span><span class="NLM_article-title">An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7956</span>– <span class="NLM_lpage">7971</span>, <span class="refDoi"> DOI: 10.1038/ncomms8956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fncomms8956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26234182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7956-7971&author=D.+M.+Janzenauthor=E.+Tiourinauthor=J.+A.+Salehiauthor=D.+Y.+Paikauthor=J.+Luauthor=M.+Pellegriniauthor=S.+Memarzadeh&title=An+apoptosis-enhancing+drug+overcomes+platinum+resistance+in+a+tumour-initiating+subpopulation+of+ovarian+cancer&doi=10.1038%2Fncomms8956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer</span></div><div class="casAuthors">Janzen, D. M.; Tiourin, E.; Salehi, J. A.; Paik, D. Y.; Lu, J.; Pellegrini, M.; Memarzadeh, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7956</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">High-grade serous ovarian cancers (HGSCs) are deadly malignancies that relapse despite carboplatin chemotherapy.  Here we show that 16 independent primary HGSC samples contain a CA125-neg. population enriched for carboplatin-resistant cancer initiating cells.  Transcriptome anal. reveals upregulation of homologous recombination DNA repair and anti-apoptotic signals in this population.  While treatment with carboplatin enriches for CA125-neg. cells, co-treatment with carboplatin and birinapant eliminates these cells in HGSCs expressing high levels of the inhibitor of apoptosis protein cIAP in the CA125-neg. population.  Birinapant sensitizes CA125-neg. cells to carboplatin by mediating degrdn. of cIAP causing cleavage of caspase 8 and restoration of apoptosis.  This co-therapy significantly improves disease-free survival in vivo compared with either therapy alone in tumor-bearing mice.  These findings suggest that therapeutic strategies that target CA125-neg. cells may be useful in the treatment of HGSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdyRnR77CebVg90H21EOLACvtfcHk0lhWKEqkugaIAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrtrbO&md5=bb38a21db055ff90b98599fedf96eba1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fncomms8956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8956%26sid%3Dliteratum%253Aachs%26aulast%3DJanzen%26aufirst%3DD.%2BM.%26aulast%3DTiourin%26aufirst%3DE.%26aulast%3DSalehi%26aufirst%3DJ.%2BA.%26aulast%3DPaik%26aufirst%3DD.%2BY.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DPellegrini%26aufirst%3DM.%26aulast%3DMemarzadeh%26aufirst%3DS.%26atitle%3DAn%2520apoptosis-enhancing%2520drug%2520overcomes%2520platinum%2520resistance%2520in%2520a%2520tumour-initiating%2520subpopulation%2520of%2520ovarian%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7956%26epage%3D7971%26doi%3D10.1038%2Fncomms8956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiartivich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiampornkul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2799</span>– <span class="NLM_lpage">2804</span>, <span class="refDoi"> DOI: 10.3892/ol.2017.5746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fol.2017.5746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28454469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVyrsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=2799-2804&author=S.+Kiartivichauthor=Y.+Weiauthor=J.+Liuauthor=R.+Soiampornkulauthor=M.+Liauthor=H.+Zhangauthor=J.+Dong&title=Regulation+of+cytotoxicity+and+apoptosis-associated+pathways+contributes+to+the+enhancement+of+efficacy+of+cisplatin+by+baicalein+adjuvant+in+human+A549+lung+cancer+cells&doi=10.3892%2Fol.2017.5746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells</span></div><div class="casAuthors">Kiartivich, Suparata; Wei, Ying; Liu, Jiaqi; Soiampornkul, Rungtip; Li, Mihui; Zhang, Hongying; Dong, Jingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2799-2804</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Scutellaria baicalensis (SB; Chinese name, huangqin) is widely used in Chinese medicine as a traditional adjuvant in the chemotherapy of lung and liver cancer.  Baicalein is one of the bioactive flavonoid components isolated from the root of SB.  The present study aimed to observe the effect of baicalein, in combination with platin-based systemic chemotherapy (cisplatin), on cytotoxicity and apoptosis of human A549 lung cancer cells.  The cell cultures were treated with baicalein, cisplatin, or a combination of the two.  Cell viability and cytotoxicity was assayed by XTT, and cell apoptosis was measured by flow cytometry.  The apoptosis-assocd. proteins were detected by western blot anal.  The cytokines in the culture supernatant were detected by ELISA.  The present study revealed that cisplatin and the baicalein-cisplatin combination inhibited viability and promoted cytotoxicity of A549 cells.  Cisplatin, baicalein and baicalein-cisplatin combination treatments were effective in the promotion of apoptosis of A549 cells.  Baicalein and baicalein-cisplatin combination treatments also inhibited B cell lymphoma-2 (Bcl-2) and increased Bcl-2-assocd. X protein (Bax) expression.  Addnl., cisplatin, baicalein and the baicalein-cisplatin combination promoted caspase-3 expression.  Furthermore, the baicalein-cisplatin combination suppressed the secretion of interleukin-6, and baicalein and the combination of baicalein cisplatin decreased the secretion of tumor necrosis factor-α of A549 cells.  The present study concluded that baicalein combined with cisplatin induced cytotoxicity and apoptosis of A549 cells, and such activity may be assocd. with the regulation of Bcl-2, Bax and caspase-3, indicating a promising alternative method for lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIQ8SKpmuZbLVg90H21EOLACvtfcHk0ljjJuID_wvR0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVyrsr3N&md5=927e6f85acac84fb89bac119ac535ed7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.5746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.5746%26sid%3Dliteratum%253Aachs%26aulast%3DKiartivich%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSoiampornkul%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520cytotoxicity%2520and%2520apoptosis-associated%2520pathways%2520contributes%2520to%2520the%2520enhancement%2520of%2520efficacy%2520of%2520cisplatin%2520by%2520baicalein%2520adjuvant%2520in%2520human%2520A549%2520lung%2520cancer%2520cells%26jtitle%3DOncol.%2520Lett.%26date%3D2017%26volume%3D13%26spage%3D2799%26epage%3D2804%26doi%3D10.3892%2Fol.2017.5746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gornowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryel-Porowska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span> <span> </span><span class="NLM_article-title">Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.3892/ol.2017.7623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fol.2017.7623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29434943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC1MrgslOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=2340-2348&author=A.+Gornowiczauthor=A.+Bielawskaauthor=W.+Szymanowskiauthor=H.+Gabryel-Porowskaauthor=R.+Czarnomysyauthor=K.+Bielawski&title=Mechanism+of+anticancer+action+of+novel+berenil+complex+of+platinum%28II%29+combined+with+anti-MUC1+in+MCF-7+breast+cancer+cells&doi=10.3892%2Fol.2017.7623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells</span></div><div class="casAuthors">Gornowicz Agnieszka; Bielawska Anna; Szymanowski Wojciech; Gabryel-Porowska Halina; Czarnomysy Robert; Bielawski Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2340-2348</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Mucin 1 (MUC1) is a high molecular weight transmembrane glycoprotein, that is overexpressed in >90% of breast cancers.  It serves a crucial role in anti-apoptosis and tumor progression.  MUC1 interacts with proteins in the extracellular matrix, at the cell membrane, in the cytoplasm and in the nucleus.  The aim of the present study was to investigate the mechanism of anticancer action induced by novel berenil complex of platinum(II) (Pt12) together with a monoclonal antibody against MUC1 in breast cancer MCF-7 cells.  The effect of combined treatment on the concentration of selected markers of apoptosis including proapoptotic B-cell lymphoma 2 associated X protein (Bax), caspase-8, cytochrome c and caspase-9, as well as selected proteins involved in intracellular signal transduction pathways including p53, phosphoinositide 3-kinase and phosphorylated protein kinase B (p-Akt) were analyzed.  The results of the present study demonstrated that combined treatment may be a promising strategy in anticancer treatment and represents an alternative to monotherapy.  All compounds used alone (Pt12, cisplatin and the anti-MUC1 antibody) increased the concentration of proapoptotic Bax, cytochrome c and caspase-9 in comparison with control, thus suggesting that they activated the mitochondrial apoptotic pathway.  Pt12 alone significantly increased the concentration of caspase-8, which is responsible for the initiation of the extrinsic apoptotic pathway.  However, the strongest effect was observed following Pt12 (20 μM) treatment combined with the anti-MUC1 antibody (10 μg/ml).  These two compounds together strongly induced apoptosis in MCF-7 breast cancer cells via the external and internal apoptotic pathways.  It was also demonstrated that combined treatment based on Pt12 and the anti-MUC1 antibody significantly reduced p-Akt concentration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhwKE-wGzFGEEgZCMqtRBifW6udTcc2ebK5aQJJTuoMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrgslOmtw%253D%253D&md5=9008395d8a858eb76104d00da26301a4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.7623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.7623%26sid%3Dliteratum%253Aachs%26aulast%3DGornowicz%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DSzymanowski%26aufirst%3DW.%26aulast%3DGabryel-Porowska%26aufirst%3DH.%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DBielawski%26aufirst%3DK.%26atitle%3DMechanism%2520of%2520anticancer%2520action%2520of%2520novel%2520berenil%2520complex%2520of%2520platinum%2528II%2529%2520combined%2520with%2520anti-MUC1%2520in%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D2340%26epage%3D2348%26doi%3D10.3892%2Fol.2017.7623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Özdemir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apaydin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Önder, N. İ.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Şen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayrim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öǧünç, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">İncesu, Z.</span></span> <span> </span><span class="NLM_article-title">Apoptotic effects of ε-viniferin in combination with cis-platin in C6 cells</span>. <i>Cytotechnology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1007/s10616-018-0197-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs10616-018-0197-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29476302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVyrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=1061-1073&author=F.+%C3%96zdemirauthor=E.+Apaydinauthor=N.+%C4%B0.+%C3%96nderauthor=M.+%C5%9Eenauthor=A.+Ayrimauthor=Y.+%C3%96%C7%A7%C3%BCn%C3%A7author=Z.+%C4%B0ncesu&title=Apoptotic+effects+of+%CE%B5-viniferin+in+combination+with+cis-platin+in+C6+cells&doi=10.1007%2Fs10616-018-0197-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptotic effects of ε-viniferin in combination with cis-platin in C6 cells</span></div><div class="casAuthors">Ozdemir, Filiz; Apaydin, Elif; Onder, Nur Ipek; Sen, Mesut; Ayrim, Aysun; Ogunc, Yuksel; Incesu, Zerrin</div><div class="citationInfo"><span class="NLM_cas:title">Cytotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">CYTOER</span>;
        ISSN:<span class="NLM_cas:issn">0920-9069</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is one of the most common and lethal forms of primary brain tumors in human adults.  Treatment options are limited, and in most cases ineffective.  Natural products are sources of novel compds. endowed with therapeutic properties in many human diseases like cancer. ε-viniferin is a resveratrol dimer and well known for having antiproliferative and apoptotic effects on cancer cells.  Cisplatin is a platinum contg. anti-cancer drug.  In this study, we aimed to investigate antiproliferative and apoptotic effects of using cis-platin and ε-viniferin alone or in combined treatment of C6 cells.  Cell proliferation was detected by WST-1.  Mitochondrial membrane potential changes in the cells (ΔVm) were evaluated using cationic dye JC1.  Apoptotic index which is a hallmark of late apoptosis was detected by using Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method and apoptotic alterations were obsd. by transmission electron microscope (TEM).  Activation of caspase-8, -9, -3 in C6 cells at various incubation periods was measured by flow cytometer.  Apoptotic index increased at highest level in only combined treatment cells (91.6%) after 48 h incubation.  These results were supported by TEM images.  Caspase-8 activation in C6 cells increased to a max. (12.5%) after 6 h by using combined cis-platin/ε-viniferin treatment (13.25/95μM).  Caspase-9 was activated at 44.5% after combined treatment for 24 h.  This rate is higher than using cis-platin (14.2%) or ε-viniferin (43.3%) alone.  The combined 13.25μM/cisplatin and 95μM ε-viniferin treatment caused max. caspase-3 activation in C6 cells (15.5%) at the end of the 72 h incubation.  In conclusion, it was obsd. that caspase-8, -9, -3 activation which was detd. in vitro, triggerred apoptotic mechanism in C6 cells by using low concns. of combined cis-platin and ε-viniferin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0d8gc3ft_PrVg90H21EOLACvtfcHk0lhHZibH7UyPzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVyrurs%253D&md5=e25b62b697ecfa3f11ff39d6086a381e</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs10616-018-0197-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10616-018-0197-5%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2596zdemir%26aufirst%3DF.%26aulast%3DApaydin%26aufirst%3DE.%26aulast%3D%25C3%2596nder%26aufirst%3DN.%2B%25C4%25B0.%26aulast%3D%25C5%259Een%26aufirst%3DM.%26aulast%3DAyrim%26aufirst%3DA.%26aulast%3D%25C3%2596%25C7%25A7%25C3%25BCn%25C3%25A7%26aufirst%3DY.%26aulast%3D%25C4%25B0ncesu%26aufirst%3DZ.%26atitle%3DApoptotic%2520effects%2520of%2520%25CE%25B5-viniferin%2520in%2520combination%2520with%2520cis-platin%2520in%2520C6%2520cells%26jtitle%3DCytotechnology%26date%3D2018%26volume%3D70%26spage%3D1061%26epage%3D1073%26doi%3D10.1007%2Fs10616-018-0197-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span> <span> </span><span class="NLM_article-title">Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin</span>. <i>Exp. Biol. Med. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">1416</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.1177/1535370215571881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1177%2F1535370215571881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFajtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2015&pages=1416-1425&author=J.+H.+Kangauthor=H.+S.+Kangauthor=I.+K.+Kimauthor=H.+Y.+Leeauthor=J.+H.+Haauthor=C.+D.+Yeoauthor=H.+H.+Kangauthor=H.+S.+Moonauthor=S.+H.+Lee&title=Curcumin+sensitizes+human+lung+cancer+cells+to+apoptosis+and+metastasis+synergistically+combined+with+carboplatin&doi=10.1177%2F1535370215571881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin</span></div><div class="casAuthors">Kang, Ji Ho; Kang, Hye Seon; Kim, In Kyoung; Lee, Hwa Young; Ha, Jick Hwan; Yeo, Chang Dong; Kang, Hyun Hui; Moon, Hwa Sik; Lee, Sang Haak</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1416-1425</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Although carboplatin is one of the std. chemotherapeutic agents for non-small cell lung cancer (NSCLC), it has limited therapeutic efficacy due to activation of a survival signaling pathway and the induction of multidrug resistance.  Curcumin, a natural compd. isolated from the plant Curcuma longa, is known to sensitize tumors to different chemotherapeutic agents.  The aim of this study is to evaluate whether curcumin can chemosensitize lung cancer cells to carboplatin and to analyze the signaling pathway underlying this synergism.  We investigated the synergistic effect of both agents on cell proliferation, apoptosis, invasion, migration, and expression of related signaling proteins using the human NSCLC cell line, A549.  A549 cell was treated with different concns. of curcumin and carboplatin alone and in combination.  Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone.  Matrix metalloproteinase (MMP)-2 and MMP-9 were more efficiently downregulated by co-treatment than by each treatment alone. mRNA and protein expression of caspase-3 and caspase-9 and proapoptotic genes was increased in cells treated with a combination of curcumin and carboplatin, whereas expression of the antiapoptotic Bcl-2 gene was suppressed.  Co-treatment of both agents substantially suppressed NF-κB activation and increased expression of p53.  Phosphorylation of Akt, a protein upstream of NF-κB, was reduced, resulting in inhibition of the degrdn. of inhibitor of κB(IκBα), whereas the activity of extracellular signal-regulated kinase (ERK1/2) was enhanced.  Our study demonstrated that the synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-κB via inhibition of the Akt/IKKα pathway and enhanced ERK1/2 activity.  Based on this mechanism, curcumin has potential as a chemosensitizer for carboplatin in the treatment of patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5L9IRhbSOmrVg90H21EOLACvtfcHk0lhHZibH7UyPzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFajtbbI&md5=d1ddb979937767d32ba067968732dc08</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1177%2F1535370215571881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370215571881%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DI.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DHa%26aufirst%3DJ.%2BH.%26aulast%3DYeo%26aufirst%3DC.%2BD.%26aulast%3DKang%26aufirst%3DH.%2BH.%26aulast%3DMoon%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BH.%26atitle%3DCurcumin%2520sensitizes%2520human%2520lung%2520cancer%2520cells%2520to%2520apoptosis%2520and%2520metastasis%2520synergistically%2520combined%2520with%2520carboplatin%26jtitle%3DExp.%2520Biol.%2520Med.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D240%26spage%3D1416%26epage%3D1425%26doi%3D10.1177%2F1535370215571881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">ABT-737 synergizes with cisplatin bypassing aberration of apoptotic pathway in non-small cell lung cancer</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.neo.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28319809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFGqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=354-363&author=E.+Y.+Kimauthor=J.+Y.+Jungauthor=A.+Kimauthor=Y.+S.+Changauthor=S.+K.+Kim&title=ABT-737+synergizes+with+cisplatin+bypassing+aberration+of+apoptotic+pathway+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.neo.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer</span></div><div class="casAuthors">Kim, Eun Young; Jung, Ji Ye; Kim, Arum; Chang, Yoon Soo; Kim, Se Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-363</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A subset of non-small cell lung cancer (NSCLC), which does not have a druggable driver mutation, is treated with platinum-based cytotoxic chemotherapy, but it develops resistance triggered by DNA damage responses.  Here, we investigated the effect of activation of STAT3 by cisplatin on anti-apoptotic proteins and the effectiveness of a co-treatment with cisplatin and a BH3 mimetic, ABT-737.  We analyzed the relationship between cisplatin and STAT3 pathway and effect of ABT-737, when combined with cisplatin in NSCLC cells and K-ras mutant mouse models.  The synergism of this combination was evaluated by the Chou-Talalay Combination Index method.  In vivo activity was evaluated by micro-CT.  In NSCLC cells, there was a time and dose-dependent phosphorylation of SRC-JAK2-STAT3 by cisplatin, followed by increased expression of anti-apoptotic mols.  When the expression of the BCL-2 protein family members was evaluated in clin. samples, BCL-xL was most frequently overexpressed.  Dominant neg. STAT3 suppressed their expression, suggesting that STAT3 mediates cisplatin mediated overexpression of the anti-apoptotic mols.  ABT-737 displaced BCL-xL from mitochondria and induced oligomerization of BAK.  ABT-737 itself showed cytotoxic effects and a combination of ABT-737 with cisplatin showed strong synergistic cytotoxicity.  In a murine lung cancer model, co-treatment with ABT-737 and cisplatin induced significant tumor regression.  These findings reveal a synergistic cytotoxic and anti-tumor activity of ABT-737 and cisplatin co-treatment in preclin. models, and suggest that clin. trials using this strategy may be beneficial in advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbv02CyJXoebVg90H21EOLACvtfcHk0lhtjqXuNcqwpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFGqtbo%253D&md5=556aeb5f043b37886132e6a0cfb6c4c1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BY.%26aulast%3DJung%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DABT-737%2520synergizes%2520with%2520cisplatin%2520bypassing%2520aberration%2520of%2520apoptotic%2520pathway%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNeoplasia%26date%3D2017%26volume%3D19%26spage%3D354%26epage%3D363%26doi%3D10.1016%2Fj.neo.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeon, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandanshive, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. M.</span></span> <span> </span><span class="NLM_article-title">Novel improved synthesis of HSP70 inhibitor, pifithrin-μ. in vitro synergy quantification of pifithrin-μ combined with Pt drugs in prostate and colorectal cancer cells</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.3390/molecules21070949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3390%2Fmolecules21070949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWktLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=949-958&author=A.+M.+McKeonauthor=A.+Eganauthor=J.+Chandanshiveauthor=H.+McMahonauthor=D.+M.+Griffith&title=Novel+improved+synthesis+of+HSP70+inhibitor%2C+pifithrin-%CE%BC.+in+vitro+synergy+quantification+of+pifithrin-%CE%BC+combined+with+Pt+drugs+in+prostate+and+colorectal+cancer+cells&doi=10.3390%2Fmolecules21070949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel improved synthesis of HSP70 inhibitor, pifithrin-μ in vitro synergy quantification of pifithrin-μ combined with pt drugs in prostate and colorectal cancer cells</span></div><div class="casAuthors">McKeon, Aoife M.; Egan, Alan; Chandanshive, Jay; McMahon, Helena; Griffith, Darren M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">949/1-949/10</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A novel improved approach for the synthesis of the important and well-known heat shock protein 70 inhibitor (HSP70), pifithrin-μ, was described with corresponding and previously unreported characterization.  The first example of a combination study comprising HSP70 inhibitor pifithrin-μ and cisplatin or oxaliplatin was reported.  Further, moderate synergistic and synergistic effects in co-treating PC-3 prostate cancer cells with pifithrin-μ and cisplatin and significant synergistic effects including strong synergism in cotreating HT29 colorectal cancer cells with oxaliplatin and pifithrin-μ was also detd. by using the Chou-Talalay method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-EWwYgXnVLrVg90H21EOLACvtfcHk0lhtjqXuNcqwpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWktLjK&md5=0251fc12a8ad117aa1839292d362a80a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21070949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21070949%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeon%26aufirst%3DA.%2BM.%26aulast%3DEgan%26aufirst%3DA.%26aulast%3DChandanshive%26aufirst%3DJ.%26aulast%3DMcMahon%26aufirst%3DH.%26aulast%3DGriffith%26aufirst%3DD.%2BM.%26atitle%3DNovel%2520improved%2520synthesis%2520of%2520HSP70%2520inhibitor%252C%2520pifithrin-%25CE%25BC.%2520in%2520vitro%2520synergy%2520quantification%2520of%2520pifithrin-%25CE%25BC%2520combined%2520with%2520Pt%2520drugs%2520in%2520prostate%2520and%2520colorectal%2520cancer%2520cells%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D949%26epage%3D958%26doi%3D10.3390%2Fmolecules21070949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyula, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newbold, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutting, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, K. J.</span></span> <span> </span><span class="NLM_article-title">HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1186/s12885-017-3084-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1186%2Fs12885-017-3084-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28143445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=86-98&author=M.+McLaughlinauthor=H.+E.+Barkerauthor=A.+A.+Khanauthor=M.+Pedersenauthor=M.+Dillonauthor=D.+C.+Mansfieldauthor=R.+Patelauthor=J.+N.+Kyulaauthor=S.+A.+Bhideauthor=K.+L.+Newboldauthor=C.+M.+Nuttingauthor=K.+J.+Harrington&title=HSP90+inhibition+sensitizes+head+and+neck+cancer+to+platin-based+chemoradiotherapy+by+modulation+of+the+DNA+damage+response+resulting+in+chromosomal+fragmentation&doi=10.1186%2Fs12885-017-3084-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation</span></div><div class="casAuthors">McLaughlin, Martin; Barker, Holly E.; Khan, Aadil A.; Pedersen, Malin; Dillon, Magnus; Mansfield, David C.; Patel, Radhika; Kyula, Joan N.; Bhide, Shreerang A.; Newbold, Kate L.; Nutting, Christopher M.; Harrington, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86/1-86/13</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Concurrent cisplatin radiotherapy (CCRT) is a current std.-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC).  However, CCRT is frequently ineffective in patients with advanced disease.  It has previously been shown that HSP90 inhibitors act as radiosensitizers, but these studies have not focused on CCRT in HNSCC.  Here, we evaluated the HSP90 inhibitor, AUY922, combined with CCRT.  The ability of AUY922 to sensitize to CCRT was assessed in p53 mutant head and neck cell lines by clonogenic assay.  Modulation of the CCRT induced DNA damage response (DDR) by AUY922 was characterized by confocal image anal. of RAD51, BRCA1, 53BP1, ATM and mutant p53 signaling.  The role of FANCA depletion by AUY922 was examd. using shRNA.  Cell cycle checkpoint abrogation and chromosomal fragmentation was assessed by western blot, FACS and confocal.  The role of ATM was also assessed by shRNA.  AUY922 in combination with CCRT was assessed in vivo.  The combination of AUY922 with cisplatin, radiation and CCRT was found to be synergistic in p53 mutant HNSCC.  AUY922 leads to significant alterations to the DDR induced by CCRT.  This comprises inhibition of homologous recombination through decreased RAD51 and pS1524 BRCA1 with a corresponding increase in 53BP1 foci, activation of ATM and signaling into mutant p53.  A shift to more error prone repair combined with a loss of checkpoint function leads to fragmentation of chromosomal material.  The degree of disruption to DDR signalling correlated to chromosomal fragmentation and loss of clonogenicity.  ATM shRNA indicated a possible rationale for the combination of AUY922 and CCRT in cells lacking ATM function.  This study supports future clin. studies combining AUY922 and CCRT in p53 mutant HNSCC.  Modulation of the DDR and chromosomal fragmentation are likely to be anal. points of interest in such trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomzeQvSHIL9rVg90H21EOLACvtfcHk0lgTdMnWE-c9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12mtb0%253D&md5=b1d0e21fb4055f22e6e9f9d7ca655d15</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3084-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3084-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DKhan%26aufirst%3DA.%2BA.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DM.%26aulast%3DMansfield%26aufirst%3DD.%2BC.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DKyula%26aufirst%3DJ.%2BN.%26aulast%3DBhide%26aufirst%3DS.%2BA.%26aulast%3DNewbold%26aufirst%3DK.%2BL.%26aulast%3DNutting%26aufirst%3DC.%2BM.%26aulast%3DHarrington%26aufirst%3DK.%2BJ.%26atitle%3DHSP90%2520inhibition%2520sensitizes%2520head%2520and%2520neck%2520cancer%2520to%2520platin-based%2520chemoradiotherapy%2520by%2520modulation%2520of%2520the%2520DNA%2520damage%2520response%2520resulting%2520in%2520chromosomal%2520fragmentation%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D86%26epage%3D98%26doi%3D10.1186%2Fs12885-017-3084-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1361</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1074/jbc.M509688200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1074%2Fjbc.M509688200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=16275646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFOgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=1361-1370&author=Y.+Jungauthor=S.+J.+Lippard&title=RNA+polymerase+II+blockage+by+cisplatin-damaged+DNA.+Stability+and+polyubiquitylation+of+stalled+polymerase&doi=10.1074%2Fjbc.M509688200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">RNA polymerase II blockage by cisplatin-damaged DNA: stability and polyubiquitylation of stalled polymerase</span></div><div class="casAuthors">Jung, Yongwon; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1361-1370</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The consequences of human RNA polymerase II (pol II) arrest at the site of DNA damaged by cisplatin were studied in whole cells and cell exts., with a particular focus on the stability of stalled pol II and its subsequent ubiquitylation.  Site-specifically platinated DNA templates immobilized on a solid support were used to perform in vitro transcription in HeLa nuclear exts.  RNA elongation was completely blocked by a cisplatin intrastrand cross-link.  The stalled polymerase was quite stable, remaining on the DNA template in nuclear exts.  The stability of pol II stalled at the site of cisplatin damage was also obsd. in live cells.  A cell fractionation expt. using cisplatin-treated HeLa cells revealed an increased level of chromatin-assocd. pol II proteins following DNA damage.  The stalled polymerase was transcriptionally active and capable of elongating the transcript following chem. removal of platinum from the template.  Transcription inhibition by α-amanitin in vitro enhanced pol II ubiquitylation at ubiquitin residues Lys-6, Lys-48, and Lys-63.  In live cells expressing epitope-tagged ubiquitin mutants, several ubiquitin lysines also participated in pol II ubiquitylation following DNA damage.  Cisplatin treatment triggered ubiquitylation-mediated pol II degrdn. in HeLa cells, which could be prevented by the proteasomal inhibitor MG132.  Fractionation of pol II from cells co-treated with MG132 and cisplatin indicated that the undegraded ubiquitylated polymerase was mostly unbound or only loosely assocd. with chromatin.  These data are consistent with a model in which only a fraction of pol II, ubiquitylated in response to cisplatin damage of DNA, dissocs. from the sites of platination.  This altered polymerase is rapidly destroyed by proteasomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAVZpbMjVWwbVg90H21EOLACvtfcHk0lgTdMnWE-c9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFOgsA%253D%253D&md5=ae80155af582f77e484b345efd2e5dc1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M509688200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M509688200%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DY.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DRNA%2520polymerase%2520II%2520blockage%2520by%2520cisplatin-damaged%2520DNA.%2520Stability%2520and%2520polyubiquitylation%2520of%2520stalled%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D1361%26epage%3D1370%26doi%3D10.1074%2Fjbc.M509688200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leithner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkoenig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quehenberger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrzenjak, A.</span></span> <span> </span><span class="NLM_article-title">Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-14-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1186%2F1476-4598-14-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25608569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1ejurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=4-19&author=C.+Fischerauthor=K.+Leithnerauthor=C.+Wohlkoenigauthor=F.+Quehenbergerauthor=A.+Bertschauthor=A.+Olschewskiauthor=H.+Olschewskiauthor=A.+Hrzenjak&title=Panobinostat+reduces+hypoxia-induced+cisplatin+resistance+of+non-small+cell+lung+carcinoma+cells+via+HIF-1%CE%B1+destabilization&doi=10.1186%2F1476-4598-14-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization</span></div><div class="casAuthors">Fischer, Carina; Leithner, Katharina; Wohlkoenig, Christoph; Quehenberger, Franz; Bertsch, Alexandra; Olschewski, Andrea; Olschewski, Horst; Hrzenjak, Andelko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Lung cancer is one of the most frequent cancer types and the leading cause of cancer death worldwide.  Cisplatin is a widely used chemotherapeutic for non-small cell lung carcinoma (NSCLC), however, its pos. effects are diminished under hypoxia.  We wanted to det. if co-treatment with cisplatin and histone deacetalyse (HDAC) inhibitor panobinostat can reduce hypoxia-induced cisplatin resistance in NSCLC cells, and to elucidate mechanism involved.  Methods: Expression status of different HDACS was detd. in two cell lines and in tumor tissue from 20 patients.  Cells were treated with cisplatin, panobinostat, or with combination of both under normoxic and hypoxic (1% O2) conditions.  Cell cycle, viability, acetylation of histones, and activation of apoptosis were detd.  HIF-1α stability and its interaction with HDAC4 were analyzed.  Results: Most class I and II HDACs were expressed in NSCLC cells and tumor samples.  Co-treatment of tumor cells with cisplatin and panobinostat decreased cell viability and increased apoptosis more efficiently than in primary, non-malignant bronchial epithelial cells.  Co-treatment induced apoptosis by causing chromatin fragmentation, activation of caspases-3 and 7 and PARP cleavage.  Toxic effects were more pronounced under hypoxic conditions.  Co-treatment resulted in destabilization and degrdn. of HIF-1α and HDAC4, a protein responsible for acetylation and de/stabilization of HIF-1α.  Direct interaction between HDAC4 and HIF-1α proteins in H23 cells was detected.  Conclusions: Here we show that hypoxia-induced cisplatin resistance can be overcome by combining cisplatin with panobinostat, a potent HDAC inhibitor.  These findings may contribute to the development of a new therapeutic strategy for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7oyuVTUGATbVg90H21EOLACvtfcHk0lg9NNdZWolMlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1ejurk%253D&md5=f333d399210ddfcbaa86b2602a80f43c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-14-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-14-4%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DC.%26aulast%3DLeithner%26aufirst%3DK.%26aulast%3DWohlkoenig%26aufirst%3DC.%26aulast%3DQuehenberger%26aufirst%3DF.%26aulast%3DBertsch%26aufirst%3DA.%26aulast%3DOlschewski%26aufirst%3DA.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DHrzenjak%26aufirst%3DA.%26atitle%3DPanobinostat%2520reduces%2520hypoxia-induced%2520cisplatin%2520resistance%2520of%2520non-small%2520cell%2520lung%2520carcinoma%2520cells%2520via%2520HIF-1%25CE%25B1%2520destabilization%26jtitle%3DMol.%2520Cancer%26date%3D2015%26volume%3D14%26spage%3D4%26epage%3D19%26doi%3D10.1186%2F1476-4598-14-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baghai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niknejad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhon, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeneuve, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroulakos, J.</span></span> <span> </span><span class="NLM_article-title">Induction of activating transcription factor 3 is associated with cisplatin responsiveness in non-small cell lung carcinoma cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1016/j.neo.2016.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.neo.2016.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27659012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Sltb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=525-535&author=J.+Barauthor=M.+S.+Hasimauthor=T.+Baghaiauthor=N.+Niknejadauthor=T.+J.+Perkinsauthor=D.+J.+Stewartauthor=H.+S.+Sekhonauthor=P.+J.+Villeneuveauthor=J.+Dimitroulakos&title=Induction+of+activating+transcription+factor+3+is+associated+with+cisplatin+responsiveness+in+non-small+cell+lung+carcinoma+cells&doi=10.1016%2Fj.neo.2016.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells</span></div><div class="casAuthors">Bar, Jair; Hasim, Mohamed S.; Baghai, Tabassom; Niknejad, Nima; Perkins, Theodore J.; Stewart, David J.; Sekhon, Harmanjatinder S.; Villeneuve, Patrick J.; Dimitroulakos, Jim</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">525-535</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1476-5586</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Non-small cell lung carcinoma (NSCLC) is the most common cause of cancer deaths, with platin-based combination chemotherapy the most efficacious therapies.  Gains in overall survival are modest, highlighting the need for novel therapeutic approaches including the development of next-generation platin combination regimens.  The goal of this study was to identify novel regulators of platin-induced cytotoxicity as potential therapeutic targets to further enhance platin cytotoxicity.  Employing RNA-seq transcriptome anal. comparing two parental NSCLC cell lines Calu6 and H23 to their cisplatin-resistant sublines, Calu6cisR1 and H23cisR1, activating transcription factor 3 (ATF3) was robustly induced in cisplatin-treated parental sensitive cell lines but not their resistant sublines, and in three of six tumors evaluated, but not in their corresponding normal adjacent lung tissue (0/6).  Cisplatin-induced JNK activation was a key regulator of this ATF3 induction.  Interestingly, in both resistant sublines, this JNK induction was abrogated, and the expression of an activated JNK construct in these cells enhanced both cisplatin-induced cytotoxicity and ATF3 induction.  An FDA-approved drug compd. screen was employed to identify enhancers of cisplatin cytotoxicity that were dependent on ATF3 gene expression.  Vorinostat, a histone deacetylase inhibitor, was identified in this screen and demonstrated synergistic cytotoxicity with cisplatin in both the parental Calu6 and H23 cell lines and importantly in their resistant sublines as well that was dependent on ATF3 expression.  Thus, we have identified ATF3 as an important regulator of cisplatin cytotoxicity and that ATF3 inducers in combination with platins are a potential novel therapeutic approach for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKamfmozcGeLVg90H21EOLACvtfcHk0lg9NNdZWolMlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Sltb3K&md5=265ec1ea01d8fc97d62b25508d8a9018</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.neo.2016.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neo.2016.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DBar%26aufirst%3DJ.%26aulast%3DHasim%26aufirst%3DM.%2BS.%26aulast%3DBaghai%26aufirst%3DT.%26aulast%3DNiknejad%26aufirst%3DN.%26aulast%3DPerkins%26aufirst%3DT.%2BJ.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DSekhon%26aufirst%3DH.%2BS.%26aulast%3DVilleneuve%26aufirst%3DP.%2BJ.%26aulast%3DDimitroulakos%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520activating%2520transcription%2520factor%25203%2520is%2520associated%2520with%2520cisplatin%2520responsiveness%2520in%2520non-small%2520cell%2520lung%2520carcinoma%2520cells%26jtitle%3DNeoplasia%26date%3D2016%26volume%3D18%26spage%3D525%26epage%3D535%26doi%3D10.1016%2Fj.neo.2016.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tzeng, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W. H.</span></span> <span> </span><span class="NLM_article-title">Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e101664</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0101664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1371%2Fjournal.pone.0101664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25010594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ersb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=T.+J.+Tzengauthor=L.+Caoauthor=Y.+Fuauthor=H.+Zengauthor=W.+H.+Cheng&title=Methylseleninic+acid+sensitizes+Notch3-activated+OVCA429+ovarian+cancer+cells+to+carboplatin&doi=10.1371%2Fjournal.pone.0101664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin</span></div><div class="casAuthors">Tzeng, Tiffany J.; Cao, Lei; Fu, YangXin; Zeng, Huawei; Cheng, Wen-Hsing</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e101664/1-e101664/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Ovarian cancer, the deadliest of gynecol. cancers, is usually not diagnosed until advanced stages.  Although carboplatin has been popular for treating ovarian cancer for decades, patients eventually develop resistance to this platinum-contg. drug.  Expression of neurogenic locus notch homolog 3 (Notch3) is assocd. with chemoresistance and poor overall survival in ovarian cancer patients.  Overexpression of NICD3 (the constitutively active form of Notch3) in OVCA429 ovarian cancer cells (OVCA429/NICD3) renders them resistance to carboplatin treatment compared to OVCA429/pCEG cells expressing an empty vector.  We have previously shown that methylseleninic acid (MSeA) induces oxidative stress and activates ataxia-telangiectasia mutated and DNA-dependent protein kinase in cancer cells.  Here we tested the hypothesis that MSeA and carboplatin exerted a synthetic lethal effect on OVCA429/NICD3 cells.  Co-treatment with MSeA synergistically sensitized OVCA429/NICD3 but not OVCA429/pCEG cells to the killing by carboplatin.  This synergism was assocd. with a cell cycle exit at the G2/M phase and the induction of NICD3 target gene HES1.  Treatment of N-acetyl cysteine or inhibitors of the above two kinases did not directly impact on the synergism in OVCA429/NICD3 cells.  Taken together, these results suggest that the efficacy of carboplatin in the treatment of high grade ovarian carcinoma can be enhanced by a combinational therapy with MSeA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqRsrVnamU5bVg90H21EOLACvtfcHk0liaCjLQ05-PFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ersb7L&md5=272d64385a39bd79cda33e00a3fb7f6b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0101664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0101664%26sid%3Dliteratum%253Aachs%26aulast%3DTzeng%26aufirst%3DT.%2BJ.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DW.%2BH.%26atitle%3DMethylseleninic%2520acid%2520sensitizes%2520Notch3-activated%2520OVCA429%2520ovarian%2520cancer%2520cells%2520to%2520carboplatin%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0101664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Circu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Osta, H.</span></span> <span> </span><span class="NLM_article-title">Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0184922</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0184922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1371%2Fjournal.pone.0184922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28945807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=M.+Circuauthor=J.+Cardelliauthor=M.+P.+Barrauthor=K.+O%E2%80%99Byrneauthor=G.+Millsauthor=H.+El-Osta&title=Modulating+lysosomal+function+through+lysosome+membrane+permeabilization+or+autophagy+suppression+restores+sensitivity+to+cisplatin+in+refractory+non-small-cell+lung+cancer+cells&doi=10.1371%2Fjournal.pone.0184922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells</span></div><div class="casAuthors">Circu, Magdalena; Cardelli, James; Barr, Martin; O'Byrne, Kenneth; Mills, Glenn; El-Osta, Hazem</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0184922/1-e0184922/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Lung cancer is the leading cause of cancer-related deaths.  Most patients develop resistance to platinum within several months of treatment.  We investigated whether triggering lysosomal membrane permeabilization (LMP) or suppressing autophagy can restore cisplatin susceptibility in lung cancer with acquired chemoresistance.  Cisplatin IC50 in A549Pt (parental) and A549cisR (cisplatin resistant) cells was 13 μM and 47 μM, resp.  Following cisplatin exposure, A549cisR cells failed to elicit an apoptotic response.  This was manifested by diminished Annexin±V staining, caspase 3 and 9, BAX and BAK activation in resistant but not in parental cells.  Chloroquine preferentially promoted LMP in A549cisR cells, revealed by leakage of FITC-dextran into the cytosol as detected by immunofluorescence microscopy.  This was confirmed by increased cytosolic cathepsin D signal on Immunoblot.  Cell viability of cisplatin-treated A549cisR cells was decreased when co-treated with chloroquine, corresponding to a combination index below 0.8, suggesting synergism between the two drugs.  Notably, chloroquine activated the mitochondrial cell death pathway as indicated by increase in caspase 9 activity.  Interestingly, inhibition of lysosomal proteases using E64 conferred cytoprotection against cisplatin and chloroquine co-treatment, suggesting that chloroquine-induced cell death occurred in a cathepsin-mediated mechanism.  Likewise, blockage of caspases partially rescued A549cisR cells against the cytotoxicity of cisplatin and chloroquine combination.  Cisplatin promoted a dose-dependent autophagic flux induction preferentially in A549cisR cells, as evidenced by a surge in LC3-II/ α-tubulin following pre-treatment with E64 and increase in p62 degrdn.  Compared to untreated cells, cisplatin induced an increase in cyto-ID-loaded autophagosomes in A549cisR cells that was further amplified by chloroquine, pointing toward autophagic flux activation by cisplatin.  Interestingly, this effect was less pronounced in A549Pt cells.  Blocking autophagy by ATG5 depletion using siRNA markedly enhances susceptibility to cisplatin in A549cisR cells.  Taken together, our results underscore the utility of targeting lysosomal function in overcoming acquired cisplatin refractoriness in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLEMt4g6rOwLVg90H21EOLACvtfcHk0liaCjLQ05-PFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFCgsbc%253D&md5=c457697a0d6a4affef9489554c1222bd</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0184922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0184922%26sid%3Dliteratum%253Aachs%26aulast%3DCircu%26aufirst%3DM.%26aulast%3DCardelli%26aufirst%3DJ.%26aulast%3DBarr%26aufirst%3DM.%2BP.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DMills%26aufirst%3DG.%26aulast%3DEl-Osta%26aufirst%3DH.%26atitle%3DModulating%2520lysosomal%2520function%2520through%2520lysosome%2520membrane%2520permeabilization%2520or%2520autophagy%2520suppression%2520restores%2520sensitivity%2520to%2520cisplatin%2520in%2520refractory%2520non-small-cell%2520lung%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0184922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreaden, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadir, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberio, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberlton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shopsowitz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, P. T.</span></span> <span> </span><span class="NLM_article-title">RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors</span>. <i>Bioeng. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1002/btm2.10086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fbtm2.10086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29376131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=26-36&author=E.+C.+Dreadenauthor=Y.+W.+Kongauthor=M.+A.+Quadirauthor=S.+Correaauthor=L.+Suarez-Lopezauthor=A.+E.+Barberioauthor=M.+K.+Hwangauthor=A.+C.+Shiauthor=B.+Oberltonauthor=P.+N.+Gallagherauthor=K.+E.+Shopsowitzauthor=K.+M.+Eliasauthor=M.+B.+Yaffeauthor=P.+T.+Hammond&title=RNA-Peptide+nanoplexes+drug+DNA+damage+pathways+in+high-grade+serous+ovarian+tumors&doi=10.1002%2Fbtm2.10086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors</span></div><div class="casAuthors">Dreaden, Erik C.; Kong, Yi Wen; Quadir, Mohiuddin A.; Correa, Santiago; Suarez-Lopez, Lucia; Barberio, Antonio E.; Hwang, Mun Kyung; Shi, Aria C.; Oberlton, Benjamin; Gallagher, Paige N.; Shopsowitz, Kevin E.; Elias, Kevin M.; Yaffe, Michael B.; Hammond, Paula T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioengineering & Translational Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-36</span>CODEN:
                <span class="NLM_cas:coden">BTMIAQ</span>;
        ISSN:<span class="NLM_cas:issn">2380-6761</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">DNA damaging chemotherapy is a cornerstone of current front-line treatments for advanced ovarian cancer (OC).  Despite the fact that a majority of these patients initially respond to therapy, most will relapse with chemo-resistant disease; therefore, adjuvant treatments that synergize with DNA-damaging chemotherapy could improve treatment outcomes and survival in patients with this deadly disease.  Here, we report the development of a nanoscale peptide-nucleic acid complex that facilitates tumor-specific RNA interference therapy to chemosensitize advanced ovarian tumors to frontline platinum/taxane therapy.  We found that the nanoplex-mediated silencing of the protein kinase, MK2, profoundly sensitized mouse models of high-grade serous OC to cytotoxic chemotherapy by blocking p38/MK2-dependent cell cycle checkpoint maintenance.  Combined RNAi therapy improved overall survival by 37% compared with platinum/taxane chemotherapy alone and decreased metastatic spread to the lungs without observable toxic side effects.  These findings suggest (a) that peptide nanoplexes can serve as safe and effective delivery vectors for siRNA and (b) that combined inhibition of MK2 could improve treatment outcomes in patients currently receiving frontline chemotherapy for advanced OC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPPQh0tegq7Vg90H21EOLACvtfcHk0lgxXo6sPNzn3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKjur4%253D&md5=0d2ddfa17618bb37c2ddcc02b3748e2a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1002%2Fbtm2.10086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbtm2.10086%26sid%3Dliteratum%253Aachs%26aulast%3DDreaden%26aufirst%3DE.%2BC.%26aulast%3DKong%26aufirst%3DY.%2BW.%26aulast%3DQuadir%26aufirst%3DM.%2BA.%26aulast%3DCorrea%26aufirst%3DS.%26aulast%3DSuarez-Lopez%26aufirst%3DL.%26aulast%3DBarberio%26aufirst%3DA.%2BE.%26aulast%3DHwang%26aufirst%3DM.%2BK.%26aulast%3DShi%26aufirst%3DA.%2BC.%26aulast%3DOberlton%26aufirst%3DB.%26aulast%3DGallagher%26aufirst%3DP.%2BN.%26aulast%3DShopsowitz%26aufirst%3DK.%2BE.%26aulast%3DElias%26aufirst%3DK.%2BM.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DHammond%26aufirst%3DP.%2BT.%26atitle%3DRNA-Peptide%2520nanoplexes%2520drug%2520DNA%2520damage%2520pathways%2520in%2520high-grade%2520serous%2520ovarian%2520tumors%26jtitle%3DBioeng.%2520Transl.%2520Med.%26date%3D2018%26volume%3D3%26spage%3D26%26epage%3D36%26doi%3D10.1002%2Fbtm2.10086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.3892/ol.2020.11905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3892%2Fol.2020.11905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=32802168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BB38fmtFKltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=46-52&author=X.+Songauthor=W.+Qiauthor=J.+Guoauthor=L.+Sunauthor=A.+Dingauthor=G.+Zhaoauthor=H.+Liauthor=W.+Qiuauthor=J.+Lv&title=Immune+checkpoint+inhibitor+combination+therapy+for+gastric+cancer%3A+Research+progress&doi=10.3892%2Fol.2020.11905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress</span></div><div class="casAuthors">Song Xiaoxu; Qi Weiwei; Guo Jing; Sun Libin; Ding Aiping; Zhao Guanghui; Li Hui; Qiu Wensheng; Lv Jing</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">46</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Gastric cancer is one of the most common types of cancer; notably, gastric cancer is one of the top five malignancies with regards to incidence and mortality rates.  The symptoms of early gastric cancer are not typical, exhibiting only slight upper abdominal discomfort.  When the symptoms become more obvious, the lesion has usually progressed to an advanced stage.  Notably, >90% of inpatients already have locally advanced or metastatic gastric cancer at the time of initial diagnosis, with limited treatment options for advanced gastric cancer.  These options include chemotherapy, targeted therapy and immune checkpoint inhibitors (ICIs).  With regards to ICIs, the clinical benefit of monotherapy for advanced gastric cancer is limited; however, combinations of ICIs and other therapies may have clinical benefit.  Relevant clinical studies have demonstrated that combinations of ICIs with chemotherapy, anti-vascular targeted therapy or other molecular targeted therapies, and the use of two ICIs, improve outcomes for patients with advanced gastric cancer.  This article is a review of progress in the use of ICIs in combination with other therapies for the treatment of gastric cancer.  The purpose of this article was to advance gastric cancer immunotherapy and to improve the overall therapeutic benefit for patients with advanced gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMGL-IdhhnmacY7HFp97qMfW6udTcc2eY8S9OU7CpIBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38fmtFKltw%253D%253D&md5=421d54ea061bbf044ed3c404792a156a</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3892%2Fol.2020.11905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2020.11905%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DJ.%26atitle%3DImmune%2520checkpoint%2520inhibitor%2520combination%2520therapy%2520for%2520gastric%2520cancer%253A%2520Research%2520progress%26jtitle%3DOncol.%2520Lett.%26date%3D2020%26volume%3D20%26spage%3D46%26epage%3D52%26doi%3D10.3892%2Fol.2020.11905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasaturo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Blasio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figdor, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hato, S. V.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2013.00417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.3389%2Ffimmu.2013.00417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24348481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsVCgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=417-430&author=A.+Vasaturoauthor=S.+Di+Blasioauthor=D.+G.+Peetersauthor=C.+C.+de+Koningauthor=J.+M.+de+Vriesauthor=C.+G.+Figdorauthor=S.+V.+Hato&title=Clinical+implications+of+co-inhibitory+molecule+expression+in+the+tumor+microenvironment+for+DC+vaccination%3A+a+game+of+stop+and+go&doi=10.3389%2Ffimmu.2013.00417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go</span></div><div class="casAuthors">Vasaturo Angela; Di Blasio Stefania; Peeters Deborah G A; de Koning Coco C H; Figdor Carl G; Hato Stanleyson V; de Vries Jolanda M</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">The aim of therapeutic dendritic cell (DC) vaccines in cancer immunotherapy is to activate cytotoxic T cells to recognize and attack the tumor.  T cell activation requires the interaction of the T cell receptor with a cognate major-histocompatibility complex-peptide complex.  Although initiated by antigen engagement, it is the complex balance between co-stimulatory and co-inhibitory signals on DCs that results in T cell activation or tolerance.  Even when already activated, tumor-specific T cells can be neutralized by the expression of co-inhibitory molecules on tumor cells.  These and other immunosuppressive cues in the tumor microenvironment are major factors currently hampering the application of DC vaccination.  In this review, we discuss recent data regarding the essential and complex role of co-inhibitory molecules in regulating the immune response within the tumor microenvironment.  In particular, possible therapeutic intervention strategies aimed at reversing or neutralizing suppressive networks within the tumor microenvironment will be emphasized.  Importantly, blocking co-inhibitory molecule signaling, often referred to as immune checkpoint blockade, does not necessarily lead to an effective activation of tumor-specific T cells.  Therefore, combination of checkpoint blockade with other immune potentiating therapeutic strategies, such as DC vaccination, might serve as a synergistic combination, capable of reversing effector T cells immunosuppression while at the same time increasing the efficacy of T cell-mediated immunotherapies.  This will ultimately result in long-term anti-tumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNtZ9JYMnH-K69lAbTj9rGfW6udTcc2eaEWtRzoLyRjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsVCgsQ%253D%253D&md5=6c033e0abf9d40edb924c2c469067ce6</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00417%26sid%3Dliteratum%253Aachs%26aulast%3DVasaturo%26aufirst%3DA.%26aulast%3DDi%2BBlasio%26aufirst%3DS.%26aulast%3DPeeters%26aufirst%3DD.%2BG.%26aulast%3Dde%2BKoning%26aufirst%3DC.%2BC.%26aulast%3Dde%2BVries%26aufirst%3DJ.%2BM.%26aulast%3DFigdor%26aufirst%3DC.%2BG.%26aulast%3DHato%26aufirst%3DS.%2BV.%26atitle%3DClinical%2520implications%2520of%2520co-inhibitory%2520molecule%2520expression%2520in%2520the%2520tumor%2520microenvironment%2520for%2520DC%2520vaccination%253A%2520a%2520game%2520of%2520stop%2520and%2520go%26jtitle%3DFront.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D417%26epage%3D430%26doi%3D10.3389%2Ffimmu.2013.00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grabosch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulatovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brozick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambotto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elishaev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlad, A. M.</span></span> <span> </span><span class="NLM_article-title">Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2393</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0581-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fs41388-018-0581-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30518877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2380-2393&author=S.+Graboschauthor=M.+Bulatovicauthor=F.+Zengauthor=T.+Maauthor=L.+Zhangauthor=M.+Rossauthor=J.+Brozickauthor=Y.+Fangauthor=G.+Tsengauthor=E.+Kimauthor=A.+Gambottoauthor=E.+Elishaevauthor=R.+P.+Edwardsauthor=A.+M.+Vlad&title=Cisplatin-induced+immune+modulation+in+ovarian+cancer+mouse+models+with+distinct+inflammation+profiles&doi=10.1038%2Fs41388-018-0581-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles</span></div><div class="casAuthors">Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Ma, Tianzhou; Zhang, Lixin; Ross, Malcolm; Brozick, Joan; Fang, YuSi; Tseng, George; Kim, Eun; Gambotto, Andrea; Elishaev, Esther; P. Edwards, Robert; Vlad, Anda M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2380-2393</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking.  New therapeutic approaches using immunotherapy via immune checkpoint blockade, which have demonstrated clin. efficacy in other tumor types, have been less promising in ovarian cancer.  To increase their clin. efficacy, checkpoint inhibitors are now being tested in clin. trials in combination with chemotherapy.  Here, we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1, in two novel murine ovarian cancer cell models.  The 2F8 and its platinum-resistant deriv. 2F8cis model, display distinct inflammatory profiles and chemotherapy sensitivities, and mirror the primary and recurrent human disease, resp.  Acute and chronic exposure to cisplatin enhances tumor immunogenicity by increasing calreticulin, MHC class I, antigen presentation and T-cell infiltration.  Cisplatin also upregulates PD-L1 expression in vitro and in vivo, demonstrating a dual, paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade.  One of the pathways activated by cisplatin treatment is the cGAS/STING pathway.  Chronic cisplatin treatment led to upregulation of cGAS and STING proteins in 2F8cis compared to parental 2F8 cells, while acute exposure to cisplatin further increases cGAS and STING levels in both 2F8 and 2F8cis cells.  Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1, MHC I and calreticulin in tumor cells.  Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival.  These studies have high translational potential in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZIZzCpm2HLVg90H21EOLACvtfcHk0lg_h8XrFCQZzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWkt7vK&md5=dab087745abb955a114017f47fd48b5f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0581-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0581-9%26sid%3Dliteratum%253Aachs%26aulast%3DGrabosch%26aufirst%3DS.%26aulast%3DBulatovic%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DRoss%26aufirst%3DM.%26aulast%3DBrozick%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DTseng%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DGambotto%26aufirst%3DA.%26aulast%3DElishaev%26aufirst%3DE.%26aulast%3DEdwards%26aufirst%3DR.%2BP.%26aulast%3DVlad%26aufirst%3DA.%2BM.%26atitle%3DCisplatin-induced%2520immune%2520modulation%2520in%2520ovarian%2520cancer%2520mouse%2520models%2520with%2520distinct%2520inflammation%2520profiles%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D2380%26epage%3D2393%26doi%3D10.1038%2Fs41388-018-0581-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey-McIntyre, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Perrot, M.</span></span> <span> </span><span class="NLM_article-title">CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1809</span>– <span class="NLM_lpage">1819</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-1014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F1535-7163.MCT-11-1014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22584123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1809-1819&author=L.+Wuauthor=Z.+Yunauthor=T.+Tagawaauthor=K.+Rey-McIntyreauthor=M.+de+Perrot&title=CTLA-4+blockade+expands+infiltrating+T+cells+and+inhibits+cancer+cell+repopulation+during+the+intervals+of+chemotherapy+in+murine+mesothelioma&doi=10.1158%2F1535-7163.MCT-11-1014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma</span></div><div class="casAuthors">Wu, Licun; Yun, Zhihong; Tagawa, Tetsuzo; Rey-McIntyre, Katrina; de Perrot, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1809-1819</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer immunotherapy has shown promising results when combined with chemotherapy.  Blocking CTLA-4 signaling by monoclonal antibody between cycles of chemotherapy may inhibit cancer cell repopulation and enhance the antitumoral immune reaction, thus improve the efficacy of chemotherapy in mesothelioma.  The impact of CTLA-4 blockade on the early stage of tumor development was evaluated in a s.c. murine mesothelioma model.  CTLA-4 blocking antibody was administered following each cycle of chemotherapy, and monotherapy was included as controls.  Antitumor effect was evaluated by tumor growth delay and survival of the animals.  Tumor cell repopulation was quantified by bromodeoxyuridine incorporation and Ki67 by immunohistochem. and/or flow cytometry.  In vitro cell killing was detd. by classic chromium-released assay, and reverse transcription PCR (RT-PCR) was carried out to det. the gene expression of assocd. cytokines.  Anti-CTLA-4 monoclonal antibody was able to inhibit tumor growth at early stage of tumor development.  Antitumor effect was achieved by administration of CTLA-4 blockade between cycles of chemotherapy.  Tumor cell repopulation during the intervals of cisplatin was inhibited by CTLA-4 blockade.  Anti-CTLA-4 therapy gave rise to an increased no. of CD4 and CD8 T cells infiltrating the tumor.  RT-PCR showed that the gene expression of interleukin IL-2, IFN-γ, granzyme B, and perforin increased in the tumor milieu.  Blockade of CTLA-4 signaling showed effective anticancer effect, correlating with inhibiting cancer cell repopulation between cycles of chemotherapy and upregulating tumor-infiltrating T lymphocytes, cytokines, and cytolytic enzymes in a murine mesothelioma model.  Mol Cancer Ther; 11(8); 1809-19. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN5maekd_K1rVg90H21EOLACvtfcHk0lhmSYofhNxfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrK&md5=0869285e2f11dbc076b9596680d42084</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-1014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-1014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DZ.%26aulast%3DTagawa%26aufirst%3DT.%26aulast%3DRey-McIntyre%26aufirst%3DK.%26aulast%3Dde%2BPerrot%26aufirst%3DM.%26atitle%3DCTLA-4%2520blockade%2520expands%2520infiltrating%2520T%2520cells%2520and%2520inhibits%2520cancer%2520cell%2520repopulation%2520during%2520the%2520intervals%2520of%2520chemotherapy%2520in%2520murine%2520mesothelioma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1809%26epage%3D1819%26doi%3D10.1158%2F1535-7163.MCT-11-1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulgrew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodorge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcook, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foltz, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCourt, M.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-14-0191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1158%2F2326-6066.CIR-14-0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=25943534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFartL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=1052-1062&author=R.+Stewartauthor=M.+Morrowauthor=S.+A.+Hammondauthor=K.+Mulgrewauthor=D.+Marcusauthor=E.+Poonauthor=A.+Watkinsauthor=S.+Mullinsauthor=M.+Chodorgeauthor=J.+Andrewsauthor=D.+Bannisterauthor=E.+Dickauthor=N.+Crawfordauthor=J.+Parmentierauthor=M.+Alimzhanovauthor=J.+S.+Babcookauthor=I.+N.+Foltzauthor=A.+Buchananauthor=V.+Bedianauthor=R.+W.+Wilkinsonauthor=M.+McCourt&title=Identification+and+characterization+of+MEDI4736%2C+an+antagonistic+anti-PD-L1+monoclonal+antibody&doi=10.1158%2F2326-6066.CIR-14-0191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody</span></div><div class="casAuthors">Stewart, Ross; Morrow, Michelle; Hammond, Scott A.; Mulgrew, Kathy; Marcus, Danielle; Poon, Edmund; Watkins, Amanda; Mullins, Stefanie; Chodorge, Matthieu; Andrews, John; Bannister, David; Dick, Emily; Crawford, Nicola; Parmentier, Julie; Alimzhanov, Marat; Babcook, John S.; Foltz, Ian N.; Buchanan, Andrew; Bedian, Vahe; Wilkinson, Robert W.; McCourt, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1052-1062</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Programmed cell-death 1 ligand 1 (PD-L1) is a member of the B7/CD28 family of proteins that control T-cell activation.  Many tumors can upregulate expression of PD-L1, inhibiting antitumor T-cell responses and avoiding immune surveillance and elimination.  We have identified and characterized MEDI4736, a human IgG1 monoclonal antibody that binds with high affinity and specificity to PD-L1 and is uniquely engineered to prevent antibody-dependent cell-mediated cytotoxicity.  In vitro assays demonstrate that MEDI4736 is a potent antagonist of PD-L1 function, blocking interaction with PD-1 and CD80 to overcome inhibition of primary human T-cell activation.  In vivo MEDI4736 significantly inhibits the growth of human tumors in a novel xenograft model contg. coimplanted human T cells.  This activity is entirely dependent on the presence of transplanted T cells, supporting the immunol. mechanism of action for MEDI4736.  To further det. the utility of PD-L1 blockade, an anti-mouse PD-L1 antibody was investigated in immunocompetent mice.  Here, anti-mouse PD-L1 significantly improved survival of mice implanted with CT26 colorectal cancer cells.  The antitumor activity of anti-PD-L1 was enhanced by combination with oxaliplatin, which resulted in increased release of HMGB1 within CT26 tumors.  Taken together, our results demonstrate that inhibition of PD-L1 function can have potent antitumor activity when used as monotherapy or in combination in preclin. models, and suggest it may be a promising therapeutic approach for the treatment of cancer.  MEDI4736 is currently in several clin. trials both alone and in combination with other agents, including anti-CTLA-4, anti-PD-1, and inhibitors of IDO, MEK, BRAF, and EGFR.  Cancer Immunol Res; 3(9); 1052-62. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0trbhV8xu_7Vg90H21EOLACvtfcHk0lhmSYofhNxfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFartL%252FN&md5=af677d33c3446f209eeac3219dea5513</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-14-0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-14-0191%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DR.%26aulast%3DMorrow%26aufirst%3DM.%26aulast%3DHammond%26aufirst%3DS.%2BA.%26aulast%3DMulgrew%26aufirst%3DK.%26aulast%3DMarcus%26aufirst%3DD.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DA.%26aulast%3DMullins%26aufirst%3DS.%26aulast%3DChodorge%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DJ.%26aulast%3DBannister%26aufirst%3DD.%26aulast%3DDick%26aufirst%3DE.%26aulast%3DCrawford%26aufirst%3DN.%26aulast%3DParmentier%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBabcook%26aufirst%3DJ.%2BS.%26aulast%3DFoltz%26aufirst%3DI.%2BN.%26aulast%3DBuchanan%26aufirst%3DA.%26aulast%3DBedian%26aufirst%3DV.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DMcCourt%26aufirst%3DM.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520MEDI4736%252C%2520an%2520antagonistic%2520anti-PD-L1%2520monoclonal%2520antibody%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D1052%26epage%3D1062%26doi%3D10.1158%2F2326-6066.CIR-14-0191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosheva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span> <span> </span><span class="NLM_article-title">Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04605-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fs41467-018-04605-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29884866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC1MblsFKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2237-2247&author=W.+Songauthor=L.+Shenauthor=Y.+Wangauthor=Q.+Liuauthor=T.+J.+Goodwinauthor=J.+Liauthor=O.+Doroshevaauthor=T.+Liuauthor=R.+Liuauthor=L.+Huang&title=Synergistic+and+low+adverse+effect+cancer+immunotherapy+by+immunogenic+chemotherapy+and+locally+expressed+PD-L1+trap&doi=10.1038%2Fs41467-018-04605-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap</span></div><div class="casAuthors">Song Wantong; Shen Limei; Wang Ying; Liu Qi; Goodwin Tyler J; Huang Leaf; Song Wantong; Li Jingjing; Dorosheva Olekasandra; Liu Rihe; Liu Tianzhou; Liu Rihe</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2237</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although great success has been obtained in the clinic, the current immune checkpoint inhibitors still face two challenging problems: low response rate and immune-related adverse effects (irAEs).  Here we report the combination of immunogenic chemotherapy and locally expressed PD-L1 trap fusion protein for efficacious and safe cancer immunotherapy.  We demonstrate that oxaliplatin (OxP) boosts anti-PD-L1 mAb therapy against murine colorectal cancer.  By design of a PD-L1 trap and loading its coding plasmid DNA into a lipid-protamine-DNA nanoparticle, PD-L1 trap is produced transiently and locally in the tumor microenvironment, and synergizes with OxP for tumor inhibition.  Significantly, unlike the combination of OxP and anti-PD-L1 mAb, the combination of OxP and PD-L1 trap does not induce obvious Th17 cells accumulation in the spleen, indicating better tolerance and lower tendency to irAEs.  The reports here may highlight the potential of applying PD-L1 inhibitor, especially locally expressed PD-L1 trap, in cancer therapy following OxP-based chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZUVp89Gd1Zi86Js-BCLiifW6udTcc2eYtbYGA3qyMqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MblsFKltg%253D%253D&md5=4f5f6a692814f6ffeaab32034db3f006</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04605-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04605-x%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGoodwin%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDorosheva%26aufirst%3DO.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DSynergistic%2520and%2520low%2520adverse%2520effect%2520cancer%2520immunotherapy%2520by%2520immunogenic%2520chemotherapy%2520and%2520locally%2520expressed%2520PD-L1%2520trap%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2237%26epage%3D2247%26doi%3D10.1038%2Fs41467-018-04605-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Za’abi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoj, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waly, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemmar, A.</span></span> <span> </span><span class="NLM_article-title">The effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particles</span>. <i>Exp. Biol. Med. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">1698</span>– <span class="NLM_lpage">1707</span>, <span class="refDoi"> DOI: 10.1177/1535370215579013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1177%2F1535370215579013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVamtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2015&pages=1698-1707&author=B.+H.+Aliauthor=M.+Al+Za%E2%80%99abiauthor=A.+Shalabyauthor=P.+Manojauthor=M.+I.+Walyauthor=J.+Yasinauthor=M.+Fahimauthor=A.+Nemmar&title=The+effect+of+thymoquinone+treatment+on+the+combined+renal+and+pulmonary+toxicity+of+cisplatin+and+diesel+exhaust+particles&doi=10.1177%2F1535370215579013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particles</span></div><div class="casAuthors">Ali, Badreldin H.; Al Za'abi, Mohammed; Shalaby, Asem; Manoj, Priyadarsini; Waly, Mostafa I.; Yasin, Javed; Fahim, Mohamed; Nemmar, Abderrahim</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1698-1707</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Particulate air pollution (PAP) exposure is assocd. with increased morbidity and mortality, particularly in patients with renal disease.  However, there are only a few studies on the interaction between PAP and renal injury, and none on agents that may ameliorate it.  We studied the interaction between cisplatin (CP) nephrotoxicity and a single exposure to diesel exhaust particle (DEP) in rats 24 h before sacrifice, and assessed the effect of co-treatment with the active ingredient in Nigella Sativa seed oil, thymoquinone (TQ) thereon.  Rats were injected i.p. with CP (6mg/kg) and four days later, they were exposed intratracheally to DEP (0.5mg/kg), and were sacrificed 24 h later.  Oral TQ (20mg/kg) was given daily throughout the exptl. period.  CP alone caused several physiol., biochem., and histopathol. changes that included reduced growth and creatinine clearance, and raised plasma neutrophil gelatinase-assocd. lipocalin (NGAL), interleukin 6 (IL-6) and C-reactive protein (CRP), creatinine and urea concns., and urinary N-acetyl-b-D-glucosaminidase (NAG) activities.  It adversely affected several indexes of oxidative damage in the kidneys, and induced renal tubular necrosis.  Most of these actions were significantly potentiated in rats given both CP and DEP.  TQ significantly abrogated many of the effects of CP and DEP, given alone and in combination.  These results provide exptl. evidence that subjects with renal diseases can be at higher risk from PAP, and that TQ, pending further pharmacol. and toxicol. studies, can be considered a useful agent in patients with renal diseases and exposed to PAP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQUHppuhzuWLVg90H21EOLACvtfcHk0lh9Gvk0v-BnnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVamtLfK&md5=7c45f2bbcb4e272e18043a9e8f196f3d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1177%2F1535370215579013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370215579013%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DB.%2BH.%26aulast%3DAl%2BZa%25E2%2580%2599abi%26aufirst%3DM.%26aulast%3DShalaby%26aufirst%3DA.%26aulast%3DManoj%26aufirst%3DP.%26aulast%3DWaly%26aufirst%3DM.%2BI.%26aulast%3DYasin%26aufirst%3DJ.%26aulast%3DFahim%26aufirst%3DM.%26aulast%3DNemmar%26aufirst%3DA.%26atitle%3DThe%2520effect%2520of%2520thymoquinone%2520treatment%2520on%2520the%2520combined%2520renal%2520and%2520pulmonary%2520toxicity%2520of%2520cisplatin%2520and%2520diesel%2520exhaust%2520particles%26jtitle%3DExp.%2520Biol.%2520Med.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D240%26spage%3D1698%26epage%3D1707%26doi%3D10.1177%2F1535370215579013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atasayar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürer-Orhan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orhan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özgüneş, H.</span></span> <span> </span><span class="NLM_article-title">Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.etp.2008.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.etp.2008.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=18684602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlygurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=23-32&author=S.+Atasayarauthor=H.+G%C3%BCrer-Orhanauthor=H.+Orhanauthor=B.+G%C3%BCrelauthor=G.+Girginauthor=H.+%C3%96zg%C3%BCne%C5%9F&title=Preventive+effect+of+aminoguanidine+compared+to+vitamin+E+and+C+on+cisplatin-induced+nephrotoxicity+in+rats&doi=10.1016%2Fj.etp.2008.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats</span></div><div class="casAuthors">Atasayar, S.; Gurer-Orhan, H.; Orhan, H.; Gurel, B.; Girgin, G.; Ozgunes, H.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-32</span>CODEN:
                <span class="NLM_cas:coden">ETPAEK</span>;
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">In this study, the antioxidant effect of aminoguanidine on nephrotoxicity of a single dose of cisplatin is investigated and compared with the effects of well-known antioxidants vitamin C and E combination.  Tubular damage and perivascular inflammation were obsd. in kidney samples of the cisplatin-administered groups.  Aminoguanidine and vitamin C-E combination are found to be capable of preventing these effects of cisplatin.  Liver tissues of all groups were intact.  Cisplatin-induced oxidative stress was evidenced by significant decrease in glutathione and significant increase in malondialdehyde levels in kidney samples.  Antioxidants with cisplatin decreased malondialdehyde levels.  Antioxidants with cisplatin prevented the decrease in liver glutathione levels.  The nephrotoxicity was confirmed biochem. by significant elevation of serum urea and creatinine levels.  Both vitamin C-E combination and aminoguanidine prevented the increase in serum urea levels according to the cisplatin group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoln5vA1W76iLVg90H21EOLACvtfcHk0lgZjheADnq_8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlygurw%253D&md5=8b7a8716f07dae3af007c139fd1b0477</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.etp.2008.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.etp.2008.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DAtasayar%26aufirst%3DS.%26aulast%3DG%25C3%25BCrer-Orhan%26aufirst%3DH.%26aulast%3DOrhan%26aufirst%3DH.%26aulast%3DG%25C3%25BCrel%26aufirst%3DB.%26aulast%3DGirgin%26aufirst%3DG.%26aulast%3D%25C3%2596zg%25C3%25BCne%25C5%259F%26aufirst%3DH.%26atitle%3DPreventive%2520effect%2520of%2520aminoguanidine%2520compared%2520to%2520vitamin%2520E%2520and%2520C%2520on%2520cisplatin-induced%2520nephrotoxicity%2520in%2520rats%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2009%26volume%3D61%26spage%3D23%26epage%3D32%26doi%3D10.1016%2Fj.etp.2008.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deegan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basinger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hande, K. R.</span></span> <span> </span><span class="NLM_article-title">Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/0300-483X(95)03182-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2F0300-483X%2895%2903182-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=8571387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK2MXpvV2nsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1996&pages=159-166&author=P.+M.+Deeganauthor=M.+A.+Basingerauthor=M.+M.+Jonesauthor=K.+R.+Hande&title=Prevention+of+cisplatin+nephrotoxicity+by+exogenous+atrial+natriuretic+peptide&doi=10.1016%2F0300-483X%2895%2903182-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide</span></div><div class="casAuthors">Deegan, Patricia M.; Basinger, Mark A.; Jones, Mark M.; Hande, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">159-66</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The ability of atrial natriuretic peptide (ANP) to prevent cisplatin-induced nephrotoxicity was compared to the protective effect of 3% NaCl.  ANP (1 μg/kg/min), 3% NaCl or peptide buffer vehicle (50 μl/min) were infused for 45 min to conscious unrestrained rats immediately after cisplatin administration (5 mg/kg i.v.).  Measurements taken 72 h after drug treatment indicated that compared to animals receiving cisplatin only, ANP co-treated rats had lower post- treatment plasma creatinine concns. (0.70 vs. 1.3 mg/dL), blood urea nitrogen (BUN) concns. (44.2 vs. 65.5 mg/dL) and higher post-treatment glomerular filtration rates (GFR) (0.71 vs. 0.14 mL/min).  ANP was as effective as 3% NaCl in preventing cisplatin nephrotoxicity in this model.  The effect of ANP co-treatment on the anti-tumor activity of cisplatin was also examd. using the Walker 256 carcinosarcoma model.  ANP treatment did not result in any observable loss in anti-tumor activity.  When ANP was administered 72 h after cisplatin treatment, improvement in GFR was obsd. for the duration of the infusion, confirming the beneficial effect of ANP on cisplatin-damaged kidneys.  ANP may have a role in the treatment and prevention of cisplatin nephrotoxicity esp. in clin. situations where treatment with a large fluid vol. is contraindicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqngvHz2DU6rLVg90H21EOLACvtfcHk0lgZjheADnq_8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpvV2nsb0%253D&md5=a9c19f1589b46335c856d6016c72c7c2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0300-483X%2895%2903182-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0300-483X%252895%252903182-F%26sid%3Dliteratum%253Aachs%26aulast%3DDeegan%26aufirst%3DP.%2BM.%26aulast%3DBasinger%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DM.%2BM.%26aulast%3DHande%26aufirst%3DK.%2BR.%26atitle%3DPrevention%2520of%2520cisplatin%2520nephrotoxicity%2520by%2520exogenous%2520atrial%2520natriuretic%2520peptide%26jtitle%3DToxicology%26date%3D1996%26volume%3D106%26spage%3D159%26epage%3D166%26doi%3D10.1016%2F0300-483X%2895%2903182-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekborn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnström, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksborg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrsson, H.</span></span> <span> </span><span class="NLM_article-title">D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(02)00277-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2802%2900277-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12031515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2002&pages=53-61&author=A.+Ekbornauthor=G.+Laurellauthor=P.+Johnstr%C3%B6mauthor=I.+Wallinauthor=S.+Eksborgauthor=H.+Ehrsson&title=D-Methionine+and+cisplatin+ototoxicity+in+the+guinea+pig%3A+D-methionine+influences+cisplatin+pharmacokinetics&doi=10.1016%2FS0378-5955%2802%2900277-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics</span></div><div class="casAuthors">Ekborn, Andreas; Laurell, Goran; Johnstrom, Peter; Wallin, Inger; Eksborg, Staffan; Ehrsson, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-61</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The use of systemic D-methionine as a protector against cisplatin ototoxicity was studied in guinea pigs.  The kinetics and distribution of [11CH3]D-methionine were analyzed by PET.  Cisplatin and the monohydrated complex of cisplatin were quantified in the blood ultrafiltrate by using reversed-phase liq. chromatog. with postcolumn derivatization.  Administration of 300 mg D-methionine/kg caused a 30% decrease in the area under the concn.-time curve (AUC) of cisplatin.  The ototoxic effect of cisplatin was studied after dose adjustment of cisplatin, i.e., with similar cisplatin AUC in the group receiving D-methionine and the saline control group.  A significant ototoxic effect, measured as difference in pre- and 96-h post-treatment electrophysiol. hearing threshold (auditory brainstem response), was obsd. at stimulus frequencies of 30 and 20 kHz.  There was no difference between the groups in the extent of threshold shift.  Quant. outer hair cell counts showed a similar loss of cells in the two groups.  All the animals had an increase in plasma creatinine but there was no difference between the groups.  The results indicate that protection from cisplatin ototoxicity by systemic D-methionine can be explained by a lowered systemic exposure to the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3gmhj7fvRDLVg90H21EOLACvtfcHk0lhiWp7Fdqe_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVWjtrk%253D&md5=b34abe89edf9850ece17ed5c37edb5ef</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2802%2900277-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252802%252900277-0%26sid%3Dliteratum%253Aachs%26aulast%3DEkborn%26aufirst%3DA.%26aulast%3DLaurell%26aufirst%3DG.%26aulast%3DJohnstr%25C3%25B6m%26aufirst%3DP.%26aulast%3DWallin%26aufirst%3DI.%26aulast%3DEksborg%26aufirst%3DS.%26aulast%3DEhrsson%26aufirst%3DH.%26atitle%3DD-Methionine%2520and%2520cisplatin%2520ototoxicity%2520in%2520the%2520guinea%2520pig%253A%2520D-methionine%2520influences%2520cisplatin%2520pharmacokinetics%26jtitle%3DHear.%2520Res.%26date%3D2002%26volume%3D165%26spage%3D53%26epage%3D61%26doi%3D10.1016%2FS0378-5955%2802%2900277-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serpeloni, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcelos, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann Angeli, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercadante, A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lourdes Pires Bianchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antunes, L. M. G.</span></span> <span> </span><span class="NLM_article-title">Dietary carotenoid lutein protects against DNA damage and alterations of the redox status induced by cisplatin in human derived HepG2 cells</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2011.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.tiv.2011.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=22138568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVOls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=288-294&author=J.+M.+Serpeloniauthor=G.+R.+Barcelosauthor=J.+P.+Friedmann+Angeliauthor=A.+Z.+Mercadanteauthor=M.+Lourdes+Pires+Bianchiauthor=L.+M.+G.+Antunes&title=Dietary+carotenoid+lutein+protects+against+DNA+damage+and+alterations+of+the+redox+status+induced+by+cisplatin+in+human+derived+HepG2+cells&doi=10.1016%2Fj.tiv.2011.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary carotenoid lutein protects against DNA damage and alterations of the redox status induced by cisplatin in human derived HepG2 cells</span></div><div class="casAuthors">Serpeloni, Juliana Mara; Barcelos, Gustavo Rafael Mazzaron; Angeli, Jose Pedro Friedmann; Mercadante, Adriana Zerlotti; Bianchi, Maria Lourdes Pires; Antunes, Lusania Maria Greggi</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-294</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Several epidemiol. and exptl. studies has been reported that lutein (LT) presents antioxidant properties.  Aim of the present study was to investigate the protective effects of LT against oxidative stress and DNA damage induced by cisplatin (cDDP) in a human derived liver cell line (HepG2).  Cell viability and DNA-damage was monitored by MTT and comet assays.  Moreover, different biochem. parameters related to redox status (glutathione, cytochrome-c and intracellular ROS) were also evaluated.  A clear DNA-damage was seen with cDDP (1.0 μM) treatment.  In combination with the carotenoid, redn. of DNA damage was obsd. after pre- and simultaneous treatment of the cells, but not when the carotenoid was added to the cells after the exposure to cDDP.  Exposure of the cells to cDDP also caused significant changes of all biochem. parameters and in co-treatment of the cells with LT, the carotenoid reverted these alterations.  The results indicate that cDDP induces pronounced oxidative stress in HepG2 cells that is related to DNA damage and that the supplementation with the antioxidant LT may protect these adverse effects caused by the exposure of the cells to platinum compd., which can be a good predict for chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFyt97pXSbDLVg90H21EOLACvtfcHk0lhiWp7Fdqe_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVOls7k%253D&md5=fc6b40da2da1a2960db5ebe2e7250811</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2011.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2011.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DSerpeloni%26aufirst%3DJ.%2BM.%26aulast%3DBarcelos%26aufirst%3DG.%2BR.%26aulast%3DFriedmann%2BAngeli%26aufirst%3DJ.%2BP.%26aulast%3DMercadante%26aufirst%3DA.%2BZ.%26aulast%3DLourdes%2BPires%2BBianchi%26aufirst%3DM.%26aulast%3DAntunes%26aufirst%3DL.%2BM.%2BG.%26atitle%3DDietary%2520carotenoid%2520lutein%2520protects%2520against%2520DNA%2520damage%2520and%2520alterations%2520of%2520the%2520redox%2520status%2520induced%2520by%2520cisplatin%2520in%2520human%2520derived%2520HepG2%2520cells%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2012%26volume%3D26%26spage%3D288%26epage%3D294%26doi%3D10.1016%2Fj.tiv.2011.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishijima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokosuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iigo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani-Kaneko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span> <span> </span><span class="NLM_article-title">Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1034/j.1600-079X.2001.300301.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1034%2Fj.1600-079X.2001.300301.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=11316323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2001&pages=129-138&author=M.+Haraauthor=M.+Yoshidaauthor=H.+Nishijimaauthor=M.+Yokosukaauthor=M.+Iigoauthor=R.+Ohtani-Kanekoauthor=A.+Shimadaauthor=T.+Hasegawaauthor=Y.+Akamaauthor=K.+Hirata&title=Melatonin%2C+a+pineal+secretory+product+with+antioxidant+properties%2C+protects+against+cisplatin-induced+nephrotoxicity+in+rats&doi=10.1034%2Fj.1600-079X.2001.300301.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats</span></div><div class="casAuthors">Hara, Masayuki; Yoshida, Minoru; Nishijima, Hironori; Yokosuka, Makoto; Iigo, Masayuki; Ohtani-Kaneko, Ritsuko; Shimada, Akinori; Hasegawa, Tatsuya; Akama, Yoshifumi; Hirata, Kazuaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pineal Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">JPRSE9</span>;
        ISSN:<span class="NLM_cas:issn">0742-3098</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">To define the role of the pineal secretory melatonin and an analog, 6-hydroxymelatonin (6-Ω), in limiting oxidative stress, the present study investigated the cisplatin (CP)-induced alteration in the renal antioxidant system and nephroprotection with the two indolamines.  Melatonin (5 mg/kg), 6-Ω (5 mg/kg), or an equal vol. of saline were administered i.p. to male Sprague-Dawley rats 30 min prior to an i.p. injection of CP (7 mg/kg).  After CP treatment, the animals each received indolamine or saline every day and were sacrificed 3 or 5 days later and plasma as well as kidney were collected.  Both plasma creatinine and blood urea nitrogen increased significantly following CP administration alone; these values decreased significantly with melatonin co-treatment of CP-treated rats.  In the kidney, CP decreased the levels of GSH (reduced glutathione)/GSSG (oxidized glutathione) ratio, an index directly related to oxidative stress.  When animals were treated with melatonin, the redn. in the GSH/GSSG ratio was prevented.  Treatment of CP-enhanced lipid peroxidn. in the kidney was again prevented in animals treated with melatonin.  The activity of the antioxidant enzyme, glutathione peroxidase (GSH-Px), decreased as a result of CP administration, which was restored to control levels with melatonin co-treatment.  Upon histol. anal., damage to the proximal tubular cells was seen in the kidneys of CP-treated rats; these changes were prevented by melatonin treatment.  6-Ω Has been shown to have some antioxidative capacity, however, the protective effects of 6-Ω against CP-induced nephrotoxicity were less than those of melatonin.  The residual platinum concn. in the kidney of melatonin co-treated rats was significantly lower than that of rats treated with CP alone.  It is concluded that administration of CP imposes a severe oxidative stress to renal tissue and melatonin confers protection against the oxidative damage assocd. with CP.  This mechanism may be reasonably attributed to its radical scavenging activity, to its GSH-Px activating property, and/or to its regulatory activity for renal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFrovCvIp9rVg90H21EOLACvtfcHk0ljTSJJAWHluTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlWjtLs%253D&md5=f06ca3aaa0659f73cf4aa6d66f1e9a1f</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1034%2Fj.1600-079X.2001.300301.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1600-079X.2001.300301.x%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DNishijima%26aufirst%3DH.%26aulast%3DYokosuka%26aufirst%3DM.%26aulast%3DIigo%26aufirst%3DM.%26aulast%3DOhtani-Kaneko%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DA.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DAkama%26aufirst%3DY.%26aulast%3DHirata%26aufirst%3DK.%26atitle%3DMelatonin%252C%2520a%2520pineal%2520secretory%2520product%2520with%2520antioxidant%2520properties%252C%2520protects%2520against%2520cisplatin-induced%2520nephrotoxicity%2520in%2520rats%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D2001%26volume%3D30%26spage%3D129%26epage%3D138%26doi%3D10.1034%2Fj.1600-079X.2001.300301.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sridevi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhiayi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1038%2Fcdd.2013.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=23660976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlCmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=953-962&author=P.+Srideviauthor=M.+Nhiayiauthor=J.+Wang&title=Genetic+disruption+of+Abl+nuclear+import+reduces+renal+apoptosis+in+a+mouse+model+of+cisplatin-induced+nephrotoxicity&doi=10.1038%2Fcdd.2013.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Sridevi, P.; Nhiayi, M. K.; Wang, J. Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-962</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNA damage activates nuclear Abl tyrosine kinase to stimulate intrinsic apoptosis in cancer cell lines and mouse embryonic stem cells.  To examine the in vivo function of nuclear Abl in apoptosis, we generated Abl-μNLS (μ, mutated in nuclear localization signals) mice.  We show here that cisplatin-induced apoptosis is defective in the renal proximal tubule cells (RPTC) from the Ablμ/μ mice.  When injected with cisplatin, we found similar levels of platinum in the Abl+/+ and the Ablμ/μ kidneys, as well as similar initial inductions of p53 and PUMAα expression.  However, the accumulation of p53 and PUMAα could not be sustained in the Ablμ/μ kidneys, leading to redns. in renal apoptosis and tubule damage.  Co-treatment of cisplatin with the Abl kinase inhibitor, imatinib, reduced the accumulation of p53 and PUMAα in the Abl+/+ but not in the Ablμ/μ kidneys.  The residual apoptosis in the Ablμ/μ mice was not further reduced in the Ablμ/μ; p53-/- double-mutant mice, suggesting that nuclear Abl and p53 are epistatic to each other in this apoptosis response.  Although apoptosis and tubule damage were reduced, cisplatin-induced increases in phospho-Stat-1 and blood urea nitrogen were similar between the Abl+/+ and the Ablμ/μ kidneys, indicating that RPTC apoptosis is not the only factor in cisplatin-induced nephrotoxicity.  These results provide in vivo evidence for the pro-apoptotic function of Abl, and show that its nuclear localization and tyrosine kinase activity are both required for the sustained expression of p53 and PUMAα in cisplatin-induced renal apoptosis.  Cell Death and Differentiation (2013) 20, 953-962; doi:10.1038/cdd.2013.42; published online 10 May 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0JvLU9rcGNLVg90H21EOLACvtfcHk0ljTSJJAWHluTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlCmtr8%253D&md5=3d255e7d832da0373082d199b035cfcd</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.42%26sid%3Dliteratum%253Aachs%26aulast%3DSridevi%26aufirst%3DP.%26aulast%3DNhiayi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DGenetic%2520disruption%2520of%2520Abl%2520nuclear%2520import%2520reduces%2520renal%2520apoptosis%2520in%2520a%2520mouse%2520model%2520of%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2013%26volume%3D20%26spage%3D953%26epage%3D962%26doi%3D10.1038%2Fcdd.2013.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waissbluth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinpelu, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, S. J.</span></span> <span> </span><span class="NLM_article-title">The impact of erdosteine on cisplatin-induced ototoxicity: a proteomics approach</span>. <i>Eur. Arch. Oto-Rhino-L</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1007/s00405-016-4399-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2Fs00405-016-4399-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2017&pages=1365-1374&author=S.+Waissbluthauthor=D.+Garnierauthor=O.+V.+Akinpeluauthor=P.+Salehiauthor=S.+J.+Daniel&title=The+impact+of+erdosteine+on+cisplatin-induced+ototoxicity%3A+a+proteomics+approach&doi=10.1007%2Fs00405-016-4399-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs00405-016-4399-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00405-016-4399-1%26sid%3Dliteratum%253Aachs%26aulast%3DWaissbluth%26aufirst%3DS.%26aulast%3DGarnier%26aufirst%3DD.%26aulast%3DAkinpelu%26aufirst%3DO.%2BV.%26aulast%3DSalehi%26aufirst%3DP.%26aulast%3DDaniel%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520impact%2520of%2520erdosteine%2520on%2520cisplatin-induced%2520ototoxicity%253A%2520a%2520proteomics%2520approach%26jtitle%3DEur.%2520Arch.%2520Oto-Rhino-L%26date%3D2017%26volume%3D274%26spage%3D1365%26epage%3D1374%26doi%3D10.1007%2Fs00405-016-4399-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gispen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G.</span></span> <span> </span><span class="NLM_article-title">Application of a neuroprotective ACTH (4–9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs</span>. <i>Eur. Arch. Oto-Rhino-L</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1007/BF00175953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1007%2FBF00175953" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1994&pages=23-29&author=F.+Hamersauthor=S.+Klisauthor=W.+Gispenauthor=G.+Smoorenburg&title=Application+of+a+neuroprotective+ACTH+%284%E2%80%939%29+analog+to+affect+cisplatin+ototoxicity%3A+an+electrocochleographic+study+in+guinea+pigs&doi=10.1007%2FBF00175953"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1007%2FBF00175953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00175953%26sid%3Dliteratum%253Aachs%26aulast%3DHamers%26aufirst%3DF.%26aulast%3DKlis%26aufirst%3DS.%26aulast%3DGispen%26aufirst%3DW.%26aulast%3DSmoorenburg%26aufirst%3DG.%26atitle%3DApplication%2520of%2520a%2520neuroprotective%2520ACTH%2520%25284%25E2%2580%25939%2529%2520analog%2520to%2520affect%2520cisplatin%2520ototoxicity%253A%2520an%2520electrocochleographic%2520study%2520in%2520guinea%2520pigs%26jtitle%3DEur.%2520Arch.%2520Oto-Rhino-L%26date%3D1994%26volume%3D251%26spage%3D23%26epage%3D29%26doi%3D10.1007%2FBF00175953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gispen, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Co-administration of the neurotrophic ACTH (4–9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(96)00213-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2896%2900213-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=9112103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADyaK2sXislGiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1997&pages=9-19&author=J.+C.+M.+J.+de%0AGrootauthor=F.+P.+T.+Hamersauthor=W.-H.+Gispenauthor=G.+F.+Smoorenburg&title=Co-administration+of+the+neurotrophic+ACTH+%284%E2%80%939%29+analogue%2C+ORG+2766%2C+may+reduce+the+cochleotoxic+effects+of+cisplatin&doi=10.1016%2FS0378-5955%2896%2900213-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Co-administration of the neurotrophic ACTH(4-9) analog, ORG 2766, may reduce the cochleotoxic effects of cisplatin</span></div><div class="casAuthors">De Groot, John C.M.J.; Hamers, Frank P.T.; Gispen, Willem-Hendrik; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">9-19</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study the effect of the neurotrophic ACTH(4-9) analog, ORG 2766, on cisplatin cochleotoxicity was investigated with both light- and TEM microscopy.  Guinea pigs were treated with either cisplatin+ORG 2766 or cisplatin+physiol. saline.  All animals treated with cisplatin+physiol. saline showed complete loss of outer hair cells (OHC) and degeneration of the organ of Corti in the basal cochlear turns, while partial OHC loss was found in the middle and apical turns.  The inner hair cells (IHC) and other cochlear tissues were not affected.  Eight animals from the group treated with cisplatin+ORG 2766 demonstrated similar pathol. changes, but to a lesser degree, esp. in the middle turns.  The three remaining animals demonstrated no cochlear alterations at all, light-microscopically, and only minor subcellular changes in the OHCs at the ultrastructural level.  Electrophysiol., these three animals showed normal compd. action potential (CAP) amplitudes at stimulus frequencies from 0.5 to 16 kHz and normal cochlear microphonics (CM) in the frequency range from 0.5 to 8 kHz.  The other animals treated with cisplatin+ORG 2766 showed a severe loss in their CAPs and CM, except for one showing intermediate loss.  All animals from the group treated with cisplatin alone showed a severe loss in their CAPs and CM.  Endolymphatic hydrops was present in all animals from the cisplatin- and the cisplatin+ORG 2766-treated groups.  These data indicate that daily, concomitant administration of ORG 2766 may reduce OHC loss and subsequent degeneration of the organ of Corti in cisplatin-treated guinea pig cochleas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ZyUBazD8Y7Vg90H21EOLACvtfcHk0lgAqgXdd_yzAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislGiu7o%253D&md5=1daeb257d7db00719aee94e5c3783483</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2896%2900213-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252896%252900213-4%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DHamers%26aufirst%3DF.%2BP.%2BT.%26aulast%3DGispen%26aufirst%3DW.-H.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DCo-administration%2520of%2520the%2520neurotrophic%2520ACTH%2520%25284%25E2%2580%25939%2529%2520analogue%252C%2520ORG%25202766%252C%2520may%2520reduce%2520the%2520cochleotoxic%2520effects%2520of%2520cisplatin%26jtitle%3DHear.%2520Res.%26date%3D1997%26volume%3D106%26spage%3D9%26epage%3D19%26doi%3D10.1016%2FS0378-5955%2896%2900213-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijbenga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, F. L.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S. F.L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluyter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Cisplatin ototoxicity involves organ of Corti, Stria vascularis and Spiral ganglion: modulation by αMSH and ORG 2766</span>. <i>Audiol. Neuro-Otol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1159/000073515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1159%2F000073515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14566101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=305-315&author=F.+P.T.+Hamersauthor=J.+Wijbengaauthor=F.+L.C.+Woltersauthor=S.+F.L.+Klisauthor=S.+Sluyterauthor=G.+F.+Smoorenburg&title=Cisplatin+ototoxicity+involves+organ+of+Corti%2C+Stria+vascularis+and+Spiral+ganglion%3A+modulation+by+%CE%B1MSH+and+ORG+2766&doi=10.1159%2F000073515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin ototoxicity involves organ of corti, stria vascularis and spiral ganglion: modulation by αMSH and ORG 2766</span></div><div class="casAuthors">Hamers, Frank P. T.; Wijbenga, Jeroen; Wolters, Francisca L. C.; Klis, Sjaak F. L.; Sluyter, Steven; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Audiology & Neuro-Otology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">305-315</span>CODEN:
                <span class="NLM_cas:coden">ANEOFO</span>;
        ISSN:<span class="NLM_cas:issn">1420-3030</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">It has been shown that αMSH and the nonmelanotropic ACTH/MSH(4-9) analog ORG 2766 can ameliorate cisplatin-induced neurotoxicity and ototoxicity.  Here, we investigated whether these peptides delay the occurrence of the cisplatin-induced shift in auditory threshold, and whether they affect the subsequent recovery of cochlear potentials.  Chronically implanted round window electrodes were used to obtain daily recordings of auditory nerve compd. action potentials (CAP) and cochlear microphonics at frequencies ranging from 2 to 16 kHz.  Cisplatin (1.5 mg/kg i.p.) plus αMSH, ORG 2766 (75 μg/kg s.c.), or saline were injected daily until the 40-dB CAP threshold shift at 8 kHz was reached.  Endocochlear potential (EP) was measured either 1-2 days or 28 days later, followed by morphometric anal. of the cochlea.  Peptide cotreatment did not consistently delay the threshold shift; however, the CAP threshold recovered faster and to a greater extent, with the potency order being αMSH > ORG 2766 > saline.  Significant recovery at the 2 highest frequencies was seen in the αMSH-treated animals only.  CAP amplitude at high sound pressures, which depends more on nerve function than on outer hair cell (OHC) function, decreased severely in all groups but recovered significantly in the αMSH- and completely in the ORG-2766-cotreated group.  EP was significantly lower in the first days after the threshold shift but had completely recovered at 28 days.  Morphometric anal. of the spiral ganglion also indicated involvement of ganglion cells.  OHC loss was most severe in the basal turn of saline-cotreated animals.  These data suggest that the cisplatin-induced acute threshold shift might be due to reversible strial failure, whereas subsequent OHC survival dets. the final degree of functional recovery.  Both OHC loss and neuronal function were ameliorated by peptide cotreatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmbYQqfAYhLVg90H21EOLACvtfcHk0lhiETAH84vNJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFertLc%253D&md5=358a389020cb9809d6f32a79e208682c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1159%2F000073515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000073515%26sid%3Dliteratum%253Aachs%26aulast%3DHamers%26aufirst%3DF.%2BP.T.%26aulast%3DWijbenga%26aufirst%3DJ.%26aulast%3DWolters%26aufirst%3DF.%2BL.C.%26aulast%3DKlis%26aufirst%3DS.%2BF.L.%26aulast%3DSluyter%26aufirst%3DS.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DCisplatin%2520ototoxicity%2520involves%2520organ%2520of%2520Corti%252C%2520Stria%2520vascularis%2520and%2520Spiral%2520ganglion%253A%2520modulation%2520by%2520%25CE%25B1MSH%2520and%2520ORG%25202766%26jtitle%3DAudiol.%2520Neuro-Otol.%26date%3D2003%26volume%3D8%26spage%3D305%26epage%3D315%26doi%3D10.1159%2F000073515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinaal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huizing, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Histological effects of co-administration of an ACTH (4–9) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(00)00061-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2800%2900061-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10831874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsVGitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2000&pages=157-167&author=R.+M.+Cardinaalauthor=J.+C.+M.+J.+de+Grootauthor=E.+H.+Huizingauthor=J.+E.+Veldmanauthor=G.+F.+Smoorenburg&title=Histological+effects+of+co-administration+of+an+ACTH+%284%E2%80%939%29+analogue%2C+ORG+2766%2C+on+cisplatin+ototoxicity+in+the+albino+guinea+pig&doi=10.1016%2FS0378-5955%2800%2900061-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Histological effects of co-administration of an ACTH(4-9) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig</span></div><div class="casAuthors">Cardinaal, R. M.; de Groot, J. C. M. J.; Huizing, E. H.; Veldman, J. E.; Smoorenburg, G. F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">157-167</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Cisplatin is one of the most potent antineoplastic drugs presently known, but its therapeutic efficacy is seriously limited by several side effects such as ototoxicity.  Several compds. that are known for their nephroprotective effects also seem to reduce the incidence and severity of cisplatin-induced ototoxicity.  Hamers et al. (1994) and De Groot et al. (1997) investigated the possibly protective effect of concomitant administration of the ACTH(4-9) analog ORG 2766 upon cisplatin ototoxicity in guinea pigs.  Animals were treated with cisplatin at a daily dose of 2.0 mg/kg for 8 consecutive days and ORG 2766 at a daily dose of 75 μg/kg for 9 days.  Concomitant administration of cisplatin plus ORG 2766 resulted in a bimodal distribution of the electrophysiol. data (compd. action potential and cochlear microphonics amplitudes) and the histol. data (outer hair cell (OHC) counts).  It was surmised that this dichotomy might occur at a certain cisplatin dose.  We investigated whether this protective effect of ORG 2766 could be enhanced by reducing the daily dose of cisplatin while maintaining the same dose of ORG 2766.  Thirty-six animals were treated with daily i.p. injections of cisplatin at a dose of 1.0 mg/kg (n=18) or 1.5 mg/kg (n=18) for 8 consecutive days.  When comparing the mean OHC counts of the different exptl. groups, treatment with cisplatin at a daily dose of 1.5 mg/kg for 8 consecutive days resulted in a considerable loss of OHCs, which was significantly reduced after co-administration of ORG 2766.  Co-treatment with ORG 2766 did not result in a change in the vol. of the scala media.  The present results are in agreement with electrophysiol. results published earlier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd3-Mu4H4RBbVg90H21EOLACvtfcHk0lhiETAH84vNJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsVGitb0%253D&md5=4357ff502787a54baa4f8d50ec87a801</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2800%2900061-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252800%252900061-7%26sid%3Dliteratum%253Aachs%26aulast%3DCardinaal%26aufirst%3DR.%2BM.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DHuizing%26aufirst%3DE.%2BH.%26aulast%3DVeldman%26aufirst%3DJ.%2BE.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DHistological%2520effects%2520of%2520co-administration%2520of%2520an%2520ACTH%2520%25284%25E2%2580%25939%2529%2520analogue%252C%2520ORG%25202766%252C%2520on%2520cisplatin%2520ototoxicity%2520in%2520the%2520albino%2520guinea%2520pig%26jtitle%3DHear.%2520Res.%26date%3D2000%26volume%3D144%26spage%3D157%26epage%3D167%26doi%3D10.1016%2FS0378-5955%2800%2900061-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, F. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S. F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(03)00396-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2803%2900396-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=14987750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVKhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2004&pages=31-40&author=F.+L.+C.+Woltersauthor=S.+F.+L.+Klisauthor=F.+P.+T.+Hamersauthor=J.+C.+M.+J.+de%0AGrootauthor=G.+F.+Smoorenburg&title=Perilymphatic+application+of+%CE%B1-melanocyte+stimulating+hormone+ameliorates+hearing+loss+caused+by+systemic+administration+of+cisplatin&doi=10.1016%2FS0378-5955%2803%2900396-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Perilymphatic application of α-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin</span></div><div class="casAuthors">Wolters, Francisca L. C.; Klis, Sjaak F. L.; Hamers, Frank P. T.; de Groot, John C. M. J.; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">It has previously been demonstrated that ototoxicity induced by systemic administration of cisplatin is reduced by concomitant systemic administration of α-MSH.  In this study the authors investigated the effects of cochlear, perilymphatic application of α-MSH during i.p. administration of cisplatin.  Guinea pigs, implanted with a round-window electrode, allowing daily monitoring of the compd. action potential (CAP), and also implanted with a mini-osmotic pump, pumping at a rate of 0.25 μl/h either physiol. saline or α-MSH soln. (0.02, 2, and 20 μg/mL), were treated daily with a bolus injection of cisplatin (2 mg/kg) until the electrocochleogram showed a persistent decrease in CAP amplitude (≥40 dB threshold shift at 8 kHz).  Then, cisplatin treatment was stopped, but intracochlear perfusion of α-MSH or physiol. saline was continued for 10 days to evaluate possible effects of α-MSH on the expected recovery.  On day 10, the animals were killed and the cochleas were fixed and processed for histol. anal.  All groups required 6-7 days of cisplatin to reach the criterion CAP threshold shift.  Ten days after cessation of the cisplatin treatment, recovery of the CAP was obsd. in all groups and at all frequencies, although it was more pronounced at the lower frequencies.  With respect to recovery, small statistically significant differences were found between the saline and the α-MSH co-treated groups.  Histol. results showed significantly less outer hair cell (OHC) loss in the group co-treated with 2 μg/mL α-MSH as compared to the group co-treated with saline.  Since α-MSH was directly delivered to the cochlea, the ameliorating effect of α-MSH on OHC survival is likely to involve a cochlear target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJpw2ntAtR7Vg90H21EOLACvtfcHk0lgACiPUsjPQqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVKhsrw%253D&md5=83418183c2169f34f83aa361a4045e92</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2803%2900396-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252803%252900396-4%26sid%3Dliteratum%253Aachs%26aulast%3DWolters%26aufirst%3DF.%2BL.%2BC.%26aulast%3DKlis%26aufirst%3DS.%2BF.%2BL.%26aulast%3DHamers%26aufirst%3DF.%2BP.%2BT.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DPerilymphatic%2520application%2520of%2520%25CE%25B1-melanocyte%2520stimulating%2520hormone%2520ameliorates%2520hearing%2520loss%2520caused%2520by%2520systemic%2520administration%2520of%2520cisplatin%26jtitle%3DHear.%2520Res.%26date%3D2004%26volume%3D189%26spage%3D31%26epage%3D40%26doi%3D10.1016%2FS0378-5955%2803%2900396-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, F. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klis, S. F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, J. C. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamers, F. P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieskorn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoorenburg, G. F.</span></span> <span> </span><span class="NLM_article-title">Systemic co-treatment with α-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs</span>. <i>Hear. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/S0378-5955(03)00080-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2FS0378-5955%2803%2900080-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=12742238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2003&pages=53-61&author=F.+L.+C.+Woltersauthor=S.+F.+L.+Klisauthor=J.+C.+M.+J.+de%0AGrootauthor=F.+P.+T.+Hamersauthor=D.+M.+Prieskornauthor=J.+M.+Millerauthor=G.+F.+Smoorenburg&title=Systemic+co-treatment+with+%CE%B1-melanocyte+stimulating+hormone+delays+hearing+loss+caused+by+local+cisplatin+administration+in+guinea+pigs&doi=10.1016%2FS0378-5955%2803%2900080-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic co-treatment with α-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs</span></div><div class="casAuthors">Wolters, Francisca L. C.; Klis, Sjaak F. L.; de Groot, John C. M. J.; Hamers, Frank P. T.; Prieskorn, Diane M.; Miller, Josef M.; Smoorenburg, Guido F.</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-61</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">It has previously been demonstrated that ototoxicity induced by systemic administration of cisplatin is reduced by concomitant administration of melanocortins, like α-MSH.  However, these expts. were hampered by large interanimal variability.  Therefore, we re-investigated the effects of systemically administered α-MSH during local (intracochlear) administration of cisplatin.  Guinea pigs, implanted with a round-window electrode, allowing daily monitoring of the compd. action potentials (CAPs), and a mini-osmotic pump, pumping either 0.5 μL/h physiol. saline or cisplatin soln. (15 μg/mL), were cotreated daily with a s.c. bolus injection of either α-MSH (75 μg/kg) or physiol. saline for 1 wk or until the electrocochleogram showed a persistent decrease in CAP amplitude (40 dB threshold shift at 8 kHz).  Next, the animals were sacrificed and the cochleas were processed for histol.  After 2-3 days, cisplatin alone caused a threshold shift at all frequencies (2-16 kHz).  Co-administration with α-MSH consistently delayed the criterion threshold shift by 1 day.  When the 40 dB criterion had been reached, similar outer hair cell losses in both the cisplatin/α-MSH- and cisplatin/saline-treated groups were obsd.  This expt. confirms that direct administration of cisplatin into the cochlea results in considerably less interanimal variability than systemic administration and that co-treatment with α-MSH delays cisplatin ototoxicity.  Since cisplatin was delivered directly to the cochlea, the ameliorating effect of α-MSH probably involves a cochlear target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9QM7-CPTLLLVg90H21EOLACvtfcHk0lgACiPUsjPQqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWks7Y%253D&md5=1182c8b4035785950e5333c1de133849</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0378-5955%2803%2900080-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5955%252803%252900080-7%26sid%3Dliteratum%253Aachs%26aulast%3DWolters%26aufirst%3DF.%2BL.%2BC.%26aulast%3DKlis%26aufirst%3DS.%2BF.%2BL.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BC.%2BM.%2BJ.%26aulast%3DHamers%26aufirst%3DF.%2BP.%2BT.%26aulast%3DPrieskorn%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DJ.%2BM.%26aulast%3DSmoorenburg%26aufirst%3DG.%2BF.%26atitle%3DSystemic%2520co-treatment%2520with%2520%25CE%25B1-melanocyte%2520stimulating%2520hormone%2520delays%2520hearing%2520loss%2520caused%2520by%2520local%2520cisplatin%2520administration%2520in%2520guinea%2520pigs%26jtitle%3DHear.%2520Res.%26date%3D2003%26volume%3D179%26spage%3D53%26epage%3D61%26doi%3D10.1016%2FS0378-5955%2803%2900080-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">Platinum(IV) anticancer prodrugs - hypotheses and facts</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">12983</span>– <span class="NLM_lpage">12991</span>, <span class="refDoi"> DOI: 10.1039/C6DT01414C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC6DT01414C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=27214873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28XotlCruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=12983-12991&author=D.+Gibson&title=Platinum%28IV%29+anticancer+prodrugs+-+hypotheses+and+facts&doi=10.1039%2FC6DT01414C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) anticancer prodrugs - hypotheses and facts</span></div><div class="casAuthors">Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">12983-12991</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In this manuscript we focus on Pt(IV) anticancer prodrugs.  We explore the main working hypotheses for the design of effective Pt(IV) prodrugs and note the exceptions to the common assumptions that are prevalent in the field.  Special attention was devoted to the emerging class of "dual action" Pt(IV) prodrugs, where bioactive ligands are conjugated to the axial positions of platinum in order to obtain orthogonal or complementary effects that will increase the efficacy of killing the cancer cells.  We discuss the rationale behind the design of the "dual action" prodrugs and the results of the pharmacol. studies obtained.  Simultaneous release of two bioactive moieties inside the cancer cells often triggers several processes that together det. the fate of the cell.  Pt(IV) complexes provide many opportunities for applying new concepts in targeting, synergistic cell killing and exploiting novel nanodelivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN31ie6PsEtLVg90H21EOLACvtfcHk0lhZc3TR6xuC8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotlCruro%253D&md5=99fca9a3216d25087a0b565f8997c3ae</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1039%2FC6DT01414C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6DT01414C%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DPlatinum%2528IV%2529%2520anticancer%2520prodrugs%2520-%2520hypotheses%2520and%2520facts%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D12983%26epage%3D12991%26doi%3D10.1039%2FC6DT01414C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Current developments in Pt(IV) prodrugs conjugated with bioactive ligands</span>. <i>Bioinorg. Chem. Appl.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">8276139</span>, <span class="refDoi"> DOI: 10.1155/2018/8276139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1155%2F2018%2F8276139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30402082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BB3cvntl2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=8276139&author=X.+Liauthor=Y.+Liuauthor=H.+Tian&title=Current+developments+in+Pt%28IV%29+prodrugs+conjugated+with+bioactive+ligands&doi=10.1155%2F2018%2F8276139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands</span></div><div class="casAuthors">Li Xuejiao; Tian Hongqi; Liu Yahong</div><div class="citationInfo"><span class="NLM_cas:title">Bioinorganic chemistry and applications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8276139</span>
        ISSN:<span class="NLM_cas:issn">1565-3633</span>.
    </div><div class="casAbstract">To overcome the side effects of and resistance to cisplatin, a variety of Pt(IV) prodrugs were designed and synthesized via different modifications including combination with lipid chains to increase hydrophobicity, conjugation with short peptide chains or nanoparticles to improve drug delivery, or addition of bioactive ligands to the axial positions of Pt(IV) complexes to exert dual-function effects.  This review summarizes the recent progress in the development of Pt(IV) prodrugs conjugated with bioactive-targeting ligands, including histone deacetylase inhibitors, p53 agonists, alkylating agents, and nonsteroidal anti-inflammatory agents.  Although Pt(IV) complexes that conjugated with bioactive ligands show satisfactory anticancer effects, none has been approved for clinical use.  Therefore, we hope that this review will contribute to further study and development of Pt(IV) complexes conjugated with bioactive and other ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyKq5BuXOBhwaK-_ZudimnfW6udTcc2eYFvkE7T1btA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvntl2rtw%253D%253D&md5=93dd0f70da754552be3a890d8fa7ae05</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1155%2F2018%2F8276139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F8276139%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DCurrent%2520developments%2520in%2520Pt%2528IV%2529%2520prodrugs%2520conjugated%2520with%2520bioactive%2520ligands%26jtitle%3DBioinorg.%2520Chem.%2520Appl.%26date%3D2018%26volume%3D2018%26spage%3D8276139%26doi%3D10.1155%2F2018%2F8276139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Rational design of anticancer platinum(IV) prodrugs</span>. <i>Adv. Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/bs.adioch.2019.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fbs.adioch.2019.10.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2020&pages=149-182&author=S.+Zhangauthor=X.+Wangauthor=Z.+Guo&title=Rational+design+of+anticancer+platinum%28IV%29+prodrugs&doi=10.1016%2Fbs.adioch.2019.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fbs.adioch.2019.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.adioch.2019.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DRational%2520design%2520of%2520anticancer%2520platinum%2528IV%2529%2520prodrugs%26jtitle%3DAdv.%2520Inorg.%2520Chem.%26date%3D2020%26volume%3D75%26spage%3D149%26epage%3D182%26doi%3D10.1016%2Fbs.adioch.2019.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalaila, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allardyce, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, P. J.</span></span> <span> </span><span class="NLM_article-title">Rational design of platinum(IV) compounds to overcome glutathione-s-transferase mediated drug resistance</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1382</span>– <span class="NLM_lpage">1383</span>, <span class="refDoi"> DOI: 10.1021/ja0432618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0432618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=1382-1383&author=W.+H.+Angauthor=I.+Khalailaauthor=C.+S.+Allardyceauthor=L.+Juillerat-Jeanneretauthor=P.+J.+Dyson&title=Rational+design+of+platinum%28IV%29+compounds+to+overcome+glutathione-s-transferase+mediated+drug+resistance&doi=10.1021%2Fja0432618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Platinum(IV) Compounds to Overcome Glutathione-S-Transferase Mediated Drug Resistance</span></div><div class="casAuthors">Ang, Wee Han; Khalaila, Isam; Allardyce, Claire S.; Juillerat-Jeanneret, Lucienne; Dyson, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1382-1383</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A rationally designed Pt(IV) anticancer compd. is described, employing the novel concept of tethering an inhibitor of glutathione-S-transferase, an enzyme assocd. with Pt-based drug-resistance, to cisplatin.  Its enzyme inhibition activity, investigated using spectrophotometric and mass spectrometry-based techniques, and cytotoxic profile in resistant cancer cells are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7VgXIgOAQKLVg90H21EOLACvtfcHk0lgSjECmQvXIbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGmsA%253D%253D&md5=814c125e4c704b8b1a3811f1e01eedfd</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fja0432618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0432618%26sid%3Dliteratum%253Aachs%26aulast%3DAng%26aufirst%3DW.%2BH.%26aulast%3DKhalaila%26aufirst%3DI.%26aulast%3DAllardyce%26aufirst%3DC.%2BS.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DDyson%26aufirst%3DP.%2BJ.%26atitle%3DRational%2520design%2520of%2520platinum%2528IV%2529%2520compounds%2520to%2520overcome%2520glutathione-s-transferase%2520mediated%2520drug%2520resistance%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D1382%26epage%3D1383%26doi%3D10.1021%2Fja0432618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2019.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jinorgbio.2019.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30731264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2019&pages=133-142&author=H.+Chenauthor=X.+Wangauthor=S.+Gou&title=A+cisplatin-based+platinum%28IV%29+prodrug+containing+a+glutathione+s-transferase+inhibitor+to+reverse+cisplatin-resistance+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.jinorgbio.2019.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer</span></div><div class="casAuthors">Chen, Hong; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A Pt(IV) prodrug of cisplatin contg. a glutathione s-transferase (GSTs) inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), complex 1, was designed and studied aiming to overcome cisplatin-resistance and reduce its toxicity by inhibiting GSTs overexpressed in cancer cells.  The complex could be reduced to release its active Pt(II) species and axial ligand in the presence of ascorbic acid.  In cytotoxicity study, complex 1 showed more potent anticancer activity than cisplatin and NBDHEX against all the tested cancer cells, esp. toward cisplatin resistant A549/DDP cells with a resistance factor value of 0.37.  By effectively inhibiting GSTs, complex 1 was found to be able to promote higher platinum uptake and cause more severe DNA damage in both A549 cells and A549/DDP cells as compared with cisplatin.  Further mechanism study indicated that it could trigger cell death via an apoptotic pathway.  In vivo tests on A549 xenograft tumor mice model showed that complex 1 presented higher tumor inhibiting rate and lower toxicity than cisplatin as well.  In all, the Pt(IV) prodrug has potential to be developed as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjC9GD7aCddbVg90H21EOLACvtfcHk0lgSjECmQvXIbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWntr8%253D&md5=601a07727f245c505bb4d1e41657ca3b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2019.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2019.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DA%2520cisplatin-based%2520platinum%2528IV%2529%2520prodrug%2520containing%2520a%2520glutathione%2520s-transferase%2520inhibitor%2520to%2520reverse%2520cisplatin-resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2019%26volume%3D193%26spage%3D133%26epage%3D142%26doi%3D10.1016%2Fj.jinorgbio.2019.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid of DNA-targeting chlorambucil with Pt(IV) species to reverse drug resistance</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.243451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1124%2Fjpet.117.243451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28916659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=221-239&author=F.+Chenauthor=G.+Xuauthor=X.+Qinauthor=X.+Jinauthor=S.+Gou&title=Hybrid+of+DNA-targeting+chlorambucil+with+Pt%28IV%29+species+to+reverse+drug+resistance&doi=10.1124%2Fjpet.117.243451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid of DNA-targeting chlorambucil with Pt(IV) species to reverse drug resistance</span></div><div class="casAuthors">Chen, Feihong; Xu, Gang; Qin, Xiaodong; Jin, Xiufeng; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-239</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Two hybrids of Pt(IV) species were designed and prepd. by addn. of a chlorambucil unit to the axial positions of the Pt(IV) complexes derived from DN603 and DN604.  In vitro studies of two hybrids against two pairs of cisplatin sensitive and resistant cancer cell lines indicated that compd. 5 had superior antitumor activity to cisplatin and chlorambucil via suppressing DNA damage repair to reverse drug resistance.  Mechanistic investigation suggested that the potent antitumor activity of compd. 5 arose from its major suppression of CK2-mediated MRE11-RAD50-NBS1(MRN) complex promotion of DNA double strand break (DSB) repair.  In nude mice with A549/CDDP xenografts, compd. 5 exhibited higher anticancer efficacy than cisplatin and chlorambucil by reversing drug resistance, displayed improved effectiveness, and had no toxicity effects.  Overall, compd. 5 is a promising drug candidate, which could promote the anticancer activity and reverse drug resistance by attenuating CK2-induced MRN-dependent DSB repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFlzpA5Kf6rVg90H21EOLACvtfcHk0lgQCTs1OeUhrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrbJ&md5=d69a3c10dff340fa5b99ef54ad21067d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.243451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.243451%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DHybrid%2520of%2520DNA-targeting%2520chlorambucil%2520with%2520Pt%2528IV%2529%2520species%2520to%2520reverse%2520drug%2520resistance%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D221%26epage%3D239%26doi%3D10.1124%2Fjpet.117.243451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">A platinum(IV) anticancer prodrug targeting nucleotide excision repair to overcome cisplatin resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">15564</span>– <span class="NLM_lpage">15568</span>, <span class="refDoi"> DOI: 10.1002/anie.201608936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fanie.201608936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=15564-15568&author=Z.+Wangauthor=Z.+Xuauthor=G.+Zhu&title=A+platinum%28IV%29+anticancer+prodrug+targeting+nucleotide+excision+repair+to+overcome+cisplatin+resistance&doi=10.1002%2Fanie.201608936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance</span></div><div class="casAuthors">Wang, Zhigang; Xu, Zoufeng; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">15564-15568</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">DNA damage response plays a key role not only in maintaining genome integrity but also in mediating the antitumor efficacy of DNA-damaging antineoplastic drugs.  Herein, we report the rational design and evaluation of a PtIV anticancer prodrug inhibiting nucleotide excision repair (NER), one of the most pivotal processes after the formation of cisplatin-induced DNA damage that deactivates the drug and leads to drug resistance in the clinic.  This dual-action prodrug enters cells efficiently and causes DNA damage while simultaneously inhibiting NER to promote apoptotic response.  The prodrug is strongly active against the proliferation of cisplatin-resistant human cancer cells with an up to 88-fold increase in growth inhibition compared with cisplatin, and the prodrug is much more active than a mixt. of cisplatin and an NER inhibitor.  Our study highlights the importance of targeting downstream pathways after the formation of Pt-induced DNA damage as a novel strategy to conquer cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5lc5oE4qMXrVg90H21EOLACvtfcHk0lgQCTs1OeUhrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK&md5=551b6004833ce071b79c923cdf9483ca</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1002%2Fanie.201608936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201608936%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DA%2520platinum%2528IV%2529%2520anticancer%2520prodrug%2520targeting%2520nucleotide%2520excision%2520repair%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D15564%26epage%3D15568%26doi%3D10.1002%2Fanie.201608936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2465</span>– <span class="NLM_lpage">2468</span>, <span class="refDoi"> DOI: 10.1039/c3cc48740g</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2Fc3cc48740g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24452361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVygsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=2465-2468&author=K.+Suntharalingamauthor=Y.+Songauthor=S.+J.+Lippard&title=Conjugation+of+vitamin+E+analog+%CE%B1-TOS+to+Pt%28IV%29+complexes+for+dual-targeting+anticancer+therapy&doi=10.1039%2Fc3cc48740g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy</span></div><div class="casAuthors">Suntharalingam, Kogularamanan; Song, Ying; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2465-2468</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The authors report two platinum(IV) complexes conjugated with a vitamin E analog, α-tocopherol succinate (α-TOS).  One of the conjugates displays the activity of both cisplatin and α-TOS in cancer cells, causing damage to DNA and mitochondria simultaneously.  Accordingly, it serves as a promising dual-targeting anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruxZumJGIJpbVg90H21EOLACvtfcHk0lhOF7CsCdXCJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVygsLY%253D&md5=dc381d990f2afa1e349752f4e81976ba</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1039%2Fc3cc48740g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc48740g%26sid%3Dliteratum%253Aachs%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DConjugation%2520of%2520vitamin%2520E%2520analog%2520%25CE%25B1-TOS%2520to%2520Pt%2528IV%2529%2520complexes%2520for%2520dual-targeting%2520anticancer%2520therapy%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D2465%26epage%3D2468%26doi%3D10.1039%2Fc3cc48740g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2793</span>– <span class="NLM_lpage">2800</span>, <span class="refDoi"> DOI: 10.1021/mp200597r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200597r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2793-2800&author=J.+Yangauthor=X.+Sunauthor=W.+Maoauthor=M.+Suiauthor=J.+Tangauthor=Y.+Shen&title=Conjugate+of+Pt%28IV%29-histone+deacetylase+inhibitor+as+a+prodrug+for+cancer+chemotherapy&doi=10.1021%2Fmp200597r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugate of Pt(IV)-Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy</span></div><div class="casAuthors">Yang, Jun; Sun, Xuanrong; Mao, Weiwei; Sui, Meihua; Tang, Jianbin; Shen, Youqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2793-2800</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixt. with VA, against various human carcinoma cell lines.  VAAP could be quickly absorbed in the cell membrane and diffused into the cytosol.  VAAP loaded in polyethylene glycol-polycaprolactone micelles (PEG-PCL) was taken up via endocytosis.  The cytosolic VAAP was intracellular reduced to Pt(II) and released VA eliciting a HDAC inhibitory effect and subsequently induced cell cycle arrest at the S phase in 24 h and cell apoptosis in a time-dependent manner.  The in vivo antitumor expt. on A549-xenograft tumor model showed that VAAP dispersed in Tween 80 or loaded in PEG-PCL nanoparticles had long blood circulation times and thereby high accumulation in tumors and exerted a significant in vivo inhibitory effect on tumor growth with low systemic toxicity.  Therefore, this novel conjugate is very promising for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeW1MFD6bedbVg90H21EOLACvtfcHk0lhOF7CsCdXCJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrK&md5=838e90dcb852b4dddeb424832f46ab15</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fmp200597r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200597r%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DSui%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DConjugate%2520of%2520Pt%2528IV%2529-histone%2520deacetylase%2520inhibitor%2520as%2520a%2520prodrug%2520for%2520cancer%2520chemotherapy%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2793%26epage%3D2800%26doi%3D10.1021%2Fmp200597r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrache, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berding, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The prodrug platin-A: simultaneous release of cisplatin and aspirin</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/anie.201308899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fanie.201308899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1963-1967&author=R.+K.+Pathakauthor=S.+Marracheauthor=J.+H.+Choiauthor=T.+B.+Berdingauthor=S.+Dhar&title=The+prodrug+platin-A%3A+simultaneous+release+of+cisplatin+and+aspirin&doi=10.1002%2Fanie.201308899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span></div><div class="casAuthors">Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer-assocd. inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers.  The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin.  Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin.  These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIPcwRalkB7Vg90H21EOLACvtfcHk0lhOF7CsCdXCJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D&md5=d40b197ee5448e5a64a60c656eb0fde9</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1002%2Fanie.201308899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201308899%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DMarrache%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DBerding%26aufirst%3DT.%2BB.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520prodrug%2520platin-A%253A%2520simultaneous%2520release%2520of%2520cisplatin%2520and%2520aspirin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fanie.201308899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">7427</span>– <span class="NLM_lpage">7430</span>, <span class="refDoi"> DOI: 10.1039/C4CC00419A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC4CC00419A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=24777030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=7427-7430&author=Q.+Chengauthor=H.+Shiauthor=H.+Wangauthor=Y.+Minauthor=J.+Wangauthor=Y.+Liu&title=The+ligation+of+aspirin+to+cisplatin+demonstrates+significant+synergistic+effects+on+tumor+cells&doi=10.1039%2FC4CC00419A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells</span></div><div class="casAuthors">Cheng, Qinqin; Shi, Hongdong; Wang, Hongxia; Min, Yuanzeng; Wang, Jun; Liu, Yangzhong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">7427-7430</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells.  Asplatin is highly accumulated in cancer cells and is activated upon the redn. by ascorbic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT52MltZpsqbVg90H21EOLACvtfcHk0lhvXglWdNnpIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVagurnO&md5=5679afe1ad21bd6c6181aa0bd6d1f2fe</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1039%2FC4CC00419A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC00419A%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DThe%2520ligation%2520of%2520aspirin%2520to%2520cisplatin%2520demonstrates%2520significant%2520synergistic%2520effects%2520on%2520tumor%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D7427%26epage%3D7430%26doi%3D10.1039%2FC4CC00419A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.jinorgbio.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28700961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCltrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2017&pages=47-57&author=W.+Huauthor=L.+Fangauthor=W.+Huaauthor=S.+Gou&title=Biotin-Pt+%28IV%29-indomethacin+hybrid%3A+A+targeting+anticancer+prodrug+providing+enhanced+cancer+cellular+uptake+and+reversing+cisplatin+resistance&doi=10.1016%2Fj.jinorgbio.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance</span></div><div class="casAuthors">Hu, Weiwei; Fang, Lei; Hua, Wuyang; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-57</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A Pt(IV) prodrug (2) composed of cancer-targeting biotin and nonsteroidal anti-inflammatory drug indomethacin in the axial positions of the six-coordinated octahedral geometry derived from cisplatin was developed, which could be highly accumulated in cancer cells more than normal ones and activated by endogenous reducing mols. to release cisplatin and indomethacin moieties simultaneously to inhibit tumor progression synergistically.  In vitro assays revealed that 2 exhibited significantly selective inhibition to the tested cancer cell lines and sensitivity to cisplatin resistant cancer cells.  Moreover, 2 presented cyclooxygenases inhibition properties to reduce tumor-assocd. inflammation, reduced the invasiveness of the highly aggressive PC-3 cells, and disrupted capillary-like tube formation in EA.hy926 cells.  In all, this study offers a new strategy to enhance sensitivity and reduce toxicity of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwSqdeg6RZY7Vg90H21EOLACvtfcHk0lhvXglWdNnpIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCltrfP&md5=fc6c894c081b68804819dead13f16cc7</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DHua%26aufirst%3DW.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DBiotin-Pt%2520%2528IV%2529-indomethacin%2520hybrid%253A%2520A%2520targeting%2520anticancer%2520prodrug%2520providing%2520enhanced%2520cancer%2520cellular%2520uptake%2520and%2520reversing%2520cisplatin%2520resistance%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2017%26volume%3D175%26spage%3D47%26epage%3D57%26doi%3D10.1016%2Fj.jinorgbio.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(IV) prodrugs</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3829</span>– <span class="NLM_lpage">3835</span>, <span class="refDoi"> DOI: 10.1039/D0SC00197J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FD0SC00197J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFegt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=3829-3835&author=S.+Zhangauthor=X.+Zhongauthor=H.+Yuanauthor=Y.+Guoauthor=D.+Songauthor=F.+Qiauthor=Z.+Zhuauthor=X.+Wangauthor=Z.+Guo&title=Interfering+in+apoptosis+and+DNA+repair+of+cancer+cells+to+conquer+cisplatin+resistance+by+platinum%28IV%29+prodrugs&doi=10.1039%2FD0SC00197J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(IV) prodrugs</span></div><div class="casAuthors">Zhang, Shuren; Zhong, Xuanmeng; Yuan, Hao; Guo, Yan; Song, Dongfan; Qi, Fen; Zhu, Zhenzhu; Wang, Xiaoyong; Guo, Zijian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3829-3835</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Two anticancer PtIV prodrugs with the formulas [Pt(NH3)2Cl2(L1)2] (1, L1 = 3-chloro-benzo[b]thiophene-2-carboxylic acid) and [Pt(NH3)2Cl2(L2)2] (2, L2 = 3-chloro-6-methylbenzo[b]thiophene-2-carboxylic acid) were designed to target Mcl-1, a protein responsible for inhibiting apoptosis and promoting DNA damage repair.  Both 1 and 2 could enter cancer cells effectively and cause DNA damage while simultaneously downregulating Mcl-1 to prompt a conspicuous apoptotic response.  Complex 2 also downregulated the DNA damage repair proteins RAD51 and BRCA2 as well as inhibited the formation of RAD51 foci, which is regarded as a crit. step and functional biomarker in homologous recombination.  The acute toxicity of 1 and 2 to mice is lower than that of cisplatin, and more importantly, they show much stronger inhibition towards the growth of non-small-cell lung cancer in nude mice than cisplatin.  Complexes 1 and 2 are the first Mcl-1-targeted PtIV prodrugs, and the latter could synchronously inhibit apoptosis and DNA repair related proteins in cisplatin-resistant cancer cells.  The strategy of tuning both apoptosis and DNA repair pathways opens a promising window to overcoming resistance to cisplatin in anticancer chemotherapy, and is also a breakthrough in the design of multitalented platinum-based anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV_cxH8CGc2rVg90H21EOLACvtfcHk0ljiKylXl1ohsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFegt78%253D&md5=28565813ce600fc6973282acf98109a1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1039%2FD0SC00197J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0SC00197J%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DQi%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DInterfering%2520in%2520apoptosis%2520and%2520DNA%2520repair%2520of%2520cancer%2520cells%2520to%2520conquer%2520cisplatin%2520resistance%2520by%2520platinum%2528IV%2529%2520prodrugs%26jtitle%3DChem.%2520Sci.%26date%3D2020%26volume%3D11%26spage%3D3829%26epage%3D3835%26doi%3D10.1039%2FD0SC00197J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.-R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immuno-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0ljiKylXl1ohsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.-R.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immuno-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">9971</span>– <span class="NLM_lpage">9974</span>, <span class="refDoi"> DOI: 10.1039/C7CC05311H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2FC7CC05311H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=28831477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=9971-9974&author=N.+Muhammadauthor=N.+Sadiaauthor=C.+Zhuauthor=C.+Luoauthor=Z.+Guoauthor=X.+Wang&title=Biotin-tagged+platinum%28IV%29+complexes+as+targeted+cytostatic+agents+against+breast+cancer+cells&doi=10.1039%2FC7CC05311H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells</span></div><div class="casAuthors">Muhammad, Nafees; Sadia, Nasreen; Zhu, Chengcheng; Luo, Cheng; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">72</span>),
    <span class="NLM_cas:pages">9971-9974</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A biotin-guided platinumIV complex is highly cytotoxic against breast cancer cells but hypotoxic against mammary epithelial cells.  The mono-biotinylated PtIV complex is superior to the di-biotinylated one and hence a promising drug candidate for the targeted therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojsf_nE7HGsrVg90H21EOLACvtfcHk0lgFQ_PafS948Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejt7vO&md5=e0003ab9a6a3ef976136f8ea223433e5</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2FC7CC05311H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC05311H%26sid%3Dliteratum%253Aachs%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DSadia%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DBiotin-tagged%2520platinum%2528IV%2529%2520complexes%2520as%2520targeted%2520cytostatic%2520agents%2520against%2520breast%2520cancer%2520cells%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D9971%26epage%3D9974%26doi%3D10.1039%2FC7CC05311H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">8790</span>– <span class="NLM_lpage">8798</span>, <span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.-R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+prodrugs+designed+to+bind+non-covalently+to+human+serum+albumin+for+drug+delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0lgFQ_PafS948Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.-R.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520designed%2520to%2520bind%2520non-covalently%2520to%2520human%2520serum%2520albumin%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laws, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span> <span> </span><span class="NLM_article-title">The next generation of anticancer metallopharmaceuticals: cancer stem cell-active inorganics</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2246</span>– <span class="NLM_lpage">2253</span>, <span class="refDoi"> DOI: 10.1002/cbic.201800358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1002%2Fcbic.201800358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=30109911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2nsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2246-2253&author=K.+Lawsauthor=K.+Suntharalingam&title=The+next+generation+of+anticancer+metallopharmaceuticals%3A+cancer+stem+cell-active+inorganics&doi=10.1002%2Fcbic.201800358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Anticancer Metallopharmaceuticals: Cancer Stem Cell-Active Inorganics</span></div><div class="casAuthors">Laws, Kristine; Suntharalingam, Kogularamanan</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2246-2253</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are heavily linked to fatal incidences of cancer relapse and metastasis.  Conventional cancer therapies such as surgery, chemotherapy and radiation are largely futile against CSCs.  Therefore, highly original approaches are needed to overcome CSCs and to provide durable, long-term clin. outcomes.  Many academia- and pharmaceutical-led studies aimed at developing chem. or biol. anti-CSC agents are ongoing; however, the application of inorg. compds. is rare.  In this minireview, we discuss how the chem. diversity and versatility offered by metals has been harnessed to develop an unprecedented, emerging class of metallopharmaceuticals: CSC-active inorgs.  A detailed account of their mechanism(s) of action is provided, and possible future directions for exploration are also put forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2ekH5pCdv7Vg90H21EOLACvtfcHk0liSDSSkG835bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2nsb%252FM&md5=4c0ad667b145406a5861cafe9e01a81c</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201800358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201800358%26sid%3Dliteratum%253Aachs%26aulast%3DLaws%26aufirst%3DK.%26aulast%3DSuntharalingam%26aufirst%3DK.%26atitle%3DThe%2520next%2520generation%2520of%2520anticancer%2520metallopharmaceuticals%253A%2520cancer%2520stem%2520cell-active%2520inorganics%26jtitle%3DChemBioChem%26date%3D2018%26volume%3D19%26spage%3D2246%26epage%3D2253%26doi%3D10.1002%2Fcbic.201800358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonagh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ffrench, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuffe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, M. P.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">72544</span>– <span class="NLM_lpage">72563</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.18632%2Foncotarget.19881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29069808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ksVKmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=72544-72563&author=L.+MacDonaghauthor=M.+F.+Gallagherauthor=B.+Ffrenchauthor=C.+Gaschauthor=E.+Breenauthor=S.+G.+Grayauthor=S.+Nicholsonauthor=N.+Leonardauthor=R.+Ryanauthor=V.+Youngauthor=J.+J.+O%E2%80%99Learyauthor=S.+Cuffeauthor=S.+P.+Finnauthor=K.+J.+O%E2%80%99Byrneauthor=M.+P.+Barr&title=Targeting+the+cancer+stem+cell+marker%2C+aldehyde+dehydrogenase+1%2C+to+circumvent+cisplatin+resistance+in+NSCLC&doi=10.18632%2Foncotarget.19881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC</span></div><div class="casAuthors">MacDonagh Lauren; Gray Steven G; Cuffe Sinead; Finn Stephen P; O'Byrne Kenneth J; Barr Martin P; Gallagher Michael F; Ffrench Brendan; Gasch Claudia; O'Leary John J; Breen Eamon; Nicholson Siobhan; Leonard Niamh; Finn Stephen P; Ryan Ronan; Young Vincent; O'Byrne Kenneth J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">72544-72563</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) accounts for a large proportion of cancer deaths and is characterized by low treatment response rates and poor overall prognosis.  In the absence of specific treatable mutations, cisplatin-based chemotherapy plays an important role in the treatment of this disease.  Unfortunately, the development of resistance has become a major therapeutic challenge in the use of this cytotoxic drug.  Elucidating the mechanisms underlying this resistance phenotype, may result in the development of novel agents that enhance sensitivity to cisplatin in lung cancer patients.  In this study, targeting the cancer stem cell activity of aldehyde dehydrogenase 1 (ALDH1) was investigated as a strategy to overcome chemoresistance in NSCLC.  Tumors from NSCLC patients showed an increase in their profile of pluripotent stemness genes.  Cisplatin exposure induced the emergence or expansion of an ALDH1-positive subpopulation in cisplatin sensitive and resistant NSCLC cell lines, respectively, further enhancing cisplatin resistance.  Using the Aldefluor assay and FACS analysis, ALDH1 subpopulations were isolated and evaluated in terms of stem cell characteristics.  Only ALDH1-positive cells exhibited asymmetric division, cisplatin resistance and increased expression of stem cell factors in vitro.  Xenograft studies in NOD/SCID mice demonstrated efficient tumorigenesis from low cell numbers of ALDH1-positive and ALDH1-negative subpopulations.  Targeting ALDH1 with Diethylaminobenzaldehyde (DEAB) and Disulfiram, significantly re-sensitized resistant lung cancer cells to the cytotoxic effects of cisplatin.  Our data demonstrate the existence of a lung CSC population and suggest a role for targeting ALDH1 as a potential therapeutic strategy in re-sensitizing NSCLC cells to the cytotoxic effects of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnxbjAjsdnFMjl5L8hwNX0fW6udTcc2ebndq6EibIn6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ksVKmsA%253D%253D&md5=b7536b1fc32fd80effce42d222a1f285</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19881%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonagh%26aufirst%3DL.%26aulast%3DGallagher%26aufirst%3DM.%2BF.%26aulast%3DFfrench%26aufirst%3DB.%26aulast%3DGasch%26aufirst%3DC.%26aulast%3DBreen%26aufirst%3DE.%26aulast%3DGray%26aufirst%3DS.%2BG.%26aulast%3DNicholson%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DCuffe%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DS.%2BP.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DBarr%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520the%2520cancer%2520stem%2520cell%2520marker%252C%2520aldehyde%2520dehydrogenase%25201%252C%2520to%2520circumvent%2520cisplatin%2520resistance%2520in%2520NSCLC%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D72544%26epage%3D72563%26doi%3D10.18632%2Foncotarget.19881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, E. J.</span></span> <span> </span><span class="NLM_article-title">Ru(II) compounds: next-generation anticancer metallotherapeutics?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5805</span>– <span class="NLM_lpage">5821</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01689</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01689" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5805-5821&author=S.+Thotaauthor=D.+A.+Rodriguesauthor=D.+C.+Cransauthor=E.+J.+Barreiro&title=Ru%28II%29+compounds%3A+next-generation+anticancer+metallotherapeutics%3F&doi=10.1021%2Facs.jmedchem.7b01689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?</span></div><div class="casAuthors">Thota, Sreekanth; Rodrigues, Daniel A.; Crans, Debbie C.; Barreiro, Eliezer J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5805-5821</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metal based therapeutics are a precious class of drugs in oncol. research that include examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and therapeutics applications.  Ruthenium compds. have shown selective bioactivity and the ability to overcome the resistance that platinum-based therapeutics face, making them effective oncotherapeutic competitors in rational drug invention approaches.  The development of antineoplastic ruthenium therapeutics is of particular interest because ruthenium contg. complexes NAMI-A, KP1019, and KP1339 entered clin. trials and DW1/2 is in preclin. levels.  The very robust, conformationally rigid organometallic Ru(II) compd. DW1/2 is a protein kinase inhibitor and presents new Ru(II) compd. designs as anticancer agents.  Over the recent years, numerous strategies have been used to encapsulate Ru(II) derived compds. in a nanomaterial system, improving their targeting and delivery into neoplastic cells.  A new photodynamic therapy based Ru(II) therapeutic, TLD-1433, has also entered clin. trials.  Ru(II)-based compds. can also be photosensitizers for photodynamic therapy, which has proven to be an effective new, alternative, and noninvasive oncotherapy modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpCNrozZw4y7Vg90H21EOLACvtfcHk0ljBa6Rso-iaFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgsbc%253D&md5=2b539999f1e68e2ea1369b8f8ff9c719</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01689%26sid%3Dliteratum%253Aachs%26aulast%3DThota%26aufirst%3DS.%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26aulast%3DCrans%26aufirst%3DD.%2BC.%26aulast%3DBarreiro%26aufirst%3DE.%2BJ.%26atitle%3DRu%2528II%2529%2520compounds%253A%2520next-generation%2520anticancer%2520metallotherapeutics%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5805%26epage%3D5821%26doi%3D10.1021%2Facs.jmedchem.7b01689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, R.</span></span> <span> </span><span class="NLM_article-title">The status of platinum anticancer drugs in the clinic and in clinical trials</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">8113</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+status+of+platinum+anticancer+drugs+in+the+clinic+and+in+clinical+trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0ljBa6Rso-iaFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520status%2520of%2520platinum%2520anticancer%2520drugs%2520in%2520the%2520clinic%2520and%2520in%2520clinical%2520trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, R. G.</span></span> <span> </span><span class="NLM_article-title">Advances in drug delivery system for platinum agents based combination therapy</span>. <i>Cancer Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.7497/j.issn.2095-3941.2015.0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.7497%2Fj.issn.2095-3941.2015.0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=26779373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=362-374&author=X.+Kangauthor=H.+H.+Xiaoauthor=H.+Q.+Songauthor=X.+B.+Jingauthor=L.+S.+Yanauthor=R.+G.+Qi&title=Advances+in+drug+delivery+system+for+platinum+agents+based+combination+therapy&doi=10.7497%2Fj.issn.2095-3941.2015.0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug delivery system for platinum agents based combination therapy</span></div><div class="casAuthors">Kang, Xiang; Xiao, Hai-Hua; Song, Hai-Qin; Jing, Xia-Bin; Yan, Le-San; Qi, Ruo-Gu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4Spec.Iss.</span>),
    <span class="NLM_cas:pages">362-374</span>CODEN:
                <span class="NLM_cas:coden">CBMADQ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Tianjin Medical University Cancer Institute and Hospital</span>)
        </div><div class="casAbstract">Platinum-based anticancer agents are widely used as first-line drugs in cancer chemotherapy for various solid tumors.  However, great side effects and occurrence of resistance remain as the major drawbacks for almost all the platinum drugs developed.  To conquer these problems, new strategies should be adopted for platinum drug based chemotherapy.  Modern nanotechnol. has been widely employed in the delivery of various therapeutics and diagnostic.  It provides the possibility of targeted delivery of a certain anticancer drug to the tumor site, which could minimize toxicity and optimize the drug efficacy.  Here, in this review, we focused on the recent progress in polymer based drug delivery systems for platinum-based combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6c7l6YI7qmbVg90H21EOLACvtfcHk0ljBa6Rso-iaFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D&md5=086ed651b447b0d2563c81c555c26702</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.7497%2Fj.issn.2095-3941.2015.0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7497%252Fj.issn.2095-3941.2015.0063%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DH.%2BH.%26aulast%3DSong%26aufirst%3DH.%2BQ.%26aulast%3DJing%26aufirst%3DX.%2BB.%26aulast%3DYan%26aufirst%3DL.%2BS.%26aulast%3DQi%26aufirst%3DR.%2BG.%26atitle%3DAdvances%2520in%2520drug%2520delivery%2520system%2520for%2520platinum%2520agents%2520based%2520combination%2520therapy%26jtitle%3DCancer%2520Biol.%2520Med.%26date%3D2015%26volume%3D12%26spage%3D362%26epage%3D374%26doi%3D10.7497%2Fj.issn.2095-3941.2015.0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daruwalla, J.</span></span> <span> </span><span class="NLM_article-title">Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect</span>. <i>Eur. J. Pharm. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.ejpb.2008.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.1016%2Fj.ejpb.2008.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=19070661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2009&pages=409-419&author=H.+Maedaauthor=G.+Y.+Bharateauthor=J.+Daruwalla&title=Polymeric+drugs+for+efficient+tumor-targeted+drug+delivery+based+on+EPR-effect&doi=10.1016%2Fj.ejpb.2008.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect</span></div><div class="casAuthors">Maeda, H.; Bharate, G. Y.; Daruwalla, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-419</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  For over half a century extensive research has been undertaken for the control of cancer.  However, success has been limited to certain malignancies, and surgical intervention is potentially curative for early stage patients.  For the majority of patients with advanced stage of cancer, the treatment is limited to chemotherapy or radiation.  Chemotherapy in particular has limitations due to the lack of selectivity with severe toxicity.  Under these circumstances tumor-targeted delivery of anticancer drugs is perhaps one of the most important steps for cancer chemotherapy.  We reported such a drug for the first time, styrene-maleic acid copolymer-conjugated neocarzinostatin (SMANCS) in 1979, and it eventually led to formulate the concept of the enhanced permeability and retention (EPR) effect of solid tumors in 1986.  Monoclonal antibody conjugates are another direction, of which interest is increasing recently though with limited success.  The EPR-effect appears as a universal phenomenon in solid tumors which warrants the development of other polymeric drugs or nanomedicine.  EPR-effect is applicable for any biocompatible macromol. compds. above 40 kDa, even larger than 800 kDa, or of the size of bacteria; thus complexed mols. like micelles and liposomes contg. anticancer drugs are hallmark examples.  The drug concn. in tumor compared to that of the blood (T/B ratio) can be usually as high as 10-30 times.  In case of SMANCS/Lipiodol given via tumor feeding artery, the T/B ratio can be as high as 2000, a real pin-point targeting.  EPR-effect is not just passive targeting for momentary tumor delivery, but it means prolonged drug retention for more than several weeks or longer.  This review describes the pathophysiol. mechanisms of the EPR-effect, architectural difference of tumor blood vessel, various factors involved and artificial augmentation of EPR-effect with respect to tumor-selective delivery, and then advantages and problems of macromol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS--P962B5eLVg90H21EOLACvtfcHk0lhl8pa5zpFY-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFWgt78%253D&md5=a385460578d0a3722f9f51d7c7ca5abd</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2008.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2008.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DBharate%26aufirst%3DG.%2BY.%26aulast%3DDaruwalla%26aufirst%3DJ.%26atitle%3DPolymeric%2520drugs%2520for%2520efficient%2520tumor-targeted%2520drug%2520delivery%2520based%2520on%2520EPR-effect%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2009%26volume%3D71%26spage%3D409%26epage%3D419%26doi%3D10.1016%2Fj.ejpb.2008.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novohradsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparkova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabec, V.</span></span> <span> </span><span class="NLM_article-title">Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28456</span>– <span class="NLM_lpage">28473</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=10.18632%2Foncotarget.25466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=29983873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FlvFWlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=28456-28473&author=V.+Novohradskyauthor=J.+Zajacauthor=O.+Vranaauthor=J.+Kasparkovaauthor=V.+Brabec&title=Simultaneous+delivery+of+olaparib+and+carboplatin+in+PEGylated+liposomes+imparts+this+drug+combination+hypersensitivity+and+selectivity+for+breast+tumor+cells&doi=10.18632%2Foncotarget.25466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells</span></div><div class="casAuthors">Novohradsky Vojtech; Zajac Juraj; Vrana Oldrich; Kasparkova Jana; Brabec Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">28456-28473</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Combination regiments involving platinum anticancer drugs and agents with unrelated mechanisms of action are a subject of widespread interest.  Here, we show that synergistic toxic action in cancer cells of combinations of antitumor platinum drug carboplatin and effective PARP inhibitor olaparib is considerably improved if these combined drugs are encapsulated into liposomes.  Notably, the formation of such nano-formulations, called OLICARB, leads to a marked enhancement of activity in human cancer cell lines (including those resistant to conventional platinum antitumor drugs) and selectivity towards tumor cells.  We used immunofluorescence analysis of γH2AX expression and examined DNA damage in cancerous cells treated with the investigated compounds.  We find that the synergistic toxic effects in cancer cells of both drugs used in combination, nonencapsulated or embedded in the OLICARB nanoparticles, positively correlates with DNA damage.  These results also suggest that the enhancement of the toxic effects of carboplatin by olaparib in cancer cells is a consequence of an accumulation of cytotoxic lesions in DNA due to the inhibition of repair of platinated DNA augmented by the synergistic action of olaparib as an effective PARP inhibitor.  Our findings also reveal that the combination of olaparib with carboplatin encapsulated in the OLICARB nanoparticles is particularly effective to inhibit the growth of 3D mammospheres.  Collectively, the data provide convincing evidence that the encapsulation of carboplatin and olaparib into liposomal constructs to form the OLICARB nanoparticles may represent the viable approach for the treatment of tumors with the aim to eliminate the possible effects of acquired resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9NFGEnVFtt1QKX3ooHxWjfW6udTcc2ebH6HgE_hlArbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FlvFWlsw%253D%253D&md5=2c5ca718f535de0e39c8f5308d1090a3</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25466%26sid%3Dliteratum%253Aachs%26aulast%3DNovohradsky%26aufirst%3DV.%26aulast%3DZajac%26aufirst%3DJ.%26aulast%3DVrana%26aufirst%3DO.%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DBrabec%26aufirst%3DV.%26atitle%3DSimultaneous%2520delivery%2520of%2520olaparib%2520and%2520carboplatin%2520in%2520PEGylated%2520liposomes%2520imparts%2520this%2520drug%2520combination%2520hypersensitivity%2520and%2520selectivity%2520for%2520breast%2520tumor%2520cells%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D28456%26epage%3D28473%26doi%3D10.18632%2Foncotarget.25466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00950&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00950%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00950" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a8c601d3f3d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
